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Over the last decade, it is becoming increasingly clear that diabetes mellitus is a global 
epidemic. The influence of diabetes is most readily apparent in its manifestation in 
foot complications across cultures and continents. In this unique collaboration of 
global specialists, we examine the explosion of foot disease in locations that must 
quickly grapple with both mobilizing medical expertise and shaping public policy to 
best prevent and treat these serious complications. 
In other areas of the world where diabetic foot complications have unfortunately been 
all too common, diagnostic testing and advanced treatments have been developed in 
response. The bulk of this book is devoted to examining the newest developments in 
basic and clinical research on the diabetic foot. It is hoped that as our understanding of 
the pathophysiologic process expands, the devastating impact of diabetic foot 
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Possible Diabetic-Foot Complications  
in Sub-Saharan Africa   
Ezera Agwu1, Ephraim O. Dafiewhare2 and Peter E. Ekanem3  
1Department of Microbiology;  
2Department of Internal Medicine;  
3Department of Anatomy  
Kampala International University, Western Campus,  
Uganda 
1. Introduction  
In Sub-Saharan Africa, fast uncontrolled urbanization and changes in standard of living are 
responsible for the rising epidemic of diabetes mellitus and the observed increase presents a 
substantial public health and socioeconomic burden in the face of scarce resources (Mbanya 
et al., 2010). Ten to fifteen percent of diabetic patients develop foot ulcers at some stage of 
their lives and nearly fifty percent of all diabetes-related admissions are due to diabetic foot 
problems (Kumar and Clark, 2009). The epidemiology of Ketosis-prone atypical diabetes in 
Africans is not well understood because of scarce data for pathogenesis and subtypes of 
diabetes. The prevalence of undiagnosed diabetes mellitus is high in most countries of sub-
Saharan Africa, and individuals who are unaware they have the disorder are at very high 
risk of chronic complications. Therefore, the prevalence of diabetes-related morbidity and 
mortality could grow substantially 
Causes of amputation in sub-Saharan Africa vary between and within countries (Ephraim et 
al., 2003, Thanni and Tade 2007) depending on ethnic background and socio-economic status 
(Leggetter et al, 2002, Rucker-Whitaker et al., 2003). In sub-Saharan Africa, tumours and 
trauma are the leading causes of lower extremities amputation (Abbas and Musa, 2007, 
Thanni and Tade 2007), with increasing incidence of cardiovascular risk factors 
(Akinboboye et al., 2003).  
In Kenya, rates of vascular amputations vary between 25% and 56% with Muyembe and 
Muhinga (1999) reporting that the leading indications of lower extremities amputation were 
trauma, tumours and complications of diabetes mellitus, each accounting for 26.5% of the 
amputations done. Another Kenya study recorded seven years later by Awori and Atinga, 
(2007) reported that 17.5% of patients who underwent amputation were due to diabetes-
related gangrene. Two years later in 2009, diabetic vasculopathy accounted for 11.4% of the 
amputations and 69.6% of the non vascular cases while other causes of amputation 
included: 35.7% trauma, 20% congenital defects, 14% infection and 12.8% tumours 
respectively (Ogeng’o et al., 2009).   
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Kidmas et al., (2004) in Nigeria reported 26.4% diabetic foot sepsis as one of the main 
indications for lower limb amputations while Sié Essoh et al., (2009) from Ivory Coast (Cote 
D’Ivoire) reported 46.9% below knee diabetes related amputation and 11.2% below elbow 
diabetes-related amputations as common procedures performed. However, in Zimbabwe, 
Sibanda et al., (2009) reported 9% diabetes related lower limb amputation rate among 100 
patients evaluated. Thus, different regions of Africa reported decreasing trend in diabetes 
related amputations.  
Non-diabetes related lower extremities amputation have also been well documented. 
Obalum and Okeke, (2009) in Nigeria reported 61.8% trauma as the most common 
indication of lower limb amputation with motorcycle related accidents accounting for 61.9% 
of the trauma related cases. This was followed by 19.0% lower limb amputations due to 
pedestrians involved in road traffic accidents. Again, Abbas and Musa (2007) reported 
42.8% trauma related lower extremities amputation and 18.4% lower extremities 
amputations due to other malignancies. Below knee amputation was the commonest 
amputation carried out constituting 62.8% of the 35 lower limb amputations. A Nigerian 
study by Kidmas et al., (2004) also found that trauma and malignant conditions of the limb 
were the main indications for lower limb amputations in 29.9% and 23% patients 
respectively. According to Awori and Atinga, (2007) in a study done in Kenya, 24.3% had 
tumours, 16.2% of which were mainly osteogenic sarcoma while trauma accounted for 
18.9%. Fifty five per cent of the amputations were above-the-knee, 24 (31%) below-the-knee, 
four (5%) hip disarticulations and seven (9%) were foot amputations. 
The prominence of diabetic foot among debilitating tropical diseases which influences the 
duration of patients hospital admission is noteworthy. Diabetic foot is a important health 
issue in sub-Saharan Africa, where it must compete for resources with other prevalent non-
communicable diseases. One of the reasons for the poor outcome of diabetic foot 
complications in developing countries is the lack of patient education and inadequate 
medical supervision. Thus, health education tailored to the individual’s risk status, which 
promotes self-care and addresses misconceptions and medical supervision are needed to 
effectively contain the multi-factorial pathology of diabetic foot ulcerations.  
Though the risk factors for developing diabetic foot ulcers are manageable, poor outcomes 
of foot complications may be due to: poor awareness among patients and some cadre of 
health care providers, poor and delayed access to health care, poor referrals for specialist 
treatment, lack of team approach for the treatment of the complicated diabetic foot, absence 
of refresher training programmes for health care providers and lack of quality assurance 
programmes. 
Diabetic foot infection is the most common soft tissue infection associated with diabetes 
mellitus, with disease-related peripheral neuropathy and peripheral vascular disease 
playing major roles in this complication of diabetes. More serious complications include 
failure of ulcers to heal and gangrene which may lead to osteomyelitis, amputation, and 
death. Diabetic foot ulcers may begin after minor trauma, become infected and may 
progress to cellulitis, soft tissue necrosis, and extension into bone. Exploration of the ulcer is 
crucial to determine its depth (the palpable bone strongly suggests osteomyelitis). It is also 
important to determine the presence of sinus tracts and to obtain a culture. Involved 
organisms include group A Streptococcus and S aureus, as well as aerobic gram-positive 
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cocci, gram-negative rods, and anaerobes. It is highly promising to know that organism’s 
involed in delayed healing diabetic foot complications in Nigeria including Staphylococcus 
and Pseudomonas species were susceptible to Quinolones (Agwu et al., 2010). If this 
information is confirmed in other parts of Africa, it will offer health care workers the 
scenario to design an intervention that will help reduce the incidences of diabetic foot 
complications and chances of lower linb amputations to barest minimum.   
To reduce the incidence of Diabetes mellitus related amputation, medical supervision and 
patient education on prevention of diabetic foot complication are recommended. The 
predominant risk factors for foot complications are underlying peripheral neuropathy, 
peripheral vascular disease (Abbas and Archibald., 2007) and infection. Gangrene is a more 
serious complication of diabetic foot disease that causes long-standing disability, loss of 
income, amputation or death. Reasons for poor outcomes of foot complications in various 
less-developed countries include: lack of awareness of foot care issues among patients and 
health care providers alike; very few professionals with an interest in the diabetic foot or 
trained to provide specialist treatment; non-existent podiatry services; long distances for 
patients to travel to the clinic; delay among patients in seeking timely medical care, or 
among untrained health care providers in referring patients with serious complications for 
specialist opinion; lack of the concept of a team approach; absence of refresher training 
programs for health care professionals; and finally lack of surveillance activities (Abbas 
and Archibald., 2007). Other important factors include use of ill-fitting foot-wears and 
complete absence of foot wears (Krasner et al., 2007).  
Abbas and Archibald., (2007) suggested the following ways of improving diabetic 
foot disease outcomes that do not require exorbitant outlay of financial resources: 
implementation of sustainable training programmes for health care professionals, focusing 
on the management of the complicated diabetic foot and educational programmes that 
include dissemination of information to other health care professionals and patients; 
sustenance of working environments that inculcate commitment by individual physicians 
and nurses through self growth; rational optimal use of existing microbiology facilities and 
prescribing through epidemiologically directed empiricism, where appropriate; and using 
sentinel hospitals for surveillance activities.  
In Uganda and indeed many other African countries, little has been documented about 
diabetes care and far fewer data exist for diabetic foot among the diabetics. The worst 
scenario is the high prevalence of unknown cases in where people only discover they are 
diabetic when they can no longer contain the associated complications. Lack of diabetes 
clinic in major hospitals and at the grass root could explain the poor education of diabetic 
foot patients on what to do and how to manage the situation. Evaluation of diabetic foot 
complications in this region is a study designed to fill the knowledge gap, sensitize the 
appropriate authorities to intervene and remind the diabetics on the need to participate in 
an integrated community directed efforts to reduce the impact of diabetic foot to the barest 
minimum. The situational analysis of diabetic foot epidemic, prevention and control in 
South Western Uganda is very necessary. The objective of this manuscript is therefore to 
outline the current prevalence and impact of diabetic foot and its associated complications 
among the diabetics in South Western Uganda 
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2. Methods  
This was a biphasic study made up of a prospective stake-holders descriptive survey and a 
retrospective cross sectional health-point survey of diabetic foot and its associated 
complications among diabetic patients attending randomly selected hospitals in Bushenyi, 
Sheema, Rubirizi and Mbarara districts of South Western Uganda. Hospital records of diabetic 
patients attending clinics at Mbarara metropolis made available for this assessment are those 
which fulfilled our data inclusion criteria which states that clinical data must be confirmed by 
laboratory investigation and laboratory data must be confirmed by clinical observation.  
For reasons not explained by participating hospitals but which may include difficulty in 
information storage and retrieval, occasioned by changing hospital policies which allow 
patients to go home with their case files, the only data made available for this study were data 
generated in the year 2005. For retrospective data, Mbarara Regional Referral Hospital was 
selected based on: 1) presence of diabetes clinic, 2) possession of a side laboratory for rapid 
tests for diabetes, 3) being a referral hospital which covers referral cases from district hospitals 
and 4) having medical and surgical records which might include data on diabetic foot.  
Pre-tested data collection tool was used to obtain socio-demographic information from the 
case-files of diabetic patients in Mbarara region of Uganda and also diabetes and diabetic 
foot associated disease complications as contained in patient’s case-files.  
To get a glimpse of the current diabetic management situation in an environment with few 
diabetic clinics, structured questionnaires were self-administered to randomly selected 
diabetes stakeholders such as Clinicians, Medical Laboratory Scientists, diabetic patients 
and nursing officers working in hospitals located in South-Western Uganda and its 
environs. Criteria for diabetes stakeholders’ selection include: having worked in- or being 
in-charge of clinical chemistry laboratories, Medical and Surgical wards of hospitals located 
in Mbarara and its environs.  Mbarara and environs were defined as hospitals located in a 
nearby Bushenyi district such as Kampala International University Teaching Hospital 
(KIUTH), Comboni Hospital, Kitagata Hospital and Lugazi Health Center IV. Information 
obtained from the officers included comments on the overall routine approaches in diabetic 
care including existence of diabetic clinic, inspection of the feet of diabetics (during ward 
round and out-patients consultations), diabetes education, surveillance, and complications 
of diabetic foot.  
At random, five clinicians and two senior nursing officers at KIUTH; two diabetic patients two 
clinicians and one nursing officer at Lugazi Health Center IV; one nursing officer at Kitagata 
hospital and one clinician at Comboni hospital were interviewed. The retrospective data 
included in this study were from patients clinically diagnosed with diabetes mellitus and 
subsequently confirmed with standard clinical chemistry methods in the side laboratories of 
the participating hospitals. Clinical data not confirmed in the laboratory and laboratory data 
not confirmed by the clinical records were excluded from the study. The Research and Ethics 
Board of Kampala International University Uganda approved this study.  
3. Results 
The 233 data reviewed were from 104 (44.6%) males and 129 (55.4%) females aged from 10 
years old to 60 years and above with a mean age of 40 years (Table 1). According to our data 
 
Possible Diabetic-Foot Complications in Sub-Saharan Africa   
 
7 
source, there were no routine diabetic clinics in most hospitals in the year 2005 when the 
retrospective data of the study population were reviewed. Known diabetic patients were 
cared for at the Medical and Surgical departments of the hospital. The hospital records 
evaluated did not distinguish between insulin dependent and non-insulin dependent diabetes 
making it difficult to determine the impact of diabetes types on disease establishment and 
progression (Table 1). The complications and co-morbidities reported in this study (Table 2) 
were obtained from the records of medical out- and in- patient departments of the clinic.  
Consequently 233 diabetic patients presented 32 different diabetes associated co-morbidities 
and complications with peripheral nephropathy (22.8%) being the most prevalent 
complications followed by infection (9.5%) (vaginal candidiasis, Urinary tract infection, skin 
infection; and 1.7% obesity. Others listed in the table are co-morbidities found among the 
diabetic patients seen during the period. Other unclassified disease conditions accounted for 
4% of the total complications/co-morbidities recorded (Table 2).  
Interestingly there were no clear records of diabetic foot among the reported 32 
complications and co-morbidities outlined above (Table 2).  This unique and conspicuous 
absence of diabetic foot in the record of 233 diabetic patients prompted a prospective 
descriptive study involving stakeholders of diabetes disease and its management in 
Mbarara district and its environs.       
 
Table 1. Age and sex distribution of 233 dependent diabetic patients attending clinics in 
Mbarara district of Uganda 
Stake-holders opinion clearly indicated that in Mbarara and environs with no diabetes 
clinics, foot inspection is not done routinely during ward-round even among known 
diabetics. Also there were inadequate diabetes education and surveillance. The main 
assistance rendered to the known diabetics include monitoring and control of blood glucose 
level and care for any major complaints they may have. Stakeholders also outlined the fact 
that most patients do not even know they have diabetic foot because of loss of sense of touch 
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2. Methods  
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due to peripheral neuropathy. The diabetic foot complications reported by stakeholders 
include: peripheral neuropathy (sensory, motor and/or autonomic), chronic leg ulcers and 
gangrene. The clinicians reported that many foot lesions treated among diabetic patients 
were not documented as part of the final diagnosis for these patients. That may account for 
the absence of diabetic foot in previous hospital records retrieved for the retrospective study  
 
Table 2. Complications and co-morbidities found among diabetic patients attending clinic at 
Mbarara Regional Referral Hospitals in 2005.  
4. Discussion 
Damage to the nervous system, is one of the serious complications of diabetes. A person 
with diabetes may not be able to feel his or her feet properly. Normal sweat secretion and oil 
complication/co-morbidity
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production that lubricates the skin of the foot is impaired. These factors together can lead to 
abnormal pressure on the skin, bones, and joints of the foot during walking and can lead to 
breakdown of the skin of the foot. Sores may develop. Damage to blood vessels and 
impairment of the immune system from diabetes make it difficult for wounds to 
heal. Bacterial infection of the skin, connective tissues, muscles, and bones can then occur. 
These infections can develop into gangrene, because of the poor blood flow. If the infection 
spreads to the bloodstream, this process can become life-threatening.  
The relative absence of diabetes clinics in the participating hospitals at the time of this 
investigation may highlight the observed apparent absence of diabetic foot in the data 
obtained in retrospect from the hospital records of the 233 diabetic patients. We could not 
confirm zero prevalence of diabetic foot among the records of the diabetic patients reviewed 
because information obtained from the prospective survey suggests that the foot findings 
may not have been documented as part of the diagnoses (since it has never been part of the 
routine practice during ward rounds and at the Out-patient department clinics). 
Stakeholders report of patients not knowing about foot infection points to lack of diabetes 
education in the society. The non-inclusion of foot inspection in the non-diabetic clinics has 
made it difficult to determine the prevalence of diabetic foot among the diabetics in the 
studied area. In this study, we could not confirm the prevalence of diabetic foot among the 
studied population and we also have no result to compare with the reported percentage 
prevalence of diabetic foot all over Africa.  
Such reports include but not limited to: 15% by Boulton, (2000); 63.9% reported by 
Monabeka and  Nsakala-Kibangou (2001); 24% reported by Nouedoui et al., (2003); 13% 
reported by (Ndip et al., 2006, Tchakonté et al., 2005, Kengne et al., 2009); 16.7% by 
Amoussou-Guenou  et al., (2006); 53% by Ogbera et al., (2006); 13.4 by Ahmed et al., (2009); 
33% reported by Mugambi-Nturibi  et al., (2009);  
The majority of the reported complications were similar to reported diabetic foot 
complications elsewhere in Africa. Notable among the reported complications is 22.8% 
peripheral neuropathy reported in this study. This is lower than:  68% old Nigerian report 
by Akanji and Adetuyidi (1990) and slightly lower than 27.3% reported by Ndip  et al., 
(2006) in Cameroon. However, it is similar to 22.7% reported by Ahmed et al., (2009) in 
Khartoum, Sudan.     
Akanji and Adetuyidi (1990) reported a 68% prevalence of neuropathy, 54% foot ischaemia 
42% hypertension, 38% chronic osteomyelitis 35% soft tissue changes. Sixty per cent were 
anaemic at presentation. Mixed bacterial organisms were cultured in 70% of the cases and 
20% nephropathy in Nigerian diabetics with foot lesions. The initiating factors were 
observed to be predominantly trivial trauma and "spontaneous" blisters. Allied with the 
golden rules of prevention (i.e. maintenance of glycemic control to prevent peripheral 
neuropathy, regular feet inspection, making an effort not to walk barefooted or 
cut foot callosities with razors or knives at home and avoidance of delays in presenting to 
hospital at the earliest onset of a foot lesion), reductions in the occurrence of adverse events 
associated with the diabetic foot is feasible in less-developed settings. 
Other possible complications associated with diabetic foot in Africa 
There are few reports relating the level of research in Africa showing different possible 
disease complications which may be associated with diabetic foot. These reports are 
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Other possible complications associated with diabetic foot in Africa 
There are few reports relating the level of research in Africa showing different possible 
disease complications which may be associated with diabetic foot. These reports are 
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impressive but definitely not enough to represent the true picture of the situation in Africa 
largely because many African countries either do not presently have any report on diabetic 
foot or the incidence are under-reported.   
The prevalence of active foot ulceration was reported by Boulton, (2000) to vary from about 
1% in Europe and North America to more than 11% in reports from some African countries. 
Monabeka and  Nsakala-Kibangou (2001) reported 2.8%  trophic disorders and  1.2% mal 
perforant with total of 22.6% mortality rate before surgical intervention was high (22.6%). 
The complications reported by Nouedoui et al., (2003) in Yaunde, Cameroon, included: 
4.39% gangrenous lesion while 89% have various un-identified infections in young patients 
with short history of diabetes and poor education about diabetes. Bouguerra et al., 2004 
reported a high prevalence of mycotic infection among diabetic patients compared to their 
non-diabetic colleagues. Tchakonté  et al., 2005 reported  a strong correlation between an 
history of foot ulcer, a neuropathy and foot deformations and the evidence of a diabetic 
foot. Ndip  et al., (2006) reported high prevalence of diabetic foot lesions and associated 
complications. Specific observations include: 21.3% ischemia and 17.3% deformity, 12.3% 
had a previous history of foot lesions, 47% had a risky nail-trimming habit and 22% wore ill-
fitting shoes.  
According to Feleke et al., (2007), infection is the most serious complication of diabetes and 
recognized as leading cause of morbidity while cardiovascular diseases were the leading 
cause of mortality. However, Diabetic foot ulcers were the major cause of infection followed 
by tuberculosis, skin infection, subcutaneous infections, Pneumonia. S. aureus from wound 
infection and E. coli from urinary tract infection were the common pathogens. Muthuuri (2007), 
found that post-amputation mortality was 28% and the mortality was found to be associated 
with high co-morbidity, mainly due to: 100% uncontrolled diabetes mellitus, 75% Sepsis, 
42% ischaemic heart disease, 25% uncontrolled hypertension and renal insufficiency.  The 
mortality associated with diabetic foot ulcer disease may be predicted by measurable 
characteristics such as high blood sugars, raised White blood cell count, high creatinine, 
high serum lipids, abnormal ECG and abnormal arterial Doppler scans (Muthuuri, 2007). 
These parameters point to conditions that are themselves complications of diabetes mellitus 
and whose management will reduce mortality. The management of diabetic foot is 
therefore, multidisciplinary.  
Abbas et al., (2009) characterised the role of ethnicity in the occurrence of diabetic foot ulcer 
disease in persons with diabetes in Tanzania and found that: ethnic Africans were more 
likely to: present with gangrene (P < 0.01) and have intrinsic complications such as neuro-
ischaemia or macrovascular disease which delays ulcer healing while Indians were more 
likely to be obese (P < 0.001), have large vessel disease (P < 0.001) and mode of intervention 
such as sloughectomy or glycaemic control with insulin or oral agents seams to determine 
the same outcome like in African counterparts. Peripheral vascular disease and gangrene are 
playing a larger role in ulcer pathogenesis and outcomes for both ethnic groups than was 
previously thought (Abbas et al., 2009). In a study by Obalum and Okeke 2009 in Nigeria, 
61% trauma found was the most common followed by below knee amputation was done in 
51 (75.0%) of cases, stump wound infection was found in 26.5% while three (4.7%) patients 
died. Ahmed et al., 2009 could not identify the causative agents of 48.7% patients with hand 
sepsis while 42.9% prevalence was due to trauma; 36.1% cellulitis, 29.5% deep seated 
abscess, 14.3% digits amputation and 1.7% of patients were unavoidably hand-amputated.  
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Kengne  et al., 2009 in reviewing the changing pattern of diabetic foot with time found 
foot ulcer to be associated with 115% more bed use and a nonsignificantly lower risk of 
death or dropout.   
Bahebeck  et al., (2010), in an effort to identify clinical patterns and outcomes related to the 
treatment of these diabetic foot infections reported that life-threatening hand 
and foot infections in diabetic patients account for a large proportion of amputations and a 
substantial number of deaths and concluded that 7 patterns of serious limb- or life-
threatening infection were identified and, in the absence of vascular surgical intervention, 
mortality can be reduced at the expense of more amputations. The seven pattern of limb 
infections were as follows: 30.36% of the patients studied had necrotizing cellulitis, 21.43% 
had wet gangrene, 16.07% had acute extensive osteomyelitis, 8.93% had dry gangrene, 8.93% 
had gas gangrene, 7.14% had necrotizing fasciitis, and 7.14% had diffuse hand infections. 
Mani et al., 2011 reported that since some 15% of the population with diabetes 
develop foot complications, the reported observations of venous incompetence in patients 
with diabetes but not foot disease offer hope of alleviating symptoms if not preventing 
ulcers. 
Tsimerman et all 2011 found that circulating micro-particle characteristics are related to the 
specific type of vascular complications and may serve as a bio-marker for the pro- 
coagulant state and vascular pathology in patients with Type 2 Diabetes Mellitus. Shapoval 
et al., 2011 defined surgical tactics based on concrete complications of the diabetic foot 
syndrome, frames conditions for the unification and uniform registration of the form and 
severity of the disease and volume of the surgical treatment. Ragunatha et al., 2011. 
Suggested that well-controlled diabetes decreases the prevalence of diabetic mellitus specific 
cutaneous disorders associated with chronic hyperglycemia. Oguejiofor  et al., 2010. Long 
duration of diabetes mellitus and peripheral neuropathy are risk factors 
for foot complication in Nigerians with diabetes mellitus. Asumanu et al., 2010, in Ghana 
reported surgical complications which included foot infections, cellulitis, and abscesses. 
There is an adage that says “prevention is better than cure” Therefore, this discussion will 
be incomplete without noting the principles of diabetic foot care which include: daily feet 
inspection; early reporting of any foot injury among diabetic patients; checking shoes inside 
and outside for sharp bodies/areas before wearing; use of lace-up shoes with adequate 
room for the toes; keeping feet away from sources of heat; and checking bath temperature 
before stepping in (Kumar & Clark). According to the stakeholders, the use of advocacy and 
health education by health care providers in prevention and control of diabetic foot 
complications is yielding good results as it is now common to see diabetic patients talking 
about how to avoid risky behavious such as avoiding certain food as a way of prevention 
and control of diabetes.   
5. Conclusion  
Africa and South Western Uganda have contributed to the knowledge about possible foot 
complications as outlined above. Relative absence of diabetic foot in the retrospective data of 
South Western Uganda was confirmed prospectively as due to lack of specialized diabetic foot 
clinic in the studied population, absence of specialised diabetes clinics, poor education and 
various complications influenced diabetic foot in South Western Uganda region of Africa. 
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Examination of the diabetic foot and appropriate documentation of findings among the 
diagnosis should be encouraged among healthcare workers, especially clinicians. Also 
refresher courses on care of diabetics should be encouraged among all healthcare workers. 
Diabetes clinics should be included in all health centres IVs and above OR major health 
centres in African countries. Another important thing is adequate and relevant health 
education for patients with diabetes mellitus in health care institutions, the media and 
diabetes associations. These measures will help reduce the morbity and mortality associated 
with the diabetic foot among diabetic patients. 
Finally, it is recommended that further local studies should be done in order to be able to 
document the true prevalence of diabetic foot ulcers among diabetics in the community. 
These shall lead to deeper studies that will help identify the causes of those ulcers and 
determination of ways of preventing or minimizing those causes, thereby giving the 
diabetics a better overall quality of life.   
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diagnosis should be encouraged among healthcare workers, especially clinicians. Also 
refresher courses on care of diabetics should be encouraged among all healthcare workers. 
Diabetes clinics should be included in all health centres IVs and above OR major health 
centres in African countries. Another important thing is adequate and relevant health 
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diabetes associations. These measures will help reduce the morbity and mortality associated 
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Finally, it is recommended that further local studies should be done in order to be able to 
document the true prevalence of diabetic foot ulcers among diabetics in the community. 
These shall lead to deeper studies that will help identify the causes of those ulcers and 
determination of ways of preventing or minimizing those causes, thereby giving the 
diabetics a better overall quality of life.   
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India has a dubious distinction of having largest number of persons with diabetes in the 
world. Type 2  diabetes has become the most common metabolic disorder. Its prevalence is 
growing more rapidly among people in the developing world, primarily due to marked 
demographic and socioeconomic changes in these regions. India currently leads the world 
with an estimated 41 million people with diabetes; this figure is predicted to increase to 66 
million by 2025. The diabetes epidemic is more pronounced in urban areas in India, where 
prevalence rates of diabetes are roughly double than those in rural areas. Diabetic foot is one 
of the most devastating chronic complications of diabetes and is the leading cause of lower 
limb  amputation. 
Although population based data are not available, rough estimates indicate that in India 
approximately 45,000 legs are amputated every year, and the numbers are increasing each 
year. Almost 75 % of these amputations are carried out in neuropathic feet with secondary 
infection, which are potentially preventable. Certain factors like bare – foot walking, 
illiteracy, low socioeconomic status, late presentation by patients, ignorance about diabetic 
foot care among  primary care physicians and  belief in alternative systems of medicine  
contribute to this high prevalence. Lack  of trained professionals in diabetes foot care in 
India and the profession of podiatry being non – existent compound the problem further. 
The novel project “Step – by – Step Improving Diabetes Foot care in the developing world” 
was initiated in India. The goal was to train healthcare professionals in basic foot care, 
improve their educational skills, and provide them hand on experience in treatment of 
trivial   foot   lesions. The aim was to encourage them to set up minimum model diabetic 
foot clinics where they would be able to prevent trivial foot lesions becoming catastrophe. 
This carefully designed and executed project to improve diabetic foot care in the developing 
world turned out to be a major success. The strength of the Step by Step project was that it 
consisted of basic and an advanced course to be attended by the same delegates. In all, 100 
teams of doctors & nurses were selected for training in diabetes foot care. The participants 
selected were specifically from smaller cities and towns, and had no previous training in 
diabetes foot care. They were offered a 2 day Basic Course in 2004 followed by a 2 day 
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foot care among  primary care physicians and  belief in alternative systems of medicine  
contribute to this high prevalence. Lack  of trained professionals in diabetes foot care in 
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The novel project “Step – by – Step Improving Diabetes Foot care in the developing world” 
was initiated in India. The goal was to train healthcare professionals in basic foot care, 
improve their educational skills, and provide them hand on experience in treatment of 
trivial   foot   lesions. The aim was to encourage them to set up minimum model diabetic 
foot clinics where they would be able to prevent trivial foot lesions becoming catastrophe. 
This carefully designed and executed project to improve diabetic foot care in the developing 
world turned out to be a major success. The strength of the Step by Step project was that it 
consisted of basic and an advanced course to be attended by the same delegates. In all, 100 
teams of doctors & nurses were selected for training in diabetes foot care. The participants 
selected were specifically from smaller cities and towns, and had no previous training in 
diabetes foot care. They were offered a 2 day Basic Course in 2004 followed by a 2 day 
 
Global Perspective on Diabetic Foot Ulcerations 
 
16
Advanced Course in 2005. The courses were held in the 4 metros of India (New Delhi, 
Mumbai, Chennai, Kolkata), with 25 teams participating in each metro. Each team was given 
educational material, books on diabetic foot, video and CDs (patient education and 
education for healthcare professionals) and special diagnostic and therapeutic instruments 
kits. A national and international faculty of experienced educators in the field was 
responsible for teaching and chaired the practical sessions.  
2. Diabetic foot Indian scenario 
Type 2 diabetes has become the most common metabolic disorder. Its prevalence is growing 
more rapidly among people in the developing world, primarily due to marked demographic 
and socioeconomic changes in these regions. India currently leads the world with an 
estimated 41 million people with diabetes; this figure is predicted to increase to 66 million 
by 2025. The diabetes epidemic is more pronounced in urban areas in India, where 
prevalence rates of diabetes are roughly double than those in rural areas.  (Mohan et al., 
2007). 
Diabetic foot is one of the most devastating chronic complications of diabetes and is the 
leading cause of lower limb amputation. (Boulton et.al., 2005).  It is often an inching, 
painless surprise that holds in its dark portals a soon rising flood of complications. It is a 
quiet dread of disability, long stretches of hospitalization, mounting impossible expenses 
with the ever dangling end result of an amputated limb. The phantom limb plays its own 
cruel joke on the already demoralized psyche. The diabetic foot, no wonder is one of the 
most feared complications of diabetes.  
From the 41 million population of diabetic persons in India, 90% do not even see a specialist 
in their life time. Majority are treated either by primary care physicians or by practitioners of 
alternative medicine while some buy and follow treatment exclusively on the basis of 
advertisements published in lay press which assure guaranteed success in cure for diabetes. 
(Pendsey,  2010). 
As the number of diabetics worldwide increase, there will be more diabetic foot problems. 
The escalating number of foot problems is due not only to the increasing diabetic population 
but to the fact that they are now living long enough to develop foot complications. Many 
healthcare professionals involved in managing persons with diabetes show little interest in 
diabetic foot problems, furthermore the diabetic foot is frequently regarded with 
hopelessness as if progression down the road to major amputation is inevitable once 
ulceration has developed.  (Pendsey, 2010). 
Although population based data are not available, rough estimates indicate that in India 
approximately 45,000 legs are amputated every year, and the numbers are increasing each 
year. Almost 75 % of these amputations are carried out in neuropathic feet with secondary 
infection, which are potentially preventable. In India clinical profile of diabetic foot differs 
because of several factors such as practice of walking barefoot, wearing inappropriate 
footwear like Hawaiian slippers, illiteracy, low socioeconomic status, late presentation by 
patients, faith in alternative system of medicine and lack of awareness among primary care 
physicians about diabetic foot and its consequences. (Pendsey, 2010). 
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Lack of trained professionals in diabetes foot care in India and the profession of podiatry 
being non – existent compound the problem further. (Pendsey ,2007). 
In India neuropathic lesions are dominant and account for 80% of foot ulcers and the 
remaining 20% being neuroischaemic. Among the causative factors, extrinsic factors like 
injuries due to sharp objects ,inappropriate footwear and thermal injuries account for 70% of 
neuropathic foot ulcerations. Intrinsic factors which are indicators of long standing 
polyneuropathy such as foot deformities, limited joint mobility, bony prominences and 
neuroarthropathy  account for remaining30% of neuropathic foot ulcerations. 
Peripheral vascular disease (PVD) has been reported to be low among Asians (Pendsey 
1998) ranging between 3 – 6% as against 25 – 45% in Western world. (Marinelli et al.,1979; 
Migdalis et al., 1992; Walters et al., 1992). The prevalence of PVD increases with advancing 
age and is 3.2% below 50 years of age and rises to 55% in those above 80 years of age. 
Similarly it also increases with increased duration of diabetes, 15% at 10 years and 45% after 
40 years (Janka,et al., 1980). In India the number of diabetic patients above the age of 80 
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Lack of trained professionals in diabetes foot care in India and the profession of podiatry 
being non – existent compound the problem further. (Pendsey ,2007). 
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remaining 20% being neuroischaemic. Among the causative factors, extrinsic factors like 
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Severely infected foot is the hallmark of Indian diabetic foot. It is not uncommon to see a 
patient with foul smelling, oedematous and severely infected foot with moribund general 
condition. Such patients have life threatening infection and therefore invariably require 
primary limb amputation. (Pendsey 2010). 
 
(a)                                                      (b) 
Fig. 2. (a). Infected heel with necrosis of the soft tissue (b). Radiograph showing 
osteomyelitis of calcaneum, soft tissue swelling with gas shadow in the area of forefoot. 
Certain  atypical  presentations  are  seen  because  of  socio  economic and cultural factors 
prevalent in India. Patients with neuropathy and consequent loss of protective sensations, 
who sleep on the floor are invariably bitten by house rats who nibble toes creating deep foot 
ulcerations. Patients notice the ulcers on waking up to find blood stained bed linen, in the 
morning.Patients notice the ulcers on waking up to find blood stained bed linen, in the 
morning. 
 
Fig. 3. Showing ulcers on second and fifth toes due to rat bite 
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Patients with neuropathy who visit religious places (temples) during summer months when 
the day temperature ranges between 43 and 47 degrees Celsius, develop severe thermal 
injuries . They are compelled to walk barefoot as religion does not permit wearing shoes.  
Indians are known for sitting cross legged for long hours at work and during worship. 
Repeated and prolonged pressure over lateral malleolar areas lead to formation of bursae. 
Such bursae over lateral malleoli are dark and hypertrophied but are usually harmless in 
non neuropathic individuals. In diabetics with neuropathy, these bursae get ulcerated and 
often secondarily infected, creating a surgical emergency. Indian women wear metal (silver 
being commonest) toe rings in one or more toes of both feet, which is part of tradition. In 
neuropathic feet with deformities of toes, these toe rings often cause strangulation in 
presence of swelling of the feet.  In tropical climate due to excessive sweating, fungal 
infection quickly sets-in, in web spaces. In diabetics with neuropathy these macerated 
ulceration often gets secondarily infected and find their way, quickly, to deep plantar 
compartments creating a limb threatening situation. (Pendsey 2010). 
 
Fig. 4. Showing thermal injury on the plantar area of right foot. 
3. Step by step diabetic foot care project in India 
In view of the magnitude of the problem of diabetic foot, it was felt that there was an urgent 
need for training of doctors and nurses in diabetic foot care, in the Indian sub continent. 
Trivial foot lesions precede 85 % of leg amputations. Training of doctors and nurses will 
help them to take care of such trivial lesions and prevent the majority of leg amputations 
and simultaneously offer preventive foot care and advice about proper footwear.  
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The Step – by – Step project was hence conceived with a common objective of improving 
diabetes foot care in the developing world. (Bakker,et al.,2006; Pendsey, 2007a, 2010b). The 
Project Committee consisted of SharadPendsey, India (Chairman), Karel Bakker, The 
Netherlands, Althea Foster, United Kingdom, Zulfiqarali G. Abbas, Tanzania, Vijay 
Vishwanathan, India.  It had academic support from International Diabetes Federation (IDF) 
, Diabetic Foot Society of India (DFSI), Muhimbili University college of health sciences 
(MUHS) and International working group on Diabetic Foot (IWGDF) . The project received 
financial grant from World Diabetes Foundation (WDF).  
3.1 Goals 
To create more awareness of diabetic foot problems  
To provide sustainable training of health care professionals in the management of diabetic 
foot 
To facilitate the cascading of information from health care professionals who have 
undergone training to other health care professionals and thus export expertise 
To reduce the risk of lower limb complications in people with diabetes 
To empower people with diabetes to care for their feet better, detect problems earlier and 
seek timely help when problems arise. 
3.2 Methods 
Special foot care education materials, both visual and audio-visual, were designed 
specifically for people with diabetes in developing countries.Foot care education materials, 
visual and audio-visual, were also designed for healthcare professionals working with 
people with diabetes in developing countries. Kits of diagnostic instruments (10gm 
monofilament, tuning fork, etc) were distributed to participants. 
Therapeutic instruments’ kits (Bard Parker handle with surgical blades, nail clipper, nail 
files, artery and tooth forceps, scoop, probe, and scissors) were also distributed to the 
participants. 
3.3 Project at a glance  
In all, 100 teams of doctors & nurses – India (94), Bangladesh (3), Sri Lanka (2), Nepal (1) 
were selected for training in diabetes foot care. The participants selected were specifically 
from smaller cities and towns, and had no previous training in diabetes foot care. They were 
offered a 2 day Basic Course in 2004 followed by a 2 day Advanced Course in 2005. The 
courses were held in the 4 metros of India (New Delhi, Mumbai, Chennai, Kolkata), with 25 
teams participating in each metro. Each team was given educational material, books on 
diabetic foot, video and CDs (patient education and education for healthcare professionals) 
and special diagnostic and therapeutic instruments kits (Pendsey 2007).  
A national and international faculty of experienced educators in the field was responsible 
for teaching and chaired the practical sessions.  
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3.4 Basic course 
In this 2 – day practical training programme, according to a step – by – step approach, 
participants were taught to take a history, perform physical examination, screen for 
neuropathy and ischaemia, and classify and stage the foot. Having identified feet at risk, 
they  were taught to organize appropriate foot care education and take timely action in cases 
of ulceration or advanced foot problems. Referral pathways were discussed and adapted to 
local circumstances. The training sessions for the basic course were designed to be 
interactive and informal with practical workshops. The formal lecturing was kept to a 
minimum. Participants were expected to educate their patients and cascade their acquired 
knowledge and skills to colleagues in their regions in order to create a spin – off effect and 
perpetuate and sustain achievements of the project.  
To practice the techniques for debridement and cutting undermined edges of ulcers, the 
participants were provided with sweet limes as ‘guinea pigs’ to imitate diabetic feet. The 
delegates were taught some quite elaborate procedures with the help of these sweet limes – 
trimming calluses, probing ulcers and cutting out undermined edges using a forceps. 
All participants had been requested not to cut their nails for one month prior to the training, 
so that they could practice nail cutting on each other using nail clipper provided by the 
project. This particular session worked as a great icebreaker and helped develop a friendly 
and collaborative atmosphere (Bakker et al., 2006). 
Patients with diabetic foot problems were presented and the faculty discussed them and 
demonstrated the practical skills of callus removal and nail trimming. Appropriate 
educational material designed for doctors, nurses and in particular for people with diabetes 
in developing countries, was discussed. In view of the many different languages and 
dialects that exist in the Indian subcontinent and considering the levels of literacy, a special 
emphasis on easy to understand audiovisual materials and pictures were given.  
In the last session, delegates were divided up into smaller discussion groups and 
brainstormed ideas and plans for implementing the Step – by – Step Project. Then each 
group reported back to the whole group. Delegates were thus equipped to educate and 
examine patients, to record what they find and what action they take, to use the written 
material to improve their knowledge of the diabetic foot, and to gradually build their own 
diabetic foot programme. The delegates left the basic course, well equipped, to start a 
minimum model diabetic foot clinic in their respective regions. (Bakker et al., 2006;.Pendsey 
,2007)  
3.5 Advanced course 
As a prerequisite for participation in the basic course, attendees agreed to attend an 
advanced course within one year. At the advanced course, they were given a specially 
prepared patient education video and another video for training health care professionals in 
their regions, thus spreading awareness about diabetic foot disease and its prevention and 
management. 
Advanced subjects – such as the management of vascular disease, biomechanics, 
neuropathic osteoarthropathy (Charcot Foot), imaging modalities of the diabetic foot, 
indications for amputations, newer treatments and effective techniques of education – were 
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taught. An important part of the advanced course was also reporting of the achievements in 
the first year. Delegates presented their activities as posters. It was gratifying to see how the 
teams were working in their respective centers. The majority had started practicing what 
they had learnt, e.g. educational activities, screening for high risk feet, use of a stepwise 
algorithm to analyse  and investigate diabetic foot cases and management of trivial lesions 
(callus removal, nail trimming, deroofing of  bullae, etc). Most posters were very good and 
showed high levels of effort and interest amongst the participants. All teams submitted 
cases for presentation and five were selected to make oral presentation. The cases were 
discussed in detail by the faculty with active participation by the delegates. To enhance 
participation, a quiz on foot care was also arranged. Paramedics were encouraged to show 
their skills on preventive foot care. They actually worked on patients removing calluses, 
cutting difficult nails, dressing wounds etc. The participation in this activity was 
spontaneous and all paramedics participated. From the way they did the job in the presence 
of a large number of people and in front of a live camera, it was quite clear that the practical 
skills they had learned during the basic course had been effectively used and frequently 
applied. All faculty members appreciated the dexterity and confidence shown by the 
paramedics. In summary, the attending delegates were adequately trained in preventative 
diabetic foot care. The delegates scored significantly higher on a questionnaire on foot care 
knowledge at the end of each course than they had done at the beginning.  
Characteristics 1st year 2nd year Increase (%) 
Patients screened 
for high risk feet 
 
Patients who received 
foot care education 
 





for trivial foot lesions 
 























































Table 1. Showing the overview of the work by the delegates. 
3.6 Impact  
100 foot care clinics (minimum model) were started. It is anticipated that they will cascade 
information to large numbers of persons with diabetes, and also to other healthcare 
professionals, including paramedics, physicians, educators, healthcare policymakers and lay 
people. The formal training is expected to reduce the amputation rate among these patients 
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by about 50% .There will be a long-term network of all the participants to ensure percolation 
of knowledge throughout the country.  
3.7 Results 
The data was collected by a questionnaire sent to all participating delegates and results of 1st 
year after the basic course and 2nd year after the advanced course were evaluated  85 teams, 
from India, responded to the questionnaire for both years. From the overview of the work 
carried out by the delegates it was apparent that there was a significant increase in every 
activity they conducted in the second year, over the first year. In the absence of any formal 
training in diabetes foot care, about 20% of patients with trivial foot lesions would be 
expected to have lower extremity amputation.( Muller et al., 2002; Ramsey et al., 1999;).  
Thus, in the 1st year, at least 900 lower limbs and in the 2nd year 1943 limbs were salvaged. 
(Pendsey 2007). 
4. Conclusion  
This carefully designed and executed project to improve diabetic foot care in the developing 
world turned out to be a major success. The strength of the Step by Step programme is that 
the project consists of a two-year set up: a basic and an advanced course to be attended by 
the same delegates. The prerequisite to participate in the first course was to agree to follow 
the second course. The attendees were supplied with a free full set of clinic equipment. 
Combined with the education and teaching materials, and the acquired knowledge, the 
participants could immediately start to improve the local foot care management. The lively 
and interactive exchange of thoughts through the presentation of case reports by the 
delegates made them more alert to common pitfalls. The delegates realised the possibility of 
improving management by means of rather simple and affordable care, including education 
of  patients. Another strength of the project was the interaction of both doctors and nurses or 
paramedics in the teams. The faculty felt that the enthusiasm of the participants to do even 
better in the future was amazing and many showed commitment to roll out the learning to 
others in the region. The clinical profile of diabetes differs across the world on account of 
differences in social, economic and cultural factors. The burden of diabetes as well as its 
complications like the diabetic foot increasing.  Every small step taken to improve diabetic 
foot care will be a step in right direction in preventing this dreaded complication of diabetic 
foot. 
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1. Introduction  
Diabetic foot is defined as infection, ulceration and/or destruction of deep tissues associated 
with neurological abnormalities and various degrees of peripheral vascular disease in the 
lower limb of the patients with diabetes mellitus (DM) (the International Working Group on 
the Diabetic Foot, 1999). Foot disorders are among the most serious and costly complications 
of DM (Apelqvist et al., 2008). When uncontrolled, diabetic foot can result in ulcer formation 
and subsequent amputation of the lower limb. Foot ulcers occur in 12 to 25 % of DM 
patients, and precede 84 % of all nontraumatic amputations in the growing DM population 
(Brem et al., 2006). It is thus quite urgently needed to prevent diabetic ulcer formation in the 
“at risk” foot by multi-disciplinary team approach (Apelqvist et al., 2008). 
How can we identify “at risk” foot in the DM patients? According to the guidelines by the 
International Working Group of the Diabetic Foot, “at risk” foot should be identified by  
inspection and examination according to symptoms such as non-sensory or sensory 
neuropathy, foot deformities, bony prominences, signs of peripheral ischemia, previous 
ulcer or amputation (Apelqvist et al., 2008). The patients are categorized according to the 
risk classification system. Based mainly on Lavery et al. (Lavery et al., 1998), these categories 
include the following: no sensory neuropathy (category 0); sensory neuropathy (category 1); 
sensory neuropathy and signs of peripheral vascular disease (PAD) and/or foot deformities 
(category 2); and previous ulcer (category 3) (the International Working Group on the 
Diabetic Foot, 1999). Clinical effectiveness of this risk classification system was indeed 
substantiated by Peters et al. (Peters & Lavery, 2001), where ulceration occurred in 5.1, 14.3, 
18.8, and 55.8% of the patients in categories 0, 1, 2, and 3, respectively during three years of 
follow-up. More recently, the International Working Group on the Diabetic Foot revised the 
risk classification system more focusing on the associated PAD (Lavery et al., 2008). 
However, we consider that there should be some limitatons in these approaches of risk 
assessment only based on conventional clinical examination. Although the report by Peter et 
al. (Peters & Lavery, 2001) showed clinical effectiveness of these approaches, occurrence rate 
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of ulcers was unacceptably high in the higher categories. This fact may indicate necessity of 
more advanced approaches to detect the pre-ulceration status in the “at risk” foot in the 
more timely manner. 
We consider that the screening of latent inflammation should be a key strategy for the 
assessment of pre-ulceration of the at risk foot. It should be kept in mind that DM patients 
may occasionally be insensitive to inflammatory pain in minor traumas caused by ill-fitting 
shoes, walking barefoot or callus formation, because of their sensory disturbances. If the 
patients continue walking, the overlooked inflammation may result in subsequent 
ulceration (Apelqvist et al., 2000; Apelqvist et al., 2008). Temperature elevation and edema 
should be accompanied by such latent inflammation. Recent advances of non-invasive 
imaging modalities such as thermography and ultrasonography may provide us with visual 
information of tissue temperature changes and edema associated with inflammation. 
In our previous publications, we used thermography and ultrasonography for assessing 
wound status of pressure ulcers, confirming their clinical versatility for detecting 
inflammation. Delayed healing of pressure ulcers due to latent inflammation could be 
prospectively evaluated by high temperature of wound bed visualized by thermography 
(Nakagami et al., 2010). Also, the subcutaneous tissue damages such as edema or the 
discontinuous fascia could be clearly visualized by ultrasonography in the patients with 
pressure ulcers of the deep tissue injury type (Aoi et al., 2009; Nagase et al., 2007; Yabunaka 
et al., 2009).  
Based on these experiences on pressure ulcers, we have introduced use of thermography 
and ultrasonography into the management of diabetic foot. In this chapter, we first mention 
variation of thermographic finding of the diabetic foot according to our own new 
classification system (Nagase et al., 2011). Furthermore, we describe our clinical research on 
the thermographic and ultrasonographic screening for the latent inflammation in the 
diabetic foot callus (Nishide et al., 2009).  
2. Variations of thermographic morphological patterns in diabetic foot 
2.1 Thermometry of diabetic foot: An overview 
Thermometry of the diabetic foot has been established as an effective way for detecting 
inflammation and for assessing risks of ulceration (Bharara et al., 2006). Acute increase of 
the plantar temperature is regarded as a predisposing sign for pre-ulcer inflammation, 
requiring urgent intervention. For example, Armstrong et al. (Armstrong et al., 2007) and 
Lavery et al. (Lavery et al., 2004; Lavery et al., 2007) showed that foot temperature 
monitoring can reduce the ulceration rate in the “at risk” foot (category 2 or 3). In their 
randomized controlled studies, the DM patients in the intervention groups were guided to 
monitor temperatures of the several landmark points of their feet at home using a digital 
handheld thermometer. When the skin temperature was elevated compared with the 
contralateral side (>2.2°C), the patients were instructed to contact the research nurses and to 
reduce their activities until the temperatures normalized. Rates of ulceration were 
significantly reduced in the intervention groups than in the non-intervention control groups.  
It has been already known that chronic temperature elevation may be observed in the 
neuropathic diabetic feet, mainly due to increased arteriovenous (A-V) shunt flow (Brem et 
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al., 2006; Chan et al., 1991; Flynn & Tooke, 1995; Sun et al., 2005; Sun et al., 2008). Chronic 
temperature decrease implies association of PAD (Benbow et al., 1994; Brem et al., 2006).  
Unstable skin temperature due to impairment of thermoregulation is also noted in the 
neuropathic diabetic feet (Kang et al., 2003; Rutkove et al., 2005). Bharara et al. (Bharara et 
al., 2008a, b) demonstrated that foot temperature recovery after cold or warm immersion 
showed different trends between in the DM patients with and without neuropathy. 
2.2 Use of thermography for assessing diabetic foot: Unsolved problems 
Thermography is regarded as an imaging modality of thermometry. Thermography can 
estimate circulation and vascular patency by visualizing temperature distribution (Bharara 
et al., 2006; Nagase et al., 1996), and thus, it may be a potentially ideal tool for assessing 
inflammation and vascular stenosis of diabetic foot. We are using infrared (IR) 
thermography (Nagase et al., 2011; Nishide et al., 2009), which were also used in some of the 
abovementioned studies of diabetic foot thermometry (Sun et al., 2005; Sun et al., 2008; Sun 
et al., 2006) and in the more recent report evaluating healing tendency of the diabetic foot 
ulcer (Bharara et al., 2010). Liquid crystal (LC) thermography was conventionally used in 
the papers published in 1980’s and 90’s (Benbow et al., 1994; Chan et al., 1991; Stess et al., 
1986). Interestingly, LC thermography has been now reappraised by many recent 
researchers (Bharara et al., 2008a, b; Frykberg et al., 2009; Roback et al., 2009). IR 
thermography can visualize thermal patterns without direct contact to the skin or wounds. 
LC thermography requires direct contact, and thus IR thermography may be better for 
detecting temperature of the non-contact area (such as the medial arch and the dorsal part of 
the feet) or the area colonized by pathogens such as the skin with tinea pedis or the infected 
wounds (Nagase et al., 2011). On the other hand, LC thermography has advantages because 
it is inexpensive, easy to use even in home-care setting, and appropriate for assessment of 
plantar temperatures under the influence of load (Bharara et al., 2008a, b; Frykberg et al., 
2009). LC thermography costs approximately $ 1,800, whereas IR thermography costs 
approximately $ 25,000, and this fact is one of the factors at present which might prohibit 
mass production of IR thermography for patient use at home. 
In either type, we consider that thermography has an outstanding advantage compared with 
the conventional pinpoint thermometry: thermography enables visualization of 
morphological patterns of temperature. A whole image of the plantar temperature 
distribution can be obtained only by thermography. However, this advantage has not been 
fully appreciated in most of the previous studies. Temperatures of several anatomical 
landmark points or areas were measured and analyzed in such papers. For example, Sun et 
al. (Sun et al., 2005; Sun et al., 2006) indicated that the temperature of the medial plantar 
arch was the highest and that of the lesser toes was the lowest in the normal and in some of 
the DM population. We consider, however, that this type of measurement can be 
accomplished also by the conventional thermometry, as Armstrong et al. (Armstrong et al., 
2007) and Lavery et al. (Lavery et al., 2004; Lavery et al., 2007) did in the clinical settings. 
Morphological thermographic patterns of the plantar temperature were previously 
described in a very limited number of articles. Using LC thermography, Chan et al. (Chan et 
al., 1991) designated temperature distribution in normal subjects as a “symmetrical butterfly 
pattern” in which the medial arch showed the highest temperature as reported by Sun et al. 
(Sun et al., 2005; Sun et al., 2006). However, Stess et al. (Stess et al., 1986) indicated that such 
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a typical symmetrical pattern was observed in only nine out of the 16 normal subjects (56%). 
They described other atypical thermographic patterns, including those of DM patients, 
simply as “mottling and discrete areas of color variation.” Wang et al. (Wang et al., 2004) 
also mentioned possible variation of thermographic patterns in the normal subjects, by 
showing data of the only three healthy volunteers.. 
We consider that there may be three reasons why interpretation of the plantar 
thermographic patterns has been so difficult and insufficient. (1) There is an absolute lack of 
the information of thermographic patterns of the normal subjects. Any interpretation is 
impossible without a normal control as a reference. (2) It is quite reasonable to consider that 
the plantar thermographic patterns can be affected by the vascular anatomy and circulatory 
status of the foot. No previous reports mention this point. (3) There has been no 
classification system of the plantar thermographic patterns, which enables more detailed 
description of the individual variations. 
2.3 Possible patterns of plantar thermography and the vascular anatomy: A concept 
of “angiosome” 
We have concluded that the new classification system of the thermographic patterns should 
be established based on the vascular anatomy of the foot. However, the vascular anatomy of 
the foot is very complicated with considerable individual anomalies (Adachi, 1928; Attinger 
et al., 1997; Yamada et al., 1993). The lower limb is supplied by the three main arteries: the 
anterior tibial artery, the posterior tibial artery, and the peroneal artery. The dorsal foot is 
supplied by the dorsalis pedis artery, which is derived from the anterior tibial artery. The 
plantar forefoot area is supplied by the two branches of the posterior tibial artery, the 
medial and lateral plantar arteries. These two arteries are connected to each other by the 
superficial and deep plantar arches. The medial plantar artery has the superficial and deep 
branches. The dorsalis pedis artery descends near the first metatarsal bone, making 
anastomosis with the deep plantar arch. The heel is supplied by the medial and lateral 
calcaneal arteries, derived from the posterior tibial artery and the peroneal artery, 
respectively. The concomitant veins run together with the main arteries.  There are also the 
superficial subcutaneous venous networks. How and to what extent should this complex 
vascular anatomy be reflected to our novel thermographic classification?   
A key word is “angiosome.” What is angiosome? Angiosome is a concept in the field of 
plastic surgery, and is defined by Taylor and Palmer (Taylor & Palmer, 1987) as the 
“composite unit of skin and underlying deep tissue, supplied by a source artery.” This 
“unit” can be considered as a possible tissue flap which can be transplanted to other places 
of the body by maintaining the vessel circulation, for example, through the microscopic 
anastomoses of the artery and vein in case of “free” flaps (Harii et al., 1974). It is noteworthy 
that the neighboring angiosomes are linked by “choke vessels”, which act as a safety valve, 
if the main source artery is damaged (Taylor & Palmer, 1987).   
Attinger et al. (Attinger et al., 2006) proposed four angiosomes in the plantar area: the 
medial plantar artery (MPA) angiosome, the lateral plantar artery (LPA) angiosome, the 
medial calcaneal artery (MCA) angiosome and the lateral calcaneal artery (LCA) angiosome 
(Fig.1A). The dorsal foot is composed of the single dorsalis pedis artery (DPA) angiosome. 
Therefore, it is quite reasonable to consider that the abnormal “mottling” patterns in DM 
patients are possibly caused by vessel stenosis or A-V shunts, and thus may well correspond 
to the territories of the plantar angiosomes.  
 




Fig. 1. (A) Four plantar angiosomes by Attinger et al. (Attinger et al., 2006). MPA: medial 
plantar artery, LPA: lateral plantar artery, MCA: medial calcaneal artery, LCA: lateral 
calcaneal artery. (B) Conceptual classification of the thermographic patterns with 20 
different categories. Orange and blue colors indicate higher and lower temperatures, 
respectively. Reprinted from Journal of Plastic, Reconstructive & Aesthetic Surgery, Vol. 64 
No.7. Nagase, T. et al. Variations of plantar thermographic patterns in normal controls and 
non-ulcer diabetic patients: Novel classification using angiosome concept. p.860-866, 2011. 
with permission from Elsevier. 
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Fig. 1. (A) Four plantar angiosomes by Attinger et al. (Attinger et al., 2006). MPA: medial 
plantar artery, LPA: lateral plantar artery, MCA: medial calcaneal artery, LCA: lateral 
calcaneal artery. (B) Conceptual classification of the thermographic patterns with 20 
different categories. Orange and blue colors indicate higher and lower temperatures, 
respectively. Reprinted from Journal of Plastic, Reconstructive & Aesthetic Surgery, Vol. 64 
No.7. Nagase, T. et al. Variations of plantar thermographic patterns in normal controls and 
non-ulcer diabetic patients: Novel classification using angiosome concept. p.860-866, 2011. 
with permission from Elsevier. 
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2.4 Development of the novel classification system of the plantar thermographic 
patterns based on the vascular anatomy  
According to the angiosome territories, we developed a novel classification of 20 different 
categories (Nagase et al., 2011) (Fig.1B). We separated the whole plantar area into the distal 
forefoot and the heel to build up the conceptual framework of the classification of the 
thermographic patterns.  
We distinguished five different patterns in the forefoot. The normal “butterfly pattern” 
(Chan et al., 1991; Stess et al., 1986) was designated as Type I. The other four patterns were 
conceptually defined according to the possible viabilities of the MPA and LPA angiosomes. 
Type II represents the condition that both the MPA and LPA angiosomes are intact. Type III 
represents the condition when the MPA is occluded and only the LPA angiosome is intact. 
(In this type, the MPA angiosome may be nourished by “choke vessels” from the adjacent 
angiosomes, and, thus, possibly shows lower temperature.) Type IV represents the condition 
when the LPA is occluded and only the MPA angiosome is intact. Type V represents that 
both the MPA and LPA are occluded. It is noteworthy that the MPA and LPA angiosomes 
are overlapped in the hallux, and the lower temperature in the hallux may be observed only 
in type I and V. We similarly distinguished four different patterns in the heel area. Type a 
represents the condition that both the MCA and LCA angiosomes are intact. Type b 
represents that MCA is occluded. Type c represents that LCA is occluded. Type d represents 
that both the MCA and LCA are occluded. We finally crossed the five forefoot patterns and 
the four heel patterns, obtaining the conceptual classification with the 20 different categories 
from Ia to Vd (Nagase et al., 2011)(Fig. 1B). 
32 healthy volunteers (36.8 ± 11.8 years old) and 129 diabetic patients (67.2 ± 10.5 years old) 
were included in our survey as the control group and as the DM group, respectively 
(Nagase et al., 2011). The DM group participants were recruited from the patients at the 
Diabetic Foot Outpatient Clinic at the University of Tokyo Hospital between November 2008 
and October 2009. Thermographic images of the bilateral feet were taken from the all 
participants. At the time of temperature measurement by thermography, the subjects were 
guided to keep resting supine position without shoes and socks for 15 minites before 
measurement as equilibration (Nagase et al., 2011; Nishide et al., 2009). The ankle brachial 
index (ABI) and toe brachial index (TBI) were also measured in the DM group. We used an 
IR thermography Thermotracer (TH5108ME, NEC Avio Infrared Technology Co.Ltd.Tokyo, 
Japan) for temperature analysis, and Form pulse-wave velocity/ankle brachial index 
(PWV/ABI) BP-203RPEII (Omron Colin Co.Ltd., Tokyo, Japan) for measuring ABI and TBI.  
Each plantar thermographic image was allocated to the 20 different categories as described 
above. If the images did not correspond to any of the 20 categories, they were designated as 
“atypical.”Thermography of the dorsal feet and digital photographs of the skin surfaces 
were also obtained from some cases with “atypical “thermographic patterns. 
2.5 Variations of plantar thermographic patterns in the normal controls 
Of 64 feet from the 32 normal controls, 48 feet (75%) were allocated to the seven categories 
from the 20 categories (Nagase et al., 2011)(Fig.2A). Notably, the typical “butterfly pattern” 
(Id) was observed in 30 feet (46.9%). The next frequent category was IIa (13 feet, 20.3%). The 
other five categories were occupied by only one foot for each.  
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We can consider that the categories Id and IIa may be the normal thermographic patterns. 
We also consider that these data from the normal subjects should be regarded as a reference 
for evaluating thermographic patterns of DM population. As stated before, Stess et al. (Stess 
et al., 1986) described that the “butterfly patterns” was observed in about a half of the 
normal subjects in their study with the smaller sample size. We confirmed their findings in 
our larger study. In other words, the normal patterns (Id and IIa) were observed in only 
about 70% of the normal subjects in our study. This fact should be kept in mind when we 
interpret the data of plantar thermometry in the normal subjects and in the DM patients.  
  
Fig. 2. Variations of the plantar thermographic patterns in the normal control group (A) and 
in the DM group (B). Representative thermographic images are included in the chart. Note 
that Id and IIa are the two main categories in the controls. Variations are broader in the DM 
group than in the control group. Reprinted from Journal of Plastic, Reconstructive & 
Aesthetic Surgery, Vol. 64 No.7. Nagase, T. et al. Variations of plantar thermographic 
patterns in normal controls and non-ulcer diabetic patients: Novel classification using 
angiosome concept. p.860-866, 2011. with permission from Elsevier. 
There were 16 “atypical” feet (15.0%) which could not be allocated to any of the 20 
categories (data not shown). We consider that 8 feet out of these cases are due to the 
anatomical variation of the arteries. Four feet from the two participants were characterized 
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by high temperature in the hallux only. We consider that, from their IR themographic data 
of the dorsal feet, the hallux is directly supplied by the DPA in these cases, as described by 
Attinger et al. (Attinger et al., 2006). High temperature was observed in the most toes in the 
other four feet. We interpreted these cases as follows: As stated above, the vertical 
descending branch of the DPA reaches the plantar arterial arch and the LPA (Attinger et al., 
2006), as the most important “choke vessel.” Adachi (Adachi, 1928) indicated that there is a 
“watershed” which divides the plantar arterial arch into the DPA dominant territory and 
the LPA dominant territory. The location of the “watershed” varies among individual, 
determining to what extent the lesser toes are mainly supplied by the DPA. The cases with 
high temperature in the most toes can be interpreted as an extreme example where the 
“watershed” is located at the point more lateral to the fifth toe. 
2.6 Variations of plantar thermographic patterns in the DM patients 
We revealed that thermographic patterns in the DM groups had a remarkable difference 
from those in the normal controls: The DM thermographic patterns had a wider variations, 
being allocated to the 18 out of the 20 categories (Nagase et al., 2011)(Fig.2B). These data can 
be interpreted as individual irregularity of blood circulation at the level of angiosomes, that 
is, stenosis of source arteries or A-V shunt between angiosomes. 
 
Fig. 3. (A) Comparison of the ratio of Id and IIa feet between the control and the DM groups. 
By chi-square test. (B) Comparison of ABI and TBI values between the type I + V subgroup 
and the type II + III + IV subgroups within the DM group. N.S.: not significant. By Student’s 
t test. Reprinted from Journal of Plastic, Reconstructive & Aesthetic Surgery, Vol. 64 No.7. 
Nagase, T. et al. Variations of plantar thermographic patterns in normal controls and non-
ulcer diabetic patients: Novel classification using angiosome concept. p.860-866, 2011. with 
permission from Elsevier. 
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Although the two most frequent categories were the same, Id and IIa, the frequency was 
reversed: Statistical analyses confirmed that feet ratio in the Id category was significantly 
lower and that in the IIa category was significantly higher in the DM group than in the 
control group (Nagase et al., 2011)(Fig.3A). We consider that the reversal may reflect chronic 
temperature elevation in the diabetic neuropathic feet (Brem et al., 2006; Chan et al., 1991; 
Flynn & Tooke, 1995; Sun et al., 2005; Sun et al., 2008). It is also noteworthy that a 
considerable percentage of the DM feet belonged to type IV (27 feet, 10.5%) and type V (14 
feet, 5.4%) (Nagase et al., 2011). These two types suggest stenosis of the LPA or the more 
proximal artery (such as the posterior tibial artery). We consider that intensive foot care for 
prevention of ulceration associated with PAD should be required for these two types. 
There were 33 “atypical “feet (12.8%) in the DM group (data not shown). An impressive 
pattern with high temperature only in the hallux and the fifth toe was observed in 5 feet in 4 
cases. We consider that this phenomenon may be due to lateral compression by the ill-fitting 
shoes. Impaired thermoregulation by neuropathy may cause this pattern even after 15 
minutes of equilibration. 
ABI and TBI are clinical gold standards for estimating blood flow of the lower leg and the 
toe, respectively. To validate that thermographic patterns really reflect circulatory status, we 
further compared values of ABI and TBI between the subgroups of the DM group: the type I 
+ V subgroup (in which the hallux temperature should be relatively low) and the type II + 
III + IV subgroup (in which the hallux temperature should be relatively high). ABI did not 
show statistically significant difference between these subgroups. However, TBI was 
significantly lower in the type I + V subgroup than in the type II + III + IV subgroup 
(Nagase et al., 2011)(Fig.3B). These findings may support our idea that the thermograpohic 
pattern with lower temperature in the toes reflects decreased blood supply in that region. 
2.7 Discussion and future perspectives: Significance of “atypical” patterns 
We newly established the novel classification system of the planter thermographic patterns, 
by which the morphological evaluation of the whole images is possible. Our paper was a 
first study clearly demonstrating the more remarkable variation of the plantar 
thermographic patterns in the DM patients compared with those in the normal controls 
(Nagase et al., 2011). 
Our findings described above can be summarized as follows. (1) Id and IIa categories can be 
regarded as normal patterns, which can be observed in about 70% of the normal subjects. (2) 
DM patients showed a remarkably wider variation compared with the normal controls, 
possibly reflecting stenosis of source arteries or A-V shunts. (3) Ratio of Id was lower and 
that of IIa was higher in the DM group than in the control group, possibly suggesting 
neuropathic temperature elevation. (4) Type IV and V seen in the DM group may reflect 
compromised circulation of the LPA, requiring interventions. 
There were several limitations in our study which should be reexamined in future. There 
was a bias between the control group and the DM group, especially in age and sex. Precise 
evaluation of the circulatory status by angiography or meticulous examination using a 
Doppler probe (Attinger et al., 2006) should be needed to substantiate relationship between 
thermographic patterns and circulation more thoroughly. Relationship between neuropathy 
and thermographic patterns should also be investigated in future. Our classification with the 
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20 different categories might be too complicated in clinical use. We consider that the 
distinction of only type I – V may be reasonable in the usual diabetic foot care. 
Here, we come to the point where the story should be returned to the Introduction. How can 
we detect latent inflammation in the at risk diabetic foot by thermography? We only briefly 
mentioned cases with “atypical” thermographic patterns. However, such atypical findings 
should be of particular clinical importance for detecting inflammation. The irregular focal 
elevation of the temperature should be a sign of latent inflammation. In our study, four feet 
from the four cases among the 16 “atypical” feet in the normal control group exhibited such 
hot spots of the temperature, which were associated with the ingrown toenails or the callus 
formation. Also, 19 feet from the 15 cases among the 33 atypical feet in the DM group 
exhibited similar hot spots associated with the callus, the ingrown nails or tinea pedis, all of 
which might be potential causal factors of ulceration.  
In the next chapter, we further describe our other study of screening for latent inflammation 
in the diabetic foot by thermography and ultrasonography, focusing on the callus (Nishide 
et al., 2009). However, it is very reasonable to consider that, in any fields of medicine, the 
abnormalities cannot be sufficiently evaluated unless the normal findings are well 
described. In conclusion, we again emphasize that the information described in this chapter 
should be a basic reference for analyzing the foot thermographic patterns. 
3. Thermographic and ultrasonographic screening for latent inflammation in 
diabetic foot callus 
3.1 Callus formation in diabetic foot 
Callus is defined a “localized hyperplasia of the horny layer of the epidermis due to 
pressure or friction” (Dorland’s medical dictionary). Callus is a quite common phenomenon 
frequently seen in the healthy people. However, callus formation is of particular clinical 
importance in the DM patients by the following reasons. 
First, callus is one of the most frequent among changes in foot structures in the diabetic foot. 
Foot structure abnormalities which are common in, or specific for, the diabetic population 
include excessive callus formation, limited joint mobility, foot deformity, and soft-tissue 
modifications not showing as bony deformity. Bus (Bus, 2008) indicated that callus 
formation (prevalence 51-59%) and prominent metatarsal heads (65%) are the most 
common, followed by claw/hammer toe deformity (32-49%), hallux valgus (33%) and 
limited joint mobility (23-35%).  
Second, pathophysiology of callus formation is very complicated and clinically relevant in 
DM patients. Peripheral neuropathy is associated with atrophy of the intrinsic foot muscles, 
hyperextension of the metatarsophalangeal joints, clawing of the toes, and distal 
displacement of the protective sub-metatarsal head fat pads, contributing to an increase in 
plantar pressures (Abouaesha et al., 2001; Bus, 2008; Pavicic & Korting, 2006). Autonomic 
neuropathy causes dry skin with fissures and tears more susceptible to pressure, and  motor 
neuropathy also contributes to gait changes further resulting in pressure increase (Pavicic & 
Korting, 2006). Once callus is formed, abnormal loading is further increased forming vicious 
cycle (Apelqvist et al., 2008). Pataky et al. (Pataky et al., 2002) indicated that peak plantar 
pressure and duration of pressure was significantly larger in the DM patients with callus 
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than in those without callus. Assuming that an average person takes about 10,000 steps a 
day, they discussed that the callus skin is exposed to the excessive pressure of 18.600 kg per 
day!  
Third, callus is one of the most important predisposing factors of ulcer formation in DM 
patients (Edmonds & Foster, 2006). As stated in the Introduction, diabetic patients with 
sensory neuropathy often overlooked their callus because of absence of the pain. They 
continue walking on the insensitive feet, and subcutaneous hemorrhage, autolytic seroma 
and subsequent skin breakdown are easily developed at the callus in DM patients 
(Apelqvist et al., 2000; Apelqvist et al., 2008; Edmonds & Foster, 2006). Indeed, it was 
reported that callus formation preceded ulceration in 82.4 % of diabetic foot ulcer patients 
(Sage et al., 2001). Murray et al. (Murray et al., 1996) also reported a relative risk of 11.0 for 
an ulcer developing under an area of callus in DM patients with neuropathy.  
 
Fig. 4. Callus removal by sharp debridement. Whitish, macerated, moist tissue is found 
under surface of callus, indicating imminent ulceration. Reproduced from British Medical 
Journal, Diabetic foot ulcers, Edmonds, M. E. & Foster, A. V. Vol. 332, p.407-410, 2006. with 
permission from BMJ Publishing Group Ltd. 
It is noteworthy that foot ulceration derived from the callus may be quite rare in healthy 
population, although callus is commonly seen in non-diabetic subjects. This may be due to 
insensitivity to inflammatory pain in the neuropathic patients, and also due to difficulty of 
noticing inflammatory edema and erythema associated with ulcer progression, because the 
plantar skin has thicker layer of the stratum corneum. Even if the surface of the callus is 
seemingly dry in DM patients, macerated, moist tissue can occasionally be found 
underneath the callus when the surface is debrided, indicating that the foot is close to 
ulceration (Fig.4)(Edmonds & Foster, 2006). Then, how can we detect such latent 
inflammation in the callus before ulcer formation is completed? Is the latent inflammation in 
the callus absent in healthy population? 
3.2 Our strategy of screening for latent inflammation in the callus: Thermography and 
ultrasonography 
In order to solve these problems, we decided to use thermography and ultrasonography in 
the next study (Nishide et al., 2009). Because the DM patients have a difficulty in noticing 
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include excessive callus formation, limited joint mobility, foot deformity, and soft-tissue 
modifications not showing as bony deformity. Bus (Bus, 2008) indicated that callus 
formation (prevalence 51-59%) and prominent metatarsal heads (65%) are the most 
common, followed by claw/hammer toe deformity (32-49%), hallux valgus (33%) and 
limited joint mobility (23-35%).  
Second, pathophysiology of callus formation is very complicated and clinically relevant in 
DM patients. Peripheral neuropathy is associated with atrophy of the intrinsic foot muscles, 
hyperextension of the metatarsophalangeal joints, clawing of the toes, and distal 
displacement of the protective sub-metatarsal head fat pads, contributing to an increase in 
plantar pressures (Abouaesha et al., 2001; Bus, 2008; Pavicic & Korting, 2006). Autonomic 
neuropathy causes dry skin with fissures and tears more susceptible to pressure, and  motor 
neuropathy also contributes to gait changes further resulting in pressure increase (Pavicic & 
Korting, 2006). Once callus is formed, abnormal loading is further increased forming vicious 
cycle (Apelqvist et al., 2008). Pataky et al. (Pataky et al., 2002) indicated that peak plantar 
pressure and duration of pressure was significantly larger in the DM patients with callus 
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than in those without callus. Assuming that an average person takes about 10,000 steps a 
day, they discussed that the callus skin is exposed to the excessive pressure of 18.600 kg per 
day!  
Third, callus is one of the most important predisposing factors of ulcer formation in DM 
patients (Edmonds & Foster, 2006). As stated in the Introduction, diabetic patients with 
sensory neuropathy often overlooked their callus because of absence of the pain. They 
continue walking on the insensitive feet, and subcutaneous hemorrhage, autolytic seroma 
and subsequent skin breakdown are easily developed at the callus in DM patients 
(Apelqvist et al., 2000; Apelqvist et al., 2008; Edmonds & Foster, 2006). Indeed, it was 
reported that callus formation preceded ulceration in 82.4 % of diabetic foot ulcer patients 
(Sage et al., 2001). Murray et al. (Murray et al., 1996) also reported a relative risk of 11.0 for 
an ulcer developing under an area of callus in DM patients with neuropathy.  
 
Fig. 4. Callus removal by sharp debridement. Whitish, macerated, moist tissue is found 
under surface of callus, indicating imminent ulceration. Reproduced from British Medical 
Journal, Diabetic foot ulcers, Edmonds, M. E. & Foster, A. V. Vol. 332, p.407-410, 2006. with 
permission from BMJ Publishing Group Ltd. 
It is noteworthy that foot ulceration derived from the callus may be quite rare in healthy 
population, although callus is commonly seen in non-diabetic subjects. This may be due to 
insensitivity to inflammatory pain in the neuropathic patients, and also due to difficulty of 
noticing inflammatory edema and erythema associated with ulcer progression, because the 
plantar skin has thicker layer of the stratum corneum. Even if the surface of the callus is 
seemingly dry in DM patients, macerated, moist tissue can occasionally be found 
underneath the callus when the surface is debrided, indicating that the foot is close to 
ulceration (Fig.4)(Edmonds & Foster, 2006). Then, how can we detect such latent 
inflammation in the callus before ulcer formation is completed? Is the latent inflammation in 
the callus absent in healthy population? 
3.2 Our strategy of screening for latent inflammation in the callus: Thermography and 
ultrasonography 
In order to solve these problems, we decided to use thermography and ultrasonography in 
the next study (Nishide et al., 2009). Because the DM patients have a difficulty in noticing 
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inflammation in their calluses by themselves, and because inflammatory calluses may be 
difficult to detect by the physical inspection and examination, “latent inflammation” was 
operationally defined in this study when both of the two following findings were observed 
in order to reduce the possibility of the false positive case: skin temperature elevation by 
thermography, and identification of low echoic lesion by ultrasonography (Nishide et al., 
2009). 
In this study, we compared 30 DM neuropathy patients having plantar calluses (the DM 
group) with 30 non-diabetic callus patients of matched age and sex (the non-DM group) 
(Nishide et al., 2009). The DM group was recruited from the patients at the Diabetic Foot 
Outpatient Clinic at the University of Tokyo Hospital between November 2006 and October 
2007. The non-DM group was the volunteers selected by the snowball sample method. 
Diagnosis of associated neuropathy was required as an inclusion criterion for the DM group. 
It was defined by the criteria by Japanese Diabetic Neuropathy Association, or by detection 
of sensory loss using 5.07 (10g) monofilament touch test in at least one of the three plantar 
regions (Pham et al., 2000). All the patients and volunteers were inspected and examined by 
a dermatologist and two experienced and certified Wound, Ostomy and Continence Nurses 
(WOCNs.) The subjects with visible inflammation, pain around the calluses, preformed foot 
ulcers, autoimmune diseases or other acute inflammatory diseases were exluded from the 
study.  
IR thermographic measurement of the skin temperature was performed as described in the 
previous chapter, with 15 minutes equilibration (Nagase et al., 2011; Nishide et al., 2009). In 
this study, we focused on temperature of the callus and the surrounding skin. The callus 
temperature was defined as an average temperature value of the 4 mm x 4 mm square, the 
center of which was on the highest temperature point. The temperature of the surrounding 
skin was defined as an average of the 4 mm x 4 mm square in an adjacent area unaffected by 
the temperature change of the callus. Previous studies suggested different criteria of 
temperature elevation in inflammatory skin: 2.2°C for prevention of diabetic foot disorder 
(Armstrong et al., 2007; Lavery et al., 2007), and 1.2°C for inflammatory leg ulcers (Sayre et 
al., 2007). We selected 1.2°C as a criterion of temperature elevation since our focus of this 
study was early screening and prevention. 
We also used ultrasonography (LOGIQ Book XP, GE Medical Systems, UK. 10 MHz, B-
mode) for detecting edematous and fluid-filled changes of the latent inflammatory callus 
(Nishide et al., 2009). Identification of low echoic lesion was defined in this study when 
lowered ultrasonographic signal was clearly observed in either the dermal, subdermal or 
muscle layers. Ultrasonography has been increasingly used as a diagnostic and assessment 
tool in the field of skin care. 20 MHz ultrasonography is more popular among dermatologic 
specialists because of higher image resolution of the more superficial skin layer such as the 
epidermis and the dermis (Schmid-Wendtner & Burgdorf, 2005). However, 20 MHz 
ultrasonography can only produce images 20 mm below the skin surface (Yabunaka et al., 
2009). We selected 10MHz ultrasonography in this study for focusing on the subcutaneous 
or muscle layers which may be more prone to be damaged by external forces (Nishide et al., 
2009). Our group routinely uses 10 MHz ultrasonography for obtaining sufficient 
visualization of the pressure-related deep tissue injury (Aoi et al., 2009; Nagase et al., 2007; 
Yabunaka et al., 2009), providing considerable justification for our choice in this study. 
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3.3 Inflammation was detected in 10% of the diabetic foot callus 
In this study, 63 and 94 calluses were observed in the 30 DM group participants and in the 
30 non-DM group participants, respectively (Nishide et al., 2009). 40 (63.5%) and 23 (36.5%) 
calluses were located in the toes and metatarsal areas in the DM group, respectively. 50 
(53.2%) and 44 (46.8%) calluses were located in the toes and metatarsal areas in the non-DM 
group, respectively. There were no significant differences in the number per person, location 
and size of the calluses between the two groups. 
 
Fig. 5. An example of latent inflammation identified by thermography and ultrasonography. 
(A) Photograph. An arrow indicates the callus. (B) Thermography. An arrow indicates 
elevated temperature. (C) Ultrasonography. An arrow indicates low echoic lesion in the 
subcutaneous layer. Reprinted from Diabetes Research and Clinical Practice, Vol. 85 No.3. 
Nishide, K. et al. Ultrasonographic and thermographic screening for latent inflammation in 
diabetic foot callus. p.304-309, 2009. with permission from Elsevier. 
Both thermographic and ultrasonographic data were available in 50 calluses in the DM 
group and 65 calluses in the non-DM group. These calluses were assessed for latent 
inflammation. Notably, no inflammatory findings were observed by thermography and 
ultrasonography in the non-DM group. Whereas, five (10%) calluses in the DM group were 
regarded as positive inflammation. Skin temperature increase could be clearly detected by 
thermography (Nishide et al., 2009) (Figs. 5A, B). Low echoic lesion was also sufficiently 
identified using ultrasonography (Fig. 5C). 
More detailed explanations of the five inflammatory calluses are given below. 
Case 1: The callus was located at the base of the first metatarsus. Temperature elevation was 
2.3 °C. Low echoic lesion was noted in the muscle layer. 
Case 2 (Fig.5): The callus was located at the base of the fifth metatarsus. Temperature 
elevation was 1.6 °C. Low echoic lesion was noted in the subcutaneous fatty layer. 
Case 3: The callus was located at the lateral side of the great toe. Temperature elevation was 
2.8 °C. Low echoic lesions were noted in the epidermis, dermis and muscle layers. 
Case 4: The callus was located at the tip of the fourth toe. Temperature elevation was 1.6 °C. 
Low echoic lesion was noted in the muscle layer. 
Case 5: The callus was located at the lateral side of the fifth toe. Temperature elevation was 
1.9 °C. Low echoic lesion was noted in the subcutaneous fatty layer. 
 
Global Perspective on Diabetic Foot Ulcerations 
 
38
inflammation in their calluses by themselves, and because inflammatory calluses may be 
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3.4 Discussion and future perspectives  
This study was the first paper demonstrating significant versatility of thermography and 
ultrasonography as screening tools for latent asymptomatic inflammation underneath the 
foot callus in DM patients. As stated above, inflammatory change in the callus has been 
considered as a high risk factor for later ulcer development. In this study, 10% of the calluses 
in the DM group had the inflammatory findings, whereas none in the non-DM group. 
In this study, it is noteworthy that thermography and ultrasonography were able to detect 
latent inflammatory changes in the callus, which could not be identified even by physical 
examination by the wound care specialists including a dermatologist and two certified 
WOCNs. This fact indicates that the inflammation underneath the seemingly dry callus can 
be easily overlooked by physicians and medical staffs not specialized in wound and foot 
care and by patients themselves. We consider that 10% of inflammatory rate in our DM 
group is awfully high. Although callus is a very common phenomenon often seen in healthy 
people, we should not underestimate clinical relevance of callus as a predisposing status of 
ulcer formation in DM population. 
As stated earlier, thermometry has been proposed as a promising way of identifying “at 
risk” foot, as shown in the randomized controlled trials by Armstrong et al. (Armstrong et 
al., 2007) and Lavery et al. (Lavery et al., 2004; Lavery et al., 2007). We again consider that 
thermography has several great advantages for identifying latent inflammation in the foot 
callus, compared with their pinpoint thermometric measurements in the bilateral plantar 
landmark points. First, their methods may overlook the inflammatory site not located in the 
anatomical landmark points. Second, temperature differences of bilateral landmark points 
are estimated in their methods. However, calluses are often developed in the same location 
of both feet, which makes the bilateral comparison difficult. Third, thermography enables 
clear visualization of morphological temperature distribution as stated in the previous 
chapter, and this advantage may also be of importance for finding the inflammation of the 
callus “at a glance.” 
We could identify subcutaneous inflammatory changes underneath the calluses by 10 MHz 
ultrasonography. Ultrasonography is a non-invasive, inexpensive and portable technique, 
and thus it has been gradually used in the broad area of medicine. For the assessment of the 
skin, a 20 MHz probe is more widely used for the search and imaging of lymph nodes, 
chronic ulcers and subcutaneous tumors in a variety of clinical settings (Schmid-Wendtner 
& Burgdorf, 2005; Yabunaka et al., 2009). However, we focused on the subcutaneous tissue 
damage using a 10 MHz probe in this study, because it is known that the deep tissue 
damages precede skin breakdown when the callus is developed into the full thickness skin 
ulcer (Apelqvist et al., 2000; Apelqvist et al., 2008; Edmonds & Foster, 2006). Indeed, our 
current study using ultrasonography revealed that three of the five inflammatory calluses 
had tissue damage downward to the muscle layer. This fact clearly indicates that the 
calluses in the diabetic foot may not be just a thickening of the horny layer. We also consider 
that the thermography should be used for the initial screening of inflammation, and that 
ultrasonography may be useful for determining severity of tissue damage after 
thermographic assessment. It is also of note that latent inflammatory findings by 
combination of thermography and ultrasonography were detected only in the DM group, 
without any observational symptoms and pains. Our data strongly suggests that 
“asymptomatic inflammation” in the callus may be a specific feature in the DM population.  
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There were several limitations in this study. Because this study was cross-sectional, we could 
not follow up patients with latent inflammation until subsequent ulceration develop. Our 
study provides no evidence to suggest that the calluses with latent inflammation eventually 
ulcerated. Future prospective observation is needed to confirm whether our findings of “latent 
inflammation” really result in diabetic foot ulcers. It should also be kept in mind that we used 
the strict criteria of latent inflammation by two methods, that is, both elevated temperature 
and low echoic lesion. Although this method can reduce the probability of the false positive, 
which ensures the patients with latent inflammatory callus were truly at risk, there would be 
more than 10 % of the cases if we used more sensitive method. (Please remember that there 
were four feet with hot spots identified by only thermography in the normal controls, and that 
some of them were associated with the callus in the previous chapter.) It will be necessary in 
future to determine the most suitable cut-off point.  
In summary, although there were such limitations in this study, we believe that 
thermographic and ultrasonographic screening for latent inflammation will effectively 
prevent callus-derived foot ulceration in DM patients in future. 
4. Concluding remarks 
Through the two abovementioned studies, we successfully showed that the non-invasive 
imaging modalities such as thermography and ultrasonography are very promising tools for 
evaluating blood circulation and inflammatory status and for preventing ulcer formation in 
the diabetic foot. The latter study (Nishide et al., 2009) was completed and published before 
the thermographic classification in the former study (Nagase et al., 2011) was established. 
One of the reasons why the work by Nishide et al. (Nishide et al., 2009) was successful 
without the classification was, probably, that we focused on the thermographic findings of 
the callus, a clinically visible skin disorder. For the broader application of thermography to a 
variety of clinical spectrum of diabetic foot in future, the knowledge about the normal 
thermographic findings should be essential as a reference. In this sense, we believe that 
future clinical importance of thermographic and ultrasonographic evaluation of the diabetic 
foot will be based on our classification described above. 
We consider that there may be some difficulties in interpreting atypical temperature 
increase in thermography. Temperature increase can be caused by not only latent 
inflammation, but also A-V shunting and increased plantar pressure as seen in the atypical 
diabetic foot with increased loading of the hallux and fifth toe described in section 2.6. For 
discriminating these causes, we consider that careful inspection of the foot and parallel use 
of ultrasonography will be helpful. Further research will provide us with a key to solve this 
problem. 
Management of diabetic foot requires intimate contact between medical staffs and patients. 
Behavioral factors, such as patients’ poor compliance with self foot care, also contribute to 
the deterioration of diabetic foot. We previously reported that prevalence of onycomychosis, 
another important predisposing factor of diabetic foot ulcers, was significantly associated 
with not washing of feet every day (Takehara et al., 2011). Temperature measurement by 
patients themselves at home will also become an important part of self care in future. The 
preventive strategies of self monitoring of the foot temperature using a handheld IR 
thermometer or recent LC thermography have a reasonable advantage in this regard 
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(Armstrong et al., 2007; Frykberg et al., 2009; Lavery et al., 2004; Lavery et al., 2007). On the 
contrary, IR thermography and ultrasonography have been previously performed mainly by 
medical doctors, radiologists and related technologists, because they require considerable 
expertise in their handling and data analyses. In order to popularize our strategy described 
above using IR thermography and ultrasonography in a community based manner, specific 
education of handling these modalities should be needed for staffs engaged in community 
health (such as nurse practitioners in United States). How is it possible? 
Our research group is composed of multidisciplinary scientists. The first author of this 
chapter (Nagase) is a plastic surgeon. Our laboratory also includes research nurses 
(including WOCNs), molecular biologists and engineering specialists. As our research 
described above has been progressed, the nursing staffs in our group have increasingly 
showed a great improvement in their technique of using thermography and 
ultrasonography. Now we routinely use these modalities without any difficulties. Our 
experience may support the idea that these modalities will be well handled by community 
based medical staffs in future under the appropriate educational system. As these 
technologies are non-invasive and “patient-friendly” without any pain and discomfort, they 
are really promising as future nursing tools. In this regard, our researches described above 
can be regarded as a pioneering attempt integrating medical technologies and nursing care, 
based on the intimate discussion and collaboration among our multidisciplinary research 
members. 
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(Armstrong et al., 2007; Frykberg et al., 2009; Lavery et al., 2004; Lavery et al., 2007). On the 
contrary, IR thermography and ultrasonography have been previously performed mainly by 
medical doctors, radiologists and related technologists, because they require considerable 
expertise in their handling and data analyses. In order to popularize our strategy described 
above using IR thermography and ultrasonography in a community based manner, specific 
education of handling these modalities should be needed for staffs engaged in community 
health (such as nurse practitioners in United States). How is it possible? 
Our research group is composed of multidisciplinary scientists. The first author of this 
chapter (Nagase) is a plastic surgeon. Our laboratory also includes research nurses 
(including WOCNs), molecular biologists and engineering specialists. As our research 
described above has been progressed, the nursing staffs in our group have increasingly 
showed a great improvement in their technique of using thermography and 
ultrasonography. Now we routinely use these modalities without any difficulties. Our 
experience may support the idea that these modalities will be well handled by community 
based medical staffs in future under the appropriate educational system. As these 
technologies are non-invasive and “patient-friendly” without any pain and discomfort, they 
are really promising as future nursing tools. In this regard, our researches described above 
can be regarded as a pioneering attempt integrating medical technologies and nursing care, 
based on the intimate discussion and collaboration among our multidisciplinary research 
members. 
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Wound fluid seems -at least theoretically- easily accessible and might open a new window 
to the local wound microenvironment that cannot be evaluated by the analysis of serum or 
plasma markers. Recently, this strategy has been supported by a first time wound fluid 
proteome analysis comparing acute and chronic wounds (Eming et al. 2010). Interestingly, 
there seem to be essential differences with respect to wound fluid protein composition when 
comparing acute and chronic wounds. The wound fluid proteome of healing tissue is 
characterised by proteins involved in tissue growth and protection from inflammatory 
activity, whereas non-healing wounds are characterised by a chronic inflammatory 
environment primarily consisting of leukocyte proteases and inflammatory mediators 
(Eming et al. 2010). This is particularly striking since the non-healing state in diabetic foot 
ulcers has previously been linked to persistent inflammatory activity (Acosta et al. 2008). 
Thus, the wound fluid of chronic wounds seems to be characterised by an altered wound 
micro-milieu and may, therefore, provide deeper insights into the causes of delayed wound 
healing. 
Tissue repair can be clearly characterised as an ubiquitous process and a wound is more 
precisely described as a transitional tissue rather than a static tissue. Physiological wound 
healing can be recognised as continuous change, which might be seen as a dynamic and 
interactive process resulting in remodelling and tissue restitution. This nature of transitional 
tissues comes down to the difficulty of obtaining appropriate sample materials. 
Nevertheless, the classical phases of healing are useful as a broad roadmap of the course of 
healing, since more precise models and clear landmarks are not available. The historical 
view on wound healing categorises the healing process in separate phases: starting with 
acute injury > I. coagulation > II. an early inflammatory phase > III. a late inflammatory 
phase > IV. a proliferative phase, and > V. remodelling, which ends with tissue restitution 
(Velnar, Bailey, and Smrkolj 2009). 
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Changes in wound fluid markers, cytokines or cell populations are more suitable for 
describing the local wound microenvironment than are alterations of systemic markers. The 
nature of systemic serum-based markers is likely the sum of different effects all over the 
body. Of course distinct and rather exceptional markers obtained from blood -such as PSA 
(prostate specific antigen) (Balk, Ko, and Bubley 2003) or troponin- have been proven to be 
tissue specific (Apple 1999) and can therefore reveal insights into local processes. However, 
most of the markers found in the bloodstream instead result from systemic alterations rather 
than from local changes. Wound healing takes place simultaneously at a variety of locations 
in the body. Therefore, the impact of serum markers on the assessment of the wound 
microenvironment is questionable so long as there is no systemic affection by septicaemia. 
In addition, many systemic inflammatory markers are altered in response to a variety of 
immune mediators which in turn are triggered by inflammatory events somewhere in the 
body. In this context, the secretion of CRP by the liver upon stimulation by circulatory 
cytokines such as IL-6 (Pepys and Hirschfield 2003) can be exemplified. In line with this 
concept, several studies evaluating CRP as a valuable marker of infection in diabetic foot 
ulcers were judged to be unable to underline its sole effectiveness (Dinh, Snyder, and Veves 
2010). 
Since most systemic markers do not exhibit clear tissue specificity, it might be of special 
interest to gain insights into the local wound microenvironment by assessing biochemical 
markers in wound fluid, which in turn might give us a clue about the local processes 
reflecting the current status of wound healing.  
In the diabetic foot in particular -which is characterised by delayed healing- local 
biomarkers facilitating the evaluation of the wound may be of great clinical value. Being 
able to determine the probability of healing and the risk of infection by assessing markers in 
wound fluid might have a great impact on clinical practice. 
2. Wound fluid 
Wound fluid is an interesting object of investigation because its composition is influenced 
by the state of the wound and the phase of healing (Mani 1999; Trengove, Langton, and 
Stacey 1996). Wound fluid generally consists of an inhomogeneous mixture of different 
endogenous and exogenous sources. It is constituted by a provisional matrix of exudates or 
transudates that originate from the blood, which in turn has already been altered by 
multiple independent pathologic and physiological factors (such as cardiac failure or 
hydration status as well as vasoconstriction or diabetes). In addition, wound fluid 
composition is further modified by factors which are secreted by local cells in the wound or 
by cells that migrate into the wound, as well as by supplementary factors derived from 
microbial contamination. Since the wound cellular population is constantly changing during 
the physiological course of healing, wound fluid should exhibit altered characteristics over 
time (especially regarding its proteome). 
Ideally, wound fluid should be collected non-invasively and with little effort, resulting in a 
better patient as well as greater physician acceptance. This is in contrast to tissue biopsies or 
techniques -which are defined as the gold standard in animal models- such as 
subcutaneously implanted wire mesh cylinders (Hunt Schilling Cylinders), which are 
inadequate for monitoring wound healing in humans (Hunt et al. 1967; Schilling, Joel, and 
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Shurley 1959). Thus, non-invasive techniques hold a relevant advantage for the future, 
allowing the assessment of longitudinal profiles and changes in wound fluid composition. 
2.1 Sampling techniques 
2.1.1 Sampling of chronic wound fluids 
Covering wounds with occlusive dressings and harvesting the accumulated exudate 
underneath is probably the most common technique for obtaining wound fluid in chronic 
wounds. Various modifications of this technique have been described with respect to used 
materials, patient preparation and time scales, as well as with respect to wound bed 
preparation (Trengove et al. 1999; Trengove, Bielefeldt-Ohmann, and Stacey 2000; Yager et 
al. 1996; Wysocki and Grinnell 1990; James et al. 2000; Wallace and Stacey 1998; Chen et al. 
1997; Wysocki et al. 1999; Gohel et al. 2008). Even very comprehensive protocols aiming for 
standardisation have been proposed, including the prior fasting of patients for eight hours 
as well as grading their hydration status by drinking one litre of water while hanging down 
the leg (Trengove, Langton, and Stacey 1996). However, this is not suitable for daily clinical 
routines. In addition, there is also major variability with respect to the time frames defined 
for exudate accumulation, ranging from about one hour (Trengove et al. 1999) to five days 
(Ono et al. 1994). Therefore, the technique of wound fluid collection may indeed impact 
upon subsequent analytic results.  
For chronic wounds in particular, techniques for harvesting even small amounts of wound 
fluid directly from the wound surface have been described. For this purpose, blunt-end 
glass micro-capillaries have been used to collect fluid directly from the wound surface 
(Weckroth et al. 1996). In venous leg ulcers, even the manual expression of wound fluid 
from absorptive dressings has been proposed (Hoffman, Starkey, and Coad 1998). 
Another method for obtaining wound fluid is to cover the wound surface with different 
types of dressings from which it is then mechanically extracted. In the past, this particular 
technique has frequently been modified. Protocols describing the extraction of fluids 
directly from dressings have been reported multiple times (Fivenson et al. 1997; Seah et al. 
2005). For example, wound exudate trapped in a foam dressing has been obtained by 
squeezing the dressing material through a syringe (Seah et al. 2005).  
Another option is placing a sterile mesh onto the wound which absorbs the wound fluid 
into a sterilised pre-weighed whatman paper, which was described as allowing the recovery 
of 50-200µl of sample material. Subsequently, wound fluid was extracted from the filters by 
washouts employing a suitable buffer (Moor, Vachon, and Gould 2009). Similarly, glass 
microfibre circle filters were inserted into wound centres in order to saturate for 2 hours 
with wound exudate. Wound fluid was then extracted by phosphate buffered saline 
(Schmidtchen 2000).  
A further technique described for the acquisition of wound fluid is a modification of the 
methodology used by the Schirmer´s test, which was originally invented to measure tear 
secretion in an ophthalmologic setting (Schirmer 1903, cited by Kallarackal et al. 2002). This 
attempt consists of absorbent paper strips which are placed on the wound surface thereby 
soaking with fluid for 5 minutes. Subsequently, the sample material is recovered by stirring 
the paper strips in a buffer for 2 hours (Muller et al. 2008). 
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Also, hydrophilic dextranomer beads layered on wounds have been used. In preliminary 
experiments with defined amounts of proteins, a recovery of 88-98% was described when 
extracting the beads with equal volumes of phosphate buffered saline for 12 hours (Cooper 
et al. 1994). 
One potential drawback to these approaches is the issue of sample dilution, thus altering the 
analyte containing matrix as well as leaving the precise amount of fluid enclosed and 
remaining in the dressing material undetermined. Furthermore, huge inter-patient 
variability in cytokine concentrations -possibly due to technical problems during wound 
fluid aspiration from under occlusive Tegaderm® dressings- was observed in one study 
(Gohel et al. 2008). 
To overcome the obstacles of methodological limitations in sample material and sampling 
difficulties, a technique using washouts of wound areas by the application of 5ml of sterile 
saline to wounds and subsequent collection of the fluid again by needle aspiration has been 
proposed (Ambrosch et al. 2008). However, a relevant dilution of the sample may again 
occur and so exert undetermined effects on the original fluid matrix.  
Microdialysis has also been proposed for collecting wound fluid. However, this is an 
invasive technique and it is not undisputed since the insertion of foreign material may affect 
the wound microenvironment and induce confounding effects on the expression of 
signalling molecules (Stenken et al. 2010; Mellergard et al. 2008). Nevertheless, this 
technique is well established for sampling the fluid of the interstitial space and the samples 
obtained are usually of high quality (Simonsen et al. 1998; Clough and Noble 2003).  
A possible major issue in all these techniques -covering wounds with foreign material to a 
minor or major extent- is the fact that the collection  materials may influence the biochemical 
or immunological properties of the wound (Schmidtchen 2000; Hoffman, Noble, and Eagle 
1999) or else interfere with the analytes that are to be measured.  
Given these findings, we have considered implementing a novel way of obtaining wound 
fluid which might overcome some of the shortcomings of the earlier proposed techniques. 
Being convinced that wound fluid is a complex substrate (displaying the recent condition of 
the wound healing process), the sample material should be rapidly harvested within a short 
processing time so as to remain unaltered. The new protocol should be neither time-
consuming nor cause much logistical effort, and thereby be suitable for daily clinical 
routines. 
The issue of limited sample volumes is diminishing in importance since novel analytic 
techniques and devices still provide good and reproducible measurements, even when 
using very little amounts of fluid (see section 4). However, the issue of acquiring suitable 
and high-quality material in a reproducible, standardised manner is increasingly relevant 
and has been sought for years (Yager, Kulina, and Gilman 2007). 
Therefore, we performed wound swabs without pressure using micro-flocked swabs 
(Minitip Flocked Swabs; nylon flocked swabs with moulded breakpoint, MicroRheologics, 
Brescia, Italy) that adsorb the wound exudate through capillary action, coating nylon fibres 
without entrapment. In our setting, wound fluid was collected from diabetic foot ulcers by 
swabbing -after sharp debridement and haemostasis- using the Levine technique (Wound 
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infection in clinical practice. An international consensus 2008). Subsequently, the wound 
fluid was recovered by immediate centrifugation of swab tips at 10 000 rpm for 3 minutes at 
room temperature, using eppendorf cups equipped with a filter to hold the swab tip in place 
(Oxy Fill centrifugal filters without RoTrac capillary pore membrane, Carl Roth GmbH, 
Karlsruhe, Germany). The resulting cell free supernatant could then be used for subsequent 
analysis (Löffler et al. 2011). 
2.1.2 Sampling of acute wound fluids 
Techniques for harvesting acute wound fluid usually differ considerably from the methods 
described above for chronic wounds. This can be attributed to the different availability of 
wound exudates in the acute setting, as well as the different time frame until tissue 
restitution is reached. In several studies, wound fluid was obtained from suction drains, 
which have been inserted intra-operatively (Yager et al. 1996; Trengove et al. 1999; Baker 
and Leaper 2000). The collection of blister fluid is another opportunity for acquiring sample 
material (Oono et al. 1997; Ortega, Ganz, and Milner 2000).  
Negative pressure therapy (Vacuum Assisted Closure, V.A.C.) permits additional access to 
wound fluid (Duckworth et al. 2004), which is also a suitable technique in diabetic foot 
ulcers (Noble-Bell and Forbes 2008). However, in this setting the disparity between methods 
seems quite obvious, so long as rather passive methods are compared to negative pressure 
therapy (Yager, Kulina, and Gilman 2007). Wound fluid obtained by V.A.C. therapy is 
characterised by an increased protein concentration. In a study of Dealey et al., the attempt 
to establish a suitable and valid technique for comparison failed due to technical reasons, 
causing the cessation of a second study arm (Dealey, Cameron, and Arrowsmith 2006).  
Nevertheless, when interpreting the results with some caution, comparisons of the values from 
acute and chronic wound fluid can be worthwhile and can give important hints as to the 
differences between non-healing and healing wounds. Furthermore, the opportunity of 
analysing wound fluid over time will surely facilitate the discovery of relevant healing factors.  
3. Sample requirements and challenges dependent on the choice of analytes 
Besides all the obstacles that have been experienced in harvesting wound fluid and the 
interconnected high logistical effort to some extent also with respect to patient preparation, it 
is reasonable to assume that the sampling technique itself is likely to influence subsequent 
analysis.  
So far, there is no gold standard to which a new sampling technique could be referenced to, 
nor any overview of the different methods that could elucidate the advantages and 
disadvantages of each particular technique. This lack of knowledge, along with the inherent 
variations in wound fluid composition -particularly in chronic wounds- complicates the 
picture and renders wound fluid a fairly complex analytic material. The missing 
standardisation in sampling wound fluid is likely to result in wound fluid being seen as an 
undefined soup, as termed decades ago by Trengove et al. (Trengove, Langton, and Stacey 
1996). However, wound fluid might also be recognised as part of the problem in recalcitrant 
non-healing wounds and it might reflect the wound healing physiology better than any 
other sample material (Widgerow 2011). 
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infection in clinical practice. An international consensus 2008). Subsequently, the wound 
fluid was recovered by immediate centrifugation of swab tips at 10 000 rpm for 3 minutes at 
room temperature, using eppendorf cups equipped with a filter to hold the swab tip in place 
(Oxy Fill centrifugal filters without RoTrac capillary pore membrane, Carl Roth GmbH, 
Karlsruhe, Germany). The resulting cell free supernatant could then be used for subsequent 
analysis (Löffler et al. 2011). 
2.1.2 Sampling of acute wound fluids 
Techniques for harvesting acute wound fluid usually differ considerably from the methods 
described above for chronic wounds. This can be attributed to the different availability of 
wound exudates in the acute setting, as well as the different time frame until tissue 
restitution is reached. In several studies, wound fluid was obtained from suction drains, 
which have been inserted intra-operatively (Yager et al. 1996; Trengove et al. 1999; Baker 
and Leaper 2000). The collection of blister fluid is another opportunity for acquiring sample 
material (Oono et al. 1997; Ortega, Ganz, and Milner 2000).  
Negative pressure therapy (Vacuum Assisted Closure, V.A.C.) permits additional access to 
wound fluid (Duckworth et al. 2004), which is also a suitable technique in diabetic foot 
ulcers (Noble-Bell and Forbes 2008). However, in this setting the disparity between methods 
seems quite obvious, so long as rather passive methods are compared to negative pressure 
therapy (Yager, Kulina, and Gilman 2007). Wound fluid obtained by V.A.C. therapy is 
characterised by an increased protein concentration. In a study of Dealey et al., the attempt 
to establish a suitable and valid technique for comparison failed due to technical reasons, 
causing the cessation of a second study arm (Dealey, Cameron, and Arrowsmith 2006).  
Nevertheless, when interpreting the results with some caution, comparisons of the values from 
acute and chronic wound fluid can be worthwhile and can give important hints as to the 
differences between non-healing and healing wounds. Furthermore, the opportunity of 
analysing wound fluid over time will surely facilitate the discovery of relevant healing factors.  
3. Sample requirements and challenges dependent on the choice of analytes 
Besides all the obstacles that have been experienced in harvesting wound fluid and the 
interconnected high logistical effort to some extent also with respect to patient preparation, it 
is reasonable to assume that the sampling technique itself is likely to influence subsequent 
analysis.  
So far, there is no gold standard to which a new sampling technique could be referenced to, 
nor any overview of the different methods that could elucidate the advantages and 
disadvantages of each particular technique. This lack of knowledge, along with the inherent 
variations in wound fluid composition -particularly in chronic wounds- complicates the 
picture and renders wound fluid a fairly complex analytic material. The missing 
standardisation in sampling wound fluid is likely to result in wound fluid being seen as an 
undefined soup, as termed decades ago by Trengove et al. (Trengove, Langton, and Stacey 
1996). However, wound fluid might also be recognised as part of the problem in recalcitrant 
non-healing wounds and it might reflect the wound healing physiology better than any 
other sample material (Widgerow 2011). 
 
Global Perspective on Diabetic Foot Ulcerations 
 
52
Consequently, there are several inherent challenges in assaying chronic wound fluid. Very 
early comparisons between acute and chronic wound fluids showed a relevant difference in 
protease levels (Tarnuzzer and Schultz 1996) that has been confirmed by various authors 
subsequently (Chen et al. 1997; Moor, Vachon, and Gould 2009; Schmidtchen 2000). The 
issue of a proteolytic microenvironment in chronic wounds may be an important factor 
contributing to the non-healing phenotype, as growth factors and matrix components are 
subject to degradation (Widgerow 2011). This is not only true for growth factors and 
cytokines, but may also apply to receptors and signalling targets, which may thereby result 
in considerable loss of function. Therefore, merely quantifying analytes probably rather 
overestimates their protein bioactivity rather than reflecting the actual situation in the 
wound.  
The composition and texture of wound fluid is influenced by the amount of exudate 
produced over a defined period of time as well as by its evaporation and absorption. 
Similarly, general factors such as leg positioning and the hydration status of the patient 
significantly alter the quality of wound fluid (Trengove, Langton, and Stacey 1996). Years 
ago, it had already been shown that the wound fluid of healing chronic leg ulcers showed 
relevant differences in global components -such as albumin and total protein content- when 
compared to the wound fluid of non-healing ulcers (James et al. 2000). Albumin reflects the 
plasma compartment of wound exudate and is, therefore, influenced by vascular leakage or 
acute vascular injury as well as by intravascular pressure.  
When measuring protein biomarkers in wound fluid, the technical approach for how to 
obtain sample material must not be underestimated. It is still under discussion, whether 
values should be normalised to volume measures or total protein content for instance. 
Obtaining meaningful results is especially problematic when protease activity is high. 
Therefore, it is highly relevant to harvest immediate and unaltered sample material which is 
likely to reflect the original matrix of the wound microenvironment. In any cases, when 
intending to assess the amounts of peptide growth factors or other proteins in wound fluid, 
it should be recommended to determine the proteolytic activity of the environment in order 
to complete the picture. In this context, inert metabolites such as lactate might be considered 
advantageous since many of the limitations that apply to proteins do not apply here (Löffler 
et al. 2011).  
There has been rapid progress in analytic techniques and devices, which allow for the 
accurate and sensitive determination of wound fluid composition. On the other hand, the 
techniques and methods used to obtain wound fluid need to catch up with this pace and 
should be thoroughly re-evaluated with regard to the requirements that have to be met for 
producing sound and meaningful results. 
4. Protein arrays for the analysis of minute sample amounts  
The analysis of cytokines and matrix metalloproteinases in complex biological fluids 
requires sensitive, accurate and reliable methods. This is usually accomplished using 
classical solid phase sandwich immunoassays, such as ELISA (de Jager and Rijkers 2006). 
However these methods are characterised by high sample consumption and the single 
analysis of only one mediator per experiment. Due to the frequently found low exudate 
levels in chronic wounds along with the inherent complexity of wound fluid, appropriate 
technologies are needed to accurately and reliably determine multiple parameters with 
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minimal sample consumption. In this context, protein microarrays are important tools for 
the simultaneous detection and quantification of multiple parameters in complex biological 
mixtures, such as plasma (Cassatella et al. 1997) or tissue lysates (Beidler et al. 2008). This 
technology has been shown to exhibit high sensitivity and optimal signal to noise ratios 
even in the case of low target concentrations (Ekins 1989, 1998). 
There are two different types of microarray systems -planar and bead based arrays can be 
employed for multiplexed immunoassays. Whereas planar microarrays can be generated 
with hundreds and thousands of different capture spots, which are distinguished by their 
corresponding xy-coordinates, bead-based systems (e.g. Luminex) represent an interesting 
and flexible alternative, especially when the number of parameters to be determined in 
parallel is rather low. All bead-based array systems employ colour or size coded 
microspheres as solid support for the capture molecules. Beads are identified in a flow 
cytometer and the amount of captured target molecules is quantified on each individual 
bead using an appropriate reporter system. Sensitivity, reliability and accuracy are similar to 
those observed with standard ELISA procedures. Using bead-based technology, thousands 
of samples can be screened within a short time. Throughput neither seems to be a problem 
anymore, nor does sample volume (Stoll 2004; Templin et al. 2004).  
Inflammatory processes such as wound healing involve a complex network of 
immunoregulatory molecules such as chemokines, cytokines, proteases and their respective 
counter-regulatory mediators (Hahm, Glaser, and Elster 2011). The analysis of a complete 
set of mediators can therefore be considered to be of more value than the single analysis of 
only one single analyte (Gardy et al. 2009; de Jager et al. 2003). Although protein microarray 
technology has been successfully applied for the analysis of multiple analytes in complex 
biological mixtures -such as plasma, serum, urine and cerebrospinal fluid- publications 
using protein arrays for the analysis of wound status are rare (Hsu et al. 2008; Weigelt et al. 
2009; Craig-Schapiro et al. 2011; Swain et al. 2011). For instance, Grimstad et al. measured 
the concentration of 27 different cytokines in wound fluid derived from acute wounds using 
a bead-based system (Grimstad et al. 2011). Beidler et al. applied this technology to measure 
the concentrations of matrix metalloproteinases and cytokines in wound tissue lysate 
(Beidler et al. 2008, 2009). In combination with appropriate wound sampling procedures, the 
complex protein-composition of wound exudate together with limitations in the anticipated 
sample volume renders protein array technology -be it planar or bead-based- as an 
interesting tool for the analysis of wound-associated biomarkers (see section 6.1). Due to the 
inherent heterogeneity of wound exudate samples from chronic leg ulcers, the normalisation 
of the data needs to be discussed. In this context, the levels of albumin and total protein in 
wound fluid might represent an interesting reference value.  
5. Infection in the diabetic foot  
Foot pathologies are among the most frequent causes of hospitalisation in diabetic patients 
(Tecilazich, Dinh, and Veves 2011), with infection being the most dangerous complication. 
However, local processes triggered by microbial activity in the wound microenvironment 
have not gathered much interest until now. Apart from the classical means of diagnosing 
infection by clinical examination and microbiological swabbing, analysing wound fluid 
might provide additional important information. Furthermore, it is crucial to understand 
that microbiological sampling should be considered as a tool for proving the clinical 
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Consequently, there are several inherent challenges in assaying chronic wound fluid. Very 
early comparisons between acute and chronic wound fluids showed a relevant difference in 
protease levels (Tarnuzzer and Schultz 1996) that has been confirmed by various authors 
subsequently (Chen et al. 1997; Moor, Vachon, and Gould 2009; Schmidtchen 2000). The 
issue of a proteolytic microenvironment in chronic wounds may be an important factor 
contributing to the non-healing phenotype, as growth factors and matrix components are 
subject to degradation (Widgerow 2011). This is not only true for growth factors and 
cytokines, but may also apply to receptors and signalling targets, which may thereby result 
in considerable loss of function. Therefore, merely quantifying analytes probably rather 
overestimates their protein bioactivity rather than reflecting the actual situation in the 
wound.  
The composition and texture of wound fluid is influenced by the amount of exudate 
produced over a defined period of time as well as by its evaporation and absorption. 
Similarly, general factors such as leg positioning and the hydration status of the patient 
significantly alter the quality of wound fluid (Trengove, Langton, and Stacey 1996). Years 
ago, it had already been shown that the wound fluid of healing chronic leg ulcers showed 
relevant differences in global components -such as albumin and total protein content- when 
compared to the wound fluid of non-healing ulcers (James et al. 2000). Albumin reflects the 
plasma compartment of wound exudate and is, therefore, influenced by vascular leakage or 
acute vascular injury as well as by intravascular pressure.  
When measuring protein biomarkers in wound fluid, the technical approach for how to 
obtain sample material must not be underestimated. It is still under discussion, whether 
values should be normalised to volume measures or total protein content for instance. 
Obtaining meaningful results is especially problematic when protease activity is high. 
Therefore, it is highly relevant to harvest immediate and unaltered sample material which is 
likely to reflect the original matrix of the wound microenvironment. In any cases, when 
intending to assess the amounts of peptide growth factors or other proteins in wound fluid, 
it should be recommended to determine the proteolytic activity of the environment in order 
to complete the picture. In this context, inert metabolites such as lactate might be considered 
advantageous since many of the limitations that apply to proteins do not apply here (Löffler 
et al. 2011).  
There has been rapid progress in analytic techniques and devices, which allow for the 
accurate and sensitive determination of wound fluid composition. On the other hand, the 
techniques and methods used to obtain wound fluid need to catch up with this pace and 
should be thoroughly re-evaluated with regard to the requirements that have to be met for 
producing sound and meaningful results. 
4. Protein arrays for the analysis of minute sample amounts  
The analysis of cytokines and matrix metalloproteinases in complex biological fluids 
requires sensitive, accurate and reliable methods. This is usually accomplished using 
classical solid phase sandwich immunoassays, such as ELISA (de Jager and Rijkers 2006). 
However these methods are characterised by high sample consumption and the single 
analysis of only one mediator per experiment. Due to the frequently found low exudate 
levels in chronic wounds along with the inherent complexity of wound fluid, appropriate 
technologies are needed to accurately and reliably determine multiple parameters with 
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minimal sample consumption. In this context, protein microarrays are important tools for 
the simultaneous detection and quantification of multiple parameters in complex biological 
mixtures, such as plasma (Cassatella et al. 1997) or tissue lysates (Beidler et al. 2008). This 
technology has been shown to exhibit high sensitivity and optimal signal to noise ratios 
even in the case of low target concentrations (Ekins 1989, 1998). 
There are two different types of microarray systems -planar and bead based arrays can be 
employed for multiplexed immunoassays. Whereas planar microarrays can be generated 
with hundreds and thousands of different capture spots, which are distinguished by their 
corresponding xy-coordinates, bead-based systems (e.g. Luminex) represent an interesting 
and flexible alternative, especially when the number of parameters to be determined in 
parallel is rather low. All bead-based array systems employ colour or size coded 
microspheres as solid support for the capture molecules. Beads are identified in a flow 
cytometer and the amount of captured target molecules is quantified on each individual 
bead using an appropriate reporter system. Sensitivity, reliability and accuracy are similar to 
those observed with standard ELISA procedures. Using bead-based technology, thousands 
of samples can be screened within a short time. Throughput neither seems to be a problem 
anymore, nor does sample volume (Stoll 2004; Templin et al. 2004).  
Inflammatory processes such as wound healing involve a complex network of 
immunoregulatory molecules such as chemokines, cytokines, proteases and their respective 
counter-regulatory mediators (Hahm, Glaser, and Elster 2011). The analysis of a complete 
set of mediators can therefore be considered to be of more value than the single analysis of 
only one single analyte (Gardy et al. 2009; de Jager et al. 2003). Although protein microarray 
technology has been successfully applied for the analysis of multiple analytes in complex 
biological mixtures -such as plasma, serum, urine and cerebrospinal fluid- publications 
using protein arrays for the analysis of wound status are rare (Hsu et al. 2008; Weigelt et al. 
2009; Craig-Schapiro et al. 2011; Swain et al. 2011). For instance, Grimstad et al. measured 
the concentration of 27 different cytokines in wound fluid derived from acute wounds using 
a bead-based system (Grimstad et al. 2011). Beidler et al. applied this technology to measure 
the concentrations of matrix metalloproteinases and cytokines in wound tissue lysate 
(Beidler et al. 2008, 2009). In combination with appropriate wound sampling procedures, the 
complex protein-composition of wound exudate together with limitations in the anticipated 
sample volume renders protein array technology -be it planar or bead-based- as an 
interesting tool for the analysis of wound-associated biomarkers (see section 6.1). Due to the 
inherent heterogeneity of wound exudate samples from chronic leg ulcers, the normalisation 
of the data needs to be discussed. In this context, the levels of albumin and total protein in 
wound fluid might represent an interesting reference value.  
5. Infection in the diabetic foot  
Foot pathologies are among the most frequent causes of hospitalisation in diabetic patients 
(Tecilazich, Dinh, and Veves 2011), with infection being the most dangerous complication. 
However, local processes triggered by microbial activity in the wound microenvironment 
have not gathered much interest until now. Apart from the classical means of diagnosing 
infection by clinical examination and microbiological swabbing, analysing wound fluid 
might provide additional important information. Furthermore, it is crucial to understand 
that microbiological sampling should be considered as a tool for proving the clinical 
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suspicion of infection rather than as a diagnostic instrument itself (Richard, Sotto, and 
Lavigne 2011). 
Diagnosing infection in diabetic foot ulcers is challenging. This is especially true when the 
clinical assessment is not conclusive. The clinical signs for the diagnosis of infection may 
even be diminished by comorbidities -such as peripheral arterial disease, impaired 
leukocyte function and neuropathy- thereby reducing local signs of inflammation (Edmonds 
2005; Williams, Hilton, and Harding 2004). However, since infection is a major cause of 
diabetes-related morbidity and mortality (Prompers et al. 2008) and as it paves the way 
towards limb amputation (Armstrong and Lipsky 2004), novel diagnostic tools that support 
prompt decision-making are urgently needed. 
Currently there is ample room for the misclassification and delayed treatment of infection in 
the diabetic foot, and many issues in diagnosing diabetic foot infections are left unsolved 
(Jeffcoate et al. 2008). Furthermore, infection can show rapid onset and progression in 
diabetic foot ulcers. 
In daily clinical practise, systemic markers of infection are the most established way of 
supporting the clinical suspicion of infection at present. The classical markers in this context 
include leukocyte count and C-reactive protein (CRP) as well as the erythrocyte 
sedimentation rate. Additionally, systemic markers specific to bacterial infection -such as 
procalcitonin, a peptide precursor of calcitonin, orosomucoid and haptoglobin- have been 
evaluated in serum of diabetic foot ulcers patients for the determination of infection 
(Jeandrot et al. 2008). Consecutively, a variety of immune mediators -including acute phase 
proteins, cytokines and chemokines- were examined in the plasma of patients with diabetic 
foot syndrome. These markers included CRP and fibrinogen as well as IL-6, IL-8, IL-18, 
macrophage inflammatory protein 1α (MIP1), interferon γ-inducible protein-10 (IP10), 
macrophage migration inhibitory factor (MIF), macrophage chemoattractant protein 1 
(MCP1) and RANTES (Weigelt et al. 2009). Both of the studies just cited were able to connect 
the occurrence of certain systemic inflammatory markers with the presence of infection in 
the diabetic foot.  
In the first of these studies, serum CRP and procalcitonin were found to be significantly 
elevated during infection. CRP was discovered to be of a higher performance than 
procalcitonin, probably triggered by TNFα, IL-6 and IL-1 derived from the site of 
inflammation (Jeandrot et al. 2008). Still, the diagnosis of infection was principally 
determined by clinical assessment and the treatment was chosen accordingly. 
Although various studies have been investigating CRP as a possible marker of infection in 
diabetic foot ulcers, sufficient support is not available for underlining its sole effectiveness 
(Dinh, Snyder, and Veves 2010) but it does add relevant supplementary information to the 
clinical assessment. 
In the study conducted by Weigelt et al., besides CRP both IL-6 and fibrinogen -as acute 
phase reactants- were observed to be associated with the severity of foot ulcerations (88% 
type 2 diabetics) but not with the grade of infection. The overall findings in this fairly large 
study population can be interpreted to underline a specific alteration of the immune status 
of in diabetic patients, opposed to a rather general immune activation (IL-6 ↑, CRP ↑, 
fibrinogen ↑, MIP1α ↑, MIF↑, IP-10↑, RANTES↓, MCP-1 →, IL-8→ upon infection) (Weigelt 
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et al. 2009). This is a further important hint towards suspecting determined alterations in the 
immune response in diabetes, which may prove relevant to the future detection and 
assessment of diabetic foot ulcers. Anyhow, it should be noted that even low levels of most 
of the cytokines in circulation would reach toxic levels relatively fast, whereas -in principle- 
at their site of action in the local environment their levels can rise manifold higher. 
When analysing serological markers and cytokine patterns in wounds together with wound 
microbiology, local IL-6 concentrations are rather likely to support the clinical suspicion of 
infection than serological markers can. The analysis of local IL-6 and TNFα was shown to be 
able to discriminate between monomicrobial and polymicrobial infections in contrast to 
serum CRP and liposaccharide binding protein (LBP). Furthermore, local IL-6 was reported 
to reflect higher bacterial loads and infection, especially with pseudomonas (Ambrosch et al. 
2008). The determination of CRP as well as LBP as serological parameters, together with the 
semi-quantitative analysis of bacterial load and microbial identification, was performed. In 
this setting, the assessment of wounds was shifted to a first primary appraisal of 
microbiological rather than clinical examination. Although critical levels of bacterial loads in 
wounds have been proposed (Bowler, Duerden, and Armstrong 2001), the types of pathogen 
species are equally important. Nevertheless, in neuropathic diabetic foot ulcers the healing 
rate was also found to be inversely correlated with high bacterial loads (Xu et al. 2007). 
Furthermore, in a study by Ambrosch et al., a good correlation between local CRP and 
TNFα levels in wound washouts and tissue punch biopsies could be shown (Ambrosch et al. 
2008). 
In addition to the controversial findings on CRP, the upstream marker IL-6 seems to become 
even more meaningful in the local context. Overall, local alterations are likely to precede 
systemic changes. On the basis of this rationale, we advocate the investigation of the local 
microenvironment and possibly the correlation of these findings with circulatory markers. 
We are convinced that this local approach is more suitable for discovering useful markers 
for the assessment of infection in diabetic foot ulcer patients than the opposite approach of 
searching for alterations in the complicated circulatory proteome.  
Of course, this local approach is not always suitable as -for instance- in the acute Charcot 
foot, which is a widely unresolved problem in diabetic foot care. Notably in this context, it 
would be of great interest to find circulatory markers disclosing the disease state and having 
possible therapeutic implications on hand. Initial attempts have already been made in this 
direction (Mabilleau et al. 2011).  
6. Wound fluid - a window reflecting the wound microenvironment? 
The question of whether wound fluid could serve as a valuable window into the wound 
environment has already been asked -years ago- by Dorne R. Yager et al. (Yager, Kulina, and 
Gilman 2007). Therefore, it is not a novel aspect but it is indeed an exciting option for having 
a closer look into the wound microenvironment. Recently, it has even been proposed that 
the corrosive nature of the chronic wound environment and the continuous breakdown of 
the extracellular matrix mediated by proteases may link wound fluid directly to the 
phenotype of chronic non-healing wounds (Widgerow 2011). If this were the case, the 
science of assessing wound fluid should be an important stepping stone in obtaining access 
to the problem of chronic non-healing wounds. Wound fluid -which has been investigated 
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suspicion of infection rather than as a diagnostic instrument itself (Richard, Sotto, and 
Lavigne 2011). 
Diagnosing infection in diabetic foot ulcers is challenging. This is especially true when the 
clinical assessment is not conclusive. The clinical signs for the diagnosis of infection may 
even be diminished by comorbidities -such as peripheral arterial disease, impaired 
leukocyte function and neuropathy- thereby reducing local signs of inflammation (Edmonds 
2005; Williams, Hilton, and Harding 2004). However, since infection is a major cause of 
diabetes-related morbidity and mortality (Prompers et al. 2008) and as it paves the way 
towards limb amputation (Armstrong and Lipsky 2004), novel diagnostic tools that support 
prompt decision-making are urgently needed. 
Currently there is ample room for the misclassification and delayed treatment of infection in 
the diabetic foot, and many issues in diagnosing diabetic foot infections are left unsolved 
(Jeffcoate et al. 2008). Furthermore, infection can show rapid onset and progression in 
diabetic foot ulcers. 
In daily clinical practise, systemic markers of infection are the most established way of 
supporting the clinical suspicion of infection at present. The classical markers in this context 
include leukocyte count and C-reactive protein (CRP) as well as the erythrocyte 
sedimentation rate. Additionally, systemic markers specific to bacterial infection -such as 
procalcitonin, a peptide precursor of calcitonin, orosomucoid and haptoglobin- have been 
evaluated in serum of diabetic foot ulcers patients for the determination of infection 
(Jeandrot et al. 2008). Consecutively, a variety of immune mediators -including acute phase 
proteins, cytokines and chemokines- were examined in the plasma of patients with diabetic 
foot syndrome. These markers included CRP and fibrinogen as well as IL-6, IL-8, IL-18, 
macrophage inflammatory protein 1α (MIP1), interferon γ-inducible protein-10 (IP10), 
macrophage migration inhibitory factor (MIF), macrophage chemoattractant protein 1 
(MCP1) and RANTES (Weigelt et al. 2009). Both of the studies just cited were able to connect 
the occurrence of certain systemic inflammatory markers with the presence of infection in 
the diabetic foot.  
In the first of these studies, serum CRP and procalcitonin were found to be significantly 
elevated during infection. CRP was discovered to be of a higher performance than 
procalcitonin, probably triggered by TNFα, IL-6 and IL-1 derived from the site of 
inflammation (Jeandrot et al. 2008). Still, the diagnosis of infection was principally 
determined by clinical assessment and the treatment was chosen accordingly. 
Although various studies have been investigating CRP as a possible marker of infection in 
diabetic foot ulcers, sufficient support is not available for underlining its sole effectiveness 
(Dinh, Snyder, and Veves 2010) but it does add relevant supplementary information to the 
clinical assessment. 
In the study conducted by Weigelt et al., besides CRP both IL-6 and fibrinogen -as acute 
phase reactants- were observed to be associated with the severity of foot ulcerations (88% 
type 2 diabetics) but not with the grade of infection. The overall findings in this fairly large 
study population can be interpreted to underline a specific alteration of the immune status 
of in diabetic patients, opposed to a rather general immune activation (IL-6 ↑, CRP ↑, 
fibrinogen ↑, MIP1α ↑, MIF↑, IP-10↑, RANTES↓, MCP-1 →, IL-8→ upon infection) (Weigelt 
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et al. 2009). This is a further important hint towards suspecting determined alterations in the 
immune response in diabetes, which may prove relevant to the future detection and 
assessment of diabetic foot ulcers. Anyhow, it should be noted that even low levels of most 
of the cytokines in circulation would reach toxic levels relatively fast, whereas -in principle- 
at their site of action in the local environment their levels can rise manifold higher. 
When analysing serological markers and cytokine patterns in wounds together with wound 
microbiology, local IL-6 concentrations are rather likely to support the clinical suspicion of 
infection than serological markers can. The analysis of local IL-6 and TNFα was shown to be 
able to discriminate between monomicrobial and polymicrobial infections in contrast to 
serum CRP and liposaccharide binding protein (LBP). Furthermore, local IL-6 was reported 
to reflect higher bacterial loads and infection, especially with pseudomonas (Ambrosch et al. 
2008). The determination of CRP as well as LBP as serological parameters, together with the 
semi-quantitative analysis of bacterial load and microbial identification, was performed. In 
this setting, the assessment of wounds was shifted to a first primary appraisal of 
microbiological rather than clinical examination. Although critical levels of bacterial loads in 
wounds have been proposed (Bowler, Duerden, and Armstrong 2001), the types of pathogen 
species are equally important. Nevertheless, in neuropathic diabetic foot ulcers the healing 
rate was also found to be inversely correlated with high bacterial loads (Xu et al. 2007). 
Furthermore, in a study by Ambrosch et al., a good correlation between local CRP and 
TNFα levels in wound washouts and tissue punch biopsies could be shown (Ambrosch et al. 
2008). 
In addition to the controversial findings on CRP, the upstream marker IL-6 seems to become 
even more meaningful in the local context. Overall, local alterations are likely to precede 
systemic changes. On the basis of this rationale, we advocate the investigation of the local 
microenvironment and possibly the correlation of these findings with circulatory markers. 
We are convinced that this local approach is more suitable for discovering useful markers 
for the assessment of infection in diabetic foot ulcer patients than the opposite approach of 
searching for alterations in the complicated circulatory proteome.  
Of course, this local approach is not always suitable as -for instance- in the acute Charcot 
foot, which is a widely unresolved problem in diabetic foot care. Notably in this context, it 
would be of great interest to find circulatory markers disclosing the disease state and having 
possible therapeutic implications on hand. Initial attempts have already been made in this 
direction (Mabilleau et al. 2011).  
6. Wound fluid - a window reflecting the wound microenvironment? 
The question of whether wound fluid could serve as a valuable window into the wound 
environment has already been asked -years ago- by Dorne R. Yager et al. (Yager, Kulina, and 
Gilman 2007). Therefore, it is not a novel aspect but it is indeed an exciting option for having 
a closer look into the wound microenvironment. Recently, it has even been proposed that 
the corrosive nature of the chronic wound environment and the continuous breakdown of 
the extracellular matrix mediated by proteases may link wound fluid directly to the 
phenotype of chronic non-healing wounds (Widgerow 2011). If this were the case, the 
science of assessing wound fluid should be an important stepping stone in obtaining access 
to the problem of chronic non-healing wounds. Wound fluid -which has been investigated 
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in a variety of studies- has added much to our understanding of wound healing. 
Nevertheless, to date there are neither techniques nor markers that have found their way 
into clinical practise.  
6.1 Biomarkers 
A biomarker can be defined as a substance that is used as an indicator of normal biological 
processes, pathologic conditions and therapeutic interventions (Hahm, Glaser, and Elster 
2011). They are widely attributed as playing a key role in the diagnosis, prognosis and 
clinical management of a broad range of disease states (Mueller, Muller, and Perruchoud 
2008). Prominent examples are prostate specific antigen (PSA) (Makarov et al. 2009), or Her-
2. However, due to complex disease pathologies and aetiological heterogeneity, it turns out 
that standalone markers are rather unlikely to be specific or else applicable on a wide-scale 
and a whole set of candidate markers are considered to be more promising e.g. as 
demonstrated by Domenici et al. (Domenici et al. 2010). According to Yager et al. there are 
as yet no accepted biomarkers, which allow the evaluation of the wound status and this 
critically hampers the improvement of appropriate treatments and effective therapies. 
Among the most promising candidate biomarkers are matrix metalloproteinases, cytokines 
and chemokines (Yager, Kulina, and Gilman 2007).  
6.2 Proteases and their inhibitors 
Chronic ulcers are characterised by a highly proteolytic microenvironment. Therefore, the 
four major biochemical classes of proteases (serine proteases, metalloproteinases, cysteine 
proteases and aspartic proteases) have generated great interest in the context of wound 
healing. In particular, matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) 
are critically involved in wound healing. Using protein array technology, Beidler et al. 
(Beidler et al. 2008) demonstrated that MMPs are differentially expressed in ulcerative and 
healthy tissue lysates. They demonstrated that MMP-8 and -9 in particular are strongly 
increased in ulcer tissue and decreased after the onset of the healing process. Yager et 
al.showed that MMP-2 and MMP-9 are elevated in chronic wound fluid compared with 
fluid from acute surgical wounds (Yager et al. 1996). Ladwig et al. (Ladwig et al. 2002) and 
Liu et al. (Liu et al. 2009) reported an increased ratio of MMP-9 to TIMP-1 in chronic non-
healing wound fluid compared with healing wounds. Together with the finding that the 
MMP2:TIMP-2 ratio is elevated in non-healing compared with healing leg ulcers (Mwaura et 
al. 2006), this suggests that a disturbed homeostasis between MMPs and TIMPs might be 
correlated with the non-healing status. Also, in chronic non-healing diabetic foot ulcers, 
MMPs and their inhibitors (TIMPs) have received much interest. In a study by Lobmann et 
al., higher concentrations of the MMPs -2, -8 and -9, in conjunction with lower 
concentrations of TIMP-2, were determined in tissue biopsies when comparing diabetic 
wounds to healthy controls (Lobmann et al. 2002). The study by Liu et al. extended these 
findings of elevated MMP-9 in diabetic foot ulcers to healing rates. Elevated MMP-9 -in 
these ulcers- was suggested to be linked to inflammatory processes and poor healing. 
Furthermore, in conjunction with low TIMP-1 and TGFβ, high MMP-9 was proposed as 
being indicative of poor wound healing (Liu et al. 2009). These findings are coincident with 
other previous findings - for instance, in pressure ulcers where diminished healing rates 
have been described in a high MMP-9/low TIMP-1 environment (Ladwig et al. 2002) and 
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with a slightly different setting regarding the MMP-9:TIMP-2 ratio in diabetic foot ulcers 
(Lobmann et al. 2006). The interconnection of elevated MMP-9/MMP-8 levels and poor 
healing has further been described in neuropathic diabetic foot ulcers, but furthermore here 
an association between high levels of MMP-1 and TIMP-1 and better healing rates has been 
shown (Muller et al. 2008). Recently, Widgerow proposed a theory focusing on neutrophil-
derived proteases -especially elevated MMP-9 in chronic wound fluid- as being involved in 
a vicious circle and stating that the corrosive nature of wound fluid was not only actively 
involved in matrix breakdown but also causative for non-healing a state probably further 
aggravated by bacterial factors (Widgerow 2011). According to this view, continued 
inflammation and leukocyte infiltration is triggered in chronic non-healing wounds, thereby 
perpetuating tissue destruction (Rayment, Upton, and Shooter 2008; cited by Widgerow 
2011). Together with an imbalance towards a proteolytic microenvironment and in 
conjunction with bacterial colonisation causing the continuous breakdown of extracellular 
matrix and growth factors, this milieu keeps wounds in a prolonged destructive state and so 
averts healing (Rayment, Upton, and Shooter 2008).  
In conclusion, we can see various overlapping motifs concerning an imbalance of MMPs and 
their inhibitory factors (TIMPs) in different types of wounds, which is also true for diabetic 
foot ulcers. MMPs seem to constitute some of the key players in this microenvironment and 
are probably linked to inflammatory activity and bacterial load, as well as the critical 
degradation of growth factors and extracellular matrix components. Nevertheless, as there 
are various MMPs involved in healing, such as MMP-1 to MMP-10, MMP-12 and MMP-13 
and several of their inhibitors (Armstrong and Jude 2002; Gill and Parks 2008); they are also 
important for physiological wound healing, although in a timely and ordinary fashion. As 
MMPs also have physiological roles and intimate links with inflammatory processes, an 
overview investigation of their roles with regard to inflammatory activity and wound 
healing rates would be desirable for coming to novel conclusions notably in non-healing 
wounds. For this endeavour, wound fluid might constitute a nearly ideal sample material.  
6.3 Cytokines and growth factors 
Besides MMPs, cytokines and chemokines are frequently discussed as potential indicators 
for the status of wound healing. In general, there is an ample variety of factors which can be 
found in the wound microenvironment and that play a role in wound healing. Nevertheless, 
the cytokines found in the local microenvironment are usually produced by local cells 
(Holzheimer and Steinmetz 2000) and may, therefore, provide us with interesting 
information on the local environment. The issue of mediators being found in wounds is 
already complex in physiological terms, and confounding factors -such as the chronic 
wound environment and exogenous factors from bacterial colonisation and the endogenous 
reactions to this scenario- make it even more complicated. Besides this, it is a fact that the 
pathogenesis of wound healing on the molecular level is poorly understood and may be 
diverse according to various different wound entities. Nevertheless, we will attempt a 
concise digression on the topic without the intent to give a comprehensive impression of 
chemokines, cytokines and growth factors in wound fluids. 
To our knowledge, there are no broad analyses available of these mediators in conjunction 
with clinical endpoints from chronic ulcers. Therefore, it may be prudent to begin with a 
glance at acute wound healing. 
 
Global Perspective on Diabetic Foot Ulcerations 
 
56
in a variety of studies- has added much to our understanding of wound healing. 
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healing wound fluid compared with healing wounds. Together with the finding that the 
MMP2:TIMP-2 ratio is elevated in non-healing compared with healing leg ulcers (Mwaura et 
al. 2006), this suggests that a disturbed homeostasis between MMPs and TIMPs might be 
correlated with the non-healing status. Also, in chronic non-healing diabetic foot ulcers, 
MMPs and their inhibitors (TIMPs) have received much interest. In a study by Lobmann et 
al., higher concentrations of the MMPs -2, -8 and -9, in conjunction with lower 
concentrations of TIMP-2, were determined in tissue biopsies when comparing diabetic 
wounds to healthy controls (Lobmann et al. 2002). The study by Liu et al. extended these 
findings of elevated MMP-9 in diabetic foot ulcers to healing rates. Elevated MMP-9 -in 
these ulcers- was suggested to be linked to inflammatory processes and poor healing. 
Furthermore, in conjunction with low TIMP-1 and TGFβ, high MMP-9 was proposed as 
being indicative of poor wound healing (Liu et al. 2009). These findings are coincident with 
other previous findings - for instance, in pressure ulcers where diminished healing rates 
have been described in a high MMP-9/low TIMP-1 environment (Ladwig et al. 2002) and 
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with a slightly different setting regarding the MMP-9:TIMP-2 ratio in diabetic foot ulcers 
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derived proteases -especially elevated MMP-9 in chronic wound fluid- as being involved in 
a vicious circle and stating that the corrosive nature of wound fluid was not only actively 
involved in matrix breakdown but also causative for non-healing a state probably further 
aggravated by bacterial factors (Widgerow 2011). According to this view, continued 
inflammation and leukocyte infiltration is triggered in chronic non-healing wounds, thereby 
perpetuating tissue destruction (Rayment, Upton, and Shooter 2008; cited by Widgerow 
2011). Together with an imbalance towards a proteolytic microenvironment and in 
conjunction with bacterial colonisation causing the continuous breakdown of extracellular 
matrix and growth factors, this milieu keeps wounds in a prolonged destructive state and so 
averts healing (Rayment, Upton, and Shooter 2008).  
In conclusion, we can see various overlapping motifs concerning an imbalance of MMPs and 
their inhibitory factors (TIMPs) in different types of wounds, which is also true for diabetic 
foot ulcers. MMPs seem to constitute some of the key players in this microenvironment and 
are probably linked to inflammatory activity and bacterial load, as well as the critical 
degradation of growth factors and extracellular matrix components. Nevertheless, as there 
are various MMPs involved in healing, such as MMP-1 to MMP-10, MMP-12 and MMP-13 
and several of their inhibitors (Armstrong and Jude 2002; Gill and Parks 2008); they are also 
important for physiological wound healing, although in a timely and ordinary fashion. As 
MMPs also have physiological roles and intimate links with inflammatory processes, an 
overview investigation of their roles with regard to inflammatory activity and wound 
healing rates would be desirable for coming to novel conclusions notably in non-healing 
wounds. For this endeavour, wound fluid might constitute a nearly ideal sample material.  
6.3 Cytokines and growth factors 
Besides MMPs, cytokines and chemokines are frequently discussed as potential indicators 
for the status of wound healing. In general, there is an ample variety of factors which can be 
found in the wound microenvironment and that play a role in wound healing. Nevertheless, 
the cytokines found in the local microenvironment are usually produced by local cells 
(Holzheimer and Steinmetz 2000) and may, therefore, provide us with interesting 
information on the local environment. The issue of mediators being found in wounds is 
already complex in physiological terms, and confounding factors -such as the chronic 
wound environment and exogenous factors from bacterial colonisation and the endogenous 
reactions to this scenario- make it even more complicated. Besides this, it is a fact that the 
pathogenesis of wound healing on the molecular level is poorly understood and may be 
diverse according to various different wound entities. Nevertheless, we will attempt a 
concise digression on the topic without the intent to give a comprehensive impression of 
chemokines, cytokines and growth factors in wound fluids. 
To our knowledge, there are no broad analyses available of these mediators in conjunction 
with clinical endpoints from chronic ulcers. Therefore, it may be prudent to begin with a 
glance at acute wound healing. 
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In a study by Grimstad et al. (already mentioned above) an attempt to characterise acute 
wound fluid from surgical drains at the first postoperative day after mastectomy was 
undertaken. This aspect therefore best describes the initial phase of the acute inflammatory 
response, which is particularly interesting in this relatively broad investigation assessing the 
levels of 27 different cytokines, chemokines and growth factors (Grimstad et al. 2011). 
Information as to this amount is generally scarce and will therefore be looked at in more 
detail here. In this context, the cytokines IL-6 and IL-8 -such as TNFα and IFNγ- were found 
in high abundance in acute wound fluid. In contrast with this pro-inflammatory pattern, the 
IL-1 receptor antagonist (IL-1RA) was also detected in high concentrations here. 
Interestingly, at this context the amounts of IL-1β detected and the anti-inflammatory 
cytokine IL-10 were found to be relatively low.  
This pattern just as observed in wound fluid at the onset of inflammation suggests a distinct 
but contained local inflammatory environment. The picture witnessed in this phase of 
wound healing can be interpreted -in our view- as an inflammatory response with strong 
inhibitory and restorative stimuli. This might be the case, as IL-8 constitutes a chemotactic 
factor for neutrophil recruitment (Baggiolini and Clark-Lewis 1992) as well as a factor 
promoting epidermal cell proliferation (Tuschil et al. 1992); moreover, IL-6 plays  an 
ambivalent role with pro- as well as anti-inflammatory properties, such as inhibiting TNFα 
and repressing IL-1β as well as inducing IL-1RA and IL-10 (Tilg et al. 1994). The low levels 
of the key pro-inflammatory marker IL-1β, which is -for instance- associated with 
inflammasome activity and the control of infection (Schroder and Tschopp 2010) is also 
notable in this early postoperative setting.  
With regard to chronic non-healing wounds, a connection with persistent inflammatory 
activity is a guiding principle, which is observed in various entities of impaired healing 
(Acosta et al. 2008; Pukstad et al. 2010). In a longitudinal study in chronic venous leg ulcers, 
decreases in IL-1α and IL-1β were observed in healing ulcers, whereas increases in IL-8 and 
MIP-1α were associated with non-healing. This was observed in conjunction with decreased 
levels of toll-like receptor (TLR) activities in healing ulcers (Pukstad et al. 2010). The 
persistent activation of innate immune responses, in dividing the healing and non-healing 
entities of wounds by TLR activation and distinct cytokine patterns (IL-1α , IL1-β, IL-8 
and MIP-1α), may even be interpreted in favour of a constant bacterial challenge in non-
healers with relevant effects on the wound microenvironment. 
The elevated expression of IL-1β and excessive TNFα in non-healing wounds (Wallace and 
Stacey 1998) may, therefore, be linked to the distinct properties observed in this 
microenvironment. This may be the case, as high TNFα has been described not only as 
inducing IL-1β and its own synthesis but also their synergistic effects resulting in the 
suppression of extracellular matrix synthesis, whereas MMP synthesis is induced and TIMP 
synthesis is inhibited (Mast and Schultz 1996), thus contributing to persistent inflammatory 
activity and tissue destruction in diabetes (Nwomeh, Yager, and Cohen 1998; Naguib et al. 
2004). This link may, therefore, constitute a part of the vicious circle that we know of, 
linking alterations observed in the microenvironment of non-healing wounds to persistent 
inflammatory activity. 
For instance, levels of TNFα have been found to be elevated in non-healing compared to 
healing leg ulcers (Wallace and Stacey 1998). Trengove et al. found elevated levels of the 
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pro-inflammatory cytokines IL-1, IL-6 and TNFα in non-healing compared with healing 
ulcers and that these mediators decreased over the course of healing (Trengove, Bielefeldt-
Ohmann, and Stacey 2000). Beidler and co-workers measured 22 mediators in healthy and 
ulcerative tissue lysates and found that IL-1α, IL-1β, IL-4, IL-6, IL-8, IL-10, IL-12p40, G-CSF, 
GM-CSF, MCP-1, IFNγ, TNFα, MIP-1α, MIP-1β and TGF1 were expressed at significantly 
higher levels in ulcer tissue compared with healthy controls. Moreover, they found the 
analytes IL-1α, IL-1β, IFNγ, IL-12p40, GM-CSF and IL-1RA to be differentially expressed in 
rapid versus delayed healing ulcers (Beidler et al. 2009). 
In summary, there are promising candidates that might be used as indicators of the healing 
status of chronic and acute wounds. However, additional efforts are needed to further 
validate the existing candidates and to discover new potential biomarkers. In this context, 
the use of entire biomarker panels instead of standalone molecules should be taken into 
account. 
Especially in diabetes, it is established that a local over-secretion of pro-inflammatory 
cytokines (notably TNFα, IL-6 and IL-1) is observed, impacting the wound healing 
microenvironment and opposing healing (Acosta et al. 2008). These factors have been 
multiply observed in the context of failure to heal and are linked with other processes 
observed in the wound environment, such as elevated proteolysis and the degradation of 
growth factors and their receptors.  
When it comes to growth factors, it is conceivable that beneath the mere abundance of these 
factors in wound fluid the aspect of bioactivity is of primary relevance. This may be best 
demonstrated by the reactions that have been described for ages, when comparing the 
diverse effects of wound fluids on cells in culture. The most important aspect of this may be 
the positive effect evoked by acute wound fluid on cellular proliferation. When acute 
wound fluid is added to cells in culture, increased proliferation of vascular endothelial cells, 
fibroblasts and endothelial cells was observed (Greenburg and Hunt 1978; Katz et al. 1991). 
Furthermore, the deposition of extracellular matrix and migration of cells are enhanced by 
acute wound fluid supplemented to cell cultures. In opposition to this, chronic wound fluid 
has been observed numerous times as inhibiting proliferation in vitro (Trengove, Bielefeldt-
Ohmann, and Stacey 2000; Bucalo, Eaglstein, and Falanga 1993; Phillips et al. 1998), thus 
hampering tissue restoration. Of course, the converse argument that the lack of proliferative 
stimulus in chronic wound fluid may be attributed to a mere lack of growth factors is 
invalid. To underline this thesis, Trengove et al. were not able to detect significant changes 
within the levels of platelet-derived growth factor (PDGF), epidermal growth factor (EGF), 
basic fibroblast growth factor (bFGF) or transforming growth factor beta (TGFβ) from 
healing and non-healing ulcers. However, in mitogenic assays in fibroblasts, wound fluid 
from healing ulcers was able to provoke a significantly enhanced proliferative response 
(Trengove, Bielefeldt-Ohmann, and Stacey 2000). Furthermore, additional growth factors 
have been implicated as playing an important role in wound healing, such as insulin-like 
growth factor (IGF) (Wagner et al. 2003) or keratinocyte growth factor (KGF) (Gibbs et al. 
2000). 
In a study by He et al., it was demonstrated that the addition of platelet derived growth 
factor (PDGF) to chronic wound fluid was able to synergistically enhance proliferation in 
fibroblasts, whereas chronic wound fluid alone also enhanced fibroblast proliferation at 
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In a study by Grimstad et al. (already mentioned above) an attempt to characterise acute 
wound fluid from surgical drains at the first postoperative day after mastectomy was 
undertaken. This aspect therefore best describes the initial phase of the acute inflammatory 
response, which is particularly interesting in this relatively broad investigation assessing the 
levels of 27 different cytokines, chemokines and growth factors (Grimstad et al. 2011). 
Information as to this amount is generally scarce and will therefore be looked at in more 
detail here. In this context, the cytokines IL-6 and IL-8 -such as TNFα and IFNγ- were found 
in high abundance in acute wound fluid. In contrast with this pro-inflammatory pattern, the 
IL-1 receptor antagonist (IL-1RA) was also detected in high concentrations here. 
Interestingly, at this context the amounts of IL-1β detected and the anti-inflammatory 
cytokine IL-10 were found to be relatively low.  
This pattern just as observed in wound fluid at the onset of inflammation suggests a distinct 
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factor for neutrophil recruitment (Baggiolini and Clark-Lewis 1992) as well as a factor 
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of the key pro-inflammatory marker IL-1β, which is -for instance- associated with 
inflammasome activity and the control of infection (Schroder and Tschopp 2010) is also 
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With regard to chronic non-healing wounds, a connection with persistent inflammatory 
activity is a guiding principle, which is observed in various entities of impaired healing 
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decreases in IL-1α and IL-1β were observed in healing ulcers, whereas increases in IL-8 and 
MIP-1α were associated with non-healing. This was observed in conjunction with decreased 
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entities of wounds by TLR activation and distinct cytokine patterns (IL-1α , IL1-β, IL-8 
and MIP-1α), may even be interpreted in favour of a constant bacterial challenge in non-
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The elevated expression of IL-1β and excessive TNFα in non-healing wounds (Wallace and 
Stacey 1998) may, therefore, be linked to the distinct properties observed in this 
microenvironment. This may be the case, as high TNFα has been described not only as 
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2004). This link may, therefore, constitute a part of the vicious circle that we know of, 
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pro-inflammatory cytokines IL-1, IL-6 and TNFα in non-healing compared with healing 
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GM-CSF, MCP-1, IFNγ, TNFα, MIP-1α, MIP-1β and TGF1 were expressed at significantly 
higher levels in ulcer tissue compared with healthy controls. Moreover, they found the 
analytes IL-1α, IL-1β, IFNγ, IL-12p40, GM-CSF and IL-1RA to be differentially expressed in 
rapid versus delayed healing ulcers (Beidler et al. 2009). 
In summary, there are promising candidates that might be used as indicators of the healing 
status of chronic and acute wounds. However, additional efforts are needed to further 
validate the existing candidates and to discover new potential biomarkers. In this context, 
the use of entire biomarker panels instead of standalone molecules should be taken into 
account. 
Especially in diabetes, it is established that a local over-secretion of pro-inflammatory 
cytokines (notably TNFα, IL-6 and IL-1) is observed, impacting the wound healing 
microenvironment and opposing healing (Acosta et al. 2008). These factors have been 
multiply observed in the context of failure to heal and are linked with other processes 
observed in the wound environment, such as elevated proteolysis and the degradation of 
growth factors and their receptors.  
When it comes to growth factors, it is conceivable that beneath the mere abundance of these 
factors in wound fluid the aspect of bioactivity is of primary relevance. This may be best 
demonstrated by the reactions that have been described for ages, when comparing the 
diverse effects of wound fluids on cells in culture. The most important aspect of this may be 
the positive effect evoked by acute wound fluid on cellular proliferation. When acute 
wound fluid is added to cells in culture, increased proliferation of vascular endothelial cells, 
fibroblasts and endothelial cells was observed (Greenburg and Hunt 1978; Katz et al. 1991). 
Furthermore, the deposition of extracellular matrix and migration of cells are enhanced by 
acute wound fluid supplemented to cell cultures. In opposition to this, chronic wound fluid 
has been observed numerous times as inhibiting proliferation in vitro (Trengove, Bielefeldt-
Ohmann, and Stacey 2000; Bucalo, Eaglstein, and Falanga 1993; Phillips et al. 1998), thus 
hampering tissue restoration. Of course, the converse argument that the lack of proliferative 
stimulus in chronic wound fluid may be attributed to a mere lack of growth factors is 
invalid. To underline this thesis, Trengove et al. were not able to detect significant changes 
within the levels of platelet-derived growth factor (PDGF), epidermal growth factor (EGF), 
basic fibroblast growth factor (bFGF) or transforming growth factor beta (TGFβ) from 
healing and non-healing ulcers. However, in mitogenic assays in fibroblasts, wound fluid 
from healing ulcers was able to provoke a significantly enhanced proliferative response 
(Trengove, Bielefeldt-Ohmann, and Stacey 2000). Furthermore, additional growth factors 
have been implicated as playing an important role in wound healing, such as insulin-like 
growth factor (IGF) (Wagner et al. 2003) or keratinocyte growth factor (KGF) (Gibbs et al. 
2000). 
In a study by He et al., it was demonstrated that the addition of platelet derived growth 
factor (PDGF) to chronic wound fluid was able to synergistically enhance proliferation in 
fibroblasts, whereas chronic wound fluid alone also enhanced fibroblast proliferation at 
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lower levels (He et al. 1999). Nevertheless, the original matrix in this study was not 
preserved and the results suggest that essential factors can be found in wound fluid 
enhancing proliferation that can be stimulated by the addition of growth factors from 
external sources, whereas the original fluid matrix is suited to suppressing proliferative 
effects. To sum up the findings, a mere lack of growth factors does not seem to be 
responsible for impaired wound healing. In fact, other factors that characterise the wound 
environment seem to be of relevance in impairing local proliferation. For instance, it has 
been shown that high glucose levels are suited to inhibit fibroblast proliferation and to 
induce resistance to growth factors (Hehenberger and Hansson 1997). Furthermore, in 
fibroblasts from chronic diabetic wounds, lactate levels above 7 mM have been shown to 
abrogate cell proliferation as a specific effect of elevated L-lactate levels (Hehenberger et al. 
1998). Another aspect that may be of relevance within this context is the enhanced 
degradation of growth factors by proteases which is observed in chronic wound fluid when 
compared with its acute counterpart (Trengove et al. 1999). 
Eventually, cellular factors (such as reaching the end of their replicative life span, which was 
suggested for fibroblasts in chronic ulcers that had not healed for 3 years, and were non-
responding to PDGF while exhibiting a normal expression of their respective receptors 
compared to their normal counterparts) are another possibility that may explain the lack of 
proliferation (Agren et al. 1999) together with the demand for antecedent therapeutic 
intervention. Interestingly, this condition of environmentally-driven cellular aging has been 
shown not to be correlated with telomere shortening but to be induced by other factors; 
possibly decreased resistance to oxidative stress (Wall et al. 2008), including the possibility 
of reversing this induced phenotype. Nevertheless, fibroblast dysfunction in late non-
healing ulcers seems to constitute an important factor propagating this condition that cannot 
be overcome anymore by mere basic growth factor supplementation. 
6.4 Role of lactate 
Tissue lactate accumulates during the physiological course of healing to concentrations of ~ 
10-12 mM as opposed to 1–3 mM normally found in blood and most uninjured, resting 
tissues (Ghani et al. 2004). Even though it has been shown that these high lactate 
concentrations persist irrespective of tissue oxygenation (Ghani et al. 2004), the concept of 
lactate as a dead end product in hypoxia has survived for many years still. Nowadays, it is 
widely accepted that tissue lactate is mainly derived from aerobic glycolysis.  
Lactate is understood to have many fundamental metabolic and signalling functions 
(Gladden 2004). Thus, lactate enhances wound healing by the stimulation of extracellular 
matrix synthesis (Hussain, Ghani, and Hunt 1989; Green and Goldberg 1964) and 
angiogenesis (Beckert et al. 2006; Hunt et al. 2007). However, at higher concentrations these 
positive effects seem to deteriorate. In fibroblast experiments, a threshold for cell 
proliferation could be determined (Hehenberger et al. 1998). Cellular proliferation was 
enhanced so long as lactate levels were lower than this particular threshold but inhibited 
when raised above. 
In chronic wounds, tissue lactate concentrations reach far higher levels compared with acute 
wounds. Inflammatory cells that are ubiquitously present in chronic wounds cover their 
energy demand mainly through aerobic glycolysis and they generate lactate as a by-product 
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and in huge amounts. Next, lactate leaves the cytosol to the extracellular space by 
monocarboxylic transferases (MCT) (Gladden 2004).  
Almost every chronic wound is more or less subject to bacterial contamination. Even 
though bacterial contamination does not necessarily lead to immediate subsequent 
infection, wound healing is impaired when the bacterial load reaches a certain level. In 
addition, many bacterial strains that have been detected in chronic wounds -and in the 
diabetic foot in particular- cover their energy demand by fermentation, thus producing 
additional lactate. 
 
Fig. 1. Lactate levels in diabetic foot ulcers (DFU) with clinical signs of soft-infection are 
shown on the left side of the continuous line as opposed to non-infected DFU on the right. 
In addition, lactate concentrations of DFU that healed within a follow-up period of 6 months 
are given to the right of the dotted line. Further right, wound fluid lactate concentrations in 
surgical wounds are shown. Wound fluid lactate concentrations are given as box plots 
(median, minimum - maximum as well as the 25th and 75th percentiles). The respective 
median lactate concentrations are given above the corresponding box plots. The possible 
clinical implications of lactate are presented in coloured boxes (modified according to 
Löffler et al. 2011). 
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positive effects seem to deteriorate. In fibroblast experiments, a threshold for cell 
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wounds. Inflammatory cells that are ubiquitously present in chronic wounds cover their 
energy demand mainly through aerobic glycolysis and they generate lactate as a by-product 
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and in huge amounts. Next, lactate leaves the cytosol to the extracellular space by 
monocarboxylic transferases (MCT) (Gladden 2004).  
Almost every chronic wound is more or less subject to bacterial contamination. Even 
though bacterial contamination does not necessarily lead to immediate subsequent 
infection, wound healing is impaired when the bacterial load reaches a certain level. In 
addition, many bacterial strains that have been detected in chronic wounds -and in the 
diabetic foot in particular- cover their energy demand by fermentation, thus producing 
additional lactate. 
 
Fig. 1. Lactate levels in diabetic foot ulcers (DFU) with clinical signs of soft-infection are 
shown on the left side of the continuous line as opposed to non-infected DFU on the right. 
In addition, lactate concentrations of DFU that healed within a follow-up period of 6 months 
are given to the right of the dotted line. Further right, wound fluid lactate concentrations in 
surgical wounds are shown. Wound fluid lactate concentrations are given as box plots 
(median, minimum - maximum as well as the 25th and 75th percentiles). The respective 
median lactate concentrations are given above the corresponding box plots. The possible 
clinical implications of lactate are presented in coloured boxes (modified according to 
Löffler et al. 2011). 
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In diabetic foot ulcers, a correlation between elevated wound fluid lactate levels and the 
clinical signs of soft-tissue infection could be demonstrated. Wounds with clinical signs of 
soft-tissue infection showed significantly higher wound fluid lactate concentrations as 
opposed to those without soft-tissue infection. Out of the wound sub-population, without 
clinical signs of soft-tissue infection, wounds that healed within a 6 months follow-up 
period were characterised by wound fluid lactate concentrations comparable with those 
found in acute healing wounds (Löffler et al. 2011). In summary, elevated lactate levels seem 
to be attributed both to inflammatory and bacterial activity. Nevertheless, lactate is likely to 
favour healing unless its concentration exceeds a certain threshold. On the other hand, 
lactate in wound fluid might be a diagnostic marker both for impaired healing and soft-
tissue-infection (Figure 1).  
7. Conclusions 
Sampling and analysing wound fluid is an inherently challenging task, since a variety of 
local and systemic factors influence its composition. This is particularly true for chronic 
wounds and for diabetic foot ulcers. In addition, there is no clear consensus yet about how 
to obtain adequate sample material. It is important nevertheless, depending on the analysis 
intended to be undertaken to choose the appropriate technique for obtaining sample 
material. Hence, to obtain meaningful results an adequate and suitable technique for 
harvesting wound fluid is a major pre-requisite when considering using sophisticated 
analytic methods. The technical developments in this field have brought novel analytical 
opportunities that require only very little amounts of sample material in order to get 
meaningful results. A variety of techniques have been proposed for obtaining sample 
materials and a multitude of possible wound fluid markers have been investigated. Finding 
meaningful biomarkers or biomarker panels allowing for the instant detection of infection or 
the determination of wound healing tendencies are urgently needed (Hahm, Glaser, and 
Elster 2011). We are convinced that it does make sense to analyse potential biomarkers in 
wound fluid, which is both easily accessible and can be harvested in a non-invasive way. 
The obstacle to overcome here is to implement techniques suitable for daily clinical routines, 
allowing for fast and reliable diagnostic procedures. In this setting, there are less 
confounding factors to deal with as opposed to systemic markers. No systemic marker has 
been proven to be capable of serving as a standalone diagnostic tool yet. To date, however, 
no wound fluid marker has been established that might fill this gap neither. We are at the 
beginning of an era which might appreciate wound fluid analysis as a novel opportunity to 
get deeper insights into a complicated and widely unknown micro-environment. There is 
still substantial room for improvement and plenty of work has to be done before we are able 
to understand the elementary mechanisms of non-healing.  
8. Perspective 
Valuable markers for clinical wound assessment are urgently needed. Wound fluid 
biomarkers are probably the best option for reaching this aim. For this purpose, wound fluid 
components -such as proteases and their inhibitors as well as cytokines and growth factors 
and other elements associated with the local inflammatory response- are worthwhile 
investigating. The wound fluid degradation products of the extracellular matrix represent 
another interesting aspect in assessing the pathophysiology of non-healing wounds 
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(Moseley et al. 2004). This is by virtue of the fact that the course of chronic wound healing 
may be directly reflected in matrix turnover due to a highly proteolytic and pro-oxidative 
environment. In addition, markers of oxidative stress and simple metabolites such as lactate 
may also give us important information on the state of wound healing. However, there is 
still ample room for the discovery of both valuable and inert wound fluid biomarkers. It can 
be anticipated that novel technical opportunities along with reproducible sampling methods 
will bring forward new biomarkers, which may aid in future wound assessment. The need 
is there, especially in the diabetic foot, and hopefully meaningful studies will soon be under 
way to bridge this gap, thereby substantiating the valour of wound fluid diagnostics.  
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1. Introduction 
In this chapter the authors aim to provide a brief introduction to wound assessment in the 
diabetic foot and discuss the role of wound measurement within that assessment process. A 
literature review describing wound measurement in diabetic foot wounds was conducted 
and a review of wound measurement tools and techniques reported. The results of a wound 
measurement study using a particular technique and the importance of wound 
measurement in clinical practice is discussed. Conclusions are drawn and a way forward is 
suggested. 
The prevalence of diabetes worldwide was estimated to be 2.8% in 2000 rising to 4.4% in 
2030. The total number of people with diabetes is projected to rise from 171 million in 2000 
to 366 million in 2030 (Wilde et al, 2004). As diabetes is the most frequent cause of non-
traumatic amputation in the developed world, it is likely that there will be a significant 
impact on patients’ health, their carers and health care systems. Progress has been made in 
recent years to manage risk factors associated with diabetic foot ulceration and to manage 
infection, ischaemia and glycaemic control. Multidisciplinary assessment, treatment and 
education programmes have been developed to prevent damage to insensitive feet. Healing 
rates and outcomes related to diabetic foot ulceration have been studied by many 
investigators and various wound measurement techniques have been employed in the quest 
to quantify outcomes. Outcomes in terms of ulcer healing have been based on ulcer area, 
ulcer duration and ulcer grade (from the superficial abrasion to the ulcer presenting with 
exposed bone in the wound base, necrosis, infection and/ or osteomyelitis). Initial wound 
measurement and regular monitoring is a useful tool in the assessment of treatment 
effectiveness (Vowden and Vowden, 2005, Gethin, 2006).  
2. Wound assessment and the role of wound measurement 
Wound assessment is complex and multi-faceted. It includes wound appearance, wound 
aetiology, prediction and monitoring of healing rates, identification of factors delaying 
healing and wound documentation. Wound measurement is an important component of 
this and has the potential to provide baseline measurements and accurately determine the 
percentage reduction/increase in wound area over time.  
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In any study involving wound measurement there are key concepts to be considered: 
1. Accuracy. This is the ability of the measuring tool to measure the true size of an object.  
2. Validity. The ability of the measuring tool to measure what it is intended to measure.  
3. Repeatability/test-retest reliability. The ability of the measuring tool to repeat an 
accurate measurement on more than one occasion with consistency. 
4. Reliability and Inter-rater reliability. The consistency of results obtained using the 
device when used by one or more than one operator. 
5. Usability. Do users find the tool convenient, effective and easy to use? (Fette, 2006). 
For a measurement tool to be successful it must satisfy these criteria and demonstrate 
reliability in its application. Failure to do so will result in inappropriate data. In the case of 
wound measurement systems the most common means of assessing the reliability of a 
system are test-retest reliability and inter-rater reliability (Gilman, 1990).  
Ideally the outcome of any treatment regimen in the management of diabetic foot wounds is 
complete wound closure. It has been suggested that the ability to measure a percentage area 
reduction may be important in differentiating between healing and non-healing wounds, 
and that it is also important for the evaluation of the efficacy of different treatment regimens 
((Kantor and Margolis, 2000; Flanagan, 2003; Sheehan et al, 2003; Gethin, 2006; Papazoglou 
et al, 2010). In wound management, three types of outcome are important: therapeutic 
efficacy, value for money and patient satisfaction (Gallagher, 2003). Oyibo et al (2001) in a 
study of diabetic foot ulcers (n=194) investigated the effect of ulcer size and site, patients’ 
age, sex and type/duration of diabetes on the eventual outcome. They found that ulcer area 
correlated well with healing time, but age, sex, type and duration of diabetes did not affect 
outcome. They concluded that ulcer area could be a useful predictor of ulcer outcome. This 
is supported by the work of several authors who concluded that percentage change in ulcer 
area at 4 weeks was a robust predictor of healing in diabetic foot wounds (Flanagan, 2003; 
Sheehan et al, 2003; Gethin, 2006; Papazoglou et al, 2010). 
3. Wound measurement tools and techniques 
A broad search of the literature was conducted to identify search terms and filters that could 
be used to yield studies specific to wound measurement tools and techniques in wound 
healing overall and more specifically in diabetic foot wounds. The electronic databases used 
to identify papers relevant to this review were Pubmed, Medline, and Cinahl (1989-2011). 
Secondary hand searching was also carried out using relevant journal articles and reference 
lists, books, and conference proceedings. Papers were included if they reported on trials 
describing and comparing wound measurement methods and tools. Papers were excluded if 
they were not written in English.  
Quantifying the size of the wound is an important component of wound assessment and has 
the potential to provide baseline measurements and accurately determine the percentage 
reduction/increase in wound area over time (Flanagan, 2003; Margolis et al, 2003). There are 
many methods of wound measurement and each possesses advantages and disadvantages. 
The ideal tool has been described by Polit & Hungler (1995) as 
“one that gives rise to results that are relevant, accurate, unbiased, sensitive, uni-
dimensional and efficient”. 
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Wound measurement techniques can be categorised as contact or non-contact in their 
application. Contact techniques include acetate tracing of the wound, the use of depth 
gauges, and volume measurement using casts or saline. Non-contact techniques involve the 
use of structured light and lasers, photography, video image analysis, magnetic resonance 
imaging and stereophotogrammetry (Williams, 1997). These tools and techniques are 
described, discussed and compared in detail. 
3.1 Simple wound measurement  
Simple wound measurement methods include those techniques that use either a length and 
width measurement or a wound tracing to calculate surface wound area. To determine 
wound surface area there are two important issues: the identification of the wound margin 
(typically using a wound tracing or alternatively a digital image) and the calculation of 
wound area.  
It is essential that the wound margin is clearly identified prior to measurement regardless of 
the measurement tool used. The appearance of the wound may be affected by various 
factors all of which may influence accurate measurement:  
1. Haemorrhage following debridement. 
2. The presence of infection and undermining of the wound edges. 
3. The presence of excess wound exudate and evidence of maceration of the surrounding 
skin. 
The wound edge may be described clinically as the area where normal skin converts to 
tissue which is red, yellow or black in colour. Normal skin may be macerated and white in 
appearance, or there may be lilac coloured tissue (new epithelial tissue) at the leading edge 
of the wound. 
Identification of the wound edge may be difficult and is largely determined by the 
subjective assessment of the observer who performs the measurement (Plassmann & Jones, 
1992; Plassmann et al, 1994;  Plassmann, 1995).  
Current practice focuses on wound measurement using a simple length and width 
measurement to calculate surface wound area. This is a crude measurement. Surface 
wound area is calculated by multiplying the maximum perpendicular length by the 
maximum width of the wound bed and is typically recorded in cm2 (Flanagan, 2003). The 
major flaw in the method is that it is subjective and normally over-estimates wound area 
by approximately twenty five percent (Majeske, 1992; Dealey, 1994; Goldman and Salcido, 
2002; Rodgers et al 2010). This method does not take into account irregularities in the 
shape of the wound or wound depth. Advantages, however, include ease of use and low 
cost. 
Wound area can also be determined by tracing the outline of the wound (wound 
circumference) onto a transparent sheet or graph paper divided into 1cm squares. Wound 
area can then be calculated by manually counting the squares within the “wound”. Griffin et 
al (1993) compared photographic and transparency-based methods for measuring wound 
area and concluded that both methods provided equally reliable measurements, but that the 
transparency method was more economical in time and equipment requirements. This is 
also a subjective measurement and the identification of the actual wound edges can be 
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difficult. The process does not provide information on the 3-dimensional aspect of the 
wound nor on wound volume and depth. It is also recognised that tracing of the wound 
edges is where the greatest source of error occurs (Kantor and Margolis, 1998). This is 
largely dependent on the experience of the clinician (Flanagan, 2003). The main advantage 
of wound tracing however is that it takes into account body curvature and irregularities of 
wound circumference.   
 
Fig. 1. Photograph illustrating the various types of tissue used to identify the wound edge in 
a diabetic foot wound 
3.2 Mathematical models 
It is recognised that simple wound surface area measurements (length x width) are likely to 
over-estimate the area of the wound by approximately twenty five percent (Goldman and 
Salcido, 2002). Ruler based schemes tend to be less reliable in wounds >5cm2 (Oien et al, 
2002). Accuracy may be improved by tracing the wound to compensate for body curvature, 
but this can be difficult to perform in certain areas e.g. the heel. In 1989 Kundin developed 
the wound gauge to calculate wound area (wound length x width x 0.785) and wound 
volume (wound area x depth x 0.327). This method appeared to be accurate in the 
measurement of small wounds but consistently underestimated the size of larger or 
irregularly shaped wounds (Thomas and Wysocki, 1990).  
Oien et al (2002) and Johnson (1995) proposed that various mathematical formulae can be 
used to improve accuracy in the calculation of wound surface area and volume. They 
recognised that most foot wounds presented as spherical or elliptical in nature, and that the 
area of these wounds could be determined using recognised standard mathematical 
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formulae and a wound tracing. This is also likely to produce some over-estimation of ulcer 
size but less error than the simple area calculation using length and width only (Goldman 
and Salcido, 2002).  
The use of the elliptical method of wound measurement was described by Shaw et al (2007). 
In a study of measurement of diabetic foot ulcers, wounds were traced, measured with a 
ruler and the standard formula for the calculation of the area of an ellipse was applied. The 
surface area was calculated by taking the radius of the longest side of the ellipse (wound), 
multiplying it by the radius of the shortest side of the ellipse (wound), at 900 to the longest 
side and multiplying that value by π (where π = 3.14) and r is the radius measurement.   
 
Fig. 2. The area (of the ellipse) is calculated using the formula π ab  
Johnson (1995) described various mathematical formulae to measure circular, elliptical and 
irregular wounds. He suggested that if wounds present with an irregular shape, 8 radii can 
be identified, each taken approximately 450 from the next radius and results can be 
approximated to actual values. The formulae to calculate the surface area is as follows: 
(r12+r22…..r82)(π /8) 
3.3 Wound planimetry 
Wound planimetry is defined as the precise measurement of the area contained within a 
wound tracing or a digital image (Flanagan, 2003). This measurement can be carried out 
using a mechanical planimeter or by using an appropriate software package and a digital 
image. Oien et al (2002) compared four methods of wound measurement in 20 patients with 
leg and foot ulcers (n=50) of mixed aetiology. Techniques included mechanical planimetry 
(using a hand held device), digital planimetry, square counting approximations and simple 
length x width measurements. All methods demonstrated a high degree of agreement for 
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formulae and a wound tracing. This is also likely to produce some over-estimation of ulcer 
size but less error than the simple area calculation using length and width only (Goldman 
and Salcido, 2002).  
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multiplying it by the radius of the shortest side of the ellipse (wound), at 900 to the longest 
side and multiplying that value by π (where π = 3.14) and r is the radius measurement.   
 
Fig. 2. The area (of the ellipse) is calculated using the formula π ab  
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length x width measurements. All methods demonstrated a high degree of agreement for 
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length x width measurement was reported to be the least reliable measure of ulcer size 
followed by square counting and mechanical planimetry. Digital planimetry was the most 
reliable of the methods described (Oien et al, 2002). 
3.4 Stereophotogrammetry and light techniques 
The availability of both contact and non contact methods of wound measurement have 
already been alluded to. Stereophotogrammetry is a non-contact technique where a stereo 
camera linked to a computer captures an image of the wound (Plassmann & Jones 1992; 
Langemo et al, 1998). The image is downloaded to the computer and the wound manually 
traced with the mouse from the image presented on the computer monitor screen. The 
software package then calculates wound length, width, area and volume. Langemo et al 
(1998) reported that the main advantage of this method was that it produced highly 
reproducible results compared to other techniques. It is also a non-contact technique, and so 
minimises the risk of cross-infection. The main disadvantage however is that it is time 




Fig. 3. Illustration of stereophotogrammetry.  
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A further non-contact method utilising light has been described by Plassmann and 
Jones,1992; and Melhuish et al, 1994. This structured light triangulation method involves use 
of a beam of structured light aimed at 45o to the wound. Analysis of the image carried out 
by computer software provides a 3-dimensional map of the wound allowing accurate 
measurement of wound area, wound circumference and wound volume. Repeated 
measurements using this method reported results with a mean error of less than 5% and so 
it was deemed to be an accurate way of objectively determining the wound boundary and 
calculating wound area. Melhuish et al (1994) demonstrated a direct correlation between 
wound circumference and wound area, and wound circumference and wound volume. The 
authors suggested that it was possible to accurately monitor wound healing by measuring 
circumference alone, as this measurement was directly linked to both volume and area.  
4. Comparison of techniques 
None of the methods of wound measurement described is perfect. Clinicians are expected to 
provide high quality, cost-effective, evidence-based wound care and so the standardisation 
of wound measurement methods may have important implications for research into the 
effects of treatments, drugs and disease (Kundin, 1989). 
4.1 Simple measurement 
Mayrovitz (1997) investigated shape and area measurement in the assessment of diabetic 
plantar ulcers (n=83). The accuracy of area calculations based on elliptical and rectangular 
shapes was considered and based on the maximum length and maximum width of the 
wounds studied. Overall error for both methods was similar with the elliptical model 
overestimating area (by 10%), and the rectangular method underestimating the area (by 
12%) when compared to conventional wound tracing over a sixteen week period. This is in 
contrast to the results reported by Majeske in 1992, and Goldman and Salcido (2002) who 
reported that wound area measurement using a simple length and width calculation 
overestimated wound area by approximately twenty five percent. 
4.2 Mathematical models 
Gilman (1999) favoured a more complex mathematical model for wound measurement. He 
argued that in many wound studies there were always wounds of varying sizes and shapes, 
and so a valid comparison of healing was difficult. He proposed using a mathematical 
model that described the average distance of advance of the wound margin towards the 
wound centre over time. This was illustrated in wounds that closed in a uniform and non-
uniform way. Bowling et al (2009) reported a strong correlation between elliptical wound 
measurement and an image processing system in a series of 36 diabetic foot wounds, 
examined over a 12 week period. 
4.3 Wound planimetry 
Kantor and Margolis (1998) reported a good correlation between planimetric wound area 
and wound width, length, width x length, perimeter and area based on the formula for an 
ellipse. The values for all correlation coefficients were greater than 0.8 for wounds that were 
less than 40cm2 in size.  
 
Global Perspective on Diabetic Foot Ulcerations 
 
76
length x width measurement was reported to be the least reliable measure of ulcer size 
followed by square counting and mechanical planimetry. Digital planimetry was the most 
reliable of the methods described (Oien et al, 2002). 
3.4 Stereophotogrammetry and light techniques 
The availability of both contact and non contact methods of wound measurement have 
already been alluded to. Stereophotogrammetry is a non-contact technique where a stereo 
camera linked to a computer captures an image of the wound (Plassmann & Jones 1992; 
Langemo et al, 1998). The image is downloaded to the computer and the wound manually 
traced with the mouse from the image presented on the computer monitor screen. The 
software package then calculates wound length, width, area and volume. Langemo et al 
(1998) reported that the main advantage of this method was that it produced highly 
reproducible results compared to other techniques. It is also a non-contact technique, and so 
minimises the risk of cross-infection. The main disadvantage however is that it is time 




Fig. 3. Illustration of stereophotogrammetry.  
 
Wound Measurement in Diabetic Foot Ulceration 
 
77 
A further non-contact method utilising light has been described by Plassmann and 
Jones,1992; and Melhuish et al, 1994. This structured light triangulation method involves use 
of a beam of structured light aimed at 45o to the wound. Analysis of the image carried out 
by computer software provides a 3-dimensional map of the wound allowing accurate 
measurement of wound area, wound circumference and wound volume. Repeated 
measurements using this method reported results with a mean error of less than 5% and so 
it was deemed to be an accurate way of objectively determining the wound boundary and 
calculating wound area. Melhuish et al (1994) demonstrated a direct correlation between 
wound circumference and wound area, and wound circumference and wound volume. The 
authors suggested that it was possible to accurately monitor wound healing by measuring 
circumference alone, as this measurement was directly linked to both volume and area.  
4. Comparison of techniques 
None of the methods of wound measurement described is perfect. Clinicians are expected to 
provide high quality, cost-effective, evidence-based wound care and so the standardisation 
of wound measurement methods may have important implications for research into the 
effects of treatments, drugs and disease (Kundin, 1989). 
4.1 Simple measurement 
Mayrovitz (1997) investigated shape and area measurement in the assessment of diabetic 
plantar ulcers (n=83). The accuracy of area calculations based on elliptical and rectangular 
shapes was considered and based on the maximum length and maximum width of the 
wounds studied. Overall error for both methods was similar with the elliptical model 
overestimating area (by 10%), and the rectangular method underestimating the area (by 
12%) when compared to conventional wound tracing over a sixteen week period. This is in 
contrast to the results reported by Majeske in 1992, and Goldman and Salcido (2002) who 
reported that wound area measurement using a simple length and width calculation 
overestimated wound area by approximately twenty five percent. 
4.2 Mathematical models 
Gilman (1999) favoured a more complex mathematical model for wound measurement. He 
argued that in many wound studies there were always wounds of varying sizes and shapes, 
and so a valid comparison of healing was difficult. He proposed using a mathematical 
model that described the average distance of advance of the wound margin towards the 
wound centre over time. This was illustrated in wounds that closed in a uniform and non-
uniform way. Bowling et al (2009) reported a strong correlation between elliptical wound 
measurement and an image processing system in a series of 36 diabetic foot wounds, 
examined over a 12 week period. 
4.3 Wound planimetry 
Kantor and Margolis (1998) reported a good correlation between planimetric wound area 
and wound width, length, width x length, perimeter and area based on the formula for an 
ellipse. The values for all correlation coefficients were greater than 0.8 for wounds that were 
less than 40cm2 in size.  
 
Global Perspective on Diabetic Foot Ulcerations 
 
78
4.4 Stereophotogrammetry and light techniques 
In keeping with the work carried out by Mayrovitz (1997), Langemo et al (1998, 2001) 
compared linear length and width using several methods: a ruler, planimetry, computerised 
stereophotogrammetry (SPG) length and width and computerised SPG area. They found 
that the most reliable method was SPG area measurement followed by computerised 
planimetry. These authors noted that conventional length x width measurement produced 
the greatest variability in wound area measurement. 
The above work was further supported by Lagan et al (2000), who compared the reliability 
of direct and photographic tracings analysed by planimetry and digital techniques in the 
measurement of various wound types. The level of repeatability of these methods and the 
level of variability in wound size was investigated. There was increased variability using 
planimetry compared to digital techniques and planimetry produced lower readings for 
wound measurement overall.  
Shaw et al (2007) evaluated and compared three wound measurement techniques: the 
Visitrak system using acetate tracings and planimetry (Smyth and Nephew Healthcare, Hull 
UK), a digital photography and image processing system (Analyse, Version 6.0; Analyse 
Direct, Lenexa, KS) and a wound tracing and elliptical measurement method using the 
standard formula (π ab) for the calculation of the area of an ellipse. These methods were 
used to measure wound surface area for a series of diabetic foot wounds (n=16), of greater 
than four weeks duration.  
Validity within each measurement method was determined using a one-sample t test. 
Repeatability within each method was investigated by calculating a coefficient of variation 
(CV) for each wound measurement. An ANOVA was used to complete a calculation of 
comparability between the methods. A paired t- test was used to examine differences 
between the elliptical and Visitrak methods. 
Validity varied across the three methods but was considered to be acceptable. The Visitrak 
method measured images <25mm2 inaccurately and the elliptical method of measurement 
tended to underestimate size in small wounds. The image processing method was inaccurate 
for both large and small wounds. Repeatability was acceptable across the three methods. The 
mean CV for all wounds was calculated as 7.0 for Visitrak, 4.7 for image processing, and 8.5 for 
the elliptical method. No one method was more repeatable than another. An analysis of 
comparability between the methods indicated variability particularly between the Visitrak and 
elliptical methods . The main limitations of the study are that the sample size was small and 
conclusions can only be drawn for diabetic foot wounds. 
5. Implications for clinical practice 
Ideally the outcome of any treatment regimen in the management of diabetic foot wounds is 
complete wound closure. The ability to measure a percentage area reduction may be 
important in differentiating between healing and non-healing wounds, and for the 
evaluation of the efficacy of different treatment regimens. Several authors have described 
the importance of regular wound measurement and reported that a percentage change in 
wound area over a 4 week period of 30% or more, reliably predicted wound healing (Kantor 
and Margolis, 2000; Sheehan et al, 2003; Gethin, 2006; Papazoglou et al, 2010).  
 




Historically wound measurement techniques have focussed on 2-dimensional methods 
using linear measurement, wound tracings and photography for wound assessment in the 
clinical setting (Langemo et al, 1998). To date there is still no standardised, universally 
accepted method with the method chosen largely depending on the level of accuracy 
required. If a broad indication of wound size is required then a simple technique that is 
minimally invasive, fast and comfortable for the patient may be adequate. If a more accurate 
measurement is required (for example in a research study or to enable clinicians to predict 
wound healing), a more robust method is necessary. Any wound measurement technique 
has to demonstrate that it is accurate, repeatable and capable of influencing patient care in a 
positive, cost-effective manner. This can be aided when used in conjunction with a wound 
measurement protocol (Plassmann and Peters, 2001). Clinicians will inevitably be influenced 
by the ease of use of a particular tool and efficient use of clinical time.  
Simple ruler-based methods provide a crude wound measurement that overestimates 
wound area by twenty five percent. Complex mathematical models may not be useful for 
busy clinicians unless incorporated into appropriate software packages that are quick and 
easy to use. However simple formulae such as those discussed earlier to calculate the area of 
an ellipse can be used easily in conjunction with wound tracings. The main advantages of 
this method were that it was quick, easy to use, and non-invasive and that it considered 
body curvature.  Limitations of this method are recognised in that there may be an 
overestimation of wound area by around 10% (Mayrovitz, 1997). However, diabetic foot 
wounds are often spherical or elliptical in nature, and Shaw et al (2007) have shown that this 
is a valid and repeatable method of measurement to use in this group of patients. In contrast 
in this study, the elliptical method was shown to underestimate wound size compared to 
tracing and planimetry (Visitrak system) and an image processing system. 
Wound planimetry can be carried out within a wound tracing or a digital image. 
Measurement of wound area is reported to be most accurate in smaller wounds <10cm2. The 
main advantages of the Visitrak method was that it was quick, easy to use, non-invasive, it 
considered body curvature and the subjectivity of manually counting squares was removed. 
The main disadvantage was that it tended to underestimate wound size compared to the 
elliptical method and was inaccurate in the measurement of wounds <25mm2 (Shaw et al, 
2007). 
Digital imaging takes considerable time and studies seldom show the total time to capture 
the image, transfer the image from the camera to the computer, and then calibrate and 
measure the wound. Computerised methods may be more accurate, but their use is limited 
due to availability, complicated calibration procedures, cost and clinician time (Plassmann 
and Jones, 1992; Xiang Liu et al 2006). The advantages of digital imaging are that it facilitates 
unique calibration at each wound measurement and subjective wound tracing is eliminated. 
However the accuracy of results does depend on the investigator’s ability to take a high 
quality image in the first instance and the accurate identification of the wound edge from 
the image. Many additional factors also require management such as lighting, environment 
and the distance of the camera from the foot. This method clearly has great potential, but 
depends largely on the clinicians’ ability to identify the wound margin accurately, as well as 
the influence of practical factors in the clinical environment. 
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7. Conclusions and the way forward 
Various methods of wound surface area measurement have been described, and the 
advantages and disadvantages of each have been discussed. It is essential that an 
appropriate method is chosen if diabetic foot wounds are to be measured accurately as well 
as to provide robust results in research wound healing studies.  
Historically wound measurement techniques have focussed on 2-dimensional methods 
using linear measurement, wound tracings and photography for wound assessment in the 
clinical setting. To date there is still no standardised, universally accepted method used. 
Digital imaging and computerised methods take considerable time and can be costly and 
complex mathematical models may not be useful for busy clinicians unless incorporated 
into appropriate software packages that are quick and easy to use. Computer software that 
automatically identifies the wound edge thus increasing accuracy and speed of 
measurement would be a major step forward. 
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The Temporary Orthesio-Therapy  
for Diabetic Foot 
Richard Florence  
Podiatrist, Peyrehorade, Pédicure – Podologue D.E. 
 France 
1. Introduction 
I was taught Temporary Orthesio-therapy by Dr Robert van Lith, a Dutch Podiatrist, who 
wrote a book called: “Podologie Appliquée”1.  
This therapy technique is used after a very careful examination of the foot, and of the fitting 
qualities of shoes; an analysis of the involved pathologies and the right use of the tools. It is 
thus possible to take out the mechanical trauma of the conflicting areas. The knowledge of 
the foot “biomechanic”, together with the knowledge of TOT allows relieving and curing a 
“keratopathy”. 
Mechanical stresses are one of the reasons of the foot ulceration appearance; this therapy 
represents therefore a relevant one for a diabetic patient. 
2. Materials and methodology 
My purpose is not to deliver a lesson on TOT: it was thoroughly explained in the author’s 
book. As its name says, this technique has to be used just before the permanent orthosis 
setting up. It is used during the scarring phase. 
Doctor Margreet van Putten, Fontys Paramedische Hogeschool manager in Eindhoven, 
wrote: “Almost 80% of diabetic ulcers will be cured by offloading the ulcer pressure. Then, you 
should never take other actions   than “unloading the pressure!”(Drôme seminary2 ).  
The list below is not exhaustive but it presents the necessary materials to prepare a 
temporary orthosis (TO) for the clinical cases described. 
2.1 Materials  
2.1.1 Adhesive pressure deflection materials  
Used products are made by Cuxson Gerrard & Co. Ltd Company, located in England.  
                                                                 
1 Van Lith Robert, July 2003, Podologie appliquée, Edition du Lau, ISBN : 2 84750 052 9,  Page 67. 
2 Van Putten Margreet, van Lith Marie-Josée, van Lith Robert, The diabetic foot, Montelimar Seminary 
(Drôme, France), March 2002. 
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These products are : 
- Hapla All Wool Felt ®: pure new wool felt, semi-packed in tight. 
- Hapla Gold Felt ®: improved felt with anti-infective agent to protect the foot from 
fungal and bacterium infection. This product is recommended by Cuxson Gerrard 
Company to be used on sensitive feet. 
- Moleskin ®:  thin fleece-lined non stretch cotton  
- Hapla Fleecy Web ®: cotton jersey with a fleece-lined cotton surface. Transversally 
strecht. 
2.1.2 Non - adhesive pressure deflection materials 
- Plastazote ®: thermoformable polyurethane rubber. 
- Walk-line ®: non-rigid thermoformable material. 
- Thermoformable Latex foam. 
2.1.3 Attachment materials 
- Hapla band ® (Cuxson & Gerrard) : thin hypoallergenique bandage. 
- Micropore ®: (3 M) micro- porus band-aid with high skin tolerance, air permeable. It 
doesn’t cause contact allergy. 
- Chirofix ®: (Cuxson & Gerrard) adhesive bandage with good skin tolerance, micro-
porus and transversally strecht. 
- Oper fix ®: (Iberhospitex S.A.) strecht tape. 
2.1.4 Bandages 
- Urgotul S. Ag/S.D. ®: Laboratory URGO 
- Mepilex Border ® : Laboratory  Mölnlycke Health Care 
- Biatain ® : Laboratory Coloplast 
- Cellosorb Silver Ag ®:  Laboratory URGO 
- Actisorb ® : Laboratory Johnson – Johnson Medical ltd 
2.2 Methodology  
The medical examination is essential to find the first cause of the infection (keropathy, 
wound or ulceration). 
One should observe : 
- Deformed foot (hallux or toes) 
- Deformed tarsus. 
One should look for : 
- Neuropathy or arteriopathy  presence, 
- Static position troubles with hyper hold in toes, metatarsal heads,  or fifth metatarsus 
stiloïd. 
- Dynamic troubles, 
- Limited joints mobility 
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The association of all these factors makes the diabetic foot a risky foot.  
Pathway to the diabetic foot ulceration3: 
 
Fig. 1. 
We need to discover what kind of stress is responsible for the pathology (chafing stress, 
pression or compression, twisting). 
Mechanical stresses are responsible for kerathonic pathology. They give skin irritation, 
accelerate cellular mitosis and enhance hyperkeratosis appearance. 
                                                                 
3 The International Working Group on the Diabetic Foot, may 1999, International Consensus on the 
Diabetic Foot,  Copyright by the International Working Group on the Diabetic Foot, ISBN : 90-9012716-
x. (page 29: Pathways to diabetic foot ulceration.) 
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It is absolutely necessary to know what kind of stress is responsible for the pathology 
appearance4 
It is also necessary to analyze the shoes. 
Shoes wearing advice : 
- Shoes must be well formed regarding the shape of the foot (length and width) 
- Shoes must give a good support because the feet must not slip while walking 
- Shoe upper must allow toes to move (mind the height) and, if possible, avoid seams  
- Shoe back needs a good stiffener 
- Sole must be soft in metatarsis junctions to allow foot flexion and it must be hard on the 
back part of it (be careful not to have twisting movement of the front part of the sole 
regarding to the back part of it). 
It must be confortable. 
When compression stress is responsible of the pathology, I use a pair of clips to put out of 






 Cure the conflictual zone by make the stresses disappear (chafing, pressure and twisting), 
 Correct if possible or protect, 
 Give a normal function to the articulations again 
 If needed, fit with prosthesis to ease step development. 
Conclusion: My aim is to enhance the patient autonomy by protecting his or her walking 
possibilities. 
                                                                 
4 Richard, F., TOT training session notes, Nantes,  September, 1998. 
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In case of a risky foot and when it is hard to find convenient shoes, suitable for the foot out 
shaping, we need to ask an orthopedist to make made to measure shoes. 
After the medical examination, I use to make a prevention assessment, I explain all the 
different treatment steps (correction, protection, contention with a disease if necessary) and I 
try to make the patient understand that he or she needs to respect his or her feet. 
This treatment is carried out after the instrumental gesture 
The used materials allow the therapist to adjust himself to the different clinical cases. 
The TO is taped on the skin. 
Felt TO is put on to offload the hyper-pressured area in order to eliminate the mechanical 
stresses of chafing (static and dynamic) 
The offloading zone delimitation will be found after the palpation of the zone to be 
protected, apart from the cellulitis (presence of swelling, erythema and heat indication an 
inflammatory reaction). 
The TO shape is adaptable according to the recovery step.5 
There is no limit: one has just to be inventive and creative. 
Hapla Felt is used in 2 mm size, 5 mm or 7 mm to offload the conflicted area.. 
One needs to take into account the loading capacity of the product (half of it) 
The felt can be doubled, or even triple according to the area which needs to be isolated. 
In order to make the TO easy to wear, it is essential to bevel the external sides. 
The more important the deformation is, the more material will be needed (felt) to allow a 
better pressure distribution. 
If the inflammation is important, it is absolutely necessary to totally stop walking and so the 
OT will be bigger. 
The basic rules and a good knowledge of the materials allow getting a spectacular result. 
Nothing is left to chance because everything can be explained. 
The immediate elimination of mechanical stress caused by chafing and pressure allows the 
patient to put on shoes again without feeling any risk. 
In case the patient would suffer neuropathy, the TO would assure scarring.   
But this will only be possible provided that everything has been made to constantly offload 
the injured part during all the scarring time. 
As Jean-Louis Richard, Denyse Vannareau et Claire Parer-Richard underlined: offloading 
the foot is a fundamental measure without which scarring is impossible.6 
                                                                 
5 Richard, F., Transitory TOT: 28th Podiatry discussions seminary, Paris, 2003. 
6 Richard, J.L. et al. Article : le pied diabétique, Service des maladies de la nutrition et de la diabétologie, 
CHU de Nîmes, Le  Grau du Roi. 
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Dr  Ha Van Georges wrote about this :  « the perforating pain cannot be cured if the patient 
is still walking on it » 7. 
The TO will allow the uninterrupted protection of the conflicting zone while the foot is 
mobilized during the walk.  
And this will retain the walking radius, not to say increase it). 
Even when confined to bed, the patient’s foot is relieved of stress pressures. 
That is why I would like to quote again Robert Van Lith‘s book “Podologie appliquée”8 
Thanks to the scientific research team, the Cuxson Gerrard & Co.  Offers materials with an 
unique adhesive system.  





Fig. 3.  
                                                                 
7 Dr. Georges Ha Van (Paris), Equilibre N°197 1996 –Qu’est-ce qu’un mal perforant  et comment le 
prévenir ?  
8 Van Lith Robert, July 2003, Podologie appliquée, Edition du Lau, ISBN : 2 84750 052 9  (Pages 70-71 & 
108) 
9Etude éditée par Cuxson et Gerrard montrant le résultat obtenu avec antimicrobial treatment de 
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3. Results  
I would like to highlight this methodology by exposing several clinical cases: domiciliary 
care, in my podiatric office or in hospital. 
I wanted to present different situations because one can notice that ulceration is different 




The invasive treatment has to be appropriate for the patient‘s condition. 
The follow-up is different when the podiatrist is alone or in a multidisciplinary medical team. 
The described cases present treatments on different conflicted areas which helps us to 
present a wide range of this technique, that is to say: 
- Treated patient for a plantar keratopathy , right heel  
- Treated patient with  plantar keratopathy with a bruise on the metatarsal-phalangeal 
joint (big toe) reducing and preventing the patient from walking  
- TO for an ulceration in order to amputate the fifth toe  
- And some impressive cases in hospital. 
                                                                 
10 The International Working Group on the Diabetic Foot, may 1999, Practical Guidelines on the 
Management and the prevention of the Diabetic Foot, Copyright by the International Working Group 
on the Diabetic Foot, ISBN : 90-9012716-x.) page 2 :Illustration of ulcer due to repetitive stress.) 
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Here are some results achieved during some consultations: 
- Skin scarring is progressive, 
- Mechanical stress elimination prevents or postpones the risk of amputation.  
3.1 Domiciliary care  
3.1.1 CASE A: Treated patient for a plantar keratopathy, right heel  
 
A-1: first consultation 
 
A-2: debridement and total 
enucleation 
A-3: felt TO installing 
(5 mm felt with an offloading 
of the conflicted area). 
 
A-4: Bandage installing and 
fixation with Hapla-band 
A-5: after two weeks 
treatment 
A-6 et A-7: two steps 
enucleation with a set with 
diamonds cracks burrs 
 
A-6 et A-7: two steps 
enucleation with a set with 
diamonds cracks burrs 
A-8: End of the instrumental 
work. 
 
A-9: Moleskine installing. 
Which covers the back part of 
the foot. 
 
The Temporary Orthesio-Therapy for Diabetic Foot 
 
91 
A-10 : After two weeks treatment : skin is totally healthy.  Apply Hydra-defense balm or 
Akildia balm (Asepta-Akiléine laboratory). Which delays the keratin implantation. 
Fig. 5.  
3.1.2 CASE B: Treated patient with  plantar keratopathy with a bruise on the 
metatarsal-phalangeal joint (big toe) reducing and preventing the patient from walking  
B-1 : First consultation B-2  : TO installing (7 mm  felt with two layers) 
B- 3 : Fixation with Hapla-
band with an opening to 
allow wound access. 
B-4 : Medicinal  dressing 
(Biatain) , which has to be 
changed every 48 hours by 
the nurse in charge. After the 
debridement, new offloading 
is necessary every one or two 
weeks by the podiatrist. 
B-5 : Enucleation B- 6: TO fitting and Moleskiine fitting. 
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A-9: Moleskine installing. 
Which covers the back part of 
the foot. 
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A-10 : After two weeks treatment : skin is totally healthy.  Apply Hydra-defense balm or 
Akildia balm (Asepta-Akiléine laboratory). Which delays the keratin implantation. 
Fig. 5.  
3.1.2 CASE B: Treated patient with  plantar keratopathy with a bruise on the 
metatarsal-phalangeal joint (big toe) reducing and preventing the patient from walking  
B-1 : First consultation B-2  : TO installing (7 mm  felt with two layers) 
B- 3 : Fixation with Hapla-
band with an opening to 
allow wound access. 
B-4 : Medicinal  dressing 
(Biatain) , which has to be 
changed every 48 hours by 
the nurse in charge. After the 
debridement, new offloading 
is necessary every one or two 
weeks by the podiatrist. 
B-5 : Enucleation B- 6: TO fitting and Moleskiine fitting. 
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B-7 : After nine weeks, 
debridement and Moleskine 
installing. 
B-8 : After eleven weeks, 
debridement 
B-9 : Moleskine installing. 
 
 
B-10 : After one month. 
Without any protection and 
with an increase of the 
walking area, skin is 
wounded. 
B-8 : New felt offloading TO 
fitting. Extra explanation about 
the importance of this TOT 
treatment with orthotis device 
just after the total scarring. 
Device confection perpetuates 
the treatment results.
Fig. 6.  
3.2 In my podiatrist office  
3.2.1 CASE C: A diabetic patient grade zero, with a fifth metatarsal pain, on the 
external side  
 
C- 1 : first consultation 
C- 2 : TO installing 
Metatarsis head is totally 
offloaded (5 mm felt)
C- 3 : OT fixation with Hapla 
Band 
 




C 4 : after one month. The temporary removable orthosis 
has been lost. Felt offloading TO installing (offloading M5 
and P2/P3 articulation on the fifth toe). Recommendation 
for a silicone device , equivalent to an TOT but which can 
be removed. 
C 5 : silicone device. 
Fig. 7.  
3.2.2 CASE D: A diabetic patient grade one (September 2004), she is under oral 
medication. She presents a bad ulceration on the external side of her third toe, 
regarding to the distal articulation, due to a too long nail and to the shoes she is 
wearing (this kind of shoes are to be proscribed for diabetic patients) 
 
 
D-1 : First consultation with 
bad  shoes D-2 : angiopathy ulcer 
D-3 : TO installing on 
September 24th  (5 mm felt) 
 
D-4 : TO on September 28th 
after four days. D-5 : On October 8
th D-6 : debridement 
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D-7 : TO on October 15th D-8 : debridement 
D-9 : On November 29th, 
Moleskine fitting to avoid 
suction with felt TO  
 
D-10 : TO has been unsticked 
and returned, then sticked on 
a neighbor toe to show how 
the wound has scarred. 
D-11 : the patient has bought a 
new pair of shoes 
(17/12/2004). 
 
D-12 : orthopaedic shoes in 
2011. 
This patient has now diabete, 
grade two. 
Fig. 8.  
 
D-13 : Plastazote TO 
D-14 : Silicone sub-digital 
device and Fleecy web under 
P1/P2 to avoid  hyper-
keratosis. 
D- 15 : Ortho-plastic surgery   
with second toe protection. 
Fig. 9.  
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This patient’s diabete (Diabete Mellitus) comes up to grade 2 in 2009; from then she’s 
insulin-dependent. She has to cope with an angiopathy and suffers a severe neuropathy. 
Thanks to a regular medical follow up and to a healthy life, this patient has still got all her toes. 
Since 2010, she wears made-to-measure shoes with an appropriate interior shape, seamless. 
To avoid an ulceration relapse a under- diaphysis protective and corrective orthosis is 
installed. 
With a regular following and a good care of the nails every two months, the patient feet are 
protected. 
3.2.3 CASE E: A patient with a Charcot foot  
 
E – 1 : foot print E-2 : Debridement and enucleation E-3 : 7 mm TO fitting 
 
E-4 : after one week. E-5 : Felt TO installing and Moleskine. E-6 : Orthotic plantar device 
Fig. 10. 
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3.2.4 CASE F: The patient had her third toe amputated  
 
F - 7: First consultation F-8: Non-rigid Plastazote TO fixed with band-aid  F-9: Plantar view 
F-10 : front view 
Fig. 11. 
3.3 In hospital  
Lots of clinical cases are presented in Dr van Lith’s book (Podologie appliquée).  
The pictures below have been made and interpreted by Mrs. Marie José van Lith. She works 
in a podiatric office with a multidisciplinary medical team in the Romans hospital’s 
endocrinology department (Drôme, France).  
She was kind enough to take part in this article writing. 
3.3.1 CASE G: The patient here suffered a diabetic retinopathy which stucked her 
blind. She also had a kidney insufficiency (she was on dialysis twice a week). She 
died five within the five years 
While she was on hospital, first x-rays show a foot which can’t be mobilized therefore no corrective 
TO is possible, only the protective one can be installed. 
 
G-1 : The first x-rays G-2 : On August 29th 2002 G-3 : After debridement of both wounds, felt TO 
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installing, sticked with Oper 
fix bandage but which will be 
changed only every 8 days. 
 
 
G-4: Wounds were almost 
totally healed . Some holes 
made in the TO allows the 
nurses to dress  the wounds 
every two days  (Actisorb Ag+ 
covered with Cellosorb). 
G-5: A new wound appeared.
 
G-6: On April the 14th , after 
incision of the hyper-
keratosis. Skin started to 
worsen. The general patient’s 
state is declining. 
G-7: This picture has been made three or four days before the death. Hand distal phalanx 
are bare-skined and the patient is now totally blind. No surgery. 
Fig. 12.  
3.3.2 CASE H: The patient suffers a toes deviation. Big toe infraductus and total claw 
of the second toe. This patient is old, diabetic with a kidney insufficiency. He’s only 
treated by a podiatrist. He has very painful angiopathic wounds 
 
H-1: On May 13th  2004. First 
corrective Hapla Band TO and 
one inter-digital felt TO. 
H-2: On May the 27th 2004. 
Fifteen days later. 
H-3: Actisorb Ag+  application 
used all the treatment long. 
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H-4 : On June 24th 2004, 
corrective  thermoformable 
latex foam TO allowing to 
treat wounds et corrective 
sub-digital latex foam and a 
inter-digital device (dorsal 
view). 
H-5: Front view H-6: Plantar view 
Fig. 13. 
The protective TO was possible to fit after the articulations softening obtained by the Hapla-
Band TO installing. It is held with Micrope. The silicone permanent orthosis couldn’t be 
made because the patient couldn’t reach his own feet.  
Only the TO  was replaced every 2 or 3 weeks. 
3.3.3 CASE I: TO for an ulceration in order to amputate the fifth toe  
 
 
I-1 : Non-rigid  thermoformed 
material TO. 
 
I-2 : Thermoformed Plastazote 
TO, with felt inside. 
 
I-3 : Offloading TO. 
Fig. 14.  
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J-1: Fistulisation of a plantar ulceration in the 
inter-digital space of the fourth and fifth toes.
J-2: Offloading thermoformed TO, with felt 
inside, directly sticked in the shoe. 
Fig. 15. 
3.3.5 CASE K: Total transmetatarsal amputation  
 
K-1 : Total amputation. 
 
K-2: Inside shoe fitting : 
Plastazote has been used to fill 
in anterior part of the shoe. A 
silicone orthosis to avoid all 
stump frictions. 
 
K-3: Offloading orthosis 
confection with Bland Rose ® 
from Fresco silicone, directly 
cast  on the stump in the shoe. 
Fig. 16.  
The TOT used for this diabetic patient, helps us to understand the specialist’s aim: he 
wanted to educate and hand-hold this patient in his decease’s evolution. 
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The issues of protection and correction in this treatment are essential to make him accept the 
installing of a digital or plantar orthosis. The podiatrist helps his patient to have a 
therapeutic behavior to delay as long as possible the amputation. 
4. What instances does the TOT method fail? 
It is not the TOT method which presents a failure risk but the patient when he or she stops 
his or her treatment. When the work is properly done, there is no failure.  
Precaution to be taken when installing a TO are those of any other treatment: 
 The TO must not hurt, it is made to relief the patient.  
 The TO helps scarring because of the offloading of the conflicted area. 
 The TO is installed on safe areas and out of the irritated ones.  
 The TO shape is adapted according to the recovery step. 
 The TO opening will be as wide as the conflicted area requires. 
Pressures repartition thanks to the TO installed on safe areas offloads the irritated area. 
Pressure is quite often the aggravating factor. 
TOT is a very good therapeutic method in biomechanical pathology of foot.This is a quick 
technique aiming a immediate relief. This is the best treatment in severe pathologies. 
The podiatrist will always try to correct but if it is impossible then, he will choose the TO 
and the silicone protection devices or the offloading plantar devices). 
5. Conclusion 
I hope this technique will be found essential to handle ulceration on a high-risk foot of a 
diabetic patient. 
Having used this technique during twenty years now, I still discover the cleverness of this 
therapeutic methodology. 
And as Mrs. Marie-José van Lith said:  “One has to be creative for each medical case he has to deal 
with”. It is for me a real pleasure to do so. 
During all his career, my teacher (Dr. Robert van Lith) tried to transmit this technique to our 
colleagues and students. 
In 2001, I thought and I told to Dr van Lith that this would be possible by taking the diabetic 
foot treatment into account (we were on a world- congress of Podiatry in Paris and Dr 
Margreet van Putten and Mrs. Marie-José van Lith were there). 
In 2010, during the Podiatrist International Federation world conference in Amsterdam, Dr 
van Putten wanted to pay tribute to my teacher, an exceptional man, and when his wife, 
Marie-José van Lith received this tribute, she announced that she had succeeded in 
launching TOT in several endocrinology departments; she said: “This technique is based on 
medical laws which makes it a real treatment. To treat the wounds of the diabetic foot, this treatment 
is essential, before all permanent silicone or plantar orthosis which could be necessary after the 
complete wound recovery”. 
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This therapeutic technique should be transmitted to all our foot specialists’ colleagues. 
In the near future, I hope that this technique will be part of the teaching curriculum for 
French Podiatrists. I wish the words Temporary Orthesio-therapy and temporary orthosis will 
find their definition in the medical terms dictionary (Garnier Delamare). 
TOT should be officially recognized as beneficial to the public at large... to ensure a less 
harrowing future to the diabetic patients. 
6. Definition 
Temporary orthesio-therapy (Dr Robert van Lith):  This technique is called erroneously 
Padding in France. This name was brought in France by Franklin Charlesworth. This is a 
very inventive technique to achieve an immediate relief, before the use of a permanent 
silicone or plantar orthosis. 
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The Biomechanics of the Diabetic Foot 
Dennis Shavelson 
The Foot Typing Center,NYC, Outreach Program, Surgical Attending,  
Department of Podiatry, Wyckoff Heights Medical Center, Member, New York 
Presbyterian Healthcare System, Brooklyn, New York 
USA 
1. Introduction 
The importance of the physician’s role in examining and assessing the diabetic foot is hard 
to overstate.1-2 Fifteen percent of the 16 million diabetic patients in the United States will 
develop foot ulcers.3,4 The diabetic foot is responsible for more than half of the 67,000 annual 
non-traumatic lower extremity amputations in the developed world.5 Lower extremity 
amputation is 15 times more likely to occur in a patient with diabetes.6 The annual cost of 
amputations is $600 million and lost wages and morbidity are estimated at $1 billion, 
annually.7 Finally, studies have shown that primary care physicians are rarely performing 
foot examinations on their diabetic patients during routine visits.8 
The underlying reasons that the foot is the number one location for comorbidities in 
diabetes places peripheral neuropathy and its sequellae that include Loss of Protective 
Sensation (LOPS) and Loss of Proprioception atop the list9 with Peripheral Arterial 
Disease (PAD) ranking a distant second. These risk factors magnify preexisting 
biomechanical risk factors that function in closed chain (Table 1) into often overlooked loss 
of balance, function, productivity and quality of life that precede or are adjacent to the more 
obvious presentations of wounds, infections, hospitalizations and amputations that are, in 
reality, end stage events for more and more diabetic patients. 
 
1. Ground Reactive Forces 
2. Hard, Unyielding Shoes 
3. Underlying Biomechanical Pathology 
4. Body Mass and Weight 
5. Activity Level 
6. Fitness Level 
7. Health State 
Table 1. Underlying Biomechanical Risk Factors In Diabetes  
Podiatry, as a profession and by degree, is the only profession armed with an underlying 
Functional Lower Extremity Biomechanics (FLEB) core. Three years of Undergraduate FLEB 
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then followed by Continuing Medical Education and most importantly, every Doctor of 
Podiatric Medicine (DPM) has an Evidence Based Practice Rooted in Biomechanics that 
includes orthotics and active and passive therapies that have been practiced for generations 
by the podiatric community.  
It is my opinion that the medical community, weak in closed chain medicine, is not 
prepared to diagnose, treat and manage their patients biomechanically. This single fact is 
the reason that Podiatry plays such an important role in the medical community and the life 
of every diabetic.  
2. Biomechanics of the foot 
Definition: Biomechanics is the art and science of applying the scientific laws of Physics, 
Architecture, Engineering and Mechanics principles to living subjects. Although not a pure 
science and therefore, difficult to research and quantify, committed practitioners of 
Functional Lower Extremity Biomechanics (FLEB) have prepared themselves to conduct 
interpersonal practices by amassing foundational knowledge, professional experience and 
use the applicable evidence that has surfaced to produce, for each practitioner, his/her 
version of an Evidence Based Biomechanics Practice10-13.  
Unlike pure science that focuses on inanimate objects, living subjects often do not obey 
Primary Scientific Laws. This is offset by the Biomechanical Literature which contains over 
200 additions providing evidence that foot orthotics work14-18 in addition to continued 
research and study being called for and conducted but like other aspects of medicine, such 
as foot surgery, biomechanics remains as much an art as a science19-20. The Podiatry 
community has accepted as its responsibility, the closed chain foundation of our functional 
lives and in the case of the diabetic population, sits as educators, mentors and front line 
practitioners as no other specialist can when it comes to biomechanics and Closed Chain 
Medicine.  
Understanding the biomechanics of the foot is an important component in the evaluation of 
the diabetic foot probably deserving greater focus than it has received. The successful 
compensation of underlying foot type-specific biomechanical pathology cannot be 
underestimated as one of the most important adjacent preventive and treatment models 
in the health history of the diabetic.  
FLEB focuses on the human body from the low back down, in closed chain (standing [stance] 
or active [gait] and weighted upon the ground. Alternatively, Allopathic Medicine studies 
subjects in open chain kinetics (on an examining table or not weighted) 21. 
The etiological forces that must be overcome in managing a patient biomechanically can be 
reviewed using Table 1. Since they differ for each individual, unless a patient encounter 
during which a biomechanical evaluation is performed as well as a historical interview to 
assess coexisting etiological factors is performed by a biomechanically oriented Podiatrist, 
the resultant orthotic and treatment plan may fall short of its potential benefits.  
Removing pathological forces from the weightbearing surface of the foot, balancing and 
supporting the posture, leveraging the muscle-tendon units and training them to perform 
and providing functional and safe footwear for the diabetic foot are the biomechanical keys 
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to preventing and treating foot ulcers, gait and balance problems and neuropathic foot 
syndromes. The use of straps, pads, foot orthotics, muscle strengthening and training 
programs and therapeutic footwear before considering surgery has been shown to reduce 
foot ulcers, foot infections, amputation and hospitalizations in a diabetic population while 
allowing the patient to maintain and improve walking and active functioning with a high 
level of efficiency and minimal injury and disability22. 
The Biomechanical Anatomy of the Foot. Biomechanically, the foot can be divided into 
functional segments in two main ways. The first divides it at the Midtarsal Joint into a 
rearfoot and forefoot and the second divides the foot at the second and third rays into 
medial and lateral arch segments (Figure 1). 
 
Fig. 1. Functional anatomy of the foot. (Adapted from Glick JB. Dynamics of the foot in 
locomotion. Pod Management 4:136, 2001, with permission). 
The medial arch is composed of the calcaneus, talus, navicular, the three cuneiforms and the 
first, second and third metatarsals. The lateral arch is composed of the calcaneus, the cuboid 
and the fourth and fifth metatarsals.9 These two arches are connected by a transverse roof of 
bone. The surface underneath these osseous supports, architecturally, is known as The Vault 
of The Foot (Figure 2).23 This Vault, when centered and supported by healthy soft tissues, 
provides a lifetime foundation for upright weightbearing and function. In contrast if The 
Vault is allowed to become off-centered exhibiting excess stiffness, flexibility, collapse or 
arch, on a case to case basis, the resulting stressful compensations in pedal and postural 
bones, joints, muscles, tendons, ligaments and integumentary organs provides an ever 
increasing burden to society as we live longer and more active lives. 
 
Fig. 2. The Vault of The Foot 
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The gait cycle 
Human stance and activity is comprised of many patterns or cycles in order to maintain us 
erect and move us in all directions as we live our lives. Movement can be forward, 
backward, side-to-side or it may rock, sway or move us up or down. Each of these 
movements has a totally different Activity Cycle that makes different demands upon the 
body biomechanically. The Walking Cycle (moving forward) and The Backward Walking 
Cycle challenge the bones, muscles, tendons and ligaments very differently. The fact that we 
have so many different biomechanical tasks to accomplish combined with the variations in 
stress that each of them has on the structures performing them makes it impossible to 
present biomechanics in an understandable manner to inexperienced minds unless we focus 
on one specific Activity Cycle.  
Historically, in order to understand biomechanics foundationally, educators, researchers 
and practitioners have universally chosen The Activity Cycle of Forward Movement 
(walking) as the cycle to use when demonstrating, researching and monitoring FLEB. This 
cycle is known as “The Gait Cycle”.24 It is important to note that there are variations in The 
Gait Cycle that include Midstance Contact Gait and Forefoot Contact Gait that impact the 
foot and posture differently than The Heel Contact Gait Cycle. 
The Gait Cycle defines a complete step from heel contact to heel contact using one limb, 
either left or right. The gait cycle is first divided into a Stance Phase (60%), when the foot is 
in contact with the ground, and a Swing Phase (40%), when the foot is free floating. The 
stance phase is further divided into a contact phase (10%), a midstance phase (40%) and a 
propulsive phase (10%) (See Figure 3). Since pathology develops most when the foot is 
touching the ground, FLEB concentrates on the stance phase of gait. 
 
Fig. 3. The Stance Phase of Gait 
Because the tendo Achilles is medially inserted on the calcaneus, it places the foot in an 
inverted position when the stance phase of gait begins and so the heel strikes the ground on 
the lateral side of the vault. As foot function cascades forward, the heel everts (pronates) in 
order to place the medial surface of the foot upon the ground. Because of pronation, the ball 
of the foot contacts the ground (midstance) with the metatarsals hitting in order of 5,4,3,2 
and finally 1 as the medial side of the vault begins to support weight. Then, as the leg moves 
forward over the planted foot, the heel comes off the ground (Heel Rise) and when muscular 
power leverages to the point where they are stronger than the ground reactive forces and 
the metatarsal heads are firmly planted, the foot pushes off the ground (Propulsion) 
beginning the Float Phase of Gait. That is then repeated as we move from point A to point B. 
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The supporting structure of the lateral side of The Vault of The Foot, composed of bones that 
when healthy, has an architecture that allows it to lock when weighted without the need for 
much muscular and ligamentous support. This enables the lateral Vault to be primarily 
strong, stable, supportive and capable of assuming an Optimal Functional Position (OFP) 
without much ligamentous and muscular primary or compensatory assistance in both the 
rearfoot and the forefoot that is different for all individuals. When the lateral column 
functions from Optimal Functional Position, there is little compensatory tissue stress of the 
bones and supporting structures or compensatory muscle engine energy on both a 
microscopic or macroscopic level.  
In opposition, the bony architecture of the medial side of The Vault of The Foot lacks the 
ability to lock on its own when weighted without the assistance of a large number of 
primary muscle engines and ligamentous systems. This means that without strong and 
trained muscle engines and a well developed and conditioned ligamentous supporting 
system, the medial Vault of the Foot is not capable of maintaining its Optimal Functional 
Position and so it serves as the anatomical location for much of the biomechanical pathology 
that exists in both the rearfoot and forefoot (figures 4) for most feet. Collapse of the bony 
position of the medial side of the foot from its OFP results in stretching and reduced 
leverage of the ligaments and muscles that are mandated to lock and support the vault in 
OFP (figure 5). This creates a subclinical vicious closed chain biomechanical cycle early on 
that stresses the tissues on a cellular level that when repeated over and over as we live our 
lives eventually rises to clinical events like pain and overuse syndromes, foot and postural 
deformities and irreversible degenerative changes. Summarily, inherited medial vault 
weakness serves as the biomechanical etiology for FLEB and unless diagnosed and 
treated, guarantees compensatory degeneration, overuse, deformity and structural and 
functional breakdown in the feet and throughout the posture, in closed chain. 
 
Fig. 4. The Ligamentous Tie Beam Supports The Bony Truss in the Medial Column 
 
Fig. 5. The Longitudinal and Vertical Collapse of The Medial Column Deforming the OFP 
The current gold standard, known as Subtalar Joint (STJ) Neutral Examination was 
developed thirty years ago by Podiatrist Merton Root et al.25 In this system, all feet are cast 
for orthotics in subtalar joint neutral position to develop orthotic shells which are then 
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modified using Orthotic Reactive Postings and Modifications such as suggested by McPoil 
and Hunt27 in order to reduce tissue stress in areas of complaint. Rootian Biomechanics 
evolved what was known as orthopedics and the prescribing of custom arch supports in the 
colleges of podiatry into the current biomechanics and custom foot orthotics in the 1970’s. 
Low level research proving that STJ Neutral casted shells and prescription orders for 
rearfoot and forefoot corrections when ordering custom foot orthotics were beneficial are 
difficult to deny14-18. Unfortunately, Rootian Biomechanics is being shown to lack scientific 
merit and a lack of reproducibility and evidentiary proof.28-30 This may be because research 
is showing that in reality, most of the problems facing us in daily life involve lengthening, 
widening and collapse of the fore part of the foot on the sagittal and transverse planes and 
not the subtalar joint as Root and his followers preach.30-33 
In response to this fact, modern theories are surfacing that when practiced by a new wave of 
biomechanically committed podiatrists are returning the podiatrist to the top of a 
Biomechanical Pyramid and exposing the claims of others to be exaggerated.  
The doctor-patient relationship that only exists between a podiatrist using modern 
biomechanics to diagnose and treat the diabetic foot biomechanically using custom casting 
and prescribing techniques as well as individually tailored “Boot Camp” type training of the 
patient expands care beyond the “get sick and come to me” model of Kirby and Scherer34 
and Fuller35 into more of a wellness model offered by Dananberg31, Glaser33 and Shavelson38 
that includes prevention, intervention and quality of life expansion as part of care using 
varied casting techniques and treatment for underlying pathology that includes prevention, 
intervention and quality of life expansion as part of care using varied casting prescribing 
and training techniques, not just complaints. One such theory gaining in popularity is called 
The Foot Centering Theory of Biomechanics or Wellness Biomechanics invented and U.S. 
Patented by this author38-42  
The foot centering theory of biomechanics  
When it comes to understanding the foot as a supportive structure, in The Foot Centering 
Theory of Biomechanics, the dynamic arches of the foot and The Vault of the Foot are 
compared to architectural arches and vaults applying the principles and terminology of 
architectural engineering to the positional structure of the foot (figure 6). The use of 
architectural language reduces the previous difficult language of physics and mechanical 
engineering that has distanced practitioners, patients and the foot suffering public 
investigating and applying biomechanics. 
The architectural arches as structures have one function and that is to support. They are 
symmetrical (no back or front). Their pillars are equal in size, their component bricks are 
equal or proportional in size and shape and their keystones are centered. They resist wear 
and tear but fail as adaptive, functional and shock absorbing entities because they cannot 
provide leverage to ropes and pulleys trying to move it when attached. In opposition, pedal 
arches are assymetrical (they have a back and front). Their pillars are disproportional, their 
bones are of different size and shape and their keystones are off-centered. This means that 
pedal arches and vaults, in order to succeed as an adaptive, shock absorbing and mobile 
entities, are destined to fail as supporters (figure 6). 
In Foot Centering, rather than treat all feet from a Subtalar Joint Neutral platform, feet are 
profiled into subgroups or types that share common characteristics called Functional Foot 
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Types or FFT’s. These shared structural, functional and compensatory tendencies for those 
that test a particular foot type provide a platform from which to provide improved custom 
care for every patient. Within each subgroup, each subject shares similarities with respect to 
weightbearing position, segmental ranges of motion, predictable areas of strengths and 
weaknesses and certain precursor signs and symptoms that can help predict past, present 
and future foot and postural breakdown and performance issues.  
 
Fig. 6. Architectural vs. Pedal Arches 
Starting from Root’s well defined position of pedal neutrality (Figure 7) 43, two simple 
open chain tests are performed for the rearfoot and two tests for the forefoot determine  
 
Fig. 7. Root’s Neutral Position. 
the Supinatory End Range of Motion (SERM) and Pronatory End Range of Motion (PERM) 
of each segment defining a rearfoot type and forefoot type for every foot. These two 
segmental foot types then combine to produce a Functional Foot Type (FFT) that serves as a 
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starting platform to develop a plan of biomechanical care in the hands of a skilled 
professional.37  
The functional foot typing system 
In The Functional Foot Typing system, the total range of motion and the positional 
relationships within the rearfoot (the subtalar joint) and the forefoot (the midtarsal joint) 
gathered in open chain can be used to describe specific foot types and how they will 
compensate when placed in closed chain against the ground. 
The RF SERM Test represents subtalar joint position in the contact phase of The Gait Cycle 
and the RF PERM Test represents subtalar joint position in the midstance phase of gait. The 
FF SERM Test represents the first ray position at the midstance phase of The Gait Cycle and 
the FF PERM Test represents the first ray at the heel lift phase of propulsion (figure 8). 
  
Fig. 8. The SERM-PERM Positions in Gait 
The Rearfoot SERM-PERM and the Forefoot SERM-PERM tests each have four possible 
types that are designated Rigid, Stable, Flexible and Flat. 
In trying to present functional foot typing in three paragraphs, we will begin by defining the 
four possible functional rearfoot types and four functional forefoot types.  
The rearfoot foot types 
In the rigid rearfoot type, the rearfoot total range of motion is less than 15 degrees with the 
calcaneus inverted to the lower leg at both SERM and PERM.  
In the stable rearfoot type, the rearfoot total range of motion is 15 degrees with  
the calcaneus inverted to the lower leg at SERM and perpendicular to the lower leg at PERM.  
In the flexible rearfoot type, the rearfoot total range of motion is greater than 15 degrees 
with the calcaneus inverted to the lower leg at SERM and everted to the lower leg at PERM. 
In the flat rearfoot type, the rearfoot total range of motion is greater than 15 degrees in both 
SERM and PERM. 
The forefoot foot types 
In the rigid forefoot type, both the SERM and PERM position of 1st met horizontal bisection 
is plantarflexed to the 5th met horizontal bisection. 
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In the stable forefoot type, the SERM position of the 1st met horizontal bisection 
plantarflexed to the 5th met horizontal bisection and the PERM position of the 1st met 
horizontal bisection is online with the 5th met horizontal bisection. 
In the flexible forefoot type, the SERM position of the 1st met horizontal bisection is 
plantarflexed to the fifth metatarsal head horizontal bisection and the PERM position of the 
1st met horizontal bisection is dorsiflexed to the 5th met horizontal bisection. 
In the flat forefoot type, both the SERM and PERM position of the 1st met horizontal 
bisection is dorsiflexed to the fifth met horizontal bisection. 
Every pair of feet can be profiled as a specific rearfoot type and forefoot type. After a subject 
has been diagnosed with a Functional Rearfoot Type and a Functional Forefoot Type the 
Functional Foot Type is determined by combining both entities. The Functional Foot Typing 
System allows every foot to be classified into one of sixteen possible FFT’s. 
 


























































Fig. 9. The Functional Foot Typing Matrix 
When the four functional rearfoot types are plotted horizontally and the four functional 
forefoot types are plotted vertically, a matrix composed of sixteen boxes is created, each box 
representing a possible functional foot type (figure 7). This means that there are 16 possible 
FFT’s, however for the purposes of this chapter, 90% of all feet classify into one of five 
Common Foot Types (see figure 9) 
After diagnosing a subject’s foot type, a podiatrist can fabricate a positional prop in the 
form of a foot orthotic casted in the Optimal Functional Position (OFP) replacing his/her 
existing footbeds, foot type-specific. This reduces the need for the muscles to overcome 
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In the stable forefoot type, the SERM position of the 1st met horizontal bisection 
plantarflexed to the 5th met horizontal bisection and the PERM position of the 1st met 
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bisection is dorsiflexed to the fifth met horizontal bisection. 
Every pair of feet can be profiled as a specific rearfoot type and forefoot type. After a subject 
has been diagnosed with a Functional Rearfoot Type and a Functional Forefoot Type the 
Functional Foot Type is determined by combining both entities. The Functional Foot Typing 
System allows every foot to be classified into one of sixteen possible FFT’s. 
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pathological collapse allowing them to concentrate on balance and movement.  
Stress risers within the foot are reduced or eliminated due to healthy redistribution of 
weight, preventing biomechanical sequelae and preparing each patient to be trained for a 
better performance, efficiency and quality of life. The goal for success is strong feet and 
posture that performs efficiently with an end goal of reducing or eliminating the prop 
orthotic.  
This means that by knowing the foot type of a diabetic, the location of future ulcerations and 
infections can be predicted and prevented utilizing biomechanical treatment to balance and 
distribute weight, pressure and shear away from areas these predictable areas while 
expanding the functional quality of life so important to the longevity and fitness of the 
patient. 
The common functional foot types 
As stated previously, we are going to focus on The Five Common Functional Foot Types 
that 90% of all feet profile into (Figure 10) and the forefoot biomechanics that leads to most 
of the biomechanical pathology seen in practice, including many ulcers and wounds that 
develop in the feet of diabetics. 
 
Fig. 10. The Common Functional Foot Types 
The goals for success in Foot Centering are strong feet and posture that perform efficiently 
with reduced deformity, degeneration and suffering. In the case of the diabetic patient,  
we add the prevention, improved healing, reduction of invasive procedure needed  
and improved functional life when dealing with closed chain ulcers, wounds and 
infections.  
 
The Biomechanics of the Diabetic Foot 
 
113 
The characteristics of the Functional Foot Types (FFT’s) 44 
Each FFT is associated with a certain profile of features that as a whole unite the members of 
that FFT. These include lesion pattern, x-ray presentation, shoe wear pattern, foot 
deformities, foot pain and postural pain and fatigue symptoms. 
This means that if given the characteristics of a given patient, a biomechanically practiced 
podiatrist can place that patient into one of the FFT’s. 
Since some foot type characteristics are shared by more than one type, some patients may 
resemble each other and not be in the same FFT but when profiled, the foot type can be 
confirmed by its overall characteristics. For example, the presence of a range of motion of 
the 1st ray to fifth of lets say, 35 degrees in a patient diagnosed as a rigid forefoot type 
probably reflects poor typing since that would definitely place that subject into the flexible 
forefoot subgroup. 
Since they are foot type specific, pathological foot type characteristics, even if not yet 
evident for a given patient can be reduced or prevented by introducing OFP and 
compensatory threshold training as part of care. 
As an example, please review the characteristics of The Rigid Rearfoot/Rigid Forefoot FFT 
(figure 11). 
The Rigid Rearfoot/Rigid Forefoot 









Fig. 11. The Rigid Rearfoot/Rigid Forefoot FFT Characteristics 
Protective callus formation1,39 
In closed chain, when an area of the foot is overloaded with weight, shear or torque, there 
are two possible reactive occurrences in the skin.  
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The first results from an overwhelming acute force that gives the skin no time to protect 
itself from injury. This acute injury is known as blistering. The skin separates into two 
layers, a base and a roof that then fills up with body fluid or blood depending on which 
organs are involved.  
The second event occurs when there is subclinical repetitive microtrauma in the form of 
shear, pressure or torque to a weightbearing area of the foot and this results in reactive 
compression and thickening of the epidermal layers in that area presenting itself as a 
cascade of changes that occur ranging from protective callus (figure 12) to ulceration and 
wounding (figure 13). The level of change depends on how strong and how long the 
microtrauma continues. 
 
Fig. 12. Protective Callus 
 
Fig. 13. Pressure Ulcer with Deep Wound 
This means that if protective callus develops Functional Foot Type-Specific due at least in 
part to underlying, inherited biomechanical pathology, then foot typing diabetic patients, 
monitoring their protective calluses and treating them biomechanically utilizing Foot 
Centering so that they don’t advance into ulcers and wounds defines the important role of 
The Podiatrist as an integral part of the health care team of every diabetic. 
Ulcer, wound and amputation prevention in diabetics utilizing foot typing 
The application of Functional Foot Typing that best serves the diabetic is to look at the 
functional forefoot type and state the location of forefoot callus for each of the Common 
Foot Types. Whether these calluses exist or not on a patients biomechanical timeline, these 
areas are accepting greater than normal tissue stress which will cascade to ulceration 
unimpeded in the face of diabetic neuropathy and must be decompensated 
biomechanically. 45-49 
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The common functional foot type/ callus-ulcer patterns 
Figure 14 introduces the reader to the predictable sites of excess closed chain weight 
forming callus. Although the body’s desire is to protect these areas from injury, like the 
fingertips of a guitar player, continued ground and shoe reactive forces cascades the clinical 
picture to that of the very injury it is attempting to prevent .  
After diagnosing a subject’s foot type, a podiatrist can fabricate a positional prop in the form 
of a foot orthotic casted in the Optimal Functional Position (OFP) for that type. This reduces 
the need for the muscles to overcome pathological collapse allowing them to concentrate on 
balance and movement. Stress risers within the foot are reduced or eliminated preventing 
biomechanical sequelae and preparing each patient to be trained for a better foundational 
positioning and muscle engine performance. In addition, the need for protective callus 
formation reduces or is eliminated42. 
Functional Foot Type Callus/Ulcer Pattern 
Rigid/Rigid FFT  
First Met Callus, 5th Met Callus 
 
Rigid/Flexible FFT  
IP Hallux Callus, 
2nd Met Callus  
 
Stable/Stable FFT  Callus Hallux IP Joint, 2nd Met If Stressed, No Ulcer or Wound Formation 
Flexible/Flexible  
Medial First Met Callus, Rolloff Hallux IP Callus, 
2nd,3rd, 4th met callus 
Flat/Flat  
Fifth Met Callus 
Fig. 14. Callus-Ulcer patterns of the Common FFT’s 
Why is the diabetic foot so prone to problems? 
All of us inherits a functional foot type and are prone to accept its strengths and weaknesses. 
This inevitably leads us to suffer predictable quality of life issues due to biomechanical wear 
and tear and inefficient compensatory mechanisms that are impacted by concomitant factors 
such as weight, body type, age, activity level, health state, ground surfaces, equipment and 
vocation. 
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However, no one factor is so overwhelmingly important to consider when rating the 
importance of podiatry care in the form of functional lower extremity biomechanics than 
Diabetes Mellitus. This is because diabetics inheriting these very same FFT’s end up with 
greater quality of life issues including ulcerations, infections, deformities and amputations 
than their non diabetic counterparts due to the devastating comorbidities of peripheral 
neuropathy and PAD. The most devastating component comorbidity of DM relates to the 
fact that neuropathic diabetics lose what is known as proprioception or the ability to “feel 
and react to the road and navigate through it”. 
Walking and many other tasks require daily closed chain sensory input to adapt and modify 
motor patterns and muscle output to carry out the desired task. Fully functioning joints and 
bones, combined with adequate muscle strength, are needed. The result of this activity is 
also coupled with local soft tissue compensations affecting the foot–ground interface. These 
can be affected by the frictional properties of the sole, internal muscle activity as well as the 
inherited underlying biomechanics of each subject that can be improved with foot 
orthotics.50  
Proprioception  
Proprioception is defined as "sensing the motion and position of the body. Knowing where 
we are in space and judging how we should navigate that space is a biological quality that 
when combined with our intelligence, elevates us from the rest of the animal kingdom. 
Specialized nerve endings called Proprioceptors are present throughout the soft tissues of 
the musculoskeletal system. They interact with the central nervous system and coordinate 
our body movements, our postural alignment, and our balance. We rely on this delicately 
controlled and finely-tuned system of receptors and feedback loops and the validity and 
reliability of the information which is sent into the spinal cord tens of thousands of times 
every day.  
Proprioceptive health allows us to “read” our environment in order to generate appropriate 
motor responses to perform the motions, actions, tasks and functional skills that we must 
perform. A reduction of Proprioception impacts our ability to stand weighted without sway 
as well as our ability to perform artistic and athletic physical activity efficiently and to move 
from point “A” to point “B”. 
Over time, areas of the body without adequate proprioception are exposed to increased 
tissue stress that weaken, deform, degenerate and eventually break down the skin, 
connective and supportive soft tissue, ligaments, tendons, muscles, bones and joints in those 
areas as well as in other areas of the body that must compensate secondarily in order keep 
the body performing. 
The current scientific literature supports the following changes in the diabetic foot as a 
result of peripheral neuropathy: limited joint range of motion, glycosylation of tendons and 
soft tissue leading to restriction of motion, diminished plantar fat padding, and intrinsic 
muscle wasting with resultant clawing deformity of toes and contractures of the forefoot.45-51 
Although it cannot be stated with certainty in all cases, there is evidence to state that 
underlying biomechanical pathology results in reductions in joint range of motion 
(functional hallux limitus, functional hallux extensus and ankle equinus to name a few) in 
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the lower extremity. This results in stress in ligaments and tendons and joints such as the 
tendo Achilles, plantar fascia and great toe joint, especially in those foot types that are 
hypermobile such as the rearfoot and forefoot stable and flexible types. This in turn 
produces enlargement and fibrosis as well as subsequent contractures and weakness in the 
foot due to the sum of the repetitive micro injuries to the soft tissues, ligaments, muscles, 
tendons, joints and bones. 52-55  
Examples of where functional foot typing predicts locations for wounds, infections and 
ulcers would be the 2nd toe hammertoe prevalent in the rigid rearfoot-flexible forefoot FFT, 
The fifth met head lesions and wounds of the flat rearfoot-flat forefoot foot type, the hallux 
IP Rolloff Ulcers that cause hallux amputations are allied to the flexible rearfoot-flexible 
forefoot functional foot type and the severe ulceration of the plantar 1st metatarsal head that 
often leads to osteomyelitis of that area is linked to the rigid rearfoot-rigid forefoot FFT. 
In diabetes, Loss of Protective Sensation (LOPS), the end stage of proprioceptor pathology, 
by eliminating the pain protection response from the equation, leads to overwhelming 
integumentary tissue stress that is not decompensated due to the fact that the body cannot 
recognize its existence. This leads to pressure callus, pressure ulcers and wounds, 
amputations and limb loss because of a lack of proprioceptive warning. Proprioceptive 
pathology is an early and common finding in the polyneuropathy peripheral neuropathy 
associated with the disease and may even precede the presence of high fasting blood sugars 
(prediabetics).  
Summarily, insufficient information supplied by Proprioceptive Sensors reduces efficiency 
of movement, causes pathologic tissue stress, injury, problems with postural coordination 
and/or joint alignment and chronic, un-resolving pain in sensate areas as well as skin and 
soft tissue wounds and ulcers in advanced cases. 
Locations of nerve receptors 
The most important sensory nerve organs for controlling the muscular system are the 
muscle spindle fibers and the Golgi tendon organs.  
Muscle spindle fibers are found interspersed within the contractile fibers of all skeletal 
muscles, with the highest concentration in the central portion (belly) of each muscle. Muscle 
spindles respond to changes in muscle length and stress. Without this basic "wiring," proper 
joint alignment can't be maintained and closed chain stance is almost impossible. 58-59 
Golgi tendon organs are located in the junctions of muscles and their tendons. These 
protective nerve endings exert an inhibitory effect on contraction of muscle fibers (figure 
15). 
 
Fig. 15. A Golgi Tendon Organ 
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Fig. 15. A Golgi Tendon Organ 
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Joint mechanoreceptors (Table 2)  
Surrounding and protecting all joints are tough, fibrous tissues that contain a variety of 
sensory nerve endings. The input from these specialized sensors keeps the nervous system 
informed as to the location of the joint, and also their degree of stress they are under by 
monitoring stretch, compression, tension, acceleration, and rotation.  
Type I mechanoreceptors are found in higher densities in the proximal joints. They sense 
the position of a joint by signaling the joint angle through normal ranges of motion. These 
help determine postural (tonic) muscle contractions.  
Type II nerve endings adapt to changes in position, and are most active at onset and 
termination of movement. These are more densely distributed though the distal joints, and 
affect phasic muscle actions.  
Type III mechanoreceptors are high-threshold, which means they require considerable joint 
stress at end ranges before firing. These receptors serve a protective function similar to the 
Golgi tendon organs.  
Type IV receptors are free nerve endings located in the ligaments, joint capsules, and 
articular fat pads which respond to pain stimulus. They can generate intense, non-adapting 
motor responses in all muscles related to a joint, resulting in the protective muscle 
contractions that restrict joint movement.  
 
muscles and tendons muscle spindle fibers  Golgi tendon organs 
joint ligaments and capsules 
(mechanoreceptors) 
type I - low threshold, slow-adapting 
type II - low threshold, fast-adapting 
type III - high threshold, slow-adapting 
type IV - nociceptive (pain endings) 
Table 2. Sensory Organs for Proprioception 
In addition, stretch-sensitive receptors in the skin known as Ruffini ending, the Merkel cells 
in hairy skin and field receptors also signal postural and sensory information.  
The biomechanics of proprioception in the diabetic foot 
There are over 200 additions to the literature showing that custom orthotic support can help 
improve structural alignment, balance, gait, and athletic performance. 66-69 In addition, 
therapeutic shoes and orthotics have been shown to be effective in treating and preventing 
wound and ulcer formation and they are approved by U.S. Medicare for annual dispensing 
to diabetics as a cost saving to the health care budget.70 
It has been suggested that this universe of improvements is due primarily to upgrades in the 
sense of proprioception.66 A quick review of the mechanisms and components of 
proprioception will help us comprehend how patients can demonstrate such a large variety 
of improvements. Being able to explain this to patients (using simpler terms, of course) will 
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help them understand the reasons you are recommending they wear in-shoe orthotics and 
train their muscle-tendon units to a higher fitness level. 
Except for the spine, the foot is the anatomical region that contains the most proprioceptive 
sensory receptors. Because of the magnitude of sensory input, the feet are quick to produce 
problems when denied proprioception. These are magnified by the fact that the foot must 
additionally deal with ground reactive forces and hard, unyielding shoe boxes. Loss of 
balance, missteps, falls and a reduced ability to navigate efficiently and accurately are just 
some of the sequelae accompanying proprioceptive disease. Underlying foot type-specific 
biomechanical pathology impacts pedal posture, pedal muscle engine efficiency and the 
ability to perform tasks such as walking, lifting and recreational activities and when they 
exist in a diabetic, cause escalation of its musculoskeletal comorbidities. 
Pedal involvement  
The six specialized nerve sensors are found throughout the musculoskeletal system, in all 
skeletal muscles and in every ligament, joint capsule, and articular connective tissue. 
However, the feet are particularly well-supplied with proprioceptive nerve endings. 
Mechanoreceptors in the joints, along with the muscle spindles of the foot muscles are 
responsible for the positive support reflexes and a variety of automatic reflexive reactions71. 
These include the flexor/extensor reflex, which converts the lower limb into a firm, yet 
compliant pillar. Weightbearing compresses the joints and muscles, evoking reflexive 
activity in the extensors and inhibition of the flexor muscles.  
The vicious cycle of proprioceptive loss and peripheral neuropathy  
Second only to glucose control when it comes to managing diabetes is the need to be active 
and exercise. Increased metabolic disease via peripheral neuropathy causes a reduction in 
sensory perception of soft touch, pinprick, vibration, and pain eliminating a diabetic from 
recognizing and reacting to them. Proprioceptive deficits, on the other hand reduce a 
diabetics ability to know where they are, where they are going and how they are positioned 
in closed chain. It is the reduced proprioception causes diabetics to live their lives at a 
slower pace and reduced activity. This in turn allows the metabolic disease to become 
progressively worse causing advancement of the peripheral neuropathy.72 
It is the job of the health care team to foster diabetics to increase their activity levels 
efficiently for the long term. In a foundational sense, this begins with pedal support, 
improved proprioception, healthy compensation of underlying biomechanical pathology 
and the incorporation of monitored training and exercise programs into the lives of all 
diabetics. Until this is accomplished, diabetes will continue to fester in greater portion when 
compared to the rest of the population and the economic and social drain that diabetes 
places on society will continue to mount73.  
Like other paradigms of functional lower extremity biomechanics and foot orthotic use, 
there is little high level evidence available for practitioners to apply in using foot typing as a 
starting platform. OFP casting and Foot Type-specific prescribing anecdotally allow for 
more organized and predictable diagnosis and treatment of underlying biomechanical 
pathology. By preventing postural collapse and reducing the need for primary muscle 
engines to participate in postural alignment and efficiency, they foster all other aspects of 
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lifestyle upgrading and therefore it should be considered in the care of diabetics that suffer 
from underlying biomechanical pathology in the face of the dilution that has occurred for 
the current Rootian standard.  
The biomechanics of Charcot Joint Disease 
To site an example of the application of functional foot typing and Foot Centering 
Biomechanics to the ever-present factors in the development and progression of the 
comorbidities of diabetes and how podiatric closed chain diagnosis and treatment of these 
entities needs to be a part of the health care team one needs only to inspect Charcot Joint 
Disease (CJD).  
Charcot Joint Disease (CJD) 
Any physician treating patients with diabetes is aware that on any visit a patient can present 
with a foot or ankle that is red, hot, and swollen that is not infected. This presentation 
signals the beginning of a destructive process affecting the soft tissues and bone structure of 
the foot and ankle called Charcot Joint Disease (CJD). It leads to joint and osseous collapse 
and degeneration, functional disability, ulceration, infection and eventual loss of limb. 
Understanding the etiology and progression of this process should be one of the goals of all 
members of the diabetes health care team, especially those involved in primary care.  
Although there is significant literature related to the diagnosis and treatment of Charcot 
joint once it develops74,76, there has been little discussion as to the predisposing 
Biomechanical Risk Factors that precede the development of Charcot foot and the need for 
preventive biomechanical treatment once it exists. 
The Precursors of Charcot Joint Disease (CJD) The pathophysiology of Charcot joint 
disease (CJD) remains unknown. One prevalent theory (Volkmann and Virchow) is named 
the neurotraumatic theory.77 This theory proposes that the joint destruction of CJD is due to 
a neuropathic foot that leads to loss of proprioception and pain sensation, thereby 
permitting joints to be exerted to the point of collapse and destruction.78 The neurotraumatic 
theory finds support in studies which demonstrate that plantar pressures are higher in the 
metatarsophalangeal joints of the forefoot in patients with acute CJD compared to patients 
with distal sensorimotor neuropathy or neuropathic ulceration.75 In addition, the motor 
neuropathy in the diabetic lower extremity tends to precipitate a weakness of muscle groups 
in the lower extremity, creating dynamic and functional imbalances that either initiate or 
compound deformities within the foot. 
Whether there is feeling the foot or not, the level of underlying biomechanical pathology 
that exists will determine the level and rate of progression of the cascade of degeneration, 
deformity, disuse and injury that an individual suffers.  
We all suffer from subclinical injury that is of a biomechanical nature. Cellular and tissue 
stress that goes beyond physiological tolerance. These injuries repair and may even 
stimulate the development of stronger and more capable cells and tissues. However, once 
these stresses pass certain thresholds, clinical injury occurs accompanied by various signs 
and symptoms. These signs and symptoms alert one to address the injury so as to keep it 
from progressing. Pain, heat, pressure and pinching present early in injury and send a 
message to change ones lifestyle, environment or metabolism in order to prevent an injury 
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from worsening. In the advanced stages of peripheral neuropathy, there is an absence of 
these cellular and tissue alarms allowing injuries to progress to a much higher level before 
becoming clinically evident. This phenomenon is known as Loss of Protective Sensation or 
LOPS. 
This phenomenon, when present in a diabetic that has inherent underlying biomechanical 
pathology, instead of presenting with painful bunions, stress injuries or ligamentous 
stresses such as plantar fasciitis, presents with a pathological collapse of the foot, 
involving insensate joints that have lost proprioception in their end nerve organs that is 
The Charcot Foot. 
In the Functional Foot Typing System, it is the stable and flexible rearfoot and forefoot foot 
types that are most commonly involved in Charcot Foot. The rigid and flat rearfoot and 
forefoot foot types, on the other hand resist collapse and the type of injury that may be a 
precursor of CJD. 
More specifically, advanced flexible rearfoot types tend to lead to ankle CJD while moderate 
ones tend more towards a medial collapse under the navicular that leads to cuboidal ulcers 
and wounds. In contrast, the flexible forefoot foot types lead to 1st MP Joint 
neuroarthropathy and transfer ulceration under the 2nd metatarsal head, the IP Hallux and 
sub 5th metatarsal head.94  
The pre-charcot foot80  
When discussing the Charcot foot, the literature consistently points to the existence of 
peripheral neuropathy and a loss of protective sensation as necessary in order to develop a 
Charcot Foot and the presence of patent, healthy circulation in order for the hyperemia of 
CJD to occur. If ischemia is present, wet or dry gangrene, rather than CJD develops. 
Finally, whether primary or secondary, trauma or repetitive micro-trauma is necessary in 
order for CJD to progress. This trauma is exacerbated by closed chain factors such as obesity 
and an active lifestyle that must be appreciated and overcome by the examiner in order to 
treat CJD successfully.  
In summary we have defined the pre-Charcot foot as a clinical entity displaying the 
following quartet of signs and symptoms: 
1. Loss of Protective Sensation (LOPS) 
2. Patent Circulation 
3. Underlying Pedal Biomechanical Pathology and Weakness 
(Functional Foot Typing) 
4. Excessive Closed Chain Factors 
(obesity, over-activity, etc.) 
Inherent pedal biomechanical pathology and weakness (see biomechanics)  
The presence of inherited, underlying biomechanical pathology is almost universal in the 
development of CJD. It is indeed rare to find a foot with normal mechanics go on to 
develop CJD probably because those diabetics find it easier to navigate through lives 
more actively.  
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Excessive closed chain factors 
The lifestyle and quality of life of each individual varies in many ways when in closed chain. 
A careful history revealing the existence and extent of closed chain factors will assist a 
practitioner to determine their impact on the need to actively treat a subject’s functional foot 
type. A person who is morbidly obese, very active and wearing worn out athletic shoes may 
need treatment even if he/she has a stable foot type. Conversely, in the face of LOPS, patent 
circulation and biomechanical pathology, a healthy and fit, light weight person, who is not 
very active and wear well fitted shoes and socks that are not outworn has much less of a 
chance to develop a Charcot Foot. 
3. Discussion 
Biomechanically, we would like individuals to have a lifestyle that includes exercise along 
with varied daily activities that promote aerobic health and functional fitness. Our goal 
should not be to reduce patients from being active and living a healthy lifestyle but instead 
to promote an active lifestyle for all while supporting them and training them 
biomechanically, injury, deformity and wound free. 
Even though podiatry has become more and more an acceptable part of the diabetes health 
care team, there remains a poor understanding of functional lower extremity biomechanics 
and the need for diagnosing and treating underlying biomechanical pathology before, 
during and after the devastating comorbidities of diabetes reveals itself clinically. It is the 
hope of the author that all readers will be stimulated to increase their knowledge base 
regarding the needs of the diabetic patient when it comes to their feet so that foot suffering 
diabetics can be better cared for.  
The podiatrist, skilled in closed chain medicine, biomechanical pathology and the diagnosis 
and treatment of the functional foot types is a necessary part of the health care team 
involved in treating diabetics. An annual foot exam and necessary follow-up that includes 
functional lower extremity biomechanics should be a mandatory part of the care of every 
diabetic and capable of being delivered by all members of the health care team. 
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1. Introduction 
The Pennsylvania Department of Health’s Diabetes Prevention and Control Program 
provided a contract to develop a Comprehensive Podogeriatric and Chronic Diseases 
Podogeriatric Assessment Protocol (Helfand Index – Appendix A). The goal was to provide 
a methodology to assess foot, ankle, and related structural problems in older patients; 
stratify those patients most at risk to develop complications; develop a surveillance 
instrument for patient care: and to serve as a public health data collection outcome 
measurement. The information obtained would also provide a protocol to develop 
prevention (primary, secondary and tertiary) and management programs for individual 
patients, institutions, and their communities, augment geriatric and chronic disease 
assessment, as well as stressing the need for appropriate patient management, professional, 
and patient education.   
Foot problems identified in older diabetic patients are the result of the aging process, 
disease, disability, deformity, and complications associated with other chronic diseases. 
They are related to societal, environmental, and life style issues. Foot discomfort and pain or 
podalgia represent some of the most distressing, disabling, and known quality of life 
limiting conditions. Diabetic foot problems in the older patient are a major cause of 
morbidity, disability, and hospitalization and contribute to a lessening of the quality and 
independence of life, thus contributing to an earlier and higher mortality. The high 
prevalence of chronic diseases in the older population, such as, diabetes mellitus, arthritis, 
peripheral arterial disease as well as those conditions that produce sensory, peripheral 
vascular, musculo-skeletal, dermatologic, onychial, and neurologic deficits, lead to serious 
complications that increase morbidity, mortality, and health care costs. (1, 2, 3, 4, 5, 6) 
Other life altering issues in the older patient include constipation, weakened muscle and 
bone structure, social isolation, mobility deficits, reduced Activities of Daily Living and 
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Instrumental Activities of Daily Living, sleep problems, agitation and compulsive disorders, 
increased perspiration, self mutilation and excoriation. The immobility that results from a 
local foot problem or as the result of a complication of a systemic disease can have a 
significant negative impact on the patient's ability to maintain a productive quality of life as 
member of society and to live life, to the end of life with dignity. The senior years should not 
become a period of “waiting for GOD”. (17, 18, 19, 20, 21) 
Diseases and disorders of foot and their related structures in the older patient and in 
particular diabetes mellitus and its neurovascular complications are a significant public 
health concern. The changes in the individuals' ability to maintain their independence 
become financial concerns for the individual, their families, and society in general. Two 
important factors involved in the older patient's ability to remain as a vital part of society 
are a keen mind and the ability to retain their mobility through ambulation. (5) 
There are many other factors, which also contribute to the development of foot problems of 
the adult population including the aging process itself as well as abuse and neglect. Some of 
these considerations include: the degree of ambulation, the duration of prior hospitalization, 
limitation of activity, prior institutionalization, episodes of social segregation, depression, 
prior care, emotional adjustments to disease and life in general, polypharmacy and drug 
interactions, and the complications and residuals associated with risk diseases. Other 
focused issues include a loss of tissue and joint elasticity; atrophy of fat and protective 
tissue; a weakening of the intrinsic muscles of the foot; a loss of balance and range of 
motion; an increase in foot size due to tissue laxity; a decrease in arch height; dry skin; and 
onychial dystrophies. (16, 18)  
High risk factors for older diabetic patients include age itself, elevated blood sugar, 
hypertension, a history of a stroke, retinopathy, nephropathy, a history and duration of 
diabetes for more than ten years, delayed treatment, failure of diabetic foot health 
education, visual impairment , the inability to bend, living alone, a history of tobacco use, 
cognitive impairment, dementia, risk taking behavior, sensory loss, a loss of protective 
sensation, structural abnormalities, altered gait, ambulatory dysfunction, abnormal or 
excessive foot pressure, subkeratotic or subungual hematoma, a history of foot ulcers, 
decreased peripheral arterial pulses, peripheral arterial and vascular disease, diabetic 
neuropathy, soft tissue and plantar fat pad atrophy and/or displacement, deformities 
(limited joint mobility, hallux valgus, hallux limitus, hammer toes, prominent metatarsal 
heads and prolapse), xerosis, fissures, obesity, and other related chronic diseases, such as 
degenerative arthritis, rheumatoid arthritis, and gout. (9, 10, 22) 
Additional systemic and/or life changes contributing to the development of high risk foot 
problems include impaired cardiovascular function, chronic constipation and incontinence, 
weakened muscle and bone structure, impaired cardiovascular function, diabetes mellitus, 
peripheral vascular and lower extremity arterial and venous disease, reduced interest 
and/or participation in social activities, decreased and/or loss of mobility, weakened 
muscle and bone structure, a reduction in independent activities of daily living and/or 
instrumental activities of daily living, sleep disorders, agitation, compulsive activities, 
increased foot perspiration, neurological and sensory deficits, neurotic excoriation, changes 
in mental status, and cognitive impairment. Self-mutilation, untreated and/or under treated 
hyperkeratosis, onychauxis, onychomycosis, ulcers, tinea pedis, xerosis, abrasions and/or 
lacerations are also contributing factors. (25, 26, 27) 
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Older patients, especially those with chronic diseases, such as diabetes mellitus are usually 
taking more than one therapeutic drug at any given moment and may have increased 
sensitivity and they are usually more susceptible to infection because of the anatomic 
location of the foot itself. Associated avascularity, atrophy of soft tissue, muscle wasting, 
neuropathic changes, and a lack of concern for foot health, is associated with the aging and 
our society. They are concerned about life, as life in a sense is a terminal illness and they 
have a lower threshold of physical and emotional stress. They may have ambulatory 
limitation and usually have one or more chronic diseases. They are more prone to injury 
involving the lower extremity that additionally limits ambulation and mobility. And, they 
are prone to present with delayed or non-healing tissues. (12) 
2. General information 
The Assessment Protocol (Appendix A) reviews information related to demographics; 
primary medical facilities and management; a history of present problems; pertinent past 
medical history; a systems review; current medications; visual evaluation, foot 
dermatologic, foot orthopedic, peripheral vascular, and neurologic evaluation; neurologic 
risk stratification; peripheral arterial risk stratification; footwear evaluation; a primary 
assessment; an initial management plan; and referral direction; Medicare's class findings; 
risk stratification of onychomycosis, plantar pressure keratotic patterns, pre and ulcer 
classification, and the classification of mechanical or pressure hyperkeratotic lesions. (22, 23, 
24) 
The evaluation process is enhanced by the use of accessible instrumentation such as a C –128 
Hz Tuning Fork; Neurologic Hammer; Percussion Hammer; Babinski Hammer; 
Neurothesiometer or similar instrumentation (Biothesiometer) to determine the Vibration 
Perception Threshold (VPT); Monofilament Sensory Testing (MST) devices such as the 
Semmes - Weinstein 5.07 nylon monofilament (SWM), Norton Monofilament, or the West 
Enhanced Sensory Test; Two Point Discriminator, Pinwheel, Tip-Therm, Tacticon; Doppler; 
Pulse Volume Recordings (PVR), Pressure-Stat, Temp-Stat, Radiometer - infrared surface 
temperature scanner for skin perfusion assessment; Ankle and Toe Brachial Index; 
Oscillometer;  Transcutaneous Oxygen (TCPO2); Radiography; MRI and CT Scans; and 
Contrast Arteriography as indicated. 
The demographics, past medical history, system review, medications and therapeutic 
programs, current health conditions should be reviewed and noted from the medical record. 
Primary foot problems as well as their relationship to chronicity and activities, including; 
swelling, pain, hyperkeratosis, joint deformities, onychial diseases and disorders, infections, 
coldness, and other problems, as well as location, quality, severity, duration, context, 
modifying factors, and associated signs and symptoms, should also be noted from the 
institutional record.  
The primary and secondary “at risk” diseases and disorders include complications 
associated with diabetes mellitus and metabolic disorders, peripheral vascular , lower 
extremity arterial and venous diseases, sensory and motor impairment, edema, degenerative 
joint changes and the residuals of arthritis and collagen diseases, ambulatory dysfunction, 
obesity, and cognitive impairment. (28) 
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In 1971, Medicare Regulations identified a number diseases and/or disorders that develop 
vascular insufficiency and neurological insensitivity and their complications as risk factors 
related to management. The primary examples include the following but are not exclusive:  
- Amyotrophic Lateral Sclerosis  
- Arteriosclerosis obliterans (A.S.O., arteriosclerosis of the extremities, occlusive 
peripheral arteriosclerosis)  
- Arteritis of the feet  
- Buerger's disease (thromboangiitis obliterans)  
- Chronic indurated cellulitis  
- Chronic thrombophlebitis  
- Chronic venous insufficiency 
- Diabetes Mellitus  
- Intractable edema - secondary to a specific disease (e.g., congestive heart failure, kidney 
disease, hypothyroidism)  
- Lymphedema - secondary to a specific disease (e.g., Milroy's disease, malignancy)  
- Peripheral neuropathies involving the feet  
Associated with malnutrition and vitamin deficiency  
- Malnutrition (general, pellagra)  
- Alcoholism  
- Malabsorption (celiac disease, tropical sprue)  
-  Pernicious anemia  
- Associated with carcinoma  
- Associated with diabetes mellitus  
- Associated with drugs and toxins  
- Associated with multiple sclerosis  
- Associated with uremia (chronic renal disease)  
- Associated with traumatic injury  
- Associated with leprosy or neurosyphilis  
- Associated with hereditary disorders  
-  Hereditary sensory radically neuropathy  
- Angiokeratoma corporis diffusum (Fabry's)  
- Amyloid neuropathy  
Peripheral vascular disease  
Raynaud's disease  
The secondary “at risk” list of diseases and disorders include the following as examples: 
Deficiency of B-complex components, Lipidoses, Amyloidosis, Peripheral autonomic 
neuropathy in disorders classified elsewhere, Hereditary and idiopathic peripheral 
neuropathy, Acute infective polyneuritis, Polyneuropathy in collagen vascular disease, 
polyneuropathy in malignant disease, Polyneuropathy in other diseases classified 
elsewhere, Alcoholic polyneuropathy, Inflammatory and toxic neuropathy, Inflammatory 
and toxic neuropathy, unspecified, Atherosclerosis of native arteries of the extremities, 
Generalized and unspecified atherosclerosis, Raynaud's syndrome, Other specified 
peripheral vascular diseases, peripheral vascular disease, unspecified, Stricture of artery, 
Other lymphedema, Postphlebitic syndrome, Compression of vein, Chronic venous 
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hypertension (idiopathic), Venous (peripheral) insufficiency, unspecified, Unspecified 
circulatory system disorder, Unspecified intestinal malabsorption, Chronic renal failure, 
Cellulitis and abscess of the toe (s), foot (feet) or leg (legs), prior foot ulceration, Hereditary 
edema of legs, Edema, and Injury to the knee, leg, ankle, and foot. 
Examples of other significant at risk diseases and disorders include as examples: old age and 
frailty, Alzheimer's Disease, Cognitive dysfunction, Osteoarthritis (Degenerative Joint 
Disease), Rheumatoid Arthritis, Gout, Coagulopathies, Hemophilia, Prior Amputation, 
Reflex Sympathetic Dystrophy, Hansen’s Disease, Mental Illness, the Mentally Challenged, 
Paralysis, Parkinson’s Disease, visual impairment, physical impairment, ambulatory 
dysfunction, . In addition, patients with a history of vascular grafts, joint implants, heart 
valve replacement, active chemotherapy, renal failure and on dialysis, anticoagulant 
therapy, hemorrhagic disease, chronic steroid therapy, and immuno – compromised states 
(HIV – AIDS), pose additional risks when considering assessment, treatment and 
prevention. (52) 
On June 16, 2009, the Department of Veterans Affairs (VHA Directive 2009-030) expanded 
the Medicare primary risk categories to appropriately include the following conditions: (50) 
- Documented peripheral arterial disease 
- Documented sensory neuropathy 
- Prior history of foot ulcer or amputation 
- Visually impaired 
- Physically impaired 
- Neuromuscular disease, i.e. Parkinson’s disease 
- Severe arthritis and spinal disc disease 
- Cognitive dysfunction 
- Chronic anticoagulation therapy 
- >70 years old without other risk factors 
- Diabetes without foot complications 
- Obesity  
3. Dermatological and onychial physical findings 
The dermatologic section provides a focus on skin integrity and multiple changes that affect 
pressure, mechanical keratosis, onychial changes, infections, and pre-ulcerative states. (7, 8, 
14) 
The primary clinical signs and findings include the following: hyperkeratosis; keratotic 
lesions without hemorrhage or hematoma; tyloma; heloma durum; heloma milliare; heloma 
molle; heloma neurofibrosuum; heloma vasculare; onychophosis; intractable plantar 
keratosis; sub-keratotic hematoma (pre-ulceration); xerosis; onychauxis; tinea pedis; 
bacterial infection; verruca; ulceration; onychomycosis; rubor; onychodystrophy; pre-
ulcerative conditions; cyanosis; and discoloration.  
Some examples of dermatologic symptoms and signs include the following: exquisitely 
painful or painless wounds, slow healing or non-healing wounds, trophic ulceration, 
necrosis, skin color changes such as cyanosis or erythema, changes in texture and turgor, 
inelasticity, tenting, pigmentation, hemosiderin deposition, pruritus, neurogenic, and/or 
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painful or painless wounds, slow healing or non-healing wounds, trophic ulceration, 
necrosis, skin color changes such as cyanosis or erythema, changes in texture and turgor, 
inelasticity, tenting, pigmentation, hemosiderin deposition, pruritus, neurogenic, and/or 
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emotional dermatoses, contact dermatitis, stasis dermatitis, atopic dermatitis, nummular 
eczema, scaling, dehydration, xerosis or dryness, excoriations, verruca, moles, psoriasis, 
fissures, hyperhidrosis, bromidrosis, diminished or absent hair growth, diabetic 
dermopathy (shin spots), necrobiosis lipoidica diabeticorum, bullous diabeticorum, 
granuloma annulare, acanthosis nigricans, and poroma. Other factors include swelling, 
redness, an increase or decrease in skin temperature, and maceration.  
Some examples of common onychial clinical changes include onycholysis, subungual 
hyperkeratosis, diabetic onychopathy, onychauxis, onychogryphosis, onychocryptosis, 
onychomycosis, onychia, paronychia, subungual abscess, subungual heloma, subungual 
exostosis, onychomadesis, onychoschizia, onychophosis, subungual hematoma, splinter 
hemorrhage, periungual ulcerative granulation tissue, onychodysplasia, onychodystrophy, 
onychorrhexis, Beau's Lines, pterygium, diabetic onychopathy, and hypertrophic 
onychodystrophy.  
Onychomycosis evaluation includes: documentation of mycosis/dystrophy causing 
secondary infection and/or pain, which results or would result in marked limitation of 
ambulation and includes discoloration, hypertrophy, subungual debris, onycholysis, 
secondary infection, and limitation of ambulation and pain. The primary clinical 
presentation of onychomycosis include distal subungual, lateral subungual, superficial 
(white), proximal subungual, endonyx, total dystrophic and candida (14). The onychial 
grades at risk, which was modified and adapted from Strauss, Hart and Winant and 
recognizes earlier risk and includes the following: Grade – 1, normal; Grade – 2, mild 
hypertrophy, Grade 3, evidence of hypertrophy, dystrophy, onychauxis, onychomycosis, 
infection, and/or onychodysplasia; and Grade – 4, evidence of hypertrophy, deformity, 
onychogryphosis, dystrophy, onychomycosis, and/or infection.  
4. Hyperkeratosis classification 
The major functions of the foot are static and dynamic. The foot is an organ of      weight 
bearing, propulsion, and locomotion. The foot is relatively rigid and changes are related to 
the activities of daily living, excessive and repetitive stress, the normal aging process, 
degeneration, and disease, producing functional disability and ambulatory dysfunction. 
Repetitive stress, hard and flat surfaces, increased shock, tissue trauma, past occupational 
stress, and the environmental factors associated with ambulation that do not provide for a 
compensatory element for weight diffusion and/or weight dispersion. Examples of related 
complications include atrophy of the intrinsic foot muscles, atrophy, and anterior 
displacement of the plantar fat pad, morphologic changes, digital contractures and 
deformities, inflammation, pain, and the residuals of biomechanical, pathomechanical, and 
balance and gait change. The stress factors related to the development of hyperkeratosis 
include; force, compression, tensile stress, shearing, friction, elasticity, and fluid pressure. 
(29, 30) 
The classification of mechanical or pressure keratosis is a modification of the program 
outlined by Merriman and Tollifield , includes the following grading descriptions as 
follows: 0 - no lesion; 1 - no specific tyloma plaque but diffuse or pinch hyperkeratotic tissue 
present or in narrow bands; 2 - circumscribed, punctate oval, or circular, well defined 
thickening of keratinized tissue; 3 - heloma milliare or heloma durum with no associated 
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tyloma; 4 - well defined tyloma plaque with a definite heloma within the lesion 
extravasation, maceration and early breakdown of structures under the tyloma or callus 
layer; and 5 -complete breakdown of structure of hyperkeratotic tissue, epidermis, 
extending to superficial dermal involvement. The plantar keratoma pattern is identified if 
present. 
5. Ulcer classification 
The Ulcer Classification was adapted from Simms, Cavanaugh and Ulbrecht  and provides 
an earlier identification of risk given its ten grade classification and better identifies pre-
ulcerative changes as follows: Grade - 0 - absent skin lesions; Grade - 1 - dense callus but not 
pre-ulcer or ulcer; Grade - 2 – pre-ulcerative changes (such as evidence of hemorrhage or 
hematoma in the keratotic lesion; Grade - 3 - partial thickness (superficial ulcer); Grade - 4 - 
full thickness (deep) ulcer but no involvement of tendon, bone, ligament or joint; Grade - 5 - 
full thickness (deep) ulcer with involvement of tendon, bone, ligament or joint; Grade - 6 - 
localized infection (abscess or osteomyelitis); Grade - 7 - proximal spread of infection 
(ascending cellulitis or lymphadenopathy); Grade - 8 - gangrene of forefoot only; and Grade 
- 9 - gangrene of majority of foot. A key factor in managing the diabetic is to prevent foot 
ulceration by finding clinical signs prior to skin breakdown. (13, 41, 41, 43, 44) 
Other classifications include the Wagner Classification System (Grades 1-5) , the Liverpool 
Classification System for diabetic ulcers (Primary – neuropathic, ischemic and 
neuroischemic and Secondary – uncomplicated or complicated i.e., with cellulitis, abscess, 
or osteomyelitis, and the University of Texas Foot Ulcer Wound Classification Systems with 
Stages A, B, C, and D and Grades 1, 2, and 3 that encompass pre or post ulceration, 
superficial,   penetration to tendon or capsule or penetration to bone, with no infection or 
ischemia, infection, ischemia, and infection with and ischemia. (46)  
6. Foot orthopedic (musculoskeletal) physical findings 
The foot orthopedic section highlights altered biomechanics and the most common foot and 
joint deformities and syndromes identified in the older patient and patients with chronic 
diseases, such as arthritis; Hallux valgus (bunion); anterior imbalance (identifies 
inappropriate weight bearing and correlates with the plantar keratoma pattern noted later in 
the examination); digiti flexus (hammer toes and rotational deformities); prominent 
metatarsal heads; Morton's Syndrome; improper weight distribution and pressure areas; soft 
tissues inflammation is also noted. Other primary findings include; diminished joint 
mobility (flexion, extension, inversion, and inversion); pes planus, pes valgo planus; pes 
cavus (equinus); hallux limitus or rigidus; bursitis; Charcot joints (neuropathic arthropathy); 
drop foot; osseous reabsorption; rear and/or forefoot varus; plantarflexed first ray; digital 
and or partial foot amputation; B/K and A/K amputation; and other clinical findings. (31, 
33) 
Other examples of musculoskeletal findings that should be considered include: gradual 
change in shape or size of the foot, decreased ranges of motion, a sudden and painless 
change in foot shape with swelling and no history of trauma, drop foot, "Rocker Bottom 
Foot" or Charcot foot, neuropathic arthropathy, elevated plantar pressure, limited joint 
mobility, abnormal foot pressure, atrophy of plantar fat pad, plantar fat pad displacement, 
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emotional dermatoses, contact dermatitis, stasis dermatitis, atopic dermatitis, nummular 
eczema, scaling, dehydration, xerosis or dryness, excoriations, verruca, moles, psoriasis, 
fissures, hyperhidrosis, bromidrosis, diminished or absent hair growth, diabetic 
dermopathy (shin spots), necrobiosis lipoidica diabeticorum, bullous diabeticorum, 
granuloma annulare, acanthosis nigricans, and poroma. Other factors include swelling, 
redness, an increase or decrease in skin temperature, and maceration.  
Some examples of common onychial clinical changes include onycholysis, subungual 
hyperkeratosis, diabetic onychopathy, onychauxis, onychogryphosis, onychocryptosis, 
onychomycosis, onychia, paronychia, subungual abscess, subungual heloma, subungual 
exostosis, onychomadesis, onychoschizia, onychophosis, subungual hematoma, splinter 
hemorrhage, periungual ulcerative granulation tissue, onychodysplasia, onychodystrophy, 
onychorrhexis, Beau's Lines, pterygium, diabetic onychopathy, and hypertrophic 
onychodystrophy.  
Onychomycosis evaluation includes: documentation of mycosis/dystrophy causing 
secondary infection and/or pain, which results or would result in marked limitation of 
ambulation and includes discoloration, hypertrophy, subungual debris, onycholysis, 
secondary infection, and limitation of ambulation and pain. The primary clinical 
presentation of onychomycosis include distal subungual, lateral subungual, superficial 
(white), proximal subungual, endonyx, total dystrophic and candida (14). The onychial 
grades at risk, which was modified and adapted from Strauss, Hart and Winant and 
recognizes earlier risk and includes the following: Grade – 1, normal; Grade – 2, mild 
hypertrophy, Grade 3, evidence of hypertrophy, dystrophy, onychauxis, onychomycosis, 
infection, and/or onychodysplasia; and Grade – 4, evidence of hypertrophy, deformity, 
onychogryphosis, dystrophy, onychomycosis, and/or infection.  
4. Hyperkeratosis classification 
The major functions of the foot are static and dynamic. The foot is an organ of      weight 
bearing, propulsion, and locomotion. The foot is relatively rigid and changes are related to 
the activities of daily living, excessive and repetitive stress, the normal aging process, 
degeneration, and disease, producing functional disability and ambulatory dysfunction. 
Repetitive stress, hard and flat surfaces, increased shock, tissue trauma, past occupational 
stress, and the environmental factors associated with ambulation that do not provide for a 
compensatory element for weight diffusion and/or weight dispersion. Examples of related 
complications include atrophy of the intrinsic foot muscles, atrophy, and anterior 
displacement of the plantar fat pad, morphologic changes, digital contractures and 
deformities, inflammation, pain, and the residuals of biomechanical, pathomechanical, and 
balance and gait change. The stress factors related to the development of hyperkeratosis 
include; force, compression, tensile stress, shearing, friction, elasticity, and fluid pressure. 
(29, 30) 
The classification of mechanical or pressure keratosis is a modification of the program 
outlined by Merriman and Tollifield , includes the following grading descriptions as 
follows: 0 - no lesion; 1 - no specific tyloma plaque but diffuse or pinch hyperkeratotic tissue 
present or in narrow bands; 2 - circumscribed, punctate oval, or circular, well defined 
thickening of keratinized tissue; 3 - heloma milliare or heloma durum with no associated 
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tyloma; 4 - well defined tyloma plaque with a definite heloma within the lesion 
extravasation, maceration and early breakdown of structures under the tyloma or callus 
layer; and 5 -complete breakdown of structure of hyperkeratotic tissue, epidermis, 
extending to superficial dermal involvement. The plantar keratoma pattern is identified if 
present. 
5. Ulcer classification 
The Ulcer Classification was adapted from Simms, Cavanaugh and Ulbrecht  and provides 
an earlier identification of risk given its ten grade classification and better identifies pre-
ulcerative changes as follows: Grade - 0 - absent skin lesions; Grade - 1 - dense callus but not 
pre-ulcer or ulcer; Grade - 2 – pre-ulcerative changes (such as evidence of hemorrhage or 
hematoma in the keratotic lesion; Grade - 3 - partial thickness (superficial ulcer); Grade - 4 - 
full thickness (deep) ulcer but no involvement of tendon, bone, ligament or joint; Grade - 5 - 
full thickness (deep) ulcer with involvement of tendon, bone, ligament or joint; Grade - 6 - 
localized infection (abscess or osteomyelitis); Grade - 7 - proximal spread of infection 
(ascending cellulitis or lymphadenopathy); Grade - 8 - gangrene of forefoot only; and Grade 
- 9 - gangrene of majority of foot. A key factor in managing the diabetic is to prevent foot 
ulceration by finding clinical signs prior to skin breakdown. (13, 41, 41, 43, 44) 
Other classifications include the Wagner Classification System (Grades 1-5) , the Liverpool 
Classification System for diabetic ulcers (Primary – neuropathic, ischemic and 
neuroischemic and Secondary – uncomplicated or complicated i.e., with cellulitis, abscess, 
or osteomyelitis, and the University of Texas Foot Ulcer Wound Classification Systems with 
Stages A, B, C, and D and Grades 1, 2, and 3 that encompass pre or post ulceration, 
superficial,   penetration to tendon or capsule or penetration to bone, with no infection or 
ischemia, infection, ischemia, and infection with and ischemia. (46)  
6. Foot orthopedic (musculoskeletal) physical findings 
The foot orthopedic section highlights altered biomechanics and the most common foot and 
joint deformities and syndromes identified in the older patient and patients with chronic 
diseases, such as arthritis; Hallux valgus (bunion); anterior imbalance (identifies 
inappropriate weight bearing and correlates with the plantar keratoma pattern noted later in 
the examination); digiti flexus (hammer toes and rotational deformities); prominent 
metatarsal heads; Morton's Syndrome; improper weight distribution and pressure areas; soft 
tissues inflammation is also noted. Other primary findings include; diminished joint 
mobility (flexion, extension, inversion, and inversion); pes planus, pes valgo planus; pes 
cavus (equinus); hallux limitus or rigidus; bursitis; Charcot joints (neuropathic arthropathy); 
drop foot; osseous reabsorption; rear and/or forefoot varus; plantarflexed first ray; digital 
and or partial foot amputation; B/K and A/K amputation; and other clinical findings. (31, 
33) 
Other examples of musculoskeletal findings that should be considered include: gradual 
change in shape or size of the foot, decreased ranges of motion, a sudden and painless 
change in foot shape with swelling and no history of trauma, drop foot, "Rocker Bottom 
Foot" or Charcot foot, neuropathic arthropathy, elevated plantar pressure, limited joint 
mobility, abnormal foot pressure, atrophy of plantar fat pad, plantar fat pad displacement, 
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foot muscle atrophy, hallux limitus, hallux rigidus, tailor’s bunion, plantar fasciitis, soft 
tissue inflammation, calcaneal spurs, decalcification, stress fractures, metatarsalgia, 
Morton's Syndrome, Haglund’s, entrapment syndrome, neuroma, sesamoid displacement, 
joint deformities as residuals of arthritis, ambulatory dysfunction, pododynia dysbasia, 
biomechanical and pathomechanical variations, and footwear evaluation. Gait evaluation 
includes mobility, gait speed, and balance as it relates to fall risk that may be associated with 
foot deformity and inappropriate footwear. Ambulatory aids such as canes, walkers, etc, as 
well as physical activities are also a consideration. Mobility should consider independent 
activity, independence with assistance, homebound status, non-ambulatory status, and 
wheel chair use. The ranges of motion include dorsiflexion, plantar flexion, inversion, and 
eversion of the foot and ankle, flexion and extension of the great toe, and intrinsic foot 
muscles. (45, 47, 48, 49) 
7. Peripheral vascular physical findings 
The Vascular Evaluation identifies those symptoms associated with arterial insufficiency 
and ischemia. The primary findings include: coldness, trophic changes, diminished or 
absent pedal pulses, such as the dorsalis pedis pulse and posterior tibial pulses; night 
cramps; edema; claudication; varicosities; atrophy and amputation if present (noted as 
above the knee (AKA), below the knee (BKA), FF (forefoot), and T (toes), which are 
particularly important in patients with diabetes and arterial insufficiency. Other findings 
include: fatigue, rest pain, decreased skin temperature, burning, trophic changes, color and 
pigmentary changes, hemosiderin deposition, petechiae, hypoxia, cyanosis, rubor, absent or 
diminished digital hair, skin fragility, skin inelasticity (tenting), tingling, numbness, 
ulceration, history of phlebitis, cramps, edema, history of repeated foot infections, 
diminished or absent popliteal and/or femoral pulse change, femoral bruits, Ankle-Brachial 
Index (ABI < 0.90), Toe-Brachial Index, prolonged subungual capillary refill (> 3 sec), 
reduced claudication time, changes in skin perfusion, color changes (rubor, erythema, or 
cyanosis), temperature changes (cool and gradient), xerosis (atrophic and dry skin), atrophy 
of soft tissue, superficial infections, onychial changes, induration, blebs, delayed venous 
filling time, prolonged capillary filling time, femoral bruits, microcirculatory dysfunction, 
ischemia, telangiectasia, stasis, delayed and/or non-healing wounds and/or ulcers, necrosis, 
and gangrene. (15, 32) 
The vascular and risk stratification includes the following as part of the initial assessment:  
0, no change; 1, mild claudication; 2, moderate claudication; 3, severe claudication; 4, 
ischemic rest pain; 5, minor tissue loss; and 6, major tissue loss. 
Medicare currently may provide payment for Therapeutic Shoes for patients with diabetes 
mellitus who meet specific criteria. The criteria include the following: a history of partial or 
complete amputation of the foot, a history of previous foot ulceration, a history of pre-
ulcerative callus, peripheral neuropathy with evidence of callus formation, evidence of foot 
and/or osseous deformity, and evidence of poor circulation.  
8. Neurological physical findings 
The neurologic evaluation identifies primary reflex and sensory changes. Those findings 
include: the deep tendon reflexes – (DTR i.e. patellar and Achilles) and superficial plantar 
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reflexes, joint position, testing vibratory sensation, vibration perception threshold (VPT), 
sharp and dull reactions, evidence of paresthesia and burning. Other findings include: 
sensory changes (burning, tingling, and/or clawing sensations), pain and hyperactivity, two 
point discrimination variation, motor changes (weakness and /or foot drop), ankle clonus, 
autonomic changes (diminished sweating or hyperhidrosis), sensory vibratory deficits 
and/or proprioceptive, loss of protective sensation, changes in pain and temperature 
perception, and high plantar pressure areas as demonstrated by marked digital contractures, 
hyperkeratosis, metatarsal prolapse, prominent metatarsal heads, and plantar fat pad 
atrophy and displacement, bowstring tendons, muscle wasting, and Charcot foot (including 
rocker bottom deformity, erythema, heat, edema, fractures, neuropathy, swelling, bounding 
pulses, absent or diminished pain and proprioception, deep tendon reflex loss, anhidrosis, 
subluxation, the minus foot, equinus, hypermobility, ulceration, hyperkeratosis, and 
infection) . The use of monofilament testing and response are essential to measure sensory 
loss. Pinching the Achilles tendon and/or placing vertical pressure on a nail plate should 
demonstrate pain. The absence of pain is also an indication of sensory loss. Palpation of the 
common peroneal, posterior tibial and sural nerves may also demonstrate enlargement and 
tenderness. (34, 35, 36, 37, 38) 
Medicare also provides a process for the evaluation and management of a diabetic patient 
with diabetic sensory neuropathy, resulting in a Loss of Protective Sensation (LOPS) to 
include the following: 1) a diagnosis of LOPS; 2) a patient history of diabetes mellitus; 3) a 
physical examination consisting of findings regarding at least the following elements, 3 a) 
visual inspection of the forefoot, hindfoot, and toe web spaces, 3 b) evaluation of protective 
sensation, 3 c) evaluation of foot structure, pathomechanics, and biomechanics, 3 d) 
evaluation of vascular status, 3 e) evaluation of skin integrity, 3 f) evaluation and 
recommendation of footwear, and 4) patient education.  
The neurological risk stratification includes the following classification: 0, no sensory loss; 1, 
sensory loss; 2, sensory loss and foot deformity; and 3, sensory loss, a history of ulceration, 
and deformity.  
9. Class findings 
Medicare also has a series of Class Findings that need to be evaluated and documented as 
qualifiers for primary foot care for those patients with primary risk diseases noted. Those 
findings include the following: A – 1, nontraumatic amputation of the foot or part of the 
foot; B – 1, absent posterior tibial pulse; B – 2, advanced trophic changes; B – 2 – a, hair 
growth (decrease or absent); B – 2 – b,  nail changes (thickening); B – 2 – c, pigmentary 
changes (discoloration);  B – 2 – d, skin texture (thin, shiny;  B – 2 – e,  skin color (rubor or 
redness); B – 3,  absent dorsalis pedis pulse; C –1,  claudication; C – 2,   temperature changes 
(cold); C – 3, edema; C – 4,  paresthesia; and  C – 5,  burning.  
10. Other findings 
Other assessment areas include footwear, hygiene, and the type of stocking (nylon, cotton, 
wool, other), or none. Stockings or socks should also be inspected for staining and excessive 
wear (friction).The shoe or footwear evaluation includes the type of shoe, fit, depth, size, 
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foot muscle atrophy, hallux limitus, hallux rigidus, tailor’s bunion, plantar fasciitis, soft 
tissue inflammation, calcaneal spurs, decalcification, stress fractures, metatarsalgia, 
Morton's Syndrome, Haglund’s, entrapment syndrome, neuroma, sesamoid displacement, 
joint deformities as residuals of arthritis, ambulatory dysfunction, pododynia dysbasia, 
biomechanical and pathomechanical variations, and footwear evaluation. Gait evaluation 
includes mobility, gait speed, and balance as it relates to fall risk that may be associated with 
foot deformity and inappropriate footwear. Ambulatory aids such as canes, walkers, etc, as 
well as physical activities are also a consideration. Mobility should consider independent 
activity, independence with assistance, homebound status, non-ambulatory status, and 
wheel chair use. The ranges of motion include dorsiflexion, plantar flexion, inversion, and 
eversion of the foot and ankle, flexion and extension of the great toe, and intrinsic foot 
muscles. (45, 47, 48, 49) 
7. Peripheral vascular physical findings 
The Vascular Evaluation identifies those symptoms associated with arterial insufficiency 
and ischemia. The primary findings include: coldness, trophic changes, diminished or 
absent pedal pulses, such as the dorsalis pedis pulse and posterior tibial pulses; night 
cramps; edema; claudication; varicosities; atrophy and amputation if present (noted as 
above the knee (AKA), below the knee (BKA), FF (forefoot), and T (toes), which are 
particularly important in patients with diabetes and arterial insufficiency. Other findings 
include: fatigue, rest pain, decreased skin temperature, burning, trophic changes, color and 
pigmentary changes, hemosiderin deposition, petechiae, hypoxia, cyanosis, rubor, absent or 
diminished digital hair, skin fragility, skin inelasticity (tenting), tingling, numbness, 
ulceration, history of phlebitis, cramps, edema, history of repeated foot infections, 
diminished or absent popliteal and/or femoral pulse change, femoral bruits, Ankle-Brachial 
Index (ABI < 0.90), Toe-Brachial Index, prolonged subungual capillary refill (> 3 sec), 
reduced claudication time, changes in skin perfusion, color changes (rubor, erythema, or 
cyanosis), temperature changes (cool and gradient), xerosis (atrophic and dry skin), atrophy 
of soft tissue, superficial infections, onychial changes, induration, blebs, delayed venous 
filling time, prolonged capillary filling time, femoral bruits, microcirculatory dysfunction, 
ischemia, telangiectasia, stasis, delayed and/or non-healing wounds and/or ulcers, necrosis, 
and gangrene. (15, 32) 
The vascular and risk stratification includes the following as part of the initial assessment:  
0, no change; 1, mild claudication; 2, moderate claudication; 3, severe claudication; 4, 
ischemic rest pain; 5, minor tissue loss; and 6, major tissue loss. 
Medicare currently may provide payment for Therapeutic Shoes for patients with diabetes 
mellitus who meet specific criteria. The criteria include the following: a history of partial or 
complete amputation of the foot, a history of previous foot ulceration, a history of pre-
ulcerative callus, peripheral neuropathy with evidence of callus formation, evidence of foot 
and/or osseous deformity, and evidence of poor circulation.  
8. Neurological physical findings 
The neurologic evaluation identifies primary reflex and sensory changes. Those findings 
include: the deep tendon reflexes – (DTR i.e. patellar and Achilles) and superficial plantar 
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reflexes, joint position, testing vibratory sensation, vibration perception threshold (VPT), 
sharp and dull reactions, evidence of paresthesia and burning. Other findings include: 
sensory changes (burning, tingling, and/or clawing sensations), pain and hyperactivity, two 
point discrimination variation, motor changes (weakness and /or foot drop), ankle clonus, 
autonomic changes (diminished sweating or hyperhidrosis), sensory vibratory deficits 
and/or proprioceptive, loss of protective sensation, changes in pain and temperature 
perception, and high plantar pressure areas as demonstrated by marked digital contractures, 
hyperkeratosis, metatarsal prolapse, prominent metatarsal heads, and plantar fat pad 
atrophy and displacement, bowstring tendons, muscle wasting, and Charcot foot (including 
rocker bottom deformity, erythema, heat, edema, fractures, neuropathy, swelling, bounding 
pulses, absent or diminished pain and proprioception, deep tendon reflex loss, anhidrosis, 
subluxation, the minus foot, equinus, hypermobility, ulceration, hyperkeratosis, and 
infection) . The use of monofilament testing and response are essential to measure sensory 
loss. Pinching the Achilles tendon and/or placing vertical pressure on a nail plate should 
demonstrate pain. The absence of pain is also an indication of sensory loss. Palpation of the 
common peroneal, posterior tibial and sural nerves may also demonstrate enlargement and 
tenderness. (34, 35, 36, 37, 38) 
Medicare also provides a process for the evaluation and management of a diabetic patient 
with diabetic sensory neuropathy, resulting in a Loss of Protective Sensation (LOPS) to 
include the following: 1) a diagnosis of LOPS; 2) a patient history of diabetes mellitus; 3) a 
physical examination consisting of findings regarding at least the following elements, 3 a) 
visual inspection of the forefoot, hindfoot, and toe web spaces, 3 b) evaluation of protective 
sensation, 3 c) evaluation of foot structure, pathomechanics, and biomechanics, 3 d) 
evaluation of vascular status, 3 e) evaluation of skin integrity, 3 f) evaluation and 
recommendation of footwear, and 4) patient education.  
The neurological risk stratification includes the following classification: 0, no sensory loss; 1, 
sensory loss; 2, sensory loss and foot deformity; and 3, sensory loss, a history of ulceration, 
and deformity.  
9. Class findings 
Medicare also has a series of Class Findings that need to be evaluated and documented as 
qualifiers for primary foot care for those patients with primary risk diseases noted. Those 
findings include the following: A – 1, nontraumatic amputation of the foot or part of the 
foot; B – 1, absent posterior tibial pulse; B – 2, advanced trophic changes; B – 2 – a, hair 
growth (decrease or absent); B – 2 – b,  nail changes (thickening); B – 2 – c, pigmentary 
changes (discoloration);  B – 2 – d, skin texture (thin, shiny;  B – 2 – e,  skin color (rubor or 
redness); B – 3,  absent dorsalis pedis pulse; C –1,  claudication; C – 2,   temperature changes 
(cold); C – 3, edema; C – 4,  paresthesia; and  C – 5,  burning.  
10. Other findings 
Other assessment areas include footwear, hygiene, and the type of stocking (nylon, cotton, 
wool, other), or none. Stockings or socks should also be inspected for staining and excessive 
wear (friction).The shoe or footwear evaluation includes the type of shoe, fit, depth, size, 
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last, flare, shoe-wear, patterns of wear, shoe lining wear, shoe wear pattern (outsole and 
upper counter distortion), foreign bodies, insoles, and orthoses. Where special shoes, such as 
those defined as “therapeutic” by Medicare, they should generally include a padded collar 
and tongue, laces, adjustable strap or “Velcro” closure, wide toe box to accommodate 
deformities, added depth in the upper section to accommodate deformities, orthotics, and 
/or padded inserts to evenly distribute plantar pressure, a steel shank for stability, 
cushioning, and a broad sole base for support and traction.  
The  mechanical factors leading to ulceration need to be reviewed and noted, such as: body 
mass; evidence of tissue trauma; weight diffusion; weight dispersion; pathomechanics 
(defined as structural change in relation to function); biomechanics (defined as forces that 
change and affect the foot in relation to function; imbalance (defined as the inability to adapt 
to alterations of stress); force ( alteration in physical condition, either shape or position); 
compression stress ( one force moves towards another); tensile stress ( a pulling away of one 
part against another); shearing stress (a sliding of one part on the other); friction (the force 
needed to overcome resistance and usually associated with a sheering stress; elasticity ( 
weight diffusion and weight dispersion); and fluid pressure (soft tissue adaptation and 
conformity to stress).  
Given the fact that assessment and re-assessment should be completed on a regular basis, 
management can then be instituted to reduce the complications of chronic disease and 
subscribe to the principles of secondary prevention of disease. The plan for care includes the 
following, as an example: plan podiatric referral, patient education, medical referral, special 
footwear, vascular studies, clinical laboratory studies, imaging (including radiographs, 
sequential bone scans, computed tomography (CT), magnetic resonance imaging (MRI), and 
Duplex Ultrasound), prescriptions, and follow-up assessment and management. (39, 40) 
11. Discussion 
The evolution of this protocol began in 1959 as the number of older individuals and those 
with chronic diseases began to increase. Those diseases and disorders that presented with 
complications, such as diabetes mellitus, peripheral arterial disease, degenerative joint 
changes, collagen diseases, and neurosensory disorders were recognized as having a 
significant effect on the future quality of older citizens. A visit to the United Kingdom by the 
Commissioner and Deputy Commissioner of Health of the City of Philadelphia 
demonstrated a need for foot care that was a part of the British heral care system. A joint 
effort with the Philadelphia Department of Health and St. Luke’s & Children’s Medical 
Center in Philadelphia resulted in the first US Public Health Service funded program 
dealing with foot health for an aging population. “Keep Them Walking” provided a three 
years study involving information, education, screening, assessment and care for in excess 
of 16,000 citizens over the age of 65 in Philadelphia. The number of foot problems that were 
uncovered was so significant that Philadelphia established podiatric services as a part of it 
community health care program, that remain today as a vital part of providing care for older 
citizens.  
About that same time, similar efforts were initiated at the Queensbridge Health 
Maintenance Program in New York, the ambulatory clinics of the Washington, DC Health 
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Department and by the Minnesota Department of Health for Long Term Care Programs. The 
data also demonstrated a similar high prevalence for diseases and disorders of the foot and 
related structures.   
In 1963, the US Public Health Service and the Gerontological Society of America began to 
develop its first clinical geriatric practice guide that also included Podiatric programs. In 
1966, the US Department of Veterans Affairs also identified a significant need for foot care 
programs, as a part of their long term care services, especially for older adults.  It became 
clear that screening had to be replaced by Assessment, Identification, Risk Stratification, 
Education, and Treatment programs to enhance the concept of the secondary prevention of 
chronic diseases in older patients.  
The presented Clinical Podogeriatric and Chronic Disease Protocol (Helfand Index) was 
developed through a coordinated effort by the Diabetes Control Program of the 
Pennsylvania Department of Health and Temple University School of Podiatric Medicine 
and provides a means to assess older patients with diabetes mellitus and other chronic 
diseases to develop proper and appropriate care prevention and care programs.    
The most recent validation study of this protocol, Foot Problems in Older Patients – A 
Focused Podogeriatric Assessment Study in Ambulatory Care demonstrated the 
prevalence of foot conditions in older individuals and their association with chronic risk 
diseases such as diabetes mellitus, peripheral arterial disease, and arthritis, and to 
develop care plans to reduce complications from local foot problems and chronic diseases. 
One thousand individuals older than 65 years who were ambulatory and not 
institutionalized underwent a standardized and validated podogeriatric examination 
assessment protocol or index.  
The Summary of the Data is attached as Appendix B. The findings demonstrated that foot 
problems in the older population result from disease, disability, and deformity related to 
multiple chronic diseases as well as changes associated with repetitive use and trauma. 
Older people are at a high risk of developing foot-related disease and should receive 
continuing foot assessment, education, surveillance, and care. (J Am Podiatric Med Assoc 
94(3): 293-304, 2004). The data also demonstrated that 77% of all patients were deemed to be 
at risk for significant complications involving the foot and its related structures that could 
impair the quality of life and significantly increase the cost of care.  
The development of this protocol (Helfand Index) provided a means to identify older and 
diabetic patients who were at risk for complications involving the foot and its related 
structures; to focus on educational needs for patients and professionals; to provide referral 
for the rapid treatment and management of foot problems; and to provide a forum to 
discuss the need for appropriate foot wear for patients at risk, as a means to secondarily 
prevent future diseases and disorders of the foot. 
The protocol provided a focus on the current patients history, the past medical history, a 
system review, current and past medications, the assessment of skin and toe nail conditions, 
foot deformities, pathomechanical and biomechanical changes, vascular assessment, 
neurological assessment and sensory deficits, risk stratification (vascular, sensory, class 
finding, mycotic, hyperkeratotic, and ulcers), footwear and foot covering, assessment, and a 
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last, flare, shoe-wear, patterns of wear, shoe lining wear, shoe wear pattern (outsole and 
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Given the fact that assessment and re-assessment should be completed on a regular basis, 
management can then be instituted to reduce the complications of chronic disease and 
subscribe to the principles of secondary prevention of disease. The plan for care includes the 
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community health care program, that remain today as a vital part of providing care for older 
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Department and by the Minnesota Department of Health for Long Term Care Programs. The 
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develop its first clinical geriatric practice guide that also included Podiatric programs. In 
1966, the US Department of Veterans Affairs also identified a significant need for foot care 
programs, as a part of their long term care services, especially for older adults.  It became 
clear that screening had to be replaced by Assessment, Identification, Risk Stratification, 
Education, and Treatment programs to enhance the concept of the secondary prevention of 
chronic diseases in older patients.  
The presented Clinical Podogeriatric and Chronic Disease Protocol (Helfand Index) was 
developed through a coordinated effort by the Diabetes Control Program of the 
Pennsylvania Department of Health and Temple University School of Podiatric Medicine 
and provides a means to assess older patients with diabetes mellitus and other chronic 
diseases to develop proper and appropriate care prevention and care programs.    
The most recent validation study of this protocol, Foot Problems in Older Patients – A 
Focused Podogeriatric Assessment Study in Ambulatory Care demonstrated the 
prevalence of foot conditions in older individuals and their association with chronic risk 
diseases such as diabetes mellitus, peripheral arterial disease, and arthritis, and to 
develop care plans to reduce complications from local foot problems and chronic diseases. 
One thousand individuals older than 65 years who were ambulatory and not 
institutionalized underwent a standardized and validated podogeriatric examination 
assessment protocol or index.  
The Summary of the Data is attached as Appendix B. The findings demonstrated that foot 
problems in the older population result from disease, disability, and deformity related to 
multiple chronic diseases as well as changes associated with repetitive use and trauma. 
Older people are at a high risk of developing foot-related disease and should receive 
continuing foot assessment, education, surveillance, and care. (J Am Podiatric Med Assoc 
94(3): 293-304, 2004). The data also demonstrated that 77% of all patients were deemed to be 
at risk for significant complications involving the foot and its related structures that could 
impair the quality of life and significantly increase the cost of care.  
The development of this protocol (Helfand Index) provided a means to identify older and 
diabetic patients who were at risk for complications involving the foot and its related 
structures; to focus on educational needs for patients and professionals; to provide referral 
for the rapid treatment and management of foot problems; and to provide a forum to 
discuss the need for appropriate foot wear for patients at risk, as a means to secondarily 
prevent future diseases and disorders of the foot. 
The protocol provided a focus on the current patients history, the past medical history, a 
system review, current and past medications, the assessment of skin and toe nail conditions, 
foot deformities, pathomechanical and biomechanical changes, vascular assessment, 
neurological assessment and sensory deficits, risk stratification (vascular, sensory, class 
finding, mycotic, hyperkeratotic, and ulcers), footwear and foot covering, assessment, and a 
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management plan. Examples for the reasons to refer patients for podiatric medical include 
but are not limited to the following: 
 Signs suggesting generalized diseases that include neuropathy, vascular disease, 
diabetes mellitus, infection, ulceration, deformity, degenerative joint changes, focal 
neoplastic diseases, collagen diseases, and other conditions as indicated involving the 
foot and related structures in those cases where concomitant therapy is indicated where 
initial management is not effective: 
 In the presence of skin lesions involving the foot: 
 In the presence of postural deformities of the foot and related structures: 
 In the presence of diabetes mellitus, neurosensory, peripheral vascular, and other 
risk diseases: 
 In the presence of foot problems combined with ambulatory and/or walking 
difficulty and/or a history of or risk of falls: 
 Where orthotics are indicated: 
 If the patient is unable to obtain and/or provide foot care: 
 If the patient complains of a foot problem or has specific questions about care 
including information on footwear. 
The assessment protocol clearly provided a means to identify the most significant risk 
factors. Although vascular and neurosensory deficits are usually thought of as most 
significant as to their potential impact for ulceration and amputation, class findings, 
mechanical or pressure keratosis, onychomycosis, onychial grades at risk, and pre-
ulceration, become equally important in relation to prevention and a means to provide rapid 
and early treatment for conditions noted. The protocol does provide a means to identify 
previous amputations; past foot ulcer history, peripheral neuropathy, foot deformity 
including Charcot’s Foot, peripheral vascular and arterial impairment, visual impairment, 
podalgia, pododynia dysbasia, and diabetic neuropath, especially in patient on dialysis.  All 
of these factors increase the amputation risk for diabetic patients (1, 2). In addition, the 
assessment protocol is not time consuming.  
There are a number of ulcer classifications in the literature including the Wagner 
Classification for Foot Ulcers, The University of Texas Diabetic Wound Classification, the 
National Pressure Ulcer Advisory Panel (NPUAP) Classification for Pressure Ulcers, as well 
as the one selected and described by Sims, Cavanagh, and Ulbrecht (46). This ten (10 grade 
classification provide three stages prior to a superficial ulcer that permitted earlier 
justification for treatment programs, associated with this assessment protocol.    
The Loss of Protective Sensation was initially developed by Dr. Paul Brand at the Leprosy 
Mission in London and then for the USPHS National Hansen’s Disease Program in Carville 
LA. With the recognition that the same findings were equal predictors of amputation in 
patients with diabetes mellitus, the use of the Semmes-Weinstein (5.07 gage) 10-gram 
monofilament has been defined universally in a consistent fashion to measure of light 
pressure. Vibration perception with the tuning fork 128 Hz (cps) and measurement of 
vibration perception threshold (Biothesiometer) were also employed. Pinching the Achilles 
tendon also provided a means to measure pain. Temperature perception, deep tendon 
reflexes and two-point discrimination are added procedures that provide addition al 
assessment benefits.    
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By early recognition of foot and related problems, not as an initial assessment tool, but as a 
subsequent re-assessment tool, patient education and rapid treatment program can be 
instituted to prevent progressing complications and maintain a maximum quality of 
independent life for older diabetic patients.  
Since this Protocol was introduced, it has been employed by a number of programs and 
institutions, included and identified in multiple presentations and publications. Examples 
include the following: Pennsylvania Department of Health; Pennsylvania Diabetes 
Academy; Temple University – School of Podiatric Medicine and Institute on Aging; 
University of Pennsylvania – School of Nursing; Griffin Hospital – Yale – Department of 
Veterans Affairs Health System; Geriatric Educational Resources for Residency Training 
in Family Medicine and Internal Medicine - The John A. Hartford Foundation Geriatric 
Education Consortium for Residency Training (Stanford University Geriatric Education 
Center, Baylor College of Medicine, Harvard University, Johns Hopkins University, 
Stanford University, University of California - Los Angeles, University of Chicago, 
University of Connecticut, University of Rochester, American Academy of Family 
Physicians); Pennsylvania Geriatric Education Center; Delaware Valley Geriatric 
Education Center; Thomas Jefferson University Hospital; American Medical Directors 
Association; American Podiatric Medical Association; as well as journals and texts; 
including the Geriatric Review Syllabus of the American Geriatrics Society, W B Saunders, 
Martin Dunitz, Elsevier, Wiley, McGraw-Hill, Health Professions Press, the American 
Public Health Association Press, Cambridge University Press, and Oxford University 
Press. 
12. Concluding remarks 
Much of the ability to remain ambulatory in the period of aging is directly related to foot 
health. In order to accomplish this aim, practitioners must think comprehensively, and 
recognize that team care must be an essential part of chronic disease management in the care 
of the older patient. Foot health education for patients and professionals should be 
employed. It is clear that adults with chronic diseases, such as diabetes mellitus, and older 
patients are a high risk for foot related disease and should maintain continuing foot 
assessment, education, surveillance, and care. The consequences of considering foot care for 
the older population as “routine” and a failure to prevent complications and maintain 
mobility and ambulation will result in ambulatory dysfunction, gait modification, podalgia, 
pododynia dysbasia, morbidity, mortality, increased health care costs, and will be reflected 
in the quality of life and the ability to remain mentally alert and active in their communities 
(51). For our future, the golden years must be more than aging in place, thinking of their 
residence as a waiting room, or waiting for God. We must recognize that aging is not a 
disease, that older individuals should be able to live life to the end of life with the dignity of 
age, and that we must protect what cannot be replaced. 
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difficulty and/or a history of or risk of falls: 
 Where orthotics are indicated: 
 If the patient is unable to obtain and/or provide foot care: 
 If the patient complains of a foot problem or has specific questions about care 
including information on footwear. 
The assessment protocol clearly provided a means to identify the most significant risk 
factors. Although vascular and neurosensory deficits are usually thought of as most 
significant as to their potential impact for ulceration and amputation, class findings, 
mechanical or pressure keratosis, onychomycosis, onychial grades at risk, and pre-
ulceration, become equally important in relation to prevention and a means to provide rapid 
and early treatment for conditions noted. The protocol does provide a means to identify 
previous amputations; past foot ulcer history, peripheral neuropathy, foot deformity 
including Charcot’s Foot, peripheral vascular and arterial impairment, visual impairment, 
podalgia, pododynia dysbasia, and diabetic neuropath, especially in patient on dialysis.  All 
of these factors increase the amputation risk for diabetic patients (1, 2). In addition, the 
assessment protocol is not time consuming.  
There are a number of ulcer classifications in the literature including the Wagner 
Classification for Foot Ulcers, The University of Texas Diabetic Wound Classification, the 
National Pressure Ulcer Advisory Panel (NPUAP) Classification for Pressure Ulcers, as well 
as the one selected and described by Sims, Cavanagh, and Ulbrecht (46). This ten (10 grade 
classification provide three stages prior to a superficial ulcer that permitted earlier 
justification for treatment programs, associated with this assessment protocol.    
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Mission in London and then for the USPHS National Hansen’s Disease Program in Carville 
LA. With the recognition that the same findings were equal predictors of amputation in 
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By early recognition of foot and related problems, not as an initial assessment tool, but as a 
subsequent re-assessment tool, patient education and rapid treatment program can be 
instituted to prevent progressing complications and maintain a maximum quality of 
independent life for older diabetic patients.  
Since this Protocol was introduced, it has been employed by a number of programs and 
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health. In order to accomplish this aim, practitioners must think comprehensively, and 
recognize that team care must be an essential part of chronic disease management in the care 
of the older patient. Foot health education for patients and professionals should be 
employed. It is clear that adults with chronic diseases, such as diabetes mellitus, and older 
patients are a high risk for foot related disease and should maintain continuing foot 
assessment, education, surveillance, and care. The consequences of considering foot care for 
the older population as “routine” and a failure to prevent complications and maintain 
mobility and ambulation will result in ambulatory dysfunction, gait modification, podalgia, 
pododynia dysbasia, morbidity, mortality, increased health care costs, and will be reflected 
in the quality of life and the ability to remain mentally alert and active in their communities 
(51). For our future, the golden years must be more than aging in place, thinking of their 
residence as a waiting room, or waiting for God. We must recognize that aging is not a 
disease, that older individuals should be able to live life to the end of life with the dignity of 
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14. Appendix A 
Assessment protocol   
Date Of Visit                   MR# 
Patient's Name                                  Age   
DATE OF BIRTH              SOCIAL SECURITY # 
ADDRESS 
CITY                                   STATE              ZIP CODE 
PHONE NUMBER    (    ) 
SEX           M    F                 RACE  B   W  A  L  NA 
WEIGHT     LBS                 HEIGHT     IN 
SOCIAL STATUS               M  S  W  D  SEP 
Name of primary physician/health care facility 
Date Of Last Visit 
History Of Present Illness 
SWELLING OF FEET                  LOCATION 
PAINFUL FEET                           QUALITY 
HYPERKERATOSIS                     SEVERITY 
ONYCHIAL CHANGES             DURATION 
BUNIONS                                     CONTEXT 
PAINFUL TOE NAILS                MODIFYING FACTORS 
INFECTIONS                                ASSOCIATED SIGNS & 
COLD FEET                                  SYMPTOMS 
OTHER 
Past medical history 
HEART DISEASE                          DIABETES MELLITUS 
HIGH BLOOD PRESSURE         *IDDM 
ARTHRITIS                                   *NIDDM 
*CIRCULATORY DISEASE         HYPERCHOLESTEROL 
THYROID                                      GOUT 
ALLERGY                                      FAMILY AND SOCIAL HISTORY   
                                                        SMOKING  
                                                        ALCOHOL     
System review 
CONSTITUTIONAL 
ENT                            CARD/VASC                            GU 
EYES                          MUSCULO- SKELETAL          NEUROLOGIC 
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SKIN/HAIR                ENDOCRINE                           GI 
RESPIRATORY        GYN                                         IMMUNOLOGIC 
PSYCHIATRIC         ALLERGIC                                  
HEMATOLOGIC      LYMPHATIC 
Medications 
Dermatologic 
*HYPERKERATOSIS                                  XEROSIS 
ONYCHAUXIS                     B-2-B             TINEA PEDIS 
INFECTION                                                 VERRUCA 
*ULCERATION                                           HEMATOMA 
ONYCHOMYCOSIS                                   RUBOR 
ONYCHODYSTROPHY                             *PREULCERATIVE 
*CYANOSIS                           B-2-E             DISCOLORED 
Foot orthopedic 
*HALLUX VALGUS                                  *HALLUX RIGIDUS-LIMITUS 
*ANTERIOR IMBALANCE                      *MORTON'S SYNDROME 
*DIGITI FLEXUS                                        BURSITIS 
*PES PLANUS                                            *PROMINENT MET HEAD 
*PES VALGOPLANUS                              *CHARCOT JOINTS 
*PES CAVUS                                               OTHER 
Vascular evaluation 
*COLDNESS                            C-2           *CLAUDICATION            C-1 
*TROPHIC CHANGES           B-2-A       VARICOSITIES 
*DP ABSENT                           B-3            OTHER 
*PT ABSENT                            B-1          *AMPUTATION 
*NIGHT CRAMPS                                  *AKA    BKA     FF    T       A-1 
*EDEMA                                  C-3           ATROPHY                        B-2-D 
Neurologic evaluation 
*ACHILLES                                               SUPERFICIAL PLANTAR 
*VIBRATORY                                           *JOINT POSITION 
*SHARP/DULL                                       *BURNING                        C-5 
*PARESTHESIA                       C-4           OTHER 
LOSS OF PROTECTIVE SENSATION 
Risk category - neurologic 
 0 = No Sensory Loss 
*1 = Sensory Loss 
*2 = Sensory Loss & Foot Deformity 
*3 = Sensory Loss, Hx Ulceration, & Deformity 
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Pennsylvania Diabetes Academy, Foundation of the Pennsylvania Medical Society, Temple 
University, School of Podiatric Medicine and Temple University, Institute on Aging.  
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 0 = No Sensory Loss 
*1 = Sensory Loss 
*2 = Sensory Loss & Foot Deformity 
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Risk category - vascular 
 0 - 0  No Change 
*I - 1  Mild Claudication 
*I - 2  Moderate Claudication 
*I - 3  Severe Claudication 
*II - 4  Ischemic Rest Pain 
*III - 5  Minor Tissue Loss 
*III - 6  Major Tissue Loss 
Footwear Satisfactory                              Hygiene Satisfactory 
                  YES  NO                                             YES  NO 
Stockings: NYLON     COTTON     WOOL     OTHER      NONE 












A1      Nontraumatic Amputation 
B1       Absent Posterior Tibial 
B2       Advanced Trophic Changes 
B2A    Hair Growth (Decrease Or Absent) 
B2B     Nail Changes (Thickening) 
B2C    Pigmentary Changes (Discoloration) 
B2D    Skin Texture (Thin, Shiny) 
B2E     Skin Color (Rubor Or Redness) 
B3      Absent Dorsalis Pedis 
C1      Claudication 
C2      Temperature Changes (Cold) 
C3      Edema 
C4      Paresthesia 
C5      Burning 
Onychomycosis 
Documentation of mycosis/dystrophy causing secondary infection and/or pain that results 
or would result in marked limitation of ambulation. 
 








Limitation of ambulation and pain 
Classification of mechanical or pressure hyperkeratosis 
Grade description 
0. No lesion 
1. No specific tyloma plaque, but diffuse or pinch hyperkeratotic tissue present or in 
narrow bands 
2. Circumscribed, punctate oval, or circular, well defined thickening of keratinized tissue 
3. Heloma milliare or heloma durum with no associated tyloma 
4. Well defined tyloma plaque with a definite heloma within the lesion 
5. Extravasation, maceration and early breakdown of structures under the tyloma or callus 
layer 
6. Complete breakdown of structure of hyperkeratotic tissue, epidermis, extending to 
superficial dermal involvement 
Plantar keratomata pattern 
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                   Mycotic 
                   Infected 
                   Onychodysplasia 
Grade IV    Hypertrophic 
                   Deformed 
                   Onychogryphosis 
                   Dystrophic 
                   Mycotic 
                   Infected 
15. Appendix B 
Summary of clinical findings in 1,000 older people (31) 
Patients Percentage (%) of Clinical Findings:    % 
History of present illness 
Swelling of feet       382 
Painful feet        746 
Hyperkeratosis       510 
Onychial changes       895 
Bunions        240 
Painful toenails       357 
Infections (bacterial)         37 
Cold feet        197 
Other        480 
Past history 
Heart disease       258 
High blood pressure       367 
Arthritis        421 
Circulatory disease       229 
Thyroid disease         94 
Allergy          53 
Diabetes mellitus       572 
Insulin-dependent       175 
Non-insulin-dependent      397 
Hypercholesterolemia      362 
Gout          71 
Smoking          63 
Alcohol abuse         94 
Systems review 
Constitutional         84 
Ears, nose, throat         87 
Eyes        487 
Skin/hair        642 
Respiratory        279 
Psychiatric        242 
Hematologic         21 
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Cardiac/vascular       410 
Musculoskeletal       842 
Gynecologic        420 
Lymphatic          32 
Genitourinary       273 
Neurologic        124 
Endocrine        619 
Gastrointestinal       270 
Immunologic         22 
Dermatologic evaluation 
Hyperkeratosis       770 
Onychauxis        470 
Infection          42 
Ulceration          24 
Onychomycosis       590 
Onychodystrophy       942 
Cyanosis          42 
Xerosis        652 
Tinea pedis        137 
Verruca            9 
Hematoma        104 
Rubor          61 
Preulcerative       114 
Discolored          89 
Foot orthopedic evaluation 
Hallux valgus       527 
Anterior imbalance       429 
Digiti flexus        589 
Pes planus        174 
Pes valgoplanus       121 
Pes cavus        192 
Hallux rigidus/limitus      322 
Morton’s syndrome, bursitis      107 
Prominent metatarsal head      642 
Charcot’s joint         46 
Other        172 
Vascular evaluation 
Coldness        483 
Trophic changes       796 
Dorsalis pedis pulse absent      347 
Posterior tibial pulse absent      322 
Night cramps       473 
Edema        418 
Claudication       223 
Varicosities        181 
Amputation          15 
Above-the-knee            2 
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Below-the-knee           4 
Forefoot            3 
Toes            6 
Atrophy        689 
Neurologic evaluation 
Achilles          42 
Vibratory        721 
Sharp/dull        432 
Paresthesia        684 
Superficial plantar         32 
Joint position       214 
Burning        621 
Other        384 
Risk category—neurologic 
No sensory loss       360 
Sensory loss        217 
Sensory loss and deformity      340 
Sensory loss, history of ulceration, and deformity     83 
Risk category—vascular 
No change        183 
Mild claudication       133 
Moderate claudication        90 
Severe claudication         52 
Ischemic rest pain       473 
Minor tissue loss           6 
Major tissue loss           9 
Class findings 
A-1: Nontraumatic amputation       15 
B-1: Absent posterior tibial pulse     322 
B-2: Advanced trophic changes     796 
B-2-a: Hair growth (decrease or absent)     780 
B-2-b: Nail changes (thickening)     942 
B-2-c: Pigmentary changes (discoloration)      89 
B-2-d: Skin texture (thin, shiny)     473 
B-2-e: Skin color (rubor or redness)       61 
B-3: Absent dorsalis pedis pulse     347 
C-1: Claudication       223 
C-2: Temperature changes (cold)     483 
C-3: Edema        418 
C-4: Paresthesia       684 
C-5: Burning       621 
Onychomycosis 
Discoloration       590 
Hypertrophy       590 
Subungual debris       483 
Onycholysis        521 
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Secondary infection       104 
Limitation of ambulation and pain     107 
Classification of pressure keratosis 
Grade 0: No lesion       230 
Grade 1: Diffuse or pinch        78 
Grade 2: Circumscribed oval or punctate    147 
Grade 3: Heloma milliare or durum     204 
Grade 4: Tyloma with heloma      203 
Grade 5: Extravasation or maceration     114 
Grade 6: Tissue breakdown        24 
Ulcer classification 
Grade 0: Absent skin lesions      230 
Grade 1: Dense callus      632 
Grade 2: Preulcerative changes     114 
Grade 3: Partial-thickness (superficial)       22 
Grade 4: Full-thickness (deep)          2 
Grade 5: Full-thickness (deep) with involvement  
 of tendon, bone, ligament, or joint           0 
Grade 6: Localized infection (abscess or  
 osteomyelitis)           0 
Grade 7: Proximal spread of infection (cellulitis)       0 
Grade 8: Gangrene of forefoot           0 
Grade 9: Gangrene of majority of foot         0 
Onychial grades at risk 
Grade I: Normal         58 
Grade II: Mild hypertrophy      888 
Grade III: Hypertrophy, dystrophy, onychauxis,  
 mycosis, infection, onychodysplasia    355 
Grade IV: Hypertrophy, deformity, onychogryphosis,  
 dystrophy, mycosis, infection     235 
Footwear satisfactory 
Yes         637 
No         363 
Hygiene satisfactory 
Yes         972 
No           28 
Stockings 
Nylon        587 
Cotton        302 
Wool          93 
Other          12 
None            7 
Plan 
Podiatric referral       1,000 
Medical referral       272 
Vascular studies       104 
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Imaging        123 
Patient education       1,000 
Special footwear       425 
Clinical laboratory evaluation        36 
Medication        824 
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1. Introduction 
The most important complications of diabetes mellitus are neuropathy and diabetic foot. 
Manifestations of resulting complications range from simple to highly complex, including 
limb amputations and life–threatening infections. Foot infections in people with diabetes are 
common; this creates complex social problems owing to the financial burden resulting from 
the high cost of treatment and healing (Aguilar, 2009). In addition to severe morbidity, foot 
infections cause prolonged hospitalization and psychological and social problems for the 
patient and his family. Even though foot pathology in diabetic patients entails high medical 
costs, it also causes loss of productivity in patients (Ramsey et al, 1999) 
Predictions regarding the prevalence of DM have failed because the expected 300 million 
people worldwide with diabetes in 2025 were exceeded in 2011, some authors figure the 
rising to 347 millions (Goodarz et al, 2011), but in Lisbon, Portugal the International 
Diabetes Federation (IDF) said that the prevalence of DM around the world is 366 millions 
(Mbanya JC, 2011). Moreover, it is predicted that within 15 years (2025) there will be 500 
million people worldwide with diabetes if we do not take the necessary measures to prevent 
the spread of this disease. On the other hand, the most common cause of non-traumatic 
amputations is diabetes mellitus, and 80% of these could be averted through adequate 
prevention and early intervention. For example, in 2002 the medical cost for treating 
patients with DM was 92 billion USD. Loss of productivity could represent an additional 40 
billion. Projections for the cost of treatment will rise to approximately 160 billion in 2010 and 
close to 200 billion in 2020, or even higher (Hogan P et al, 2003).  Therefore, complications 
arising from diabetic foot represent an important medical challenge in growing proportions. 
The cost of treatment of ulcerations without surgical interventions approaches several 
thousand dollars, and in some cases even more, compared to ulcers that are treated through 
amputation (Kruse & Edelman 2006). Foot ulcerations represent 85% of all amputations. 
Hence, the association between ulcers and lower extremity amputations is patently obvious. 
Taking into account that the major risk factor leading to amputation is ulceration, around 
15% of all foot ulcers will ultimately require amputation at some point. Other risk factors for 
amputation include a long history of diabetes, peripheral neuropathy and structural changes 
of the foot, peripheral vascular disease, poor glycemic control, a prior history of foot ulcers, 
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previous foot surgery and/or amputation, retinopathy and nephropathy. (Clayton et al, 
2009, Aguilar & Rayo 2000) 
The management of wounds requires meticulous care and early treatment by a 
multidisciplinary foot care team. This management team may include: infectious disease 
specialists, microbiologists, podiatrists, nurses specializing in diabetes and physicians with 
knowledge of DM, all striving to provide quality care and good metabolic control. Optimal 
care and early detection of diabetic ulcers can greatly reduce the occurrence of infections. 
We think that all specialists who treat diabetic foot need to remember this important 
message: “Neuropathic symptoms correlated poorly with sensory loss, and the absence of sensory 
loss must not be equated to no risk of foot ulcers. Therefore, the assessment of foot ulcer risk MUST 
ALWAYS include a careful foot examination, with the removal of shoes and socks, regardless of  the 
patient’s neuropathic history.”(Boulton et al, 1998). 
Unfortunately, diabetic foot ulcers (infected or not), are quite often treated improperly. 
Amputation rates have shown a variation of both gender and ethnicity. Males are at higher 
risk than females. Hispanics -particularly Mexicans- and African-Americans have been 
associated with higher risk of amputation (Velasco Mondragon et al, 2010). Difficulty of access 
to continuing medical education for physicians, especially in emerging countries exhibiting 
high prevalence, has caused many difficulties in providing early care for patients and in 
establishing preventive care routines. Another worrisome matter is the propagation of 
erroneous beliefs regarding treatment of DM (for example, insulin being linked to blindness) 
and wound healing (for example the inappropriate use of honey, spider webs, gelatin, herbal 
preparations, etc. as cures) and also poor involvement of the Federal Government in health 
programs. These factors all lead to a rise in the disease, and consequently increased risk of 
amputation (Tentolouris 2010). Many scientific studies have led to the establishment of 
programs designed to prevent and promote awareness on diabetic foot complications. As a 
result, the rate of amputations dropped by nearly 50% (Li R et al, 2010). 
The underlying causes of risk factors leading to the onset of diabetic foot ulcers have recently 
been identified. The afore-mentioned conditions, together with peripheral neuropathy, 
contribute to a lack of sensation in poorly vascularized lower extremities that are prone to the 
development of chronic wounds. Lack of sensation leads to exacerbation of the injury. Dry, 
stiff skin cracks easily and causes splits or fissures. A fissure in the protective epidermal 
covering (stratum corneum), can become infected, resulting in localized cellulitis or even small 
longitudinal ulcerations that can potentially become infected and frequently lead to the spread 
of infection and the ultimate loss of the lower limb, either partial or full. Poor circulation 
occurs in conducting vessels, consequently affecting microcirculation, which in turn affects the 
basement membrane, thickening and diminishing vascular reparative capacity (Tanenberg RJ 
& Donofrio PD 2008). The most important risk factors for the development of diabetic foot 
ulcers are: peripheral neuropathy (motor, sensory and autonomic), structural and anatomical 
deformities, environmental factors, peripheral vascular disease, a compromised immune 
system and poor metabolic control, in addition to social influences such as emotional, 
psychological and behavioral problems (Lyons 2008). 
The purpose of this chapter is to help gain an understanding of different types of 
management strategies, ranging from general through specific strategies, starting with the 
initial examination of the patient who comes in for examination of a foot injury all the way  
through the final diagnosis. The clinical exam begins with a complete examination, 
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classification of the ulcer, basic measures, treatment with antibiotics (if the wound is 
infected) in order to establish the appropriate intervention and follow-up treatment to avert 
major complications, including amputation. 
We hope that better insight of the pathogenesis of diabetic foot complications will contribute to 
creating improved, effective and successful preventive strategies in order to save lower limbs.  
2. Pathogenesis of the wounds 
Risk factors for the development of foot ulcers in diabetic patients should be evaluated from 
3 different dimensions: 
1. Physiopathology 
2. Anatomical and structural alterations 
3. Environmental influences 
2.1 Physiopathology 
These changes occur at a biomolecular level and are caused by hyperglycemia, which leads 
to the development of neuropathy, as described in Fig 1. 
Over the past two decades considerable evidence has been accumulated to support the 
potentially pathogenetic role of a number of mechanisms that lead diabetic persons to 
develop wounds. The major mechanisms are: (Aguilar F, 2009a) 
 Nerve hypoxia/ischemia 
 Auto oxidative stress 
 Polyol pathway overactivity 
 Increased advanced glycation end-products 
 Deficiency of gamma linolenic acid 
 Protein kinase C, especially B-isoform increase 
 Cytokines dysfunction 
 Disorders of collagen molecules (elastin, proteoglycans) 
 Endothelial dysfunction 
 Mitochondrial dysfunction 
 Growth factors deficiency 
 Alteration of the immune mechanism 
 Increased secretion of proteases 
 Others 
Under normal circumstances, wound repair is a highly orchestrated event that involves the 
interaction of the elements described above. Each stage of the healing process entails this 
orchestrated effort. The damaged tissue quickly releases tissue factor and other stimuli, such 
as expulsed collagen, to activate a variety of physical mechanical, biological or chemical 
events. These changes cause damage to the nerve fiber and even peripheral vascular disease, 
which in turn takes its toll at the molecular level. Endothelial dysfunction is the most serious 
impairment affecting microcirculation, owing to changes in the proliferation of endothelial 
cells, thickening of the basement membrane, decreased synthesis of nitric oxide, increased 
blood viscosity, alterations in microvascular tone and decreased blood flow. On the other 
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hand, the immune system is compromised by lowered leukocyte activity, inappropriate 
inflammatory response and the disruption of cellular immunity (inhibition of fibroblast 
proliferation and impairment of the basal layer of keratinocytes, reducing epidermal cell 
migration). (Aguilar F, 2005, Boulton AJM, 2003) 
 
Fig. 1. Role of different mechanisms in neuropathy. The most important are oxidative stress 
and endothelium dysfunction; these mechanisms produce disorders in metabolism and 
microcirculation. EDFH= Endhotelium derived hyperpolarizing factor, NBF=nerve blood 
flow, NGF=nerve growth factors NVC= Nerve velocity conduction, PXG= Glutathion 
Peroxidase, SOD= Superoxide Dismutase (Modified from Aguilar R, 2009a). 
Another important factor that affects neuropathic foot microcirculation is the disability of 
the nerve axon reflex. The stimulation of the C-nociceptive fibers produces retrograde 
stimulation of adjacent fiber (Caselli A, et al, 2003). These fibers instantly secrete a 
vasomodulator, such as substance P (SP), a calcitonine gene-related peptide (GCRP), 
neuropeptide Y (NPY), and histamine. These peptides produce vasodilation ( this response 
is known as Lewis Triple Flair Response) (Lyons 2008). The Lewis response mechanism is: 
red spot due to capillary dilation, flare due to redness in the surrounding area, in turn due 
to arteriolar dilatation mediated by axon reflex and wheal due to exudation of fluid from 
capillaries and venules, drawn up in Fig 2 for normal and diabetic patients. 
The main substances are histamine and peptides. In the absence of this response the skin 
blood flow is affected when the injury occurs and this is one of the major factors related to 
impaired wound healing (Parkhouse N, 1988). 
 




Fig. 2. Injury and inflammation in normal subjects and diabetic patients. The nerve axon 
reflex.  Stimulation of C-nociceptive fibers produces retrograde stimulation of adjacent 
fibers to release vasomodulators. The results are hyperemia during injury or inflammation. 
The Lewis Triple Flare Response is absent in diabetic patients affecting wound healing. 
(Modified from Lyons 2008a) 
2.2 Anatomical and structural alterations 
The anatomical and structural alterations that are the result of diabetic neuropathy are 
divided into three types: sensory, motor and autonomic. 
2.2.1 Peripheral sensory neuropathy 
Close to 30-50% of all diabetic patients present peripheral sensory neuropathy. Sensory 
neuropathy is the most common predictor of foot ulceration in a patient with diabetes 
(Nather et al., 2011). The development of foot ulceration reported in sensory neuropathy 
occurs in 78% of cases. Peripheral sensory neuropathy initiates a series of events that 
together with peripheral motor and autonomic damage eventually result in foot ulceration. 
In a normal situation, treatment centers would tell the patient to continue walking or walk 
some with changes in gait. The recipients of this information are the sensory nerves. In 
diabetic foot, sensation is affected and the stimulus to refrain from ambulation does not 
exist. These are the causes that lead the patient to continue walking even when no sensation 
of pain is present, which in turn prolongs affectation and delays healing of the traumatized 
area. The damage to sensation that provides protection is the key element in the 
development of ulcers (Reiber GE., et al 1999). 
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2.2.2 Peripheral motor neuropathy 
Motor neuropathy typically presents structural alterations of the dynamic anatomy of the 
foot and joints, causing weakness and wasting of small intrinsic muscles. This causes a loss 
of balance in the gait because of damage to the muscles, as mentioned above, in addition to 
another characteristic: clawing of toes and plantar flexion of the metatarsal head (Carine 
HM et al 2004).  The atrophy of the interosseous and small intrinsic muscles of the foot acts 
to stabilize and hold the phalanges of the toes straight, as the long flexor and extensor 
tendons act through the insertions into the distal phalanges of the toes up into dorsiflexion, 
similar to a foot pressing the accelerator of the car. 
Alterations in the morphology of the structure of the foot, toes, forefoot and limited joint 
mobility impaired the ability of the foot to absorb and redistribute the forces relayed to 
impact the ground while walking. Effects on the foot include the reduction of motion and 
changes to the angle of the subtalar and first metatarsophalangeal joints (MTPJ). Vital 
musculoskeletal structures, such as equinus deformity through the shortening of the 
Achilles tendon and the collapse of the plantar fascia, facilitating abduct to adductor equine 
changes to the forefoot. In diabetic patients, the flexor tendons and extensor tips tend to be 
straight and rigid. If the intrinsic muscles are unable to do this, the toes shrink back to form 
what is called hammer toes and favor the thrust of one toe over another or a toe on the 
metatarsal head with the weight forced to the anterior surface with high force.  
On the other side, the contraction that the hammer toes causes on the plantar fat pad and the 
metatarsal heads reduces soft tissue plantar MTPJ, making them more susceptible to 
fracture of the skin, including the bone next to the formation of traumatic ulcers, owing to 
inappropriate weight loads. The mechanism is related to the high pressure exerted on the 
foot that occurs during the gait, in turn caused by motor neuropathy, which itself in turn 
causes structural changes in the anatomy and sliding of the fat pads of the foot, in addition 
to occasional blows received.  
Fig. 3 presents three different images at different stages of changes in architecture of the 
foot, allowing us to better understand the condition. In addition to the shortening and 
thickening of the joints, the decreased capacity of distribution of plantar pressure in DM 
patients contributes to the development of high foot pressure and ensuing ulcerations. 
Excessive pressure and structural deformities in individuals with neuropathy is a 
prerequisite for the development of wounds. Consequently, structural changes and offload 
pressure favors the formation of calluses on various prominent parts of the foot, including 
the plantar region, the heel, the big toe, etc. 
The structure of the foot is a major determinant of plantar pressure. Although some 
structural factors are independent of the DM, others are predisposed to high pressure and 
appear to be a consequence of the disease. Obviously, the major collapse is seen in Charcot   
neuroosteoarthropathy in which foot fractures lead to increased pressure. (Lyons et al., 
2006). A significant reduction of plantar soft tissue thickness is seen in diabetic patients with 
a form of neuropathy such as rheumatoid arthritis. Metatarsalgia is a common, frequent 
symptom of offloading of MTPJ with pressure on the head of the first metatarsal (MTT). It 
could explain almost 70% of the variation in plantar pressure in the joint on the thickness of 
soft tissue (Schie CHM, & Boulton. 2006). 
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It is necessary to clarify the concepts that influence structural and biomechanical 
abnormalities (Fryckberger RG, et al 1998, Lawrence L, et al 2008) as shown schematically in 
Fig 3. 
Clawing toes: hyperextension of MTT phalange joints, usually accompanied by cavus foot 
and calluses on the dorsal surface of the fingers and the plantar surface of the metatarsal 
head or the tip of fingers. 
Cavus Foot: under normal conditions the foot is shaped convexly due to the longitudinal 
medial arch that is extended from the head of the first MTT and the calcaneus; if this arch is 
abnormally high it produces an abnormal distribution of weight loads, favoring the 
formation of calluses in the forefoot and rearfoot . 
Equinus Deformation: shortening of Achilles tendon (three muscles:  lateral, internal 
gastrocnemius and soleus), falling of plantar fascia and facilitating abduct or adduct in the 
forefoot, beside the lost at the long flexor and extensor tendons that produce dorsiflexion.  
1st toe rigid: it is due to hardening of the first MTT phalange joint with loss of dorsiflexion, 
resulting in excessive weight forces on the plantar surface and callus formation. 
Joint stiffness: The limitation of joint movement is produced by the glycosylation of 
collagen and thickening of periarticular structures (tendons, ligaments, joint capsule, etc.) 
which favors deformities and plantar pressures, upsetting the biomechanics of the foot 
during walking by limiting plantar flexion and promoting equinus foot.  
 
Fig. 3. The different deformities of “at risk” diabetic foot. The three different stages of 
changes in the architecture of the foot which causes hammer toes and contraction of the 
plantar fat pad (look arrow). Above: normal foot. Middle: beginning of deformation. 
Bottom: Complete deformation. (Modified from Levin & O´Neal 2008. Right images 
courtesy from Ramos F, MD) 
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2.2.2 Peripheral motor neuropathy 
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Deformity of the nail: Thickening or deformity of the nail atrophies the nail plate with 
convex deformity, causing pressure on the ridge tissues and, in turn, ingrown nail. The nail 
flange forms a callus in response to pressure and inflammation. As a result the tissue of the 
trauma may become ulcerated and infected and penetrate the nail flange. 
2.2.3 Autonomic neuropathy 
Autonomic neuropathy is common in longstanding DM. In the lower extremities, autonomic 
neuropathy may result in arteriovenous shunting, resulting in the dilation of small arteries 
and producing distension of the foot veins, not alleviated through elevation of the foot. 
Consequently, neuropathic edema hinders treatment through diuretic therapy. Neuropathic 
feet have a tendency to swell and to feel warm as a result of arteriovenous shunting. 
Autonomic neuropathy results in decreased autonomic nerve roots that innervate the sweat 
skin glands with appendage tissue, causing dryness of the skin and decreased elasticity, 
especially from the middle third of the leg down, where there is also discoloration of the 
skin shown in Fig 4. Dry, stiff skin produce cracks more easily forming splits, fissures or 
fractures of the skin and callusing around the foot injury, more frequently in the heel rim, 
plantar medial and first MTP -especially during the dryer months, as observed in both 
images of Fig 5. The first one (A) shows the first stages and the second one depicts the final 
stages. These fractures or skin fissures can become infected, resulting in local cellulitis and 
then on to small longitudinal ulcerations. (Aguilar R, 2009) 
 
Fig. 4. Lower extremities of a patient with DM presenting the 3 types of neuropathy: 
sensitive (pain, burning, disesthesias, numbness), motor (cavus foot and claw toes) and 
autonomic (dry skin, absence of hair, changes in skin color). (Courtesy of Aguilar F & Terán 
JM, 2011) 
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2.3 Environmental influences 
Environmental influences acutely and chronically accelerate ulceration, starting with lesions 
in the soft tissue followed by stratum corneum of the skin, subcutaneous tissue, muscle and 
fat pad. 
2.3.1 Limited joint mobility 
Restriction of joint mobility is a part of diabetic neuropathy, related mainly to collagen 
glycosylation that results in thickening of the periarticular structures such as tendons, 
ligaments and joint capsules. At the foot level, all joints may be involved –ranging from the 
talar, subtalar, MTPJ, to flattening of the arch or pronation. These structures absorb the 
shock of gait, and reduce and attenuate ground reactive forces. In diabetic patients the 
absence of this mechanism impairs the ability of the foot to adapt to the ground surface and 
absorb the shock that develops when the heels make contact with the ground during 
walking.  High pressure develops more in the forefoot area, consequently becoming an 
additional factor in the development of foot wounds (Pham HT et al., 2000). 
The footwear designed in diabetic patients reduces the risk of foot ulcerations. We 
recommend the design and manufacturing of footwear and other items designed to 
potentially reduce foot pressure in neuropathic feet and offloading, thus redistributing and 
reducing foot pressure in areas that are prone to ulceration. Shoes are an important 
consideration for patients that are at risk for foot ulcerations (Sicco A, et al 2011). 
2.3.2 The gait 
Diabetic ulcers can occur anywhere on the foot but clinically the most frequent presentation 
is on the plantar surface. This predilection of diabetic ulcer on the plantar surface is related 
to the trauma that is developed in this area due to increased discharge pressure on the 
plantar surface during walking. Under normal conditions the foot has the ability to 
distribute the load equally over the entire surface -the forefoot, middle foot and rear foot- 
consequently preventing the development of ulcers. This capability is lessened in diabetics, 
first of all because of changes in the architecture of the foot related to the fundamental motor 
neuropathy that produces disorders in the mobility of joints, limited both by neuropathy as 
well as by the metabolic changes producing glycosylation of the collagen structure through 
a covalent bonding process which increases the rigidity of the ligament structures, tendons, 
and the joint capsule of both the subtalar and metatarsal region. Additionally, there is 
decreased mobility of the Achilles tendon, in turn creating an equinus deformity that directs 
plantar forces to the region of the forefoot. As a result of these changes, the pressure of 
certain areas of the foot is considered at high risk for producing a tissue injury, even after 
walking short distances. It is important to note that the presence of sensory neuropathy in a 
patient at risk and using inappropriate shoes will induce injury of the subcutaneous cellular 
tissue during the gait, compromising the integrity of skin tissue; this, together with the 
absence of pain, is conducive to the onset of foot ulceration (DÁmbrogi E et al., 2003). 
These 3 dimensions (physiopathology, anatomical and structural alterations, and 
environmental influences), contribute to the formation of ulcers. The dimensions are 
integrated by 2 mechanisms:  
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Fig. 5. Two different feet with “cavus foot”. (A) Cavus foot with skin hydrated (first stages). 
(B) Cavus foot wit dry skin, fissures, peripheral vascular disease and ulcered ankle. 
(Courtesy of Aguilar R & Terán JM, 2011) 
 
Table 1. Risk factors for the development of ulcers (Modified from Lipsky 2004). 
 Internal mechanism: Associated with structural deformities of the foot anatomy which 
are favored by sensory, motor and autonomic neuropathy disorders. Together, limited 
joint mobility and structural alterations are caused by glycosylation of collagen  and 
thickening of the periaarticulares structures that are produced for a disorder in the 
production of elastin (tendons, ligaments, articular capsule and, etc.), at  subtalar, 
metatarsal and metatarsophalangeal head levels. Because the diabetic condition invariably 
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involves hyperglycemia, non-enzymatic glycation of collagen and a deterioration of 
elastin, fibronectin, proteoglycans, epithelial cells and other proteins are noteworthy in 
wound healing during repair sequence (Ahmed N 2005, Huijberts MS 2008). 
 External mechanism: Related to chronic trauma of the soft tissues of the foot that 
precipitate the onset of an injury on the same structures that later produce the wound. 
These mechanisms, together with risk factors, do not act independently to cause ulcers.  
They require the combination of numerous events (sometimes fewer than others) to produce 
wounds in different areas of the foot, different sizes and different components. In fact, the 
most important factors that produce foot injury and lesion of the extracellular basement 
matrix of the skin are: neuropathy, deformity, trauma, peripheral circulation failure, 
inflammation, dryness and calluses on the foot (Boulton AJM 2006). 
The accumulation of the principal components corresponds to the causal pathways that result 
in diabetic foot ulcer when applying the Rothman model of causation (Reiber GE 1999). These 
factors that are insufficient on their own, combined will ultimately result in the formation of a 
diabetic foot ulcer; the interaction of a number of component causes may result in sufficient 
cause for ulceration, as shown in Fig 6. The most common causes interact between one another 
to result in ulceration in the diabetic foot. These risk factors are: neuropathy, deformity, 
trauma and impaired healing (present in 63% of cases) (Pecoraro RE, 1990). 
 
Fig. 6. Sufficient cause. The factors that comprise sufficient cause for ulceration are: 
neuropathy, deformity, trauma, and impaired healing. It is imperative that the 4 factors be 
present to create sufficient cause. If any of the factors is absent, the ulcer cannot be formed 
(Modify for, Lyons 2008, Boulton 2006, Ziegler 2003) 
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The classical example is a patient with insensitive feet who buys shoes too small that 
traumatize the feet with maximum pressure exerted on different points caused by the tight 
fit, as shown in Fig 7. In our experience, neuropathy was the first component cause (present 
in 100% of patients with ulcers), and the ischemia was a component cause in 35% of ulcers. 
Another independent component of the triad is the difficulty of healing the ulcer that is 
related with alterations in the immune response, decreased blood flow to the wound area, 
cellular components of the inflammatory system, abnormal expression of growth factors, 
cytokines and their receptors that are involved in the healing process; it is usually the 
combination of the various components that leads to chronic ulceration and amputation. 
 
Fig. 7. Diabetic patient with neuropathy, callus and claw toes using inappropriate shoes that 
cause repetitive trauma, thus forming the fracture of the callus and infecting the skin. The 
final result is a wound that later evolves to an infected ulcer. Sufficient cause is complete. 
(Courtesy of Aguilar F & Terán JM 2011) 
3. Clinical presentation 
About 50% of patients with foot ulcers due to DM present clinical signs of infection. By 
definition, infection is characterized by the presence of purulent secretions or at least two of 
the classic signs of inflammation (erythema, hyperemia, edema, or swelling and pain) but 
these data can be masked by lack of the sensitivity in the patient due to sensory neuropathy 
or impaired immune response.  It is also common that patients with infection are associated 
with poor metabolic control. Therefore, we must take into account other aspects of infected 
ulcers due to diabetes, including lack of granulation tissue, delayed healing or odor.  
The prevalence of ulcer is highest in the presence of neuropathy, anatomical disorders, 
structural and environmental factors such as offloading, high-pressure processes on the 
plantar foot, the forefoot, midfoot, rearfoot and especially the metatarsals heads. These 
overloads on the limb associated with limited joint mobility lead the plantar fascia to 
undergo changes, such as shortening and thickening that can cause a skin fracture due to 
poor quality of skin in this area (callused, thick, dry, etc) causing their own skin germs to 
progress or introduce bacterial into the skin cracks and potential progression over time 
resulting in critical colonization (presence of at least 100,000 bacteria per gram of tissue) and 
finally culminating in infection (Lipsky BA, & Berendt AR 2006). 
It’s important to consider that pain is not a prominent sign in patients with infected diabetic 
foot owing to the loss of sensitivity caused by affected short and long fibers (A-beta and A-
delta) secondary to hyperglycemia. In the same way, we have to consider a possible 
 
The Pathogenesis of the Diabetic Foot Ulcer: Prevention and Management 
 
167 
infection in any patient with DM who presents a fever, leukocytosis, or recent metabolic 
uncontrolled. (Pataky Z, & Assal JP, & Conne P, et al 2005) 
The molecular pathways that are involved in the ulcer formation are: 
1. The ulcer develops because structures of connective tissue fail. 
2. Absence of an important matrix of cellular organization resulting in deterioration in the 
protection of normal epithelial growth. 
3. Reduced angiogenesis and fibroplasia. 
4. Persistence of inflammatory cells, neutrophils or macrophages, which act in an 
appropriate immunological environment. 
 
Table 2. Record the characteristics of the wound in every exam of diabetic foot (every week). 
This decalogue helped to evaluate ulcer evolution, prognosis and the healing process. PEDIS 
(*): see table 3, Wagner (**): see table 4 and San Antonio (***): see table 5. (Courtesy of 
Aguilar R & Terán JM). 
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(*): see table 3, Wagner (**): see table 4 and San Antonio (***): see table 5. (Courtesy of 
Aguilar R & Terán JM). 
 
Global Perspective on Diabetic Foot Ulcerations 
 
168 
The elements listed above persist and lead to deterioration in the integrity and restoration of 
tissue, resulting in a chronic ulcer with persistence of bacterial infection, which alone 
stimulates an inappropriate inflammatory cellular response. There is also a chemical injury 
that leads to loss of oxygenation with absence or decrease of tissular perfusion, local cellular 
ischemia and tissue necrosis or death.  
If the trauma persists and overload pressure continues, the healing of the ulcer is delayed 
due to failure in the formation of granulation tissue and to the development of epithelial 
tissue. At this point proteolytic degradation surrounding the injury is the most important 
cause of secretion of proteins, including elastase, protease and metalloproteinase, capable of  
degrading not only the adhesive substrate for cell migration but also signaling molecules 
that would promote wound healing, such as development of  growth factors and cytokines.  
In conclusion, the accelerated proteolysis can cause a high level of breakdown products of 
connective tissue cellular processes that activate inappropriate inflammation. That's why the 
necrotic tissue should be debrided extensively and aggressively from the start of ulcer 
treatment, as this tissue is a negative factor in the wound healing, with difficulty due to the 
high content of substances mentioned above (Davidson JM, & Di Pietro L 2006; Cooper DM 
et al 1994; Sheehan P et al 2006). 
4. Diabetic foot infections 
In diabetic patients with foot wounds, the physician should perform a systematic 
examination to determine if the wound is infected and the degree of severity of said 
infection. The examination should start with vital signs, consciousness, complete review of 
the limb to the foot end, always removing the patient’s shoes and socks, and should 
include a neurological, vascular, dermatological and musculoskeletal examination to 
determine the external characteristics of the skin, the shape and structure of the foot and 
alterations in the fingers, protruding metatarsal, heel, etc. The physician should also 
perform an instrumental exploration, neurological reflex hammer, tuning fork 128 cycles, 10 
gm monofilament, thermograph, etc, Table 6. A clinical vascular examination will focus on 
the search for foot pulses. All this will determine the stage of neuropathy with or without 
ischemia. Fig 8 (American Diabetes Association (ADA) 2011) 
After locating the ulcer, evaluate the wound characteristics, just as proposed in Table 2, 
(number of ulcers, depth, size, color, exudation, edges, adjacent skin, maceration, pain, 
infection, etc.). In most cases an x-ray should be taken to dismiss presence of gas, or a 
foreign body or osteomyelitis. During initial ulcer debridement, look for aerobes and 
anaerobe organisms. As concerns a blood test, we recommend a complete blood count, 
blood chemistry and if it is considered prudent speed glomerular sedimentation and 
reactive "C” protein (Eneroth M, & Larsson J, & Apelqvist J 1999; Kaleta JL, & Fleischli JW, & 
Reilly CH 2001) 
This complete examination will help the doctor to draw up a clinical classification of the 
degree of infection (mild, moderate or severe), table 3, as well to evaluate the depth, 
extension, table 4, and ischemia with presence of infection, table 5. The severity ratings 
guide us to reference the patient to further hospital care, and start empirical implementation 
of antibiotics. The types of diabetic foot infections can start from a simple paronychia, 
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onychomycosis, cellulitis, foot infection, deep tissue infection, septic arthritis, osteomyelitis, 
necrosis or gangrene. Infections can be painless, persist for days, weeks or months and 
progress rapidly even in a few hours. Bed debridement, incision and drainage of the ulcer 
will be necessary in most circumstances. (Lipsky et al 2004) 
 
Fig. 8. Diabetic foot infection for insensitive repetitive trauma. The wound is close to deep 
tissues, involving bone as well. This patient need antibiotics and appropriate debridement 
(Courtesy Aguilar F & Terán JM, 2011). 
 
Table 3. Table with PEDIS* grade of foot infection correlated with the most common classic 
scales for wounds (Wagner** and San Antonio***). Each item “asterisk and color” was 
selected according to the scale (modified from Lispky BA 2004) 
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Table 4. Meggit-Wagner classification (Deep and Extension) (Meggit B ,1977 & Wagner FW, 
1981) 
 
Table 5. San Antonio scale. (Infection and Ischemia) (Armstrong et al, 1998) 
 
Table 6. Evaluating the diabetic patient who has an infected foot (Lipsky et al, 2004 
modified for Aguilar & Terán 2011) 
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4.1 Evaluating the diabetic patient who has an infected ulcer 
All diabetic foot infections require antibiotic treatment. However, not all ulcers are infected 
from the beginning and therefore do not require antibiotics. The main premise is that 
antibiotic treatment will be used to clear up infection and not for wound healing, which 
takes longer (Lipsky BA, 1999). Take into account the following aspects to choose the right 
antibiotics: 
1. Understand the microbiology of the wound, starting with broad-spectrum empirical 
therapy for moderate and severe infections and a relatively small range for moderate 
infections. We can’t forget factors such as recent antibiotic use, exposure to hospital 
facilities and local antibiotic susceptibility. 
2. The route of administration is of great importance for the success of treatment; for 
serious infections the recommended route is parenteral, and mild to moderate 
infections can start with oral or parenteral impregnation treatment for further oral 
treatment, adjusting to highly bio-available drugs like quinolones and the 
oxazolidinones. 
3. The duration of antibiotic treatment should be determined according to the severity of 
the infection; mild infections only require 2 to 4 weeks, severe infections may require 6 
to 12 weeks or more. Unfortunately in severe infections the amputation of part or the 
entire foot is a high probability. 
4. The selection of a specific agent or combination of antibiotics is based on the 
considerations discussed above and the condition of each patient (renal failure, 
allergies, etc.), restrictions of presentation, convenience and monetary cost. (Lipsky BA, 
Berendt AR 2006) 
5. Basics measures in the treatment of diabetic foot 
The treatment of foot ulcers in diabetic patients varies constantly depending on the severity of 
the ulcer and the presence or absence of ischemia. However the basic points of treatment are: 
 Debridement in case the ulcer presents thick edges or necrotic tissue. 
 Reduction in overload pressure.  
 Complete rest of the foot (orthotics). 
 Treatment of the infection. 
 Local wound care. 
To start this care we require the knowledge of the patophysiology listed above in relation to 
wound healing. The care and products that have shown to improve wound healing are: 
1. Debridement .- The goal is complete debridement of all necrotic tissue with impaired 
vascular and non-viable tissue, large incision and maintain good drainage when 
necessary in order to allow a granular bed and a better flow of the wound.  
2. Reduced offloading. – Reduction of pressure is essential in the healing of foot ulcers; as 
has been said, ulcers occur in areas of high pressure on a foot without sensitivity or 
with damaged sensitivity. There are several methods to reduce the pressure; the most 
popular includes mandatory resting of the foot with a cast and other new light 
materials, special shoes, leg braces and bandages using felt and/or foam. 
3. Treatment of Infection. - The ulcers that are already colonized with bacteria serve as a 
port of entry to further infection. The diagnosis of infection is first based on clinical 
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appearance and cardinal symptoms (erythema, edema, pain, tenderness and warmth). 
Meanwhile, care must be taken, aside from the bacteriological diagnosis, to treat 
cellulite, start antibiotics empirically and request the necessary x-rays employing the 
most advanced techniques available to reject the possibility of abscess with 
osteomyelitis (such as MRI or CT scan of the foot). Tables 7 & 8. 
4. Wound care. -The effective use of bandages is essential to ensure optimal management 
of foot ulcers in diabetic patients, applying the concepts of cleanliness, humidity and 
proper environment for wound healing to prevent tissue dehydration and cell death, 
accelerate angiogenesis and facilitate the development of growth factors with the 
epithelial cells resulting in less discomfort for patients. 
5. Products for advanced wound care: These products have been developed in response 
to an improved understanding of the holistic healing of injured tissue in diabetic foot 
ulcer. A greater knowledge of the patophysiology of wound microenvironment 
deficiencies decreased development, growth factors, inactivity, altered cell, to the 
development of products to correct these deficiencies. These include human growth 
factor platelet derived, Epidermal growth factor recombinant human DNA (Heberprot-
P®), colony stimulating factor granulocytes,  biological cultivate skin substitutes 
(Dermagraft®, Epifast®) hyperbaric oxygen, larva therapy, etc. (Boulton JM 2003) 
 
Table 7. Pathogens associated with various clinical foot-infection syndromes. (Modified 
from Lipsky 2004) 
 




Table 8. Suggested empirical antibiotic regimens accord the severity of disease. 
*recommended by the authors (Aguilar & Terán 2011). ** For patients in whom methicillin-
resistant S.aureus infection is proven likely. (Lipsky 2004). 
6. Ulcer recurrence 
The clinical evaluation of patients with diabetes, particularly in the assessment of the foot 
should be referred to the history of previous ulceration or amputation. A history with a 
record of ulceration or amputation increases the risk of a future return of ulceration, 
infection and amputation. Above 60% of diabetic patients with a history of foot ulcer may 
develop another ulcer within a year of healing ulcers. (Luca DP 2003) 
There are 3 possible explanations: 
1. Risk factors that caused ulceration in the first place in many cases will be still present. 
2. The skin and soft tissue at the site of previous ulceration do not retain the same 
properties after healing compared with the conditions they had before the ulcer. Thus, 
the skin and soft tissue, after the ulcer is healed, are more fragile and break more easily, 
as shown in Fig 9. 
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3. Areas of previous amputation can leave residual deformities which in themselves are 
areas of increased pressure that may lead to ulceration. In addition, any previous 
surgery can alter biomechanics, leading to irregularities of the gait and imbalance 
where high pressure areas will develop new ulcers in the future. 
A musculoskeletal examination will allow us to understand the structure and dynamics of 
the forces of the foot. The presence of foot deformities, joint mobility and their limitations 
must be recorded as both increased pressure and the cause of foot ulceration. Bone 
prominences can be observed on second plane as Charcot osteoarthropathy, motor 
neuropathy, foot deformities, hallux valgus limitus-rigiduz and hammer toes. Also, in the 
plantar region there may be callus formation, as we now know that many of these calluses 
are focal areas of increased pressure that can lead to a potential site of ulceration. Any area 
of erythema owing to the use of inappropriate shoes should be protected with padded 
patches and as soon as possible changed to proper shoes to relieve the pressure (Abbott CA 
& Carrington AL, & Ashe H, et al. 2002). 
 
Fig. 9. After the wound is healed, the patient needs to protect the foot due to changes in the 
architecture and labile skin in order to prevent ulcer recurrence. The use of orthetics, correct 
shoes, special socks and rehabilitation of the foot is a priority (Courtesy of Aguilar F & 
Terán JM 2011). 
7. Conclusions 
Despite progress in knowledge regarding the pathophysiology of ulcers, the mechanisms 
involved nowadays are not completely clear. The main mechanisms: neuropathy, deformity 
and trauma along with physiopathogenic information at the molecular level and knowing 
the structural and anatomic alterations (clawing toes, hammer toes, cavus foot, equinus foot, 
etc), are all important to draw up strategies for treatment and prevention This information is 
summarized in Fig 10. On the other side, offloading increases pressure on the foot, thus 
leading to alterations in environmental factors such as gait, instability and limited joint 
mobility. All of this suffices to explain the changes in the architecture of the foot and this, in 
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turn, allows for drawing up prevention policies. Changes in the microcirculation of the foot 
in patients with diabetes remains one of the major causes of difficulty in wound healing 
associated with thickening of the vascular endothelium, the release of vasodilator 
substances and the participation of endothelial cells in angiogenesis and reparative 
processes of the wound. These together represent the most advanced knowledge available at 
the molecular level.  The vasodilatation depending on the endothelium cell reduces the 
expression of nitric oxide synthase which further deteriorates the microenvironment of the 
wound. More recent mechanisms, such as the knowledge of the deterioration on the nerve 
cell particularly the reflex nerve-axon, coupled with changes in the polymerase activity 
(ADP ribose) and the increase of the formation of nitrous tyrosine give us hope for the 
future of healing ulcers. A better understanding of cellular changes and the interplay 
between formation of connective tissue, collagen tissue formation (collagen is part of the 
skin, bone, tendons and ligaments) the expression of growth factors and cytokines are 
involved in tissue repair of wounds in people with diabetes as shown Fig 10. In addition, we 
proposed increased care in early injury or trauma and prevention of use of inadequate shoes 
and offload pressures to stop formation of ulcers. If ulcers do form, adequate treatment, foot 
care and complete rest for the foot could prevent amputation. Fig 10 (red) 
It is clear that the spectrum of treatment of diabetic foot ulcers requires the participation of 
several specialists. Foot ulcers are not the responsibility of a single medical professional, 
they are the responsibility of a multidisciplinary team working for the care and healing of 
foot ulcers. On this team we can find first contact physicians, surgeons, orthopedic, vascular 
surgeons, podiatrists, neurologists, endocrinologists, orthotics, specialist nurses and all 
practitioners and specialists interested in the care and attention of the foot. In this chapter 
we have tried to give a clear, complete and current vision of the management of ulcers in 
diabetic patients by detecting and treating risk factors at an early stage, directing the entire 
team of health professionals as one would an orchestra in which the symphony focuses on 
sparing the patient with diabetic foot from dire consequences. 
7.1 What is expected for the future? 
There are various factors that will work together to improve wound care in the next few 
years. We must urge scientists, clinicians and even government regulators to get involved in 
the control of diabetes mellitus and wound healing. The problem is overwhelming 
worldwide and demands greater attention focusing on the occurrence of diabetes morbidity 
and mortality. Diabetic wounds continue to spiral out of control. New trends show interest 
and progress in the biology of healing and wound care. There is a great deal of exciting 
science and work done that has defined some of the basic pathogenesis of chronic wounds. 
This can be divided into the biological scientific and technical care of wounds. 
7.1.2 Biological scientific  
1. Modulation of temperature. Recently advances with modulation of temperature to 
control pressure of diabetic foot necrosis prevent cell death and progression of the ulcer 
formation in patient with DM. Cooling as well as pressure relief will be an important 
tool in the management of diabetic foot wound. With this measure we can to prevent 
the inflammatory changes due to the pressure and the flow-reflow phenomena. 
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Fig. 10. This algorithm summarize all events that are at play in the development ulcers and 
potential amputations. Prevention is the key. (red block) 
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2. Proteases. The early inflammatory response of diabetic foot wounds produces excessive 
proteases. Although the protease issue is relevant, it is only the tip of the iceberg. The 
healing of the wound requires angiogenic factors and these are destroyed by proteases. 
New therapy would be enhancement of endogenous antiproteases in order to improve 
healing. Another important issue is the control of free radical production by 
polymorphonuclear leukocytes (PMNs) as free radicals stimulate inflammation and 
increase proteases.  
3. Oxidative Stress. Although there are many metabolic disturbances that occur in DM, 
the oxidative stress (OS) play an important pathogenesis roll of a numerous 
mechanisms in DM and diabetic neuropathy. Diabetes contributes both directly and 
indirectly to increased oxidative stress. Thus, there is elevated production of reactive 
oxygen species (ROS) and a reduced endogenous capacity of free radical cell 
scavengers. Contributors to the increased oxidative stress include auto-oxidation of 
glucose and its metabolites, advanced glycation, mitochondrial abnormalities, 
ischemia reperfusion, microvascular damage, and enhanced flux through the polyol 
pathway. OS produce endothelium dysfunction, and diminishing nitric oxide release. 
Alpha lipoic acid in combination with arginine and citrulline increase nitric oxide, 
reduce OS by both benefits improved free radical scavenger and metal chelator. 
Besides, there is evidence that improved nerve functional deficit, endoneural 
perfusion and vascular bed perfusion and the microcirculation and capillary blood 
perfusion. Nevertheless antioxidant vitamins potentially improve healing of the 
wound. 
4. Gene therapy. We are still grappling with this area of medical knowledge. On the other 
hand, this care is expensive, though we expect that we will see cost-effective gene 
therapy in the future. The focuses are: stimulating growth factor production and gene 
therapy to inhibit proteases to permit growth factors to work well. 
5. New drugs to treat diabetes. The best option is to keep blood sugar within normal 
range; this produces less glycosylation of all sorts of tissues in the body, reducing 
diabetic complications. 
6. Education. Continuing medical education (CME) is important to every professional to 
treat DM. CME needs to develop strategic projects to stimulate initiatives for early 
prevention and detection of complications in DM and neuropathy. Updated medical 
information needs to cover all news about nutrition, hypertension, obesity and 
dyslipidemia (metabolic syndrome). 
7.1.3 Technical care 
1. Industry.  The relevant industry must listen to scientist and improve the quality of 
studies and on a scientific basis produce potential products for clinical application. 
2. Wound healing centers. The concept of the wound healing center is excellent if we 
have evidence and monitoring of formal education for health care providers at these 
centers and implement frequent reviews and updates. 
3. Progress in communications. We live in an era in which computerized communication 
is superb, yet we have not taken advantage of this benefit for our patients, especially for 
wound healing. Google®, PubMed®, Cochrane® and the American Diabetes 
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Association journals database are a big help for medical information and updates. The 
team of wound care health workers needs to have readily accessible information. Being 
a doctor is hard work, but part of this work is being updated through new technologies.  
4. Emotional aspects. Every patient needs to be referred to psychological specialists so as 
to better handle their emotional problems, equally important as the physical aspects. 
Everyone on the team is involved in the pathological process and must heed details. 
The initial assessment of the DM patient with neuropathy and ulcer demands a 
thorough examination and MUST ALWAYS include a careful foot exam after removal 
of shoes and socks. Additionally, the exam includes:  inspection of foot deformity, 
pressures, neurologic exam, vascular exam, monofilament, vibration and so on. It is 
surprising to note how many patients seek expensive, inadequate, quack or esoteric 
therapies in an attempt to save their leg. 
5. Federal Government Policies. The federal government should be more involved in 
supporting scientific and clinical projects and encouraging medical prevention in all 
communities in countries with a high prevalence of this disease, such as Mexico. 
6. Education.  Many courses on wound healing it are necessary to disseminate and 
updated information, to offer clear ideas and give practical advice. Regrettably, there 
are even national conferences in which there is an absence of information about new 
concepts on wound healing, proper evaluation and treatment. There is a window of 
opportunity here. 
7. Offloading the diabetic foot: New role of footwear. Several methods of measuring and 
reducing foot pressure include new advances but we need to be aware of their 
limitations. Extra-deep footwear, jogging shoes, hosiery, insoles, and orthotic hosiery 
have been shown to decrease plantar foot pressures. Furthermore these devices can 
prevent the occurrence and recurrence of foot ulceration. Research at present is still in 
the initial phase of developing methods and measuring shoe shear forces. Piezoelectric 
transducers are currently being evaluated; these may be able to measure both vertical 
and share forces in the near future. 
8. New devices 
Actually in some countries are available some systems to promote the support of wound 
healing such as the negative pressure wound therapy (V.A.C®), the wound cleansing and 
debridement system (Jetox®) and the infrared therapy system (Anodyne®). 
The process in wound healing is a cascade of inflammatory reactions and cellular 
interactions. Modern technologies are focused on reversing this unfortunate complication. 
For that reason we propose the points mentioned above in technical care. The science, 
knowledge and practice are attempting to promote vascularization, devices and molecules 
of tissue growth and a better understanding of pathophysiology of the wounds; 
therapeutical approach and prevention. 
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1. Introduction  
Diabetes and its subsequent complications present a significant challenge to our healthcare 
system. In particular, chronic diabetic wounds are a major cause of morbidity and use of 
healthcare resources in the U.S. Recent statistics reveal that 15% of diabetic patients develop 
foot and ankle chronic ulcers (Singh et al., 2005). Of these chronic wounds, 1 in 5 results in 
amputation. Further statistics reveal that 60% of nontraumatic lower-limb amputations 
occur in people with diabetes (Reiber, 2001). Chronic diabetic wounds result in a state of 
chronic inflammation about the wound site with decreased collagen and nitric oxide (NO) 
levels. The aims of these studies were to examine whether NO donor compounds will 
decrease inflammation and extracellular matrix destruction and simultaneously improve 
collagen production and wound healing. Specifically, we examined the effects of NO donors 
NOR-3 and SNOG on expression of matrix metalloproteinases (MMP)-1, -2. -8, -9 and -13, 
the inflammatory mediator interleukin-6 and collagen types I and type III by normal and 
diabetic fibroblasts under both normoxic and hypoxic states. 
2. Methods 
Prior studies by others have resulted in the development of a catalog of factors (altered 
MMP/TIMP ratio, decreased cell proliferation and migration, changes in growth factors 
[TGF-, VEGF, PDGF-BB] and cytokines [IL-1, IL-6, TNF-], extracellular matrix, 
oxygenation, and nitric oxide) which are important in normal wound healing and 
demonstrate the dysregulation that exists in chronic wounds (Chen et al., 1999; Cook et al., 
2000; Lobmann et al., 2002; Efron and Moldawer, 2004;Vandeberg et al., 2005). What was 
intriguing to us was the observation that a number of MMPs were known to be elevated in 
chronic wounds and that nitric oxide levels were quite low, but no one had drawn the 
connection that nitric oxide may regulate MMPs and promote wound healing by altering the 
MMP/TIMP ratio. By returning the MMP/TIMP ratio to near normal levels, matrix 
remodelling and growth factor regulation of the healing process could begin. The 
experiments described in this chapter were designed to examine these questions by testing 
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short-acting and long-acting NO donor compounds in fibroblast culture and in an in vivo 
skin wound repair model. We chose to evaluate enhancement of matrix production by 
measuring type I and III collagen expression and amelioration of inflammation by 
measuring interleukin-6 (IL-6) production. We have previously demonstrated that long-
acting NO donors significantly raise NO levels and reduce MMP gene expression in human 
diabetic skin fibroblast cultures (Burrow et al., 2007). 
2.1 Diabetic ulcer model 
Genetically diabetic, male C57BL/KsJ-m+/+Leprdb mice and control parental strain 
C57BL/KsJ mice were obtained from Jackson Laboratories (Bar Harbor, ME). According to 
an IACUC-approved protocol, mice were anesthetized and a 10mm full thickness wound 
was created on the dorsum. Treated mice received a single topical application of vehicle or 
500 nM (±)-(E)-ethyl-2-[(E)-hydroxyimino]-5-nitro-3-hexeneamide (NOR-3) or S-
nitrosoglutathione (SNOG) applied to the wound. The rate of wound healing was compared 
throughout the experimental period and wound area was determined by tracing the edge of 
the wound onto a glass microscope slide and determining changes in wound area by use of 
Adobe Photoshop.  
2.2 Cell culture and treatment 
Primary dermal fibroblasts were isolated from normal and diabetic mice by mincing excised 
skin samples and digesting for 2 hours in 0.20% collagenase (type I, Worthington, Freehold, 
NJ) in serum-free Dulbecco’s modified Eagle’s medium (Mediatech Inc., Manassas, VA) at 
37°C. The dissociated cells were cultured in Dulbecco’s modified Eagle’s medium with 20% 
FBS (Atlanta Biologicals, Norcross, GA) and 1% antibiotic/antimycotic supplement at 37°C 
with 100% humidity in 5% CO2 in air. Third passage fibroblasts were treated with control 
media, short-acting NOR-3, or long-acting SNOG NO donor compounds. Cells were 
incubated at 37ºC in Dulbecco’s Modified Eagle’s Medium + 20% FBS + antibiotics for 1, 3 or 
7 days. Similar experiments were carried out using human skin fibroblasts from age- and 
gender-matched non-diabetic and diabetic human subjects. Human diabetic and control 
fibroblasts (catalog no. GM00043, normal fibroblasts, and catalog no. GM01486, maturity 
onset diabetes fibroblasts) were obtained from the Coriell Institute for Medical Research 
(Camden, NJ). GM00043 cells were obtained at passage 11 and used for experiments at 
passages 14–16. GM01486 cells were obtained at passage 3 and used at passages 4–6. The 
cells were grown in T75 tissue culture flasks (Falcon BD, Bedford, MA) in minimal essential 
medium containing 15% fetal bovine serum (catalog no. 100-602; Gemini Bio-Products, West 
Sacramento, CA) and 1% penicillin-streptomycin at 37°C, following the recommended split 
ratios of 1:4 for the normal GM00043 cells and 1:3 for the diabetic GM01486 cells. For 
experiments, cells were plated in 24-well tissue culture plates (BD Biosciences, San Jose, CA) 
at a seeding density of 40,000 cells/well and cultured to confluence. The experiments were 
conducted under normoxic conditions (20% oxygen) and hypoxic conditions (2 % oxygen) 
using a Model NU-4950 CO2 incubator with the ability to accurately regulate the oxygen 
level (Nuaire Corp., Plymouth, MN). 
2.3 MMP/gelatin zymography 
MMP-2 and MMP-9 activity in control and 500 nM SNOG-treated fibroblasts were assessed 
by gelatin zymography. Samples were separated under non-reducing conditions on 10% 
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SDS-PAGE mini-slab gels co-polymerized with 150 μg/ml type I gelatin, washed in 5% 
Triton X-100, and equilibrated with collagenase assay buffer  (50 mM Tris, 200 mM  NaCl,   
5 mM CaCl2, pH 7.2) at 37°C. Counterstaining with Coomassie brilliant blue revealed MMP-
2 and -9 as cleared bands. 
2.4 MMP and collagen gene expression 
Total RNA was isolated from the non-diabetic and diabetic skin fibroblast cultures using 
TRIzol and then reverse transcribed using specific primers for MMP-2, -9 and -13, and Types I 
and III collagen. To determine the effects of NO donor on mRNA levels for each MMP, we 
performed real-time PCR analyses using 18S rRNA as the index gene, specific primers/probes 
for each MMP, and a Prism 7000 detection system (Applied Biosystems, Foster City, CA). 
2.5 Determination of growth factor and cytokine levels 
Release of cytokines and growth factors into the media of the cultures was quantified by use 
of Quantikine ELISA kits from R and D Systems. Colorimetric determination of interleukin-
6 and PDGF-BB levels were done following manufacturer’s specifications. 
3. Results 
3.1 Effects of NO donors on MMP expression 
Expression of mouse MMP-2, MMP-9, and MMP-13 was measured using real time PCR. 
MMP-2 and MMP-9 were expressed in both normal and diabetic fibroblast cultures after 1 
day of culture, but expression in the diabetic cells was 5-8 times higher than that found in 
normal (Figure 1). In contrast, MMP-13 was expressed by both cells at equivalent levels. 
When S-nitroso-N-acetylpenicillamine (SNAP), a NO donor with a half-life of 5 hours, was 
added to the cultures, a dose-dependent decrease in MMP-9 expression was observed 
(Figure 2). These results validate our previous findings in human skin fibroblasts (Burrow et 
al., 2007) and confirm that it is reasonable to expect mouse fibroblast MMP expression to be 





























Fig. 1. Matrix metalloproteinase gene expression in control and diabetic mouse fibroblasts. 
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Fig. 1. Matrix metalloproteinase gene expression in control and diabetic mouse fibroblasts. 
 







































Fig. 2. Effect of NO donor SNAP on MMP-9 expression by control and diabetic mice 
fibroblast. 
3.2 Effects of NO donors on skin wound healing 
In the diabetic ulcer model, it can be clearly seen that wound area in the diabetic animals 
does not appreciably change over time. In contrast, normal mice mount a significant healing 
response and the wounds are virtually healed by 4 weeks. Treatment with 500 nM NO 
donor compound SNOG (Figure 3) or SNAP (data not shown) elicited a healing response in 
the diabetic animals that temporally approximated the normal healing process. 
Interestingly, normal animals treated with NO donors also displayed accelerated healing 
compared with normal controls. When 500 nM NOR-3, the fast acting donor was used, there 
was no effect on wound healing (Figure 4). 




























Fig. 3. Effect of NO donor SNOG on skin wound healing in normal and diabetic mice 
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Fig. 4. Effect of NO donor NOR-3 on skin wound healing in normal and diabetic mice 
3.3 Effects of NO donors on MMP activity determined by gelatin zymography 
Cultured fibroblasts from the skin tissue of the normal and genetically-diabetic mice were 
examined for differences in MMP activity using gelatin zymography. Clear zones indicate 
MMP activity and the results demonstrate that equivalent cell numbers of diabetic fibroblasts 
show higher MMP-9 enzyme activity as compared to normal fibroblasts (Figure 5, compare 
MMP-9 signal in lane 3 versus lane 7). When treated for 24 hours with 500 nM SNOG, a 
significant reduction in MMP-9 activity was evident for both the non-diabetic and diabetic 
fibroblast cultures (see lanes 4 and 8). There was no such effect observed for MMP-2. 
 
Fig. 5. Zymographic analysis of MMP enzyme activity before and after SNOG treatment of 
mouse fibroblast cultures. 
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Fig. 4. Effect of NO donor NOR-3 on skin wound healing in normal and diabetic mice 
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3.4 Effects of NO donors on collagen gene expression 
Type I and III collagen gene expression was significantly lower under hypoxic conditions 
and in diabetic fibroblasts. Significant differences were noted in regards to collagen gene 
expression in diabetic fibroblasts and under hypoxic conditions, mimicking the in vivo 
situation of chronic wounds. Collagen type I and III gene expression in our control samples 
was decreased in diabetic fibroblasts when compared to normal fibroblasts. Also, when 
comparing normoxic to hypoxic states, expression of type I and III collagen genes was less 
in the hypoxic group. 
Type III collagen gene expression was significantly increased under normoxic conditions 
with the addition of the nitric oxide donor compound SNOG. Treatment with 1 nM SNOG, 
the long-acting NO donor, was noted to increase the levels of type III collagen expression by 
diabetic fibroblasts after three days of culture (Figure 6). In addition, the effect was dose-
dependent for the diabetic cultures. No significant effect was noted on day 1 of culture at 
any concentration tested (data not shown). In contrast to the diabetic fibroblasts, normal 
fibroblasts only responded with increased expression at the 100 nM dose. 























Effect of SNOG on Type III Collagen Expression








Fig. 6. Effect of NO donor SNOG on Type III collagen expression by normal and diabetic 
human fibroblasts cultured for three days under normoxic conditions. 
Type III collagen gene expression was increased under hypoxic conditions with the addition 
of SNOG. Treatment with 1nM SNOG was noted to increase the levels of type III collagen 
expression by the diabetic fibroblasts on day 3 of culture (Figure 7). In addition, the effect 
was dose-dependent. However, the effect was only significant for the normal fibroblasts at 
10 nM and 100 nM SNOG-treated cultures. No significant effect was noted on day 1 of 
culture at any concentration tested (data not shown).  
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Fig. 7. Effect of NO donor SNOG on Type III collagen expression by normal and diabetic 
human fibroblasts cultured for three days under hypoxic conditions. 
Type I collagen gene expression by normal fibroblasts at day 3 was not affected by SNOG 
treatment under normoxic conditions (Figure 8). A similar trend was noted with diabetic 
cells under normoxic conditions for  type I collagen expression, except that a significant 
increase was observed with  100 nM SNOG treatment. No effect on type I collagen 
expression was noted for either normal or diabetic fibroblasts cultured for 3 days under 
hypoxic conditions (Figure 9). 
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Fig. 8. Effect of NO donor SNOG on Type I collagen expression by normal and diabetic 
human fibroblasts cultured for three days under normoxic conditions. 
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Fig. 8. Effect of NO donor SNOG on Type I collagen expression by normal and diabetic 
human fibroblasts cultured for three days under normoxic conditions. 
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Effect of SNOG on Type I Collagen Expression




Fig. 9. Effect of NO donor SNOG on Type I collagen expression by normal and diabetic 
human fibroblasts cultured for three days under hypoxic conditions. 
However, after seven days of culture under normoxic conditions following a single addition 
of SNOG, type I collagen expression by normal and diabetic fibroblasts was found to be 
increased (Figure 10). A significant increase was observed at 1nM SNOG for the normal 
fibroblasts and  the effect was dose-dependent. Significant increases were also noted for the 
diabetic cultures, however only at the 10 and 100nM doses. Dose-dependent increases in 
type I collagen expression for normal and diabetic fibroblasts were also seen under hypoxic 
conditions (Figure 11). 
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Fig. 10. Effect of NO donor SNOG on Type I collagen expression by normal and diabetic 
human fibroblasts cultured for seven days under normoxic conditions 
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Fig. 11. Effect of NO donor SNOG on Type I collagen expression by normal and diabetic 
human fibroblasts cultured for seven days under hypoxic conditions. 
In contrast, the short-acting NOR-3 NO donor had no significant effect upon collagen gene 
expression by either normal or diabetic fibroblasts cultured under either normoxic or 
hypoxic conditions. No effect was observed under normoxic (data not shown) or hypoxic 
conditions for type III collagen expression by normal or diabetic fibroblasts cultured for 
three days in the presence of NOR-3 (Figure 12). Similarly, there was no effect on type I 
collagen expression for cultures grown under hypoxic conditions for three days (Figure 13). 
Additonally, no effects were noted on days 1 or 7 of culture (data not shown). 
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Fig. 12. Effect of NO donor NOR-3 on Type III collagen expression by normal and diabetic 
human fibroblasts cultured under hypoxic conditions. 
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Fig. 9. Effect of NO donor SNOG on Type I collagen expression by normal and diabetic 
human fibroblasts cultured for three days under hypoxic conditions. 
However, after seven days of culture under normoxic conditions following a single addition 
of SNOG, type I collagen expression by normal and diabetic fibroblasts was found to be 
increased (Figure 10). A significant increase was observed at 1nM SNOG for the normal 
fibroblasts and  the effect was dose-dependent. Significant increases were also noted for the 
diabetic cultures, however only at the 10 and 100nM doses. Dose-dependent increases in 
type I collagen expression for normal and diabetic fibroblasts were also seen under hypoxic 
conditions (Figure 11). 
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Fig. 13. Effect of NO donor NOR-3 on Type I collagen expression by normal and diabetic 
human fibroblasts cultured under hypoxic conditions. 
3.5 Effects of NO donors on interleukin-6 production 
The nitric oxide donor SNOG reduced IL-6 production by normal and diabetic skin 
fibroblasts grown under normoxic conditions and hypoxic conditions. At the control (0 nM) 
concentration, diabetic cells show significantly greater production of IL-6 than normal 
fibroblast cultures. The long-acting nitric oxide donor  SNOG  dose-dependently reduced 
IL-6 production for diabetic fibroblasts cultured either under normoxic conditions (Figure 
14) or hypoxic conditions (Figure 15). In contrast, normal fibroblasts only demonstrated an 
effect at the highest dose of NO donor under either normoxic or hypoxic conditions. 
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Fig. 14. Effect of NO donor SNOG on IL-6 production by normal and diabetic human 
fibroblasts cultured under normoxic conditions.  
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Fig. 15. Effect of NO donor SNOG on IL-6 production by normal and diabetic human 
fibroblasts cultured under hypoxic conditions. 
The short-acting NO donor NOR-3 had no significant effect upon IL-6 production in either 
normal or diabetic fibroblasts cultures grown under either normoxic conditions (Figure 16) 
or hypoxic conditions (Figure 17). 
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Fig. 16. Effect of NO donor NOR-3 on IL-6 production by normal and diabetic human 
fibroblasts cultured under normoxic conditions. 
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Fig. 13. Effect of NO donor NOR-3 on Type I collagen expression by normal and diabetic 
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3.5 Effects of NO donors on interleukin-6 production 
The nitric oxide donor SNOG reduced IL-6 production by normal and diabetic skin 
fibroblasts grown under normoxic conditions and hypoxic conditions. At the control (0 nM) 
concentration, diabetic cells show significantly greater production of IL-6 than normal 
fibroblast cultures. The long-acting nitric oxide donor  SNOG  dose-dependently reduced 
IL-6 production for diabetic fibroblasts cultured either under normoxic conditions (Figure 
14) or hypoxic conditions (Figure 15). In contrast, normal fibroblasts only demonstrated an 
effect at the highest dose of NO donor under either normoxic or hypoxic conditions. 
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Fig. 15. Effect of NO donor SNOG on IL-6 production by normal and diabetic human 
fibroblasts cultured under hypoxic conditions. 
The short-acting NO donor NOR-3 had no significant effect upon IL-6 production in either 
normal or diabetic fibroblasts cultures grown under either normoxic conditions (Figure 16) 
or hypoxic conditions (Figure 17). 
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Fig. 16. Effect of NO donor NOR-3 on IL-6 production by normal and diabetic human 
fibroblasts cultured under normoxic conditions. 
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Fig. 17. Effect of NO donor NOR-3 on IL-6 production by normal and diabetic human 
fibroblasts cultured under hypoxic conditions. 
3.6 Effects of NO donors on PDGF-BB production 
Nitric oxide donor treatment had no effect on PDGF-BB production by normal fibroblasts 
grown under normoxic or hypoxic conditions. Under normoxic conditions, the normal cells 
produced twice as much PDGF as the diabetic cells, whereas in the hypoxic environment the 
normal cells produced five times as much PDGF (data not shown). Neither of the nitric 
oxide donors tested had any significant effect on PDGF production in either of the 
environmental conditions that were statistically significant. 
3.7 Summary 
MMP-9 and interleukin-6 expression is higher, and type I and type III collagen expression is 
lower, in diabetic fibroblasts in both normoxic and hypoxic states as compared to normal 
fibroblasts. With the addition of the NO donor with the relatively long half-life (SNOG), 
MMP-9 gene expression and enzyme activity were decreased. Additionally, production of 
the inflammatory cytokine interleukin-6 was decreased by increasing NO levels with SNOG. 
Concurrently, type I and type III collagen expression were increased. Treatment with SNOG 
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resulted in a significant effect upon collagen type III production in a dose-dependent 
fashion in both normal and diabetic fibroblasts under both normoxic and hypoxic states. In 
diabetic fibroblasts, under a normoxic state, the effect did not become significant until the 
1nM SNOG-treated cells on day 3, and continued at the 10nM and 100nM concentrations on 
days 3 and 7. The effect upon collagen type III production in diabetic fibroblasts, under a 
hypoxic state, was found to be significant at the 1nM, 10nM, and 100nM in SNOG-treated 
cells on days 3 and 7. The effect of the addition of SNOG to both normal and diabetic 
fibroblasts under both normoxic and hypoxic states also results in a significant increase in 
collagen type I production in a dose dependent fashion. The effect in diabetic fibroblasts, 
under a normoxic state, was noted to be significant at the 100nM concentration of the SNOG 
donor compound on day 3. The effect in diabetic fibroblasts, under a hypoxic state, was 
found to be significant at the 10nM and 100nM level on day 7. The addition of NOR-3 had 
no significant effect upon the production of type I or III collagen in normal or diabetic 
fibroblasts. 
4. Conclusion 
Chronic diabetic wounds present a significant challenge to healthcare providers and 
resources. Significant amounts of time, money and resources have gone into prevention and 
treatment of these wounds. However, despite these efforts, chronic wounds continue to pose 
a serious problem. This has led researchers to focus more on understanding the molecular 
organization and function of normal wound healing and how this process is altered in 
chronic diabetic wounds. This is a very complex process that occurs through a series of 
highly integrated interactions between a multitude of varying cell types, growth factors, and 
cytokines. In diabetics, these wound healing interactions are disrupted and the process of 
wound healing seems to be locked in a perpetual state of chronic inflammation.  
In diabetic wound healing, a physiologic state consistent with decreased nitric oxide (NO) 
levels results, leading to an impaired inflammatory response, decreased collagen 
production, and decreased wound-breaking strength (Witte et al., 2002). Prior studies have 
also revealed the MMP levels are significantly elevated in chronic diabetic wounds, thus 
creating an imbalance in matrix breakdown and release of growth factors that are important 
for normal wound healing (Wysocki et al., 1993; Trengove et al., 1999; Lobmann et al., 2002). 
Chronic diabetic wounds appear to be physiologically trapped in the inflammatory stage of 
wound healing and nitric oxide may promote normal healing by selectively reversing 
dysregulated factors (e.g.: localized ischemia, cell proliferation, MMP/TIMP ratio, growth 
factors/ cytokines, matrix synthesis) which prevent progression to the reepithelialization 
phase of wound healing. Additionally, nitric oxide may play a larger role in diabetic foot 
problems as low levels of endothelial nitric oxide synthase, an enzyme responsible for nitric 
oxide production, is associated with bone fractures (Loveridge et al., 2002) and Charcot 
neuroarthropathy (La Fontaine et al., 2008).  
Prior studies have shown that introduction of a NO donor can improve wound healing 
(Shabani et al., 1996; Bohl-Masters et al., 2002). The mechanism(s) responsible for NO-
induced healing remains unclear. Our studies reveal significant differences in the levels of 
MMP-9, NO synthetases, PDGF-BB, interleukin-6 and types I and III collagen in normal 
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Fig. 17. Effect of NO donor NOR-3 on IL-6 production by normal and diabetic human 
fibroblasts cultured under hypoxic conditions. 
3.6 Effects of NO donors on PDGF-BB production 
Nitric oxide donor treatment had no effect on PDGF-BB production by normal fibroblasts 
grown under normoxic or hypoxic conditions. Under normoxic conditions, the normal cells 
produced twice as much PDGF as the diabetic cells, whereas in the hypoxic environment the 
normal cells produced five times as much PDGF (data not shown). Neither of the nitric 
oxide donors tested had any significant effect on PDGF production in either of the 
environmental conditions that were statistically significant. 
3.7 Summary 
MMP-9 and interleukin-6 expression is higher, and type I and type III collagen expression is 
lower, in diabetic fibroblasts in both normoxic and hypoxic states as compared to normal 
fibroblasts. With the addition of the NO donor with the relatively long half-life (SNOG), 
MMP-9 gene expression and enzyme activity were decreased. Additionally, production of 
the inflammatory cytokine interleukin-6 was decreased by increasing NO levels with SNOG. 
Concurrently, type I and type III collagen expression were increased. Treatment with SNOG 
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resulted in a significant effect upon collagen type III production in a dose-dependent 
fashion in both normal and diabetic fibroblasts under both normoxic and hypoxic states. In 
diabetic fibroblasts, under a normoxic state, the effect did not become significant until the 
1nM SNOG-treated cells on day 3, and continued at the 10nM and 100nM concentrations on 
days 3 and 7. The effect upon collagen type III production in diabetic fibroblasts, under a 
hypoxic state, was found to be significant at the 1nM, 10nM, and 100nM in SNOG-treated 
cells on days 3 and 7. The effect of the addition of SNOG to both normal and diabetic 
fibroblasts under both normoxic and hypoxic states also results in a significant increase in 
collagen type I production in a dose dependent fashion. The effect in diabetic fibroblasts, 
under a normoxic state, was noted to be significant at the 100nM concentration of the SNOG 
donor compound on day 3. The effect in diabetic fibroblasts, under a hypoxic state, was 
found to be significant at the 10nM and 100nM level on day 7. The addition of NOR-3 had 
no significant effect upon the production of type I or III collagen in normal or diabetic 
fibroblasts. 
4. Conclusion 
Chronic diabetic wounds present a significant challenge to healthcare providers and 
resources. Significant amounts of time, money and resources have gone into prevention and 
treatment of these wounds. However, despite these efforts, chronic wounds continue to pose 
a serious problem. This has led researchers to focus more on understanding the molecular 
organization and function of normal wound healing and how this process is altered in 
chronic diabetic wounds. This is a very complex process that occurs through a series of 
highly integrated interactions between a multitude of varying cell types, growth factors, and 
cytokines. In diabetics, these wound healing interactions are disrupted and the process of 
wound healing seems to be locked in a perpetual state of chronic inflammation.  
In diabetic wound healing, a physiologic state consistent with decreased nitric oxide (NO) 
levels results, leading to an impaired inflammatory response, decreased collagen 
production, and decreased wound-breaking strength (Witte et al., 2002). Prior studies have 
also revealed the MMP levels are significantly elevated in chronic diabetic wounds, thus 
creating an imbalance in matrix breakdown and release of growth factors that are important 
for normal wound healing (Wysocki et al., 1993; Trengove et al., 1999; Lobmann et al., 2002). 
Chronic diabetic wounds appear to be physiologically trapped in the inflammatory stage of 
wound healing and nitric oxide may promote normal healing by selectively reversing 
dysregulated factors (e.g.: localized ischemia, cell proliferation, MMP/TIMP ratio, growth 
factors/ cytokines, matrix synthesis) which prevent progression to the reepithelialization 
phase of wound healing. Additionally, nitric oxide may play a larger role in diabetic foot 
problems as low levels of endothelial nitric oxide synthase, an enzyme responsible for nitric 
oxide production, is associated with bone fractures (Loveridge et al., 2002) and Charcot 
neuroarthropathy (La Fontaine et al., 2008).  
Prior studies have shown that introduction of a NO donor can improve wound healing 
(Shabani et al., 1996; Bohl-Masters et al., 2002). The mechanism(s) responsible for NO-
induced healing remains unclear. Our studies reveal significant differences in the levels of 
MMP-9, NO synthetases, PDGF-BB, interleukin-6 and types I and III collagen in normal 
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and diabetic fibroblasts. With the addition of NO donor compounds, the levels of 
extracellular matrix-degrading MMP-9 and inflammatory mediator interleukin-6 were 
decrease in skin fibroblast cultures. NO donors stimulated type I and III collagen 
expression in both normal and diabetic fibroblasts and under both normoxic and hypoxic 
states. Thus, the results of this study combined with previous studies involving chronic 
diabetic wounds, the potential exists to develop a topical media to apply to chronic 
wounds that would introduce these NO donors to the wound site to improving the 
healing potential of these wounds. 
Although it is known that diabetic patients display impaired wound healing, the mechanism 
for this impairment is not fully understood. Because fibroblasts are essential for dermal 
wound repair, the current study compared the in vitro behavior of human dermal 
fibroblasts. It has been reported that fibroblasts from diabetic wounds continue to display 
impaired proliferation even when taken out of their in vivo diabetic environment and 
cultured in vitro (Burrow et al., 2007; Loot et al., 1999; Hehenberger et al., 1998). Therefore, 
identical tissue culture conditions should not obscure differences between our experimental 
groups. 
Diabetic cells when compared to normal cells demonstrated a decreased gene expression in 
types I & III collagen, eNOS and iNOS, and PDGF-BB, with an increased production of IL-6. 
Within the hypoxic condition the expression of types I & III collagen, eNOS and iNOS and 
PDGF-BB were further reduced in both the diabetic and normal cells, whereas the IL-6 
production was only significantly increased within the diabetic fibroblasts. With the 
treatments of the NO donors, it was demonstrated that when evaluating the types I & III 
collagen and eNOS and iNOS only SNOG was seen to have an effect on either type, with its 
most profound effect on type III collagen in both environmental conditions. The IL-6 
production was only decreased by the long-acting NO donor SNOG. Neither NO donor 
demonstrated a significant effect upon PDGF-BB production.  
In 2005, we demonstrated that the addition of the NO donor SNAP to skin wounds in a 
diabetic mouse model significantly increased the rate and extent of wound healing (Stehly et 
al., 2005). The wound healing rates in the diabetic treatment groups approximated the 
normal mice. In a study by Bohl-Masters et al., 2002, a polyvinyl alcohol hydrogel 
impregnated with NO donor was used to increase the local NO concentration in a wound 
healing model in diabetic and normal mice. They found that wound healing in the NO 
donor-treated diabetic mice was either the same or slightly less than in the control group. 
However, the quality of granulation tissue was much improved in the presence of nitric 
oxide donor. 
NO has been shown to be significantly reduced in chronic ulcers. Impaired healing of 
diabetic wounds is thought to be related to diminished NO production (Witte et al., 2002; 
Schaffer et al., 1997). Because the level of NO in chronic wounds is low, and elevation of 
NO enhances wound healing, a number of other approaches have been tried to deliver 
NO therapeutically. Studies using compounds such as L-arginine (Shi et al., 2003), vitamin 
B12 (Bauer et al., 1998), and multivitamin therapy using a combination of folic acid, 
vitamin B6, and vitamin B12 (Boykin et al., 2005) have reported concomitant increases in 
wound tissue NO level and healing. The latter study demonstrated that serum 
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homocysteine, an inhibitor of NOS, is elevated in patients with chronic wounds; with 
multivitamin therapy, this inhibitor is decreased and associated with enhanced healing. 
Both of these approaches employ systemic delivery of the compounds to raise NO, but do 
not involve a local targeted delivery of NO directly into the wound site. Very few 
investigations have sought to deliver NO directly into wounds. For example, one study 
using a NO-modified polyvinyl alcohol hydrogel effectively healed cutaneous wounds in 
diabetic mice (Bohl-Masters et al., 2002). Increased production of extracellular matrix 
molecules was noted in this study, but no attempt was made to measure changes in MMP 
activity. Other approaches used to deliver NO to the wound have used linear 
polyethyleneimine/NO adducts (Bauer et al., 1998) and delivery of iNOS naked DNA via 
a collagen sponge (Thornton et al., 1998). Both of these approaches reported toxic effects 
related to the delivery of excessive levels of NO to the wound, suggesting the need for a 
more finely controlled transient release of NO. The longer-acting NO donor compounds, 
SNAP and SNOG, used in the current study, and similar cell-permeable compounds 
which produce transient increases in tissue NO concentration, should provide a means of 
optimizing the therapeutic effect. NO donor compounds may ultimately provide a new 
therapeutic tool for the treatment of diabetic foot wounds.  
The purpose of this study was to assess the effect that NO donor compounds would have 
upon the production of type I and type III collagen production in diabetic fibroblasts both in 
normoxic and hypoxic (representative of chronic diabetic wounds) states. Prior studies have 
mainly focused upon the effect in normal fibroblasts under normoxic conditions. This study 
demonstrated that collagen type I and type III production was decreased in diabetic 
fibroblasts under both normoxic and hypoxic states when compared to normal fibroblasts 
without the addition of NO donor compounds. Thus, providing a catalyst to increase the 
amount of type I and type III collagen could potentially improve wound healing in diabetic 
chronic wounds.  
To examine the time dependence of NO action in wound healing, this study utilized a 
shorter acting NO donor compound (NOR-3) and a relatively long-acting NO donor, SNOG, 
to assess their effects upon collagen production. Through the introduction of these agents in 
this study, significant increases in collagen type I and type III production were observed. In 
fact, the effect of the SNOG NO donor compound upon type III collagen production in 
diabetic fibroblasts demonstrated a significantly greater dose dependent effect than that 
observed in normal fibroblasts. Type I collagen levels were also significantly increased with 
the addition of the SNOG NO donor compound in both diabetic and normal fibroblasts. 
However, the dose dependent relationship for collagen type I production was essentially the 
same for both normal and diabetic fibroblasts. 
The short acting NO donor compound (NOR-3), was not found to have any significant effect 
upon collagen type I or III production in diabetic fibroblasts. This finding, along with 
previous findings with the use of NOR-3 potentially indicate that relatively longer-acting 
NO donor compounds are more effective at NO and collagen production in diabetic 
fibroblasts. Thus, using a relatively longer-acting NO donor compound could potentially 
expose the chronic wound to longer duration of NO further increasing the wound healing 
potential and being present throughout more of the wound healing stages. 
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and diabetic fibroblasts. With the addition of NO donor compounds, the levels of 
extracellular matrix-degrading MMP-9 and inflammatory mediator interleukin-6 were 
decrease in skin fibroblast cultures. NO donors stimulated type I and III collagen 
expression in both normal and diabetic fibroblasts and under both normoxic and hypoxic 
states. Thus, the results of this study combined with previous studies involving chronic 
diabetic wounds, the potential exists to develop a topical media to apply to chronic 
wounds that would introduce these NO donors to the wound site to improving the 
healing potential of these wounds. 
Although it is known that diabetic patients display impaired wound healing, the mechanism 
for this impairment is not fully understood. Because fibroblasts are essential for dermal 
wound repair, the current study compared the in vitro behavior of human dermal 
fibroblasts. It has been reported that fibroblasts from diabetic wounds continue to display 
impaired proliferation even when taken out of their in vivo diabetic environment and 
cultured in vitro (Burrow et al., 2007; Loot et al., 1999; Hehenberger et al., 1998). Therefore, 
identical tissue culture conditions should not obscure differences between our experimental 
groups. 
Diabetic cells when compared to normal cells demonstrated a decreased gene expression in 
types I & III collagen, eNOS and iNOS, and PDGF-BB, with an increased production of IL-6. 
Within the hypoxic condition the expression of types I & III collagen, eNOS and iNOS and 
PDGF-BB were further reduced in both the diabetic and normal cells, whereas the IL-6 
production was only significantly increased within the diabetic fibroblasts. With the 
treatments of the NO donors, it was demonstrated that when evaluating the types I & III 
collagen and eNOS and iNOS only SNOG was seen to have an effect on either type, with its 
most profound effect on type III collagen in both environmental conditions. The IL-6 
production was only decreased by the long-acting NO donor SNOG. Neither NO donor 
demonstrated a significant effect upon PDGF-BB production.  
In 2005, we demonstrated that the addition of the NO donor SNAP to skin wounds in a 
diabetic mouse model significantly increased the rate and extent of wound healing (Stehly et 
al., 2005). The wound healing rates in the diabetic treatment groups approximated the 
normal mice. In a study by Bohl-Masters et al., 2002, a polyvinyl alcohol hydrogel 
impregnated with NO donor was used to increase the local NO concentration in a wound 
healing model in diabetic and normal mice. They found that wound healing in the NO 
donor-treated diabetic mice was either the same or slightly less than in the control group. 
However, the quality of granulation tissue was much improved in the presence of nitric 
oxide donor. 
NO has been shown to be significantly reduced in chronic ulcers. Impaired healing of 
diabetic wounds is thought to be related to diminished NO production (Witte et al., 2002; 
Schaffer et al., 1997). Because the level of NO in chronic wounds is low, and elevation of 
NO enhances wound healing, a number of other approaches have been tried to deliver 
NO therapeutically. Studies using compounds such as L-arginine (Shi et al., 2003), vitamin 
B12 (Bauer et al., 1998), and multivitamin therapy using a combination of folic acid, 
vitamin B6, and vitamin B12 (Boykin et al., 2005) have reported concomitant increases in 
wound tissue NO level and healing. The latter study demonstrated that serum 
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homocysteine, an inhibitor of NOS, is elevated in patients with chronic wounds; with 
multivitamin therapy, this inhibitor is decreased and associated with enhanced healing. 
Both of these approaches employ systemic delivery of the compounds to raise NO, but do 
not involve a local targeted delivery of NO directly into the wound site. Very few 
investigations have sought to deliver NO directly into wounds. For example, one study 
using a NO-modified polyvinyl alcohol hydrogel effectively healed cutaneous wounds in 
diabetic mice (Bohl-Masters et al., 2002). Increased production of extracellular matrix 
molecules was noted in this study, but no attempt was made to measure changes in MMP 
activity. Other approaches used to deliver NO to the wound have used linear 
polyethyleneimine/NO adducts (Bauer et al., 1998) and delivery of iNOS naked DNA via 
a collagen sponge (Thornton et al., 1998). Both of these approaches reported toxic effects 
related to the delivery of excessive levels of NO to the wound, suggesting the need for a 
more finely controlled transient release of NO. The longer-acting NO donor compounds, 
SNAP and SNOG, used in the current study, and similar cell-permeable compounds 
which produce transient increases in tissue NO concentration, should provide a means of 
optimizing the therapeutic effect. NO donor compounds may ultimately provide a new 
therapeutic tool for the treatment of diabetic foot wounds.  
The purpose of this study was to assess the effect that NO donor compounds would have 
upon the production of type I and type III collagen production in diabetic fibroblasts both in 
normoxic and hypoxic (representative of chronic diabetic wounds) states. Prior studies have 
mainly focused upon the effect in normal fibroblasts under normoxic conditions. This study 
demonstrated that collagen type I and type III production was decreased in diabetic 
fibroblasts under both normoxic and hypoxic states when compared to normal fibroblasts 
without the addition of NO donor compounds. Thus, providing a catalyst to increase the 
amount of type I and type III collagen could potentially improve wound healing in diabetic 
chronic wounds.  
To examine the time dependence of NO action in wound healing, this study utilized a 
shorter acting NO donor compound (NOR-3) and a relatively long-acting NO donor, SNOG, 
to assess their effects upon collagen production. Through the introduction of these agents in 
this study, significant increases in collagen type I and type III production were observed. In 
fact, the effect of the SNOG NO donor compound upon type III collagen production in 
diabetic fibroblasts demonstrated a significantly greater dose dependent effect than that 
observed in normal fibroblasts. Type I collagen levels were also significantly increased with 
the addition of the SNOG NO donor compound in both diabetic and normal fibroblasts. 
However, the dose dependent relationship for collagen type I production was essentially the 
same for both normal and diabetic fibroblasts. 
The short acting NO donor compound (NOR-3), was not found to have any significant effect 
upon collagen type I or III production in diabetic fibroblasts. This finding, along with 
previous findings with the use of NOR-3 potentially indicate that relatively longer-acting 
NO donor compounds are more effective at NO and collagen production in diabetic 
fibroblasts. Thus, using a relatively longer-acting NO donor compound could potentially 
expose the chronic wound to longer duration of NO further increasing the wound healing 
potential and being present throughout more of the wound healing stages. 
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The results observed in this study are very encouraging in regards to possible future 
treatment of chronic diabetic wounds. By studying the effects of these NO donor 
compounds in diabetic fibroblasts under normoxic and hypoxic states we have been able to 
create an environment more closely resembling a chronic wound state in human diabetic 
patients. From the results of this and other studies in our laboratory we now have the 
potential to develop a topical treatment for chronic diabetic wounds based upon optimal 
delivery of NO to assist with wound healing. Preliminary studies are currently being 
performed examining SNOG attachment and release from both collagen-based and 
hydroxyapatite-based scaffolds. The goals of these studies are to develop new types of 
synthetic graft materials for the treatment of diabetic skin and bone wounds respectively. 
Future research will be directed toward development and optimization of these and other  
NO delivery systems for the treatment of wounds and other diabetic complications.  
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Diabetic Foot Ulcers (DFUs) represent a frequent occurrence in the diabetic population and 
up to 15% of these subjects may be expected to develop a foot ulcer at least one time in 
his/her life1,2. DFUs cause personal, social and economic problems and are a serious risk 
factor for death3,4. These ulcers can be broadly classified as neuropathic, vascular5 or mixed, 
although the pathogenesis is much more complex. Biochemical6, hygienic7, structural 
deformity8,9, dynamic, pressure, skeletal, nutritional, socioeconomic factors, reduced 
antibacterial activity10,11,12, workplace influences, all concur to cause and maintain the lesion. 
A multicenter study attributed 63 percent of diabetic foot ulcers to the critical triad of 
peripheral sensory neuropathy, trauma, and deformity13. Most often healing requires the 
cooperation of many specialists, including surgeons, podiatrists, wound nurses and 
endocrinologists. In many cases, the definitive treatment demands minor or major surgery. 
While the treatment of vascular ulcers is straightforward and requires a bypass or a 
radiologic procedure if the damage to the limb is to be limited or cured, the treatment of 
neuropathic ulcers is much more complex. Most often relief of the abnormal pressure does 
not lead to the healing of the ulcer, rather these wounds are characteristically chronic, with 
alternating periods of partial improvement and relapse. Sometimes a superimposing 
infection worsens the clinical condition. These ulcers in general do not lead to major 
amputation of the limb but frequently cause considerable economic, social and 
psychological burden on the patient and his relatives.  
2. Etiology of the ulcer  
The distinctive characteristic of the diabetic ulcer is the tendency to become chronic. There 
are many definitions of “chronic”. The American Heritage Medical Dictionary and 
Stedman’s Medical Dictionary define chronic ulcers as a “longstanding ulcer with fibrous 
scar at its base. A thorough search through the literature does not give an exact definition of 
this term. Sometimes one can read of “ulcers lasting more than six months” but this ignores 
the wide array of biological backgrounds and the phenotypic presentations of these ulcers. 
We propose an equally subjective but more realistic definition: “an ulcer lasting more than one 
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could expect on the basis of previous experience in nondiabetic subjects”. The characteristic 
chronicity of the DFU was one of the bases for the diagnosis of diabetes before the 
introduction of the blood glucose assay. This idea penetrated the lore, and it is still possible 
to hear sentences like “I do not have diabetes, my ulcers heal quickly”.   
Chronic neuropathic ulcers usually occur as a result of a repeated trauma in the most 
exposed areas of the foot and ankle. However, not infrequently, may be the result of an 
acute trauma that is not recognized at the time of injury due to the relative pain 
insensitivity. The acute pathologic process is probably different and the outcome more 
favorable in the acute events versus the chronic ones. 
The neuropathic ulcers have many concurrent factors that come into play to initiate and 
sustain the ulcer process. Among the risk factors, the presence of peripheral neuropathy 
with the consequent reduced or absent pain sensation, of bone deformity that exposes the 
bone heads to an abnormal load, and of trauma are prevalent13. Some form of diabetic 
neuropathy is present in nearly 65 % of diabetic patients. Fifty percent of  these have a 
peripheral14 that causes the loss of protective sensation. The often associated autonomic 
nerve dysfunction decreases sweating and causes thin, dry, fissured skin15,16 that breaks 
easily. This autonomic dysfunction is one of the main causes of the severely damaged 
“Charcot foot”17,18. Trauma of any kind almost always has an initiating role. Acute wounds 
often are inadvertently self-inflicted during nail care or minor inadvertent injuries. Due to 
concomitant nerve damage, patients may not recognize or remember the trauma. The use of 
heaters to warm the feet or of overheated water to wash may cause burns or blisters that 
later develop into chronic wounds. The initiating factor in chronic pressure wounds most 
often is the repeated impact of an ill-fitting shoe on one area of the foot. Furthermore, 
diabetic patients have a peculiar rigidity of the joints that do not allow the foot to mold to 
the shoe or the floor19, thus creating an abnormal pressure and increasing the risk of injury. 
In many instances, calluses are an independent cause of injury, and is not uncommon to 
discover an ulcer beneath a callus.  
Diabetic neuropathies appear with such wide array of different clinical presentations and in 
so many different places, sometimes symmetrically, less frequently as mononeuropathies, 
that finding a common cause has till now been impossible.20,21 The most obvious culprit is 
hyperglycemia22, and at least at the beginning of the disease the normalization of the blood 
glucose can frequently revert to normal symptoms and signs of neuropathy.23,24 Chronic 
hyperglycemia plays an important role in the appearance of neuropathy. It is well known 
from the Diabetes Control and Complication Trial (DCCT) that strict control of blood 
glucose in newly diagnosed non complicated type 1 diabetics decreases the development of 
peripheral neuropathy in 60% of the cases over 5 years 25,26. However, the exclusive role of 
hyperglycemia has been challenged on the basis of the failure in some cases to achieve 
improvement of neuropathy with blood glucose control27,28 and other observations among 
which the increased incidence of this condition in prediabetes, 29,30,31 a state in which the 
blood glucose is still normal. Alternatively, a role of insulinopenia has been suggested.32,33 
Insulin receptors are present in the peripheral nervous system, and it is conceivable that any 
malfunction of insulin delivery34 may damage the function of neurons. There is also proof 
that in an experimental model of diabetes, a modest reduction of insulin levels even without 
an increase of the blood glucose levels can reduce the pain threshold.35,36 Thus it is possible 
that the insulin level required to regulate the nerve function is higher than that needed for 
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glucose control. Further, neuropathy can appear early also in type 2 diabetes37,38 where at 
least in the prediabetic stages, there is a compensatory hyperinsulinemia coupled with an 
increase in insulin resistance. This and the previous observation that a higher level of 
insulinemia is probably required for the regulation of the nervous than the glycemic system 
may point to a role of insulin resistance. In this case, the compensatory hyperinsulinemia 
could be present for many years and be effective to prevent the occurrence of overt diabetes, 
but not to prevent the nerve damage. Or, in turn, the insulin resistance could involve the 
nervous receptors to a higher degree than those involved in glucoregulation. It has also been 
shown that Insulin Growth Factor 1 (IGF1), a molecule that mimics many insulin 
effects,39,40,41 induces recovery of the nerve function in rats42. Taken together, these 
hypotheses fail to explain the pathogenesis of diabetic peripheral neuropathy and do not 
confirm an exclusive role of hyperglycemia. On the other hand, there is no doubt that 
hyperglycemia causes the microvascular damage frequently associated with the DFU. In a 
recent study the Authors found a graded association between HbA1C and carotid Intima 
Media Thickness (IMT) that is currently considered the best marker of progression of 
atherosclerosis.43 In this study LDL and HDL cholesterol, plasma triglycerides, and waist-to-
hip ratio were significantly associated with HbA1c after multivariable adjustment. Among 
other factors interfering with healing at the cellular level, the prevalence of infections in 
diabetics should not be overlooked. Chemotaxis, phagocytosis and all the bactericidal 
actions of neutrophils are impaired in uncontrolled diabetes4445. Also the formation of 
Advanced Glycation Endo Products (AGE), that  can bind to specific receptors on the 
leucocyte membrane (RAGE), may further impair the leucocyte antibacterial activity.46 Thus, 
at present we have not identified a distinctive cause nor we have a definite role for the co-
causal factors. One hypothesis put forward to explain the appearance and/or the 
progression of diabetic neuropathy is that impairment of synthesis of proteins may be the 
primary insult leading to the centripetal necrosis of the neuron 4748,49,50,51. Because this aspect 
is strictly connected with the topic of nutrition we will deal with it later in this chapter. This 
and many other hypotheses and their support were recently discussed in depth52 and are 
beyond the scope of his chapter 
3. The body composition of the subjects with an ulcer 
The body of a diabetic is different from the body of a person who has a normal blood 
glucose level. The well known changes at the molecular level, notably the accumulation of 
AGEs53 cause in time morphological changes of the tissues, with diffuse damage to the 
vascular walls, reduction of the body cell mass and lean body mass54, skin stiffness and 
prevalence of fat.  
What we broadly define lean body mass is in reality a composite of what is mostly the 
structural - protein component of the body including muscle, parenchymal organs, red 
blood cells, enzymes, mitochondria and the like,55 and has a critical role in maintaining the 
integrity of the body and permitting the survival. Although surprising there are very few 
studies of the body composition of type 2 diabetic subjects. To fill this gap we compared the 
body composition of 244 subjects with type 2 diabetes mellitus and demonstrated a 
reduction in the Body Cell Mass index (an index of the % mass of cells normalized for the 
actual height of the subject) in both sexes versus 266 non diabetic matched controls. 
Furthermore in 715 diabetics we also demonstrated that this reduction was proportional to 
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both the prevailing level of HbA1c in the last year and the duration of disease, although 
with the multiple regression analysis the former appears to account for most of the actual 
reduction52.  
There are many possible explanations for the protein/lean body mass loss: (1) the body of 
the diabetic is in a continuous catabolic state due to insulin deficiency and to the 
phenomenon of neoglucogenesis continuously turning aminoacids and fat into harmful 
glucose. This process lasts throughout the day in uncompensated diabetes56 without 
interruption at mealtime and is proportional to the blood glucose level57, in accordance with 
our observations. (2) Most diabetics have a persistent microalbuminuria, which represents 
another source of protein loss58 (3) the wound itself is a source of protein loss proportional 
to the size and depth of the lesion.59 (4) Because of the concomitant kidney damage these 
patients are frequently put on a protein reduced diet, on unsupported grounds60, thus 
aggravating their protein depletion. 
Furthermore the presence of the wound tends to change the metabolic environment towards 
catabolism: the secretion of proinflammatory cytokines in proportion to the size and the 
condition of the lesion increases the insulin resistance deranging glucose metabolism, and 
drives the body into a catabolic state. This phenomenon is particularly dangerous in 
diabetics who already have high circulating levels of cytokines secreted by the excess 
abdominal fat. The increased cortisol secretion as part of the stress response to the wound 
adds to the catabolism: less energy is derived from the fat mass, and the protein catabolism 
is increased. In turn the release of aminoacids drives the neoglucogenesis in the liver.  
To add further to this catabolic state, diabetic subjects have reduced levels of most anabolic 
hormones. Beyond the obvious absence or ineffectiveness of insulin on protein 
metabolism61,62,63 these subjects have a subnormal level of testosterone (low testosterone 
syndrome)64,65,66,67 with a characteristic hypogonadotropic hypogonadism64 responsible for 
the decreases the lean body mass. In view of all these events occurring together it is not 
surprising that most of these subjects are in a protein depleted state. As suggested before, it 
is possible that the failure of proteins synthesis involved in nerve functioning may result in 
impaired nerve regeneration and death.68,69,70,71  
 






Fat derived cytokines 
Diet 
Protein losing enteropathy 
diarrhea 
Table 1. Common causes of protein malnutrition in the diabetic 
It is thus clear that decompensated diabetes is a catabolic condition further aggravated by 
the stress reaction and this creates a conflict with the ancestral mechanisms of survival of 
the body. A better comprehension of the wound healing process can be acquired through 
an analysis of these processes. The human body is programmed for survival and has a 
hierarchy of priorities for this aim72. The primary need is the conservation of the lean 
body mass defined as above as a composite of muscle, circulating enzymes, red blood 
cells, all the parenchymal organs, the immune organ and the water representing the 
metabolic and structural machinery of the body. Stated more simply the lean body mass is 
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all that is not fat. Any reduction of this mass poses a risk to survival. This compartment is 
continuously refilled with the proteins derived from the diet. The average energy need of 
a healthy young 70 kg person is 2500 cal / die obtained from the diet. Usually 20% of 
these (125 gr) derive from protein. However in times of abundance, when the lean body 
mass is replete, the organism deals with the wound as a nutritional priority and any 
aminoacid and protein supply acquired through the diet are diverted to the wound to 
promote the closure73. This diversion to the skin is a damage to the lean body mass 
because subtracts the aminoacids from the diet in proportion to the size and the depth of 
the ulcer. If the lesion is exceedingly large and deep also the protein content of the lean 
body mass is catabolized to aminoacids to support the repair of the skin. When more than 
15-20% 74,75,76 of the lean body mass is lost the survival mechanism changes radically its 
perspective and the true priority becomes the maintenance of this structure. Under these 
conditions the body uses all the hormonal and metabolic tools available to support the 
lean body mass, that includes antibodies and immune cells and almost nothing is left for 
the wound. The integrity of this lean mass is so critical that its reduction to <60% of the 
initial value usually leads to failure of the immune function and death due to 
pneumonitis77.  
 
Fig. 1. Main causes of protein malnutrition in diabetes 
We should envisage the body as  a sophisticated system with a central compartment (Lean 
Body Mass, LBM) supplying the periphery on demand. If a peripheral lesion (the ulcer) 
supervenes the central compartment supplies protein until a danger level of depletion is 
reached. The human body does not have a reservoir of spare proteins, and these have a low 
energetic yield. Thus a critical level of depletion is reached soon. This phenomenon is even 
more prominent in the protein depleted diabetics. In these subjects the central compartment 
of LBM is frequently already in borderline-low conditions and subtracts all the alimentary 
supply of proteins. In these conditions an ulcer will never heal. 
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both the prevailing level of HbA1c in the last year and the duration of disease, although 
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In summary, in the presence of a chronic ulcer in a longstanding diabetic subject, we must 
always assume the existence of a certain degree of lean body mass (LBM) loss. The Body 
Bioimpedance analysis (BIA) is a widely used method for estimating the body composition 
and the presence of this condition. The technology is relatively simple, quick and 
noninvasive and evaluates the electrical impedance of body tissues, which provides an 
estimate of total body water (TBW). This value can be used to calculate the fat-free mass 
(FFM) and body fat (adiposity).In addition this technology can be used to evaluate the body cell 
mass (BCM). When the BCM is corrected for the actual height of the subject (Body Cell Mass 
Index, BCMI) gives a very accurate estimate of the total cellular mass and is a useful tool to 
assess the nutritional state, more so if a previous report is available for comparison to 
estimate the degree of damage. 78  
Diabetic foot ulcers tend to occur in the advanced stages of the disease. The usual saying 
that a characteristic of early diabetes is the slow healing of wounds dates back to a period 
when the diagnosis of the disease was delayed. Today a diagnostic delay only occurs in the 
poor and the underprivileged. In these subjects the catabolic state is usually well advanced 
and the skin is thin with widespread loss of the subcutaneous tissue, and a chronic 
nonhealing ulcer can be a presenting sign of diabetes. We demonstrated in 700 diabetics that 
at this stage the loss of the lean body mass is already advanced, and that the use of  re-
feeding solutions containing an increased percentage of proteins can help to recreate the 
lean body mass52 and the subcutaneous tissue79 
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Current treatments 
Since a single cause of the nonhealing diabetic foot ulcer has not been identified a variety 
of different products acting on, mimicking, or purportedly having magic qualities, have 
been introduced on the market without substantial proof of benefit, and often lacking 
rationale. 
Although frequently emphasized, the general condition of the patient, the strict control of 
his blood glucose and the general nutritional status are too frequently overlooked, mostly 
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in the general medical or surgical wards, where the attention is focused on the ulcer itself. 
The concern for the local factors and the commercial pressure of the pharmaceutical 
companies generated an incredible number of local treatments, including ointments, 
growth factors and the so called “advanced medications” containing a variety of metals 
and ions that should stimulate the reparative process. However the use of these 
substances did not demonstrate any substantial improvement in clinical studies. Although 
we do not think that these medications have a great role, we must acknowledge that 
proving the efficacy of these substances in healing ulcers with randomized controlled 
studies is a complicated and expensive task. It is evident that recruiting an adequate 
number of subjects with the same duration of disease, a similar degree of diabetic control, 
and an ulcer of the same characteristics for a randomized controlled trial is very difficult, 
and unless a substance has truly magical properties the statistical results will be open to 
discussion80,81,82 
What starts the cascade of problems in the diabetic is an alteration of glucose metabolism 
that in turn causes a series of metabolic derangements, and the dire consequences that 
follow. In a recent study the Authors found a significant prevalence of HbA1c >7% (53 
mmol/mol) and HDL < 50 mg/dl  in diabetic subjects with lower extremity disease 
versus those without.83 But if things are so simple, why is the normalization of blood 
glucose alone not able to induce tissue regrowth and ulcer healing? The answer is that a 
diabetic foot ulcer only appears after a long period of decompensated diabetes, when the 
nerves, the skin and all the supporting tissues and structures are already severely 
damaged or impaired and the simple correction of the causal abnormality is not enough. 
In this respect is worthwhile to mention the results of the Accord study casting doubt on 
the feasibility of intensive blood glucose control in diabetic patients with complications. 
In this study after an average of 3.5 years, 257 people in the intensive blood glucose 
lowering strategy group died, compared to 203 participants in the standard strategy 
group. This difference of 54 deaths resulted in a 22 percent increased death rate in the 
intensive group. Since the presence of a DFU is a complication these results have an 
important bearing on the treatment of these subjects.84 
Under normal circumstances the healing of an ulcer requires energy supplied by lipids 
and glucose. The role of glucose is probably the most complex because this molecule is 
part of the structural glycoproteins, of some enzymes85,86 and fuels the inflammatory 
cells87. Lipids for the energetic needs of healing can be obtained from the diet or from fat 
deposits. As happens for glucose, lipids have multiple functions: the most well known is 
energy storage, but these molecules also have signaling capacity and are structural 
components of the cell membrane. Both glucose and lipids must be available for the 
normal healing processes of the ulcers, but diabetics have a characteristic difficulty 
disposing of glucose inside the cells that can be only partially reversed with the available 
treatments. Proteins are structural components of the skin, but these subjects almost 
always have a degree of preexistent protein deficiency that must be taken into account 
when planning a diet. Estimating the degree of deficiency is the difficult part because the 
body composition is an individual characteristic and no “normal values” exist. The 
available tools to evaluate the degree of LBM and indirectly the degree of protein loss, like 
Bioimpedance Analysis and Skin Fold Thickness,  are only useful in the presence of 
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previous records of the same subject. The body weight loss, another simple and 
sequentially available measurement does not give any information on the body 
compartments and is thus of limited utility. However the presence of a nonhealing ulcer 
implies the loss of at least 20% of the LBM. When estimating the calorie-protein need of a 
diabetic the most reasonable option is to err on the excessive side.  
Although the role of nutrition is crucial and usually acknowledged, it is surprising how 
often is overlooked in practice. The most recent edition of the ADA book on the treatment of 
DFU88 does not even mention the general condition and the nutritional status of the patient 
among the aspects to evaluate. 
Our hypothesis is that the damage to the tissues is both preventable and at least partially 
reversible if the treatment is directed towards all the main causal factors. In other words, in 
our opinion if the vascular blood supply is normalized, the blood glucose level is kept under 
control, the abnormal pressure is reduced with adequate biophysical support and the 
texture of the skin is reconstituted there is absolutely no place for growth factors, colloids, 
metals or whatever else. The diabetic now has the same ability to heal as nondiabetics. The 
reconstitution of the skin requires the supply of proteins and other biological material that is 
usually reduced in the diabetic and must be supplied with adequate nutrition. The 
avoidance of relapses requires attention to postural and neurologic factors. 
4. Treatment 
The role of the nutritional condition of the patient with a DFU is crucial to the pathogenesis 
and treatment of the lesion, but infrequently recognized or treated. Accordingly, we think 
that the term “treatment of the DFU” is a misnomer and should be substituted with 
“treatment of the subject with a DFU”. We suggest a series of steps89: 
1. Whenever possible the nutritional condition should be assessed as accurately as 
possible, with Bio-Impedance Analysis, Skin Fold Thickness, Body Weight and Blood 
chemistry studies (protein electrophoresis, BUN, Hemogram). If previous values are 
available the change should be included as part of this assessment. 
2. The resting caloric requirement should be calculated as 20-25 kcal/kg body weight. This 
value  decreases  in the elderly. The value so obtained should be multiplied by 1.2-1.5 
according to the severity of the lesion.90 This figure should be increased if there is 
evidence of malnutrition. 
3. Add the caloric expenditure of activity. All these measurements can be obtained with 
the use of indirect calorimetry or with the recently introduced non-invasive tools worn 
at the arm that are worn over a longer period of time. The statistical elaboration of the 
Bio-Impedance Analysis can yield a reliable estimate of the Basal Metabolic Rate 
4. The value so obtained should be multiplied by a “stress factor” that varies from 1.2 for 
clean wounds, to 1.5 in the case of infected wounds 
All these calories should be replaced with an adequate diet, with no less that 20-22% protein 
given in at least three divided doses throughout the day. These values should be increased 
by 30-50% according to the co-morbidities of the subject. Paddon Jones suggests that non 
diabetic elders should have a minimum of 15 g of essential amino acids, equivalent to about 
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30 g of high-quality dietary protein at each meal.91Although there are no fast and hard rules 
this figure must be increased in the diabetic with a chronic wound. 
Another critical component is hydration92. We suggest to drink at least 2-3 lt of water per 
day. In addition to the maintenance of the circulation and the tissue exchange of 
metabolites, the water induced diuresis helps the body to get rid of the excess glucose. 
Some trace substances and vitamins are also absolutely needed for the healing process. In 
particular Vitamin C, E, Selenium and -carotene with strong antioxidant properties that 
antagonize the harmful oxygen free radicals (ROS) present in excess in the chronic wound93. 
Vitamin C is also needed for collagen formation.94 
The progression of the ulcer should be evaluated with inspection, with photographic 
records including a ruler close to the lesion, with the biochemical analytes useful to monitor 
the inflammation and the nutritional state (ESR, Hemogram, CRP, Albumin and Prealbumin 
levels), and the BIA. 
5. The role of supplements 
The body of the diabetic is in a general catabolic state and restituting the normal catabolism 
is a distinctive advantage for the treatment. According to this principle testosterone 
treatment has been instituted.95 We use transdermal testosterone supplement in testosterone 
deficient subjects with apparent reduction in healing time, although we did not conduct a 
systematic study. Other anabolic hormones have been used with variable results.96 We have 
a good experience with an oral nutritional supplement, a blend containing Argine, 
glutamine and -hydroxy- -methyl-butyrate (HMB). HMB is normally present in the 
muscle, is an active leucine metabolite and a potent stimulator of mTOR (Mammalian Target 
of Rapamycin), an intracellular protein controlling protein synthesis.97,98 Due to this 
anabolic property, the substance is widely used by the athletes worldwide, and to reverse 
the effects of aging.99 Glutamine also has a spectrum of positive effects100, notably 
stimulation of protein synthesis and support of immune function.101,102 and a positive effect 
on intestinal integrity.103 Its effectiveness in collagen formation has also been consistently 
proven.104 Arginine also has a positive effect on wound healing105, and stimulates immune 
function.106,107 Arginine also has a vasodilator action108 that was exploited for male erectile 
dysfunction before the introduction of the phosphodiesterase inhibitors. In our experience 
the use of this blend reduced to 1/3 the time to healing in a group of 12 diabetic patients 
while improving the lean body mass.109 We also found an unexpected reduction of 
microalbuminuria in 16 diabetic subjects under treatment with this blend, which might 
concur to explain the increase in lean body cell mass110  
It should be emphasized that the use of anabolic substances or blends is no substitute for an 
adequate nutrition with enough protein, calories, minerals, vitamins and iron that can be 
found in the normal Western diet. Therefore, the best nutritional approach to the diabetic 
patient is: (1) the evaluation of the degree of wasting of the lean body mass and of the 
degree of current needs; (2) institution of a diet supplying what is missing and what is 
currently required, supplemented with enough protein, and distributed in at least three 
meals per day. This diet should be integrated with vitamins, minerals and iron; (3) use of 
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anabolic agents or a blend of the three substances we used. Irrespective of which medical 
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1. Introduction 
Foot ulceration is among the most significant complications of diabetes. It is estimated that 
15% of the diabetic patients develop ulcers at some point in their lives (Reiber, 1996). The 
therapeutic management of a diabetic patient carrying a diabetic foot ulcer (DFU) is 
currently based on: metabolic control, debridement (Brem et al., 2004), moist cures, wound 
dressing, local pressure off-loading, antimicrobial treatment of infections, and 
revascularization procedures, when indicated. More recent therapies such as topical growth 
factors (Tsang et al., 2003; Brem et al., 2004; Eldor et al., 2004; Hong et al., 2006; Viswanathan 
et al., 2006), skin substitutes (Marston et al., 2003; Veves et al., 2001), and others have shown 
efficacy in pure neuropathic, non-complicated ulcers. However, these products would still 
have to be tested in advanced lesions including those with an ischemic etiopathogenic 
component. Still 10 to 30% of the cases progress to amputation, frequently preceded by 
gangrene and infection (Lipsky, 2004). After amputation of a lower limb, the five year 
mortality rate reaches 50-60% (Reiber, 1996). Therefore, despite progress in the diagnosis 
and treatment of infection and other complications (Lipsky, 2004; Williams et al., 2004), the 
advanced DFU is still an unmet medical need. 
The local (intralesional) instillation of recombinant human epidermal growth factor (rhEGF) 
to promote granulation and healing of chronic, advanced DFU has been recently introduced 
in medical practice in some countries. This chapter will review the rationale, experimental 
background, and clinical development of such procedure.  
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2. Why can Epidermal Growth Factor (EGF) be used for the treatment of 
Diabetic Foot Ulcers (DFU)? 
Epidermal growth factor (EGF) is a 53 aminoacid polypeptide that was isolated for the first 
time by Cohen from mice submaxillary glands (Cohen, 1962). It stimulates the proliferation 
of fibroblasts, keratinocytes and vascular endothelial cells, which contribute to its scar tissue 
formation property. Its action is launched by the interaction with specific receptors located 
on the cellular membrane. The EGF receptor is a glycoprotein with an extracellular binding 
domain, a transmembrane region and a cytoplasmic portion with tyrosine kinase activity 
(Bazley & Gullick, 2005). This receptor is expressed on most human cell types including 
those which play critical roles for wound repair such as fibroblasts, endothelial cells and 
keratinocytes (undifferentiated, marginal, leading edge, hair follicles, sweat ducts and 
sebaceous glands). Only hematopoietic cell lineages lack the EGF receptor (Werner & Grose, 
2003). The rationale of the use of Epidermal Growth Factor (EGF) for the treatment of (DFU) 
is based on: 
2.1 Impairment of healing in diabetic patients, partially due to a relative deficit of 
growth factors (EGF among them) in the wound area 
Wound healing is an ancestral mechanism evolutionarily designed to ensure the structural 
and functional restoration of an injured area. The mechanism involves cellular responses 
from two major classes: (i) repair-committed cells such as fibroblasts, other mesenchymal-
derived cells, endothelial / angiogenic precursor cells and epithelial keratinocytes and (ii) 
inflammatory cells that are transiently recruited and temporarily infiltrate the wound 
(Eming et al., 2007). Under physiological conditions this process is ensued by inflammatory 
cells’ progressive apoptosis and inflammation cessation. Although in diabetic wounds the 
cells and the pro-inflammatory cytokines are the same than in non-diabetic, acute 
counterparts; inflammation is more a condition than a reaction. The perpetuation of 
neutrophils, macrophages and their related pro-inflammatory cytokines in diabetic wounds 
contribute to the onset of a pro-degradative microenvironment which results from the 
imbalance between matrix synthesis and degradation (Berlanga et al., 2008). 
Under these circumstances the local pool of growth factors (GFs) and their corresponding 
receptors turn detrimental due to a reduced transcriptional expression by the wound bed 
committed cells and/or to increased enzymatic degradation (Clark, 2008). The role of GFs 
turns more important in the context of a diabetic wound since high glucose levels and other 
associated metabolic by-products are toxic for endothelial and fibroblastic cells, which 
become arrested and senescent. In this environment the granulation tissue promoting cells 
launch a pro-apoptogenic program which eventually hinders the granulation process 
(Goren et al., 2006). The observation that diabetic wounds are enriched in proteases supports 
the premise that impaired GFs availability may act as a rate limiting factor in diabetic 
wound healing (Burrow et al., 2007), which justifies an appropriate wound bed preparation 
and a GFs replacement therapy. 
2.2 The growth stimulating, healing promoting, and cytoprotective actions of EGF, 
including angiogenesis 
The EGF family of ligands exhibit mitogenic activity upon binding to four different high-
affinity receptors: EGFR/ErbB1, HER2/ErbB2, HER3/ErbB3, and HER4/ErbB4. Upon 
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ligand binding, the formation of a functionally active EGFR-EGFR homodimer or EGFR-
HER2, EGFR-HER3, or EGFR-HER4 heterodimers causes the ATP-dependent 
phosphorylation of specific tyrosine residues in the EGFR intracellular domain, which 
triggers a complex program of intracellular signals to the cytoplasm and then to the nucleus 
(Citri & Yarden, 2006).  
Another biological action unleashed by the EGF-EGFR binomium is the locomotion 
stimulation of epithelial and fibroblastic cells (Barrandon & Green, 1987). This pro-
motogenic impulse induced by the EGF-EGFR complex on keratinocytes is important for re-
epithelialization. EGF can also control fibroblasts extension, attachment or detachment 
directly or indirectly via modifications of the injured tissue extracellular matrix composition 
(Maheshwari et al., 1999). 
The EGF-induced mitogenic, motogenic, and cyto-protective actions are instrumental for 
healing events that may be summarized as: (a) stimulation of productive cells migration 
toward the injured area, (b) stimulation of granulation tissue outgrowth – including 
extracellular matrix accumulation, maturation and de novo angiogenesis, (c) stimulation of 
wound contraction by myofibroblast activation and proliferation, (d) stimulation of the 
damaged area resurfacing by epithelial cells migration and proliferation (Werner & Grose, 
2003).  
EGF is also endowed with angiogenic activity thus promoting the growth of a vascular 
mesh within the wound bed. The mechanisms behind this angiogenic effect appears to be 
related to chemotaxis of endothelial cells and the enhancement of other angiogenic factors 
expression (van Cruijsen et al., 2005). This EGF-mediated neoangiogenic action is significant 
for ischemic wounds (Grazul-Bilska et al., 2003). 
2.3 The nerve restoration action of EGF in sciatic nerve section experiments, where it 
prevented distal limb ulcers and toe loss 
Several experiments demonstrated that single or repeated EGF systemic injections exerted 
cyto-protective and proliferative responses, supporting the intrinsic ability of EGF at supra-
physiological concentrations to unleash biological events required for an effective tissue 
repair (Berlanga et al., 1998a, 1999, 2001, 2002a, 2002b). 
The effect of an EGF local injection was evaluated for the first time in tissues unrelated to 
the digestive system (which at the moment was the most common experimental substrate 
- Curling’s ulcers prevention) through the perilesional injection of EGF in rats that had 
been subjected to a complete sciatic nerve section. Two independent studies demonstrated 
that the intralesional injection of EGF produced: (i) recovery of the motor nerve impulse 
conduction; (ii) axonal recovery and remyelination, and (iii) prevented or delayed the 
onset of trophic changes of the hind limb soft tissues (plantar ulcers and toe necrosis). 
These sciatic nerve experiments suggested the possibility for a pharmacological 
management of trophic ulcers derived from a neurogenic ischemia (Prats et al., 1998). This 
animal model somewhat mirrored the condition of a neurogenic diabetic lower extremity 
in which both neuropathy and angiopathy concertedly predispose to ulceration (Dyck & 
Giannini, 1996). 
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3. Why EGF has to be injected intralesionally? 
3.1 The availability of the growth factor on the surface of the wound is limited as it 
can be degraded by proteases from the biofilm that covers the lesion and/or from its 
fluid 
The need for a prolonged interaction between EGF and its receptor to achieve a significant 
granulation tissue response in controlled wounds in mice had been reported (Buckley et al., 
1985). Proteolysis exerted by the wound-derived exudate was observed incubating the 
ulcers´ material at neutral pH with a fluorescent-synthetic peptide at room temperature. 
Pre-incubation with a protease inhibitor prevented substrate’s degradation. These 
observations suggested a possible reduction of EGF bioavailability by proteases derived 
from controlled wounds (Berlanga et al., 1998b). Other studies had already established 
proteolysis of growth factors and their receptors in chronic circumstances (Mast & Schultz, 
1996; Saarialho-Kere, 1998; Trengove et al., 1999;, Medina et al., 2005). 
Furthermore, profiles of 125I-EGF in a rat full-thickness wound model, demonstrated 
tissue-bound radioactivity 2 h after the administration. Within this period, 125I-EGF 
degraded subspecies with no diffusion of the peptide to the surrounding skin were 
identified. The receptor expression was increased 2 h after wounding, followed by a slow 
decline up to 12 h below baseline. These results point out that 125I-EGF is rapidly cleared 
from the application site probably by protease-driven cleavage and receptor-mediated 
endocytosis. The mean residence time (MRT) values suggested that more than 60% of the 
amount administered could have disappeared as early as 2 hour post-administration 
(Prats et al., 2002). Previous clinical evidences of topically applied EGF had already 
rendered disappointing results possibly due to local bioavailability limitations (Falanga et 
al., 1992;, Falanga, 1992).  
3.2 Responding granulation tissue develops from the deep layers of the wound 
An immuno-histochemical characterization of biopsy cylinders from diabetic wound beds 
shed more light on the biological sustentation for the infiltrative modality. Granulation 
tissue biopsy cylinders (approximately 7 millimeters length) from neuropathic patients were 
collected and paraffin-processed for different histochemical techniques and for incubation 
with anti-EGF receptor and anti-prohibitin (PHB) antibodies. The monoclonal antibody 
against EGF receptor EGFR-pY1197 (1:250, DAKO) binds to tyrosine residue 1197 when it is 
phosphorylated, indicating downstream signaling activation. Prohibitin rabbit monoclonal 
(Abcam. EP2804Y) was diluted at 1:200. EnVision + Dual Link System-HRP was used to 
develop the reaction. Slides were hematoxylin counterstained. Pictures were obtained at 
X 40 constant magnification. The figure shows three strata along the longitudinal axis of the 
biopsy material were defined: upper, middle, and bottom. Fibroblasts populating the more 
superficial stratum expressed more prohibitin and less EGF-receptor. Prohibitin is an 
inhibitor of cell cycle progression and may therefore contribute to the onset of wound’s 
chronic phenotype. (Mishra et al., 2010; Lee et al., 2010; Dong et al. 2010). This expression 
profile became progressively inverted going through deeper cells layers (Fig. 1). Advanced 
glycation end products and elastase also appeared more intensely labeled next to the wound 
surface than in deeper cells strata (not shown). 
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approximately one half of the patients with deficient irrigation of the corresponding leg 
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ulcers corresponded to grades 3 or 4 of the Wagner´s classification (Armstrong et al., 
1998).These patients, which can represent 50% of the whole DFU population, lead to most of 
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Patients with hemoglobin <100 g/l, uncontrolled chronic diseases, psychiatric disorders, 
malignancies, pregnant or breastfeeding, were excluded. Signed, informed consent was an 
inclusion requisite in all trials, which were approved by the corresponding Ethics 
Committees and by the National Regulatory Authority. 
Intralesional rhEGF was administered adjuvant to the conventional good wound care 
measures: metabolic control, thorough debridement of necrotic and infected tissue, pressure 
off-loading, and antimicrobials if needed. The product was dissolved in 5 ml of water for 
injection or saline and distributed evenly throughout the lesion in 5 to 10 punctures, starting 
from the cleanest zones. The needle was changed between injections in order to prevent 
infection dissemination. Treatment was given three times per week on alternate days, until 
complete granulation response or a maximum of 8 weeks. Only in trial No. 0705 treatment 
was continued until wound closure. Subjects were hospitalized during treatment in all trials 
and then followed-up, generally for one year, as outpatients. 
The main outcome variable in most of the studies was the development of granulation 
tissue, classified, according to the lesion area covered, in: (i) no response: less than 25% 
granulation; (ii) minimal response: 25 to 50%; partial response: 50 to 75%; complete 
response: more than 75% of the lesion area, that could support a skin graft to complete ulcer 
closure. A 100% granulation response was nonetheless achieved in most complete 
responders. 
In these, more advanced ulcers, granulation is a valid outcome since it is part of the healing 
process and should necessarily precede the final healing. Besides, granulation over the ulcer 
area permits skin grafting to attain final healing, so a group of patients does not reach 
complete spontaneous healing to be evaluated. Additionally, a significant correlation was 
found between granulation and healing in the confirmatory study No. 0503 (Fernandez-
Montequin et al., 2009b). Previous studies had identified partial wound closure as predictive 
of complete healing for Wagner’s grade 1 or 2 DFU (Sheehan et al., 2006), and other ulcers 
(van Rijswijk & Polansky, 1994;, Kantor & Margolis, 2000), but this was the first report of an 
early surrogate endpoint in Wagner’s grade 3 or 4 DFU. 
4.1 Pilot, exploratory trial in 29 patients who were bound to amputation 
Patients bore advanced DFU, Wagner´s grade 3 (10 cases) or 4 (19 cases); 23 of them were 
ischemic and had no other therapeutic alternative. Some granulation response was obtained in 
25 cases (86%) and the complete response and lesion closure in 17 (59%; one of them through 
skin graft), thus preventing amputation. Recurrence appeared in only one patient after a one-
year follow-up (Berlanga et al., 2006). An immuno-histochemical study suggested that TGF β 
could be the main effector mediating the EGF-stimulated granulation process. Biopsies taken 
from neuropathic and ischemic patients showed the stimulation of granulation tissue growth 
and organization as well as the formation of new blood vessels after the treatment with rhEGF, 
illustrating its angiogenic effect (Figure 2 in Berlanga et al., 2006). 
4.2 Dose exploratory trial 
A controlled, double-blinded, randomized and multicenter clinical trial was later carried out 
in five institutions to explore a possible dose-dependent response (Fernandez-Montequín et 
al., 2007). 
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Forty-one patients bearing Wagner’s grade 3 and 4 lesions were included. They were 
randomly distributed in two groups receiving rhEGF at 75 μg or 25 μg. A tendency to 
better results with the higher dose was observed: higher granulation response rate and 
faster, but groups behaved similar concerning wound closure during follow-up. Only one 
patient relapsed in the follow-up. In some of the cases wound contraction could be 
evidenced as part of the healing process (Figure 2). This property is usually abolished in 
diabetic patients. 
 
Fig. 2. Evidence of granulation and healing in two patients from study No. 0202. Upper line: 
65 years-old female. An ischemic 38 cm2 transmetatarsal amputation base was treated with 
rhEGF. A: before the beginning of treatment; B: after 5 weeks (15 infiltrations) complete 
granulation was achieved; C: healing occurred at 29 weeks. Lower line: 46 years-old female 
with ischemic and infected DFU. After toe disarticulation and antibiotics, she was treated 
with rhEGF. D: before treatment; E: after 4 weeks (12 infiltrations) complete granulation was 
achieved; F: Healing was reported at 17 weeks. Wound contraction is evident as part of the 
healing mechanism.  (Picture taken from Fernandez-Montequin et al. 2007) 
4.3 Series of 12 patients treated with the 75 µg dose (not published) 
The results obtained agree with those obtained in previous trials. Most of the patients 
responded satisfactorily. The observed total response rate was 75%. Major amputations 
were carried out in 3 patients (25%), all ischemic, associated to the occurrence of local 
infection in two of them. 
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4.4 Monitoring of patients treated after initial conditional marketing approval of the 
product (not published) 
A multicenter, non-controlled, phase IV-type study was based on the reports of all treated 
cases after an initial conditional marketing approval in Cuba. The rhEGF began to be used 
throughout the country and was administered at 25 μg, three times per week until complete 
granulation or up to 8 weeks. Results were consistent with the previous ones. Relapse was 
present in only one patient after one year follow-up. 
4.5 Series of patients treated with 75 µg up to wound closure 
Twenty patients were included and treated with intralesional rhEGF, three times per week, 
until the lesion closure was attained (Fernandez-Montequín et al, 2009a). According to 
Wagner’s classification, 16 patients (80%) were grade 3 and 4 (20%) were grade 4. The mean 
initial area of the lesions was 16.3 ± 21.3 cm2. There was evidence of ischemia in 5 patients 
(25%), whose limb occlusion pattern was at a distal level. A complete granulation response 
was obtained in all cases, complete lesion closure in 17 (85%) and none of them required 
amputation. The mean healing time was only 6 weeks. There was one wound recurrence 6 
months after healing. This study indicated that rhEGF can be used after total granulation 
until the lesion is completely closed or until its area is significantly reduced (≤ 1 cm2). 
4.6 Multicenter, double-blind, placebo-controlled confirmatory trial 
A confirmatory, multicenter, randomized, double-blind trial was carried out (Fernandez-
Montequín et al, 2009b). Besides, it was compared to placebo. The latter was required to 
provide unquestionable evidence on the efficacy of intralesional rhEGF administration; to 
rule out that the results obtained were explained by good wound care that improves under 
clinical trial settings or due to the endogenous local production of growth factors induced 
by the debridement and injection procedures. 
The study was carried out at 20 institutions in all Cuban provinces. The treatment consisted 
of three applications of 75 μg EGF, 25 μg, or placebo for 8 weeks or until complete 
granulation, adjuvant to general good wound care. 
Due to ethical reasons, to avoid giving placebo to a non-responder, if less than 25% of the 
ulcer area was covered by granulation tissue after two weeks of treatment, the patient´s 
code was opened and the patient switched to 25 μg rhEGF, when on the placebo, or 75 μg, 
when on 25 μg. The main evaluation variable was the existence of at least a partial response 
(50% of the lesion area covered by granulation tissue) after two weeks of treatment, since 
this was the period when all patients were randomized and double-blinded in their original 
treatment groups. The hypothesis of the trial was to obtain at least 30% advantage in the 
proportion of individuals with an objective response at that moment in the groups treated 
with rhEGF as compared to the placebo. The secondary variables taken into account were 
the existence of a complete granulation response at the end of treatment, the time to 
complete response, lesion closure during the 12 months follow-up, time to closure, the 
occurrence of relapses and the need for amputation. Safety was evaluated by adverse events 
monitoring and laboratory variables. All the analyses were made under the principle of 
“intention to treat”. 
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One hundred and forty-nine patients were included. Groups were equivalent in regard to 
demographic and baseline variables. Both dosage groups fulfilled the study hypothesis of 
more than 30% advantage over the placebo group, in the proportion of patients with more 
than 50% of the lesion area covered by granulation tissue. Differences (and their 95% CI) 
with respect to the placebo are shown in Table 1. Superiority in relative terms (OR) was 7.5 
(2.9 – 18.9) and 3.7 (1.6 – 8.7) for the high and the low doses, respectively. 
After eight weeks, the proportion of patients with complete granulation response was 
significantly higher only for the 75 μg treatment compared to placebo. The benefits of the 
treatment were more evident for the neuroinfectious origin cases than in those with an 
ischemic component. The time required for a complete response was 3 weeks for each group 
receiving EGF and 5 weeks for the placebo. This difference was statistically significant for 
both dosage levels. 
The evaluation of the complete closure of the ulcers was performed during the 12-month 
follow-up. The statistical multivariate analysis of lesion healing showed that the factors that 
favored ulcer closure were rhEGF 75 μg vs. control (OR: 3.6; 95% CI: 1.4 – 9.5), the “pure” 
neuropathic vs. ischemic character (5.5; 2.3 – 13.5), and an initial smaller ulcer size (0.98; 0.96 
– 0.99). Relapses only occurred in the placebo group. Although amputations were too few to 
support any statistical analysis, it is remarkable that there was only one amputation among 
the neuropathic patients treated with rhEGF at any of the dosages, while 15% of the 
neuropathic cases required amputation in the placebo group. There was only one failure 
after two weeks in the group receiving rhEGF at 75 μg. 
This trial confirmed the efficacy of intralesional rhEGF in advanced DFUs. The results were 
better in the group using the high dose, although both dosage levels fulfilled the efficacy 
hypothesis for the main variable (partial granulation response after two weeks). Besides, 
only the high dose showed significant differences compared to the control group for some 
secondary variables, suggesting a dose-dependent effect. This is particularly important for 
patients with ischemia, which is an adverse condition for granulation and healing 
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follow-up  17 (59%)  
Time to complete 
granulation in weeks (mean 
± SD)  
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ischemic and neuropathic; 
Design: multicenter, 
randomized, double blind.
Treatment: 25 µg or 75 µg, 
3 times per week until 
complete granulation or 8 
weeks maximum. Follow-
up for one year 
Ref.: Fernandez et al., 2007
Wound closure during 
follow-up 13 (57%) 9 (50%)  
Time to complete 
granulation in weeks (mean 
± SD) 
3.8 ± 2.2 4.9 ± 2.2  
Time to wound closure in 
weeks (95% CI) 21 (17; 24) 20 (16; 23)  
Amputations 8 (35%) 6 (33%)  
Code: 0504 
Lineal, patient series. 
Ulcers: grade 4, ischemic 
and  neuropathic;  
Treatment: 75 µg, 3 times 
per week until granulation 
or 8 weeks maximum 
Not published 
N 12 
Complete granulation at the 
end of treatment 9 (75%)   
Amputations 
3 (25%)   
Code: 0604;  
Lineal, phase IV – type 
study after conditional 
approval; Ulcers: grade 3 
and 4, ischemic and 
neuropathic. 
Treatment: 25 µg, 3 times 
per week until granulation 
or 8 weeks maximum. 
3- year follow-up. 
Not published 
N 93
Complete granulation at the 
end of treatment  78 (84%)  
Wound closure during 
follow-up  (16 patients lost)  46 (49%)  
Time to wound closure in 
weeks (95% CI)  10 (9; 11)  
Amputations
 26 (28%)  
Code: 0705;  
Lineal, patient series. 
Ulcers: grade 3 and 4, 
ischemic and neuropathic; 
Treatment: 75 µg, 3 times 
per week until healing or 
12 weeks maximum  
Ref.: Fernandez et al., 
2009a 
N 20
Complete granulation at the 
end of treatment 20 (100%)  
Wound closure 17 (85%)
Time to complete 
granulation in weeks (mean 
± SD)
3.4 ± 0.5   
Time to wound closure in 
weeks (95% CI) 6.3 (4; 9)  
Amputations 0  
Code: 0503 
Confirmatory multicenter, 
randomized, double blind, 
placebo-controlled trial; 20 
sites;  
Ulcers: grade 3 and 4, 
N 53 48 48 
No response at 2 weeks; 
code opened 1 (2%) 5 (10%) 8 (17%) 
≥50% granulation at 2 weeks 
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ischemic and neuropathic; 
Treatment: 25 µg, 75 µg, or 
placebo 3 times per week 
until complete granulation 
or 8 weeks maximum. 
Follow-up for one year. 
If no response at 2 weeks, 
code opened and if 
placebo, switched to 25 µg; 
if 25 µg, switched to 75 µg.
Ref.: Fernandez et al., 
2009b 
Complete granulation at the 
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24) 21.4 (8; 35) 
Amputations 7 (13%) 10 (21%) 12 (25%) 
Pooled analysis N 108 188 48 
Complete granulation at the 
end of treatment 94 (87%) 141 (75%) 28 (58%) 
Wound closure during 
follow-up 
71/96 
(74%) 97 (52%) 27 (56%) 
Time to wound closure in 
weeks (95% CI) 14  (12; 16) 12 (10; 14) 21.4 (8; 35) 
Amputations 18 (17%) 54 (29%) 12 (25%) 
Table 1. Summary of characteristics and results of clinical trials with rhEGF in DFU. SD: 
standard deviation; CI: confidence interval  
4.7 Long-term follow-up of the patients included in all clinical trials 
Overall, 323 individuals were enrolled in clinical trials since 2001 (one patient took part in 
studies 0604 and 0503). They were visited in 2010 looking for information on survival, 
recurrences, new foot ulcers, amputations, adverse events and co-morbidities, including 
neoplasia. The median follow-up period was 3 years (maximum, 8 years). The results are 
summarized in Table 2. Patients from study No. 0705 were not followed-up since they live 
abroad. Patients from study No. 0503 were considered “per protocol” for this evaluation, 
since some had switched treatment at 2 weeks. 
No evidence was gathered indicating that intralesional rhEGF administration could 
stimulate cancer growth. Two patients had developed malignancies: one who had received 
rhEGF at 25 µg; the other was from the placebo group of the phase III trial.  
Thirty nine percent of the patients had deceased. The more frequent causes of death were 
heart infarct, chronic renal failure, and stroke. Median survival was longer in patients that 
had attained ulcer-healing: 5.7 ± 0.8 years vs. 4.2 ± 0.7 years in those who did not heal 
(p=0.004). 
The frequency of relapses at any moment was significantly lower (p<0.001) in patients that 
received rhEGF (10% and 4% for the 75 µg and 25 µg doses, respectively) as compared to the 
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Table 1. Summary of characteristics and results of clinical trials with rhEGF in DFU. SD: 
standard deviation; CI: confidence interval  
4.7 Long-term follow-up of the patients included in all clinical trials 
Overall, 323 individuals were enrolled in clinical trials since 2001 (one patient took part in 
studies 0604 and 0503). They were visited in 2010 looking for information on survival, 
recurrences, new foot ulcers, amputations, adverse events and co-morbidities, including 
neoplasia. The median follow-up period was 3 years (maximum, 8 years). The results are 
summarized in Table 2. Patients from study No. 0705 were not followed-up since they live 
abroad. Patients from study No. 0503 were considered “per protocol” for this evaluation, 
since some had switched treatment at 2 weeks. 
No evidence was gathered indicating that intralesional rhEGF administration could 
stimulate cancer growth. Two patients had developed malignancies: one who had received 
rhEGF at 25 µg; the other was from the placebo group of the phase III trial.  
Thirty nine percent of the patients had deceased. The more frequent causes of death were 
heart infarct, chronic renal failure, and stroke. Median survival was longer in patients that 
had attained ulcer-healing: 5.7 ± 0.8 years vs. 4.2 ± 0.7 years in those who did not heal 
(p=0.004). 
The frequency of relapses at any moment was significantly lower (p<0.001) in patients that 
received rhEGF (10% and 4% for the 75 µg and 25 µg doses, respectively) as compared to the 
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control group of the confirmatory, No. 0503, trial (23%). This effect was obtained for both 
neuropathic and ischemic patients. On the contrary, no effect was seen on the appearance of 
DFU on other locations (mainly on the contralateral limb). The rates were 26%, 24%, and 
32% for patients treated with 75 µg rhEGF, 25 µg, and placebo, respectively. It seems as if the 
tissue keeps a sort of “memory” of the treatment received, which is not transferable to non-
treated zones. Molecular and immunohistochemistry studies are in course to elucidate these 
mechanisms. 
 
Trial Dose Enrolled Followed-up Recurrences New ulcers Amputations Cancer 
0102 25 µg 29 29 1 7 13 
0202 
25 µg 18 18 0 6 9 
75 µg 23 22 1 11 12 
0504 75 µg 12 11 1 0 4 
0604 25 µg 93 66 3 20 29 1 
0503 
25 µg 49 43 1 12 15 
75 µg 57 51 5 11 16 
Placebo 43 42 8 13 15 1 
Table 2. Long term follow-up of patients from all clinical trials with rhEGF in DFU 
Amputations were necessary in 114 patients at some moment after rhEGF treatment. The 
amputation rates were 35% for both rhEGF dose levels, the same as for the control group of 
the confirmatory trial. However, if only neuropathic and mild ischemic patients are taken 
into account amputations were less among patients treated with rhEGF 75 µg (14%) or 25 µg 
(20%) than among those who only received the good standard care (33%). Thus, severe and 
critic ischemia is still an adverse condition, difficult to overcome. Probably rhEGF should be 
used in those cases after appropriate revascularization procedures that improve tissue blood 
supply. 
4.8 Consistency of the efficacy results from the different trials 
Efficacy measurements across the different studies, summarized in Table 1, are consistent. 
More than 80% granulation was obtained globally for both dose levels used. They are much 
better than what was obtained for a group of patients that received only standard care (the 
placebo group of study No. 0503). The fact than only one study had a control group is a 
limitation to this comparison, but there is homogeneity among the different studies with 
respect to the results obtained and the 95% confidence interval of the result in the placebo 
group falls below those of the treated groups. There seems to be a dose-dependent effect, 
since results were always better for the higher dose. Subgroup analyses, limited by the fact 
that they were not previewed in the protocols, suggest that the difference between doses is 
given by patients with more complicated ulcers (larger, with more severe ischemia). 
Results on healing are clinically relevant as well, for the 75 µg dose. Treatment-dependency 
was also found for complete closure, despite being reached during follow-up, as 
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outpatients, only under general wound care measures (except for study No. 0705, where 
treatment was continued until healing). This apparent “EGF-memory” effect on wound 
closure can be explained by the granulation tissue stimulation, which was predictive of 
closure. Granulation can also reduce the probability of infection progression, since the fresh 
tissue is better prepared to “fight” against invading micro-organisms and better irrigation 
can increase the local bioavailability of systemic antibiotic treatment. As mentioned above, 
some persistent action of rhEGF treatment should take place, leading to less relapses as well. 
Time-to-closure was also shortened in approximately 4 weeks, which is a clinically 
significant feature. 
With respect to amputations, the number of events has been very small in each study in 
order to make a proper statistical analysis. For that reason this outcome has been secondary 
in all trials. The pooled analysis after long-term follow-up, mentioned above is interesting 
for the 75 µg dose. 
5. Overview of safety 
Since all trials included very similar populations and the same therapeutic schedule (only 
the dose varied), a pooled analysis was done. Intralesional rhEGF was well tolerated. About 
half of the included patients (58.5%) reported some adverse event. Those occurring in more 
than 1% of the patients are summarized in Table 3. Pain and burning sensation at the 
administration site were the most frequent. A dose-effect relation associated to the 
appearance of shivering and chills was systematically obtained in all trials that used both 
doses and in the pooled analysis. 
Concerning intensity, the adverse events reported were 65.6 % mild, 28.6% moderate, and 
only 3.7% severe. Serious adverse events were reported in 13% of the patients from the 
clinical studies. Local infection was the more frequent serious adverse event. It caused 
hospitalization and/or amputation. It was the adverse event that most frequently lead to 
treatment interruption. It is difficult to establish a causal relationship between its 
appearance and rhEGF administration since this event is also a frequent complication of 
Wagner´s grade 3 and 4 DFU and a significant risk factor for amputation. It has been 
reported that lower extremities infection is the most frequent reason for the hospitalization 
of patients with diabetes (Edmonds & Foster, 2004). Likewise, it appeared in the placebo 
group of the controlled study 0503. Some of the factors that leave patients predisposed to 
the progress of local infection include the presence of an entryway for bacteria and the fact 
that the immune response of diabetic patients is often compromised. 
The analysis of the relationship of adverse events with demographic or baseline 
characteristics only yielded significant results for the age and ulcer etiopathogeny. A 
multivariate logistic regression model yield a significant more frequent appearance of any 
adverse event in patients ≥ 65 years old vs. younger (OR: 1.86; 95% CI: 1.09 – 3.15), and less 
frequent if the ulcer was neuropathic (OR: 0.25; 95% CI: 0.14 – 0.45). Local infection 
appeared significantly more frequently in patients with Diabetes type II than in type I: 
45/222 (16.9%) vs. 2/62 (3.1%). 
Three of the patients in the clinical trials died: one with placebo and one with each of the 
doses. Other 8 deaths occurred during follow-up (up to one year). None of the deaths can be 
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control group of the confirmatory, No. 0503, trial (23%). This effect was obtained for both 
neuropathic and ischemic patients. On the contrary, no effect was seen on the appearance of 
DFU on other locations (mainly on the contralateral limb). The rates were 26%, 24%, and 
32% for patients treated with 75 µg rhEGF, 25 µg, and placebo, respectively. It seems as if the 
tissue keeps a sort of “memory” of the treatment received, which is not transferable to non-
treated zones. Molecular and immunohistochemistry studies are in course to elucidate these 
mechanisms. 
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Table 2. Long term follow-up of patients from all clinical trials with rhEGF in DFU 
Amputations were necessary in 114 patients at some moment after rhEGF treatment. The 
amputation rates were 35% for both rhEGF dose levels, the same as for the control group of 
the confirmatory trial. However, if only neuropathic and mild ischemic patients are taken 
into account amputations were less among patients treated with rhEGF 75 µg (14%) or 25 µg 
(20%) than among those who only received the good standard care (33%). Thus, severe and 
critic ischemia is still an adverse condition, difficult to overcome. Probably rhEGF should be 
used in those cases after appropriate revascularization procedures that improve tissue blood 
supply. 
4.8 Consistency of the efficacy results from the different trials 
Efficacy measurements across the different studies, summarized in Table 1, are consistent. 
More than 80% granulation was obtained globally for both dose levels used. They are much 
better than what was obtained for a group of patients that received only standard care (the 
placebo group of study No. 0503). The fact than only one study had a control group is a 
limitation to this comparison, but there is homogeneity among the different studies with 
respect to the results obtained and the 95% confidence interval of the result in the placebo 
group falls below those of the treated groups. There seems to be a dose-dependent effect, 
since results were always better for the higher dose. Subgroup analyses, limited by the fact 
that they were not previewed in the protocols, suggest that the difference between doses is 
given by patients with more complicated ulcers (larger, with more severe ischemia). 
Results on healing are clinically relevant as well, for the 75 µg dose. Treatment-dependency 
was also found for complete closure, despite being reached during follow-up, as 
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outpatients, only under general wound care measures (except for study No. 0705, where 
treatment was continued until healing). This apparent “EGF-memory” effect on wound 
closure can be explained by the granulation tissue stimulation, which was predictive of 
closure. Granulation can also reduce the probability of infection progression, since the fresh 
tissue is better prepared to “fight” against invading micro-organisms and better irrigation 
can increase the local bioavailability of systemic antibiotic treatment. As mentioned above, 
some persistent action of rhEGF treatment should take place, leading to less relapses as well. 
Time-to-closure was also shortened in approximately 4 weeks, which is a clinically 
significant feature. 
With respect to amputations, the number of events has been very small in each study in 
order to make a proper statistical analysis. For that reason this outcome has been secondary 
in all trials. The pooled analysis after long-term follow-up, mentioned above is interesting 
for the 75 µg dose. 
5. Overview of safety 
Since all trials included very similar populations and the same therapeutic schedule (only 
the dose varied), a pooled analysis was done. Intralesional rhEGF was well tolerated. About 
half of the included patients (58.5%) reported some adverse event. Those occurring in more 
than 1% of the patients are summarized in Table 3. Pain and burning sensation at the 
administration site were the most frequent. A dose-effect relation associated to the 
appearance of shivering and chills was systematically obtained in all trials that used both 
doses and in the pooled analysis. 
Concerning intensity, the adverse events reported were 65.6 % mild, 28.6% moderate, and 
only 3.7% severe. Serious adverse events were reported in 13% of the patients from the 
clinical studies. Local infection was the more frequent serious adverse event. It caused 
hospitalization and/or amputation. It was the adverse event that most frequently lead to 
treatment interruption. It is difficult to establish a causal relationship between its 
appearance and rhEGF administration since this event is also a frequent complication of 
Wagner´s grade 3 and 4 DFU and a significant risk factor for amputation. It has been 
reported that lower extremities infection is the most frequent reason for the hospitalization 
of patients with diabetes (Edmonds & Foster, 2004). Likewise, it appeared in the placebo 
group of the controlled study 0503. Some of the factors that leave patients predisposed to 
the progress of local infection include the presence of an entryway for bacteria and the fact 
that the immune response of diabetic patients is often compromised. 
The analysis of the relationship of adverse events with demographic or baseline 
characteristics only yielded significant results for the age and ulcer etiopathogeny. A 
multivariate logistic regression model yield a significant more frequent appearance of any 
adverse event in patients ≥ 65 years old vs. younger (OR: 1.86; 95% CI: 1.09 – 3.15), and less 
frequent if the ulcer was neuropathic (OR: 0.25; 95% CI: 0.14 – 0.45). Local infection 
appeared significantly more frequently in patients with Diabetes type II than in type I: 
45/222 (16.9%) vs. 2/62 (3.1%). 
Three of the patients in the clinical trials died: one with placebo and one with each of the 
doses. Other 8 deaths occurred during follow-up (up to one year). None of the deaths can be 
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considered as related to treatment but to the underlying diabetes and/or the age of the 
patients. The death causes were: acute myocardial infarct (4), bronchopneumonia (2), 
mesenteric thrombosis, acute renal failure, acute pulmonary edema, and infection. At the 
time of follow-up, 12 months after the conclusion of the treatment, no long term adverse 
effects related to the product were reported.  
 
Adverse events 75 µg  N=116 




N % N % N % 
Pain at the administration site 21 18.1% 52 28.7% 20 41.7% 
Burning sensation at the administration site 26 22.4% 25 13.8% 14 29.2% 
Shivering 34 29.3% 18 9.9% 2 4.2% 
Local infection 20 17.2% 18 9.9% 8 16.7% 
Chills 30 25.9% 15 8.3% 1 2.1% 
Fever 9 7.8% 18 9.9% 6 12.5% 
Anemia 5 4.3% 5 2.8% 5 10.4% 
Vomiting 7 6.0% 4 2.2% 1 2.1% 
Pain on the lesion 9 7.8% 2 1.1% 0 
Nauseas 5 4.3% 3 1.7% 2 4.2% 
Chest pain 3 2.6% 4 2.2% 0 
Table 3. Frequency of patients with each adverse event in Clinical Trials. Events that 
appeared in more than 1% of the patients (pooled). 
The presence of anti-EGF autoantibodies has not been considered detrimental for adult 
animals (Raaberg et al., 1995a, 1995b) or in the healing process (Casaco et al., 2004). 
Nevertheless, immunogenicity of rhEGF was evaluated in three studies since, as a 
recombinant protein, it could exert antibody production and this is an important safety issue 
for all agencies. Anti-EGF antibodies were detected in some patients (4 in study 0202 and 5 
in study 0503). Some other patients had these antibodies naturally, before treatment. All the 
titers found were very low and there was no clear relationship with efficacy or safety results. 
The adverse event profile from the first report of the postmarketing pharmacovigilance in 
Cuba (from 1851 patients) is very similar to that from clinical trials. The most frequent 
events are shivering, pain and burning sensation at the administration site, and chills. Local 
infection is less frequent, but the most frequent among the serious events found (manuscript 
in preparation). 
A particular concern on the therapeutic use of growth factors is the possibility of 
development or stimulation of a pre-existing malignancy in the patients. The concern is 
justified by the growth stimulating property of these active principles. Practically, anti-
growth factor therapy is approved or extensively experimented for several neoplasia 
(Gonzalez et al., 2011; Caraglia et al., 2006;  Geva et al., 2010). Additionally an increase in 
any-site cancer incidence was observed in DFU patients treated with platelet-derived-
growth factor (PDGF; becaplermin), which generated a warning from regulatory agencies 
(FDA-USA, 2008).  
EGF is not an exception to this concern. In fact, the presence or history of neoplasia has been 
an exclusion criteria in all clinical trials with intralesional rhEGF and is a precaution for the 
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use of the procedure in medical practice. However, there are several theoretical and 
experimental considerations that do not support the idea that EGF treatment, at the doses 
and schedules used, could stimulate any tumor growth. These aspects are thoroughly 
discussed by Berlanga et al., 2009. Briefly: 
EGF, although growth stimulating and thus a possible tumor promoter, does not induce 
malignant transformation. 
EGF stimulation of cell lines and tumor grafts growth is not a consistent result. There are 
cases of growth inhibition by exogenously administered EGF. (Knowles et al., 1985; Barnes, 
1982) 
EGF overexpression in transgenic animals not always lead to increase in tumor development 
(Chan & Wing-Chuen, 2000). 
No increase in tumors in patients treated with topical EGF for burns, in a controlled trial 
done in Cuba in 1993-94. These patients were visited in 2008 – 2009 and their incidence of 
cancer was not above that expected for that age group in Cuba for that long period of time 
(not published result, reported by Berlanga et al., 2009) 
The pharmacokinetics study in DFU patients showed short residence in blood of 
intralesionally administered rhEGF. After 2 hours all EGF was cleared and no accumulation 
was detected after repeated injections (not published result; manuscript in preparation). 
These data are inconsistent with long-term systemic actions. 
Treatments with rhEGF are short-term: not more than 8-12 weeks, contrary to a tumor 
promoting action that would require a longer exposure. 
Lack of treatment-related cancer development in the long-term follow up of patients from 
clinical trials with rhEGF (mentioned above). This argument is nonetheless still weak since 
the result comes from few individuals. 
6. Benefit-risk analysis 
The clinical studies in patients with advanced DFU (Wagner´s grade 3 or 4, median size >20 
cm2, ischemic not excluded) have shown that intralesionally injected rhEGF, adjuvant to 
standard good wound care, has the potential to promote granulation, complete wound 
healing, even in subjects unresponsive to other treatments, faster than subjects treated with 
standard good wound care alone. The relapse rate is reduced as well. The procedure has the 
potential to reduce amputation rates, particularly in neuropathic or mild ischemic patients, 
with a considerable personal and public health improvement. 
Potential risks of the use of intralesional rhEGF in DFU can be evaluated by the safety 
profile obtained from the clinical trials and the possibility of cancer stimulation, discussed 
above. No particular treatment-related serious adverse event was observed. All can be 
explained by the underlying disease. No increase in cardiovascular, respiratory or renal 
complications was reported. Adverse events attributed to treatment have been generally 
limited to shivering, chills, and injection site pain. These have been mild and self-limiting. 
No increase in cancer development in treated patients has been observed. Local infection 
progression is the more frequent serious adverse event. Since the injection procedure can 
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considered as related to treatment but to the underlying diabetes and/or the age of the 
patients. The death causes were: acute myocardial infarct (4), bronchopneumonia (2), 
mesenteric thrombosis, acute renal failure, acute pulmonary edema, and infection. At the 
time of follow-up, 12 months after the conclusion of the treatment, no long term adverse 
effects related to the product were reported.  
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Table 3. Frequency of patients with each adverse event in Clinical Trials. Events that 
appeared in more than 1% of the patients (pooled). 
The presence of anti-EGF autoantibodies has not been considered detrimental for adult 
animals (Raaberg et al., 1995a, 1995b) or in the healing process (Casaco et al., 2004). 
Nevertheless, immunogenicity of rhEGF was evaluated in three studies since, as a 
recombinant protein, it could exert antibody production and this is an important safety issue 
for all agencies. Anti-EGF antibodies were detected in some patients (4 in study 0202 and 5 
in study 0503). Some other patients had these antibodies naturally, before treatment. All the 
titers found were very low and there was no clear relationship with efficacy or safety results. 
The adverse event profile from the first report of the postmarketing pharmacovigilance in 
Cuba (from 1851 patients) is very similar to that from clinical trials. The most frequent 
events are shivering, pain and burning sensation at the administration site, and chills. Local 
infection is less frequent, but the most frequent among the serious events found (manuscript 
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A particular concern on the therapeutic use of growth factors is the possibility of 
development or stimulation of a pre-existing malignancy in the patients. The concern is 
justified by the growth stimulating property of these active principles. Practically, anti-
growth factor therapy is approved or extensively experimented for several neoplasia 
(Gonzalez et al., 2011; Caraglia et al., 2006;  Geva et al., 2010). Additionally an increase in 
any-site cancer incidence was observed in DFU patients treated with platelet-derived-
growth factor (PDGF; becaplermin), which generated a warning from regulatory agencies 
(FDA-USA, 2008).  
EGF is not an exception to this concern. In fact, the presence or history of neoplasia has been 
an exclusion criteria in all clinical trials with intralesional rhEGF and is a precaution for the 
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use of the procedure in medical practice. However, there are several theoretical and 
experimental considerations that do not support the idea that EGF treatment, at the doses 
and schedules used, could stimulate any tumor growth. These aspects are thoroughly 
discussed by Berlanga et al., 2009. Briefly: 
EGF, although growth stimulating and thus a possible tumor promoter, does not induce 
malignant transformation. 
EGF stimulation of cell lines and tumor grafts growth is not a consistent result. There are 
cases of growth inhibition by exogenously administered EGF. (Knowles et al., 1985; Barnes, 
1982) 
EGF overexpression in transgenic animals not always lead to increase in tumor development 
(Chan & Wing-Chuen, 2000). 
No increase in tumors in patients treated with topical EGF for burns, in a controlled trial 
done in Cuba in 1993-94. These patients were visited in 2008 – 2009 and their incidence of 
cancer was not above that expected for that age group in Cuba for that long period of time 
(not published result, reported by Berlanga et al., 2009) 
The pharmacokinetics study in DFU patients showed short residence in blood of 
intralesionally administered rhEGF. After 2 hours all EGF was cleared and no accumulation 
was detected after repeated injections (not published result; manuscript in preparation). 
These data are inconsistent with long-term systemic actions. 
Treatments with rhEGF are short-term: not more than 8-12 weeks, contrary to a tumor 
promoting action that would require a longer exposure. 
Lack of treatment-related cancer development in the long-term follow up of patients from 
clinical trials with rhEGF (mentioned above). This argument is nonetheless still weak since 
the result comes from few individuals. 
6. Benefit-risk analysis 
The clinical studies in patients with advanced DFU (Wagner´s grade 3 or 4, median size >20 
cm2, ischemic not excluded) have shown that intralesionally injected rhEGF, adjuvant to 
standard good wound care, has the potential to promote granulation, complete wound 
healing, even in subjects unresponsive to other treatments, faster than subjects treated with 
standard good wound care alone. The relapse rate is reduced as well. The procedure has the 
potential to reduce amputation rates, particularly in neuropathic or mild ischemic patients, 
with a considerable personal and public health improvement. 
Potential risks of the use of intralesional rhEGF in DFU can be evaluated by the safety 
profile obtained from the clinical trials and the possibility of cancer stimulation, discussed 
above. No particular treatment-related serious adverse event was observed. All can be 
explained by the underlying disease. No increase in cardiovascular, respiratory or renal 
complications was reported. Adverse events attributed to treatment have been generally 
limited to shivering, chills, and injection site pain. These have been mild and self-limiting. 
No increase in cancer development in treated patients has been observed. Local infection 
progression is the more frequent serious adverse event. Since the injection procedure can 
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potentially contribute to infection spreading, caution is recommended in this sense. Clinical 
signs of infection should be cleared before treatment with rhEGF. 
This benefit-risk balance seems quite favorable. This was also suggested by the analysis 
done using a Bayesian approach (Spiegelhalter et al., 2004) comparing the probability of 
benefit (given by complete healing) with the probability of risk (given by the occurrence of 
serious adverse events, including amputation), taking into account data from all clinical 
trials. These results are shown in Fig. 3.  
Assuming that there are two hypotheses H1 (benefit, given by ulcer healing) and H2 (risk, 
given by the occurrence of serious adverse events or amputation) proposed for the patients 
outcome data set and under Hk the data are related to the parameter vector ψk by a 
distribution with probability density �(�����	��)		. Given the prior probabilities p(benefit) 
and p(risk) = 1 – p(benefit), the data produce the posterior probabilities �(���������) and 
�(����|�) � � � �(�������|�).  




representing a summary of the evidence provided by the data in favor of benefit, as opposed 
to risk. A value larger than 1 means a favorable benefit-risk ratio.  
 
Fig. 3. Benefit and risk probability distributions of the outcome of DFU patients treated with 
intralesional rhEGF.  
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The results shown are:  
Upper graph: placebo (study No. 0503): Bbr= 1.69; difference between the probabilities: 23% 
(95% CI: 11% – 36%). 
Middle graph: treatment with 25 µg rhEGF; Bbr= 1.92; difference between probabilities: 26% 
(95% CI: 13% – 40%). 
Lower graph: treatment with 75 µg rhEGF. Bbr= 3.36; difference between probabilities: 51% 
(95% CI: 40% – 63%). 
In all cases the differences between benefit and risk probabilities favor the former; the Bayes 
factors and differences are larger for the rhEGF treated groups than for the controls. The 
balance of the higher dose is much favorable. 
7. Conclusion 
The intralesional administration of rhEGF offers a new alternative for the treatment of 
advanced DFU, reluctant to other treatments, which frequently lead to a lower limb 
amputation. Further extension of the procedure should yield impact data 
(pharmacoeconomic, limb salvage). 
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1. Introduction 
Lactoferrin is a protein of mammalian origin secreted in the milk of several animals, 
including human beings, cows, horses, pigs, goats and mice (Masson & Heremans, 1971). 
From the moment that bovine (Tomita et al., 2009) and human lactoferrin (Weinberg, 2001) 
were isolated from the milk of their respective species, they began to receive great attention 
due to their multifunctional properties that are distinctive from lactoferrin from other 
mammals. In general, lactoferrin is regarded as a modulator of humoral and cellular 
components involved in inflammatory and immune responses (Actor et al., 2009; Legrand et 
al., 2004), which has broad implications. For instance, lactoferrin displays antimicrobial 
activity against a wide range of pathogens, including virus, bacteria, fungi and parasites 
(Jenssen & Hancock, 2009). It is also able to promote skin integrity by regulating the 
generation of humoral components of the inflammatory and immune responses, including 
such cytokines as the tumor necrosis factor (TNF) alpha  and interleukin (IL) 1beta, as well 
as the migration of Langerhans cells (Kimber et al., 2002). Moreover, lactoferrin enhances 
collagen gel contractile activity of fibroblasts, leading to skin wound healing (Takayama & 
Takezawa, 2006).  
The broad scope of activities of lactoferrin with potential clinical applications, depicted in 
the Table 1, has led to large scale production of native and recombinant preparations of this 
glycoprotein for commercial and/or clinical applications (Drago-Serrano, 2007). Among 
these products are Talactoferrin alfa ®, a recombinant human lactoferrin (Agennix, Houston 
TX, USA), and Bioferrin®, a native lactoferrin from bovine origin (Glanbia, Nutritionals Inc, 
Monroe, WI, USA). Through the modulation of inflammation, Talactoferrin alfa has proven 
effective as a wound healing factor in the experimental model of diabetic mice (Engelmayer 
et al., 2008). Indeed, the promising healing properties of Talactoferrin alfa have been tested 
in a phase 1/2 clinical study for the treatment of ulcers in patients with diabetic 
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ORIGIN ACTIVITY REFERENCE 
 Antibacterial effect  
Bovine Lf ↓ Pseudomonas aeruginosa anti-biofilm formation in 
combination with xilitol (a sugar derivative alcohol) 
(in vitro test) 
Ammons et al., 2011A 
Ammons et al, 2009 
 Phagocytic cell function  
Neutrophil 
human Lf 
↑ Bacterial killing by enhancing reactive oxygen 
species (ROS) generation (in vitro test) 




↓ oxidative effect of ROS released by degranulated 
neutrophils (in vitro test) 
Britigan et al, 1991 
 Anti-Inflammatory effect  
Bovine Lf ↓ Tumor necrosis factor (TNF) production induced 
during bacteremia in mice 
Zimecki et al., 2004 
Human Lf ↓ Lipopolysaccharide (LPS)-induced expression of 
endothelial adhesion molecules (E-selectin, ICAM) 
(in vitro test) 
Baveye et al., 2000A 
 Pro-inflammatory effect   
bLf/hLf ↑ human neutrophil derived interleukin (IL)-8 
production (in vitro test) 




↑ human dendritic cell derived IL-8 production (in 
vitro test) 
Spadaro et al., 2008 
 Granulopoiesis  
Bovine Lf ↑ output of neutrophil precursors in human 
volunteers 
Zimecki et al., 1999B 
Mouse Lf ↑ colony stimulating factor (CSF) in mice Sawatzki & Rich, 1989 
Human Lf ↓ output of granulocyte macrophage progenitor cells 
from spleen and femur of mice 
Gentile & Broxmeyer, 
1983 
 Effects on skin  
Human Lf anti-allergen effect by decreasing Langerhans cell 
migration induced by allergens in humans 
Griffiths et al., 2001  
rHLf ↑ re-epithelialization (in vitro test) 
 
Tang et al., 2010A 
Tang et al., 2010B 
Bovine Lf ↑ gel contractile activity in human fibroblasts (in vitro 
test) 
Takayama et al., 2003 
Bovine Lf ↑ nerve growth factor synthesis/secretion in mouse 
fibroblasts (in vitro test) 
Shinoda et al., 1994 
Bovine Lf ↑ hyaluronan synthesis in human dermal fibroblast 
(in vitro test) 
Saito et al., 2011 
 Wound healing  
(rHLf) Healing enhancement of foot ulcers in diabetic 
mouse model 
Engelmayer et al., 2008 
(rHLf) Healing enhancement of diabetic foot ulcers in 
human patients 
Lyons et al., 2007 
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foot (Lyons et al., 2007). Bioferrin, on the other hand, has been found to have antibacterial 
activity, for which reason it has been used in the control of bacterial infections associated 
with diabetic foot ulcers (Ammons et al., 2011A; Ammons et al., 2009). Such infections 
represent a serious challenge, since they can lead to devastating consequences and possibly 
to limb amputations (Powlson & Coll, 2010). Hence, this glycoprotein is endowed with 
natural antibacterial and wound healing properties that can be beneficial in the treatment of 
either infected or uninfected diabetic foot ulcers. However, given the complex convergence 
of pathologies which encompass diabetic foot syndrome, lactoferrin should not be 
considered as a panacea able by itself to cure this disorder.  
The aim of this chapter is to describe the applications of lactoferrin as an antibacterial and 
wound healing agent. We explore its use as an adjunctive agent to enhance the antibacterial 
activity of antibiotics and/or improve the efficacy of other adjunctive methods of antibiotic 
treatment, the latter of which include growth factors, dressings and other topical 
applications, debridement, and hyperbaric oxygen therapy (O´Meara et al., 2000). In parallel 
we give an overview of the biological and modulating properties of lactoferrin in relation to 
the inflammatory and immune responses, as these properties underlie the reestablishment 
of homeostasis at the dermal level and thus contribute to ulcer skin healing. Finally, we 
discuss the precautions that should be taken into account for the clinical applications of this 
glycoprotein. 
2. Lactoferrin: An overview 
2.1 Structural features 
Lactoferrin is a member of transferrins, a family of proteins with iron chelating properties. 
This monomeric glycoprotein has a molecular weight of 80 kDa, and is highly cationic with 
an isoelectric point of 9.6 (Baker & Baker, 2009). Its tertiary structure consists of two main N 
and C lobes, within which are found the N1/N2 and C1/C2 domains, respectively. The N 
and C lobes are linked at the N1 and C1 domains by a three turn alpha chain (Baker & 
Baker, 2009). Human milk lactoferrin contains two sites of glycosylation (Anderson et al., 
1987) with N-acetylneuraminic acid, N-acetylglucosamine, galactose and mannose (Spik et 
al., 1982).  In spite of the fact that bovine milk lactoferrin has five glycosylation sites, only 
four of them are actually glycosylated (Moore et al., 1997) with N-acetylneuraminic acid, 
galactose, manose, fucose, N-acetylglucosamine and N-acetylgalactosamine (Coddeville et 
al., 1992). Between the N1/N2 and C1/C2 regions, a cleft is formed by R amino acid groups 
of an aspartic, a histidine and two tyrosine residues. At this cleft, iron in ferric form (Fe3+) 
along with the bicarbonate (HCO31-) ion can be bound reversibly to lactoferrin (Anderson et 
al., 1987; Moore et al., 1997). The iron loaded state of lactoferrin is called hololactoferrin, 
while its iron free form is known as apolactoferrin. On the other hand, the N1 domain, 
devoid of any iron chelating activity, has a region known as lactoferricin, which is 
characterized by its strong cationic charge. Lactoferricin can be obtained as a free peptide by 
the enzymatic proteolysis of parental lactoferrin with pepsine. The iron independent 
properties of lactoferrin, such as some forms of antibacterial activity as well as various 
modulating properties of the immune and inflammatory responses, arise from this 
lactoferricin domain (Gifford et al., 2005).  
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ORIGIN ACTIVITY REFERENCE 
 Antibacterial effect  
Bovine Lf ↓ Pseudomonas aeruginosa anti-biofilm formation in 
combination with xilitol (a sugar derivative alcohol) 
(in vitro test) 
Ammons et al., 2011A 
Ammons et al, 2009 
 Phagocytic cell function  
Neutrophil 
human Lf 
↑ Bacterial killing by enhancing reactive oxygen 
species (ROS) generation (in vitro test) 




↓ oxidative effect of ROS released by degranulated 
neutrophils (in vitro test) 
Britigan et al, 1991 
 Anti-Inflammatory effect  
Bovine Lf ↓ Tumor necrosis factor (TNF) production induced 
during bacteremia in mice 
Zimecki et al., 2004 
Human Lf ↓ Lipopolysaccharide (LPS)-induced expression of 
endothelial adhesion molecules (E-selectin, ICAM) 
(in vitro test) 
Baveye et al., 2000A 
 Pro-inflammatory effect   
bLf/hLf ↑ human neutrophil derived interleukin (IL)-8 
production (in vitro test) 




↑ human dendritic cell derived IL-8 production (in 
vitro test) 
Spadaro et al., 2008 
 Granulopoiesis  
Bovine Lf ↑ output of neutrophil precursors in human 
volunteers 
Zimecki et al., 1999B 
Mouse Lf ↑ colony stimulating factor (CSF) in mice Sawatzki & Rich, 1989 
Human Lf ↓ output of granulocyte macrophage progenitor cells 
from spleen and femur of mice 
Gentile & Broxmeyer, 
1983 
 Effects on skin  
Human Lf anti-allergen effect by decreasing Langerhans cell 
migration induced by allergens in humans 
Griffiths et al., 2001  
rHLf ↑ re-epithelialization (in vitro test) 
 
Tang et al., 2010A 
Tang et al., 2010B 
Bovine Lf ↑ gel contractile activity in human fibroblasts (in vitro 
test) 
Takayama et al., 2003 
Bovine Lf ↑ nerve growth factor synthesis/secretion in mouse 
fibroblasts (in vitro test) 
Shinoda et al., 1994 
Bovine Lf ↑ hyaluronan synthesis in human dermal fibroblast 
(in vitro test) 
Saito et al., 2011 
 Wound healing  
(rHLf) Healing enhancement of foot ulcers in diabetic 
mouse model 
Engelmayer et al., 2008 
(rHLf) Healing enhancement of diabetic foot ulcers in 
human patients 
Lyons et al., 2007 
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foot (Lyons et al., 2007). Bioferrin, on the other hand, has been found to have antibacterial 
activity, for which reason it has been used in the control of bacterial infections associated 
with diabetic foot ulcers (Ammons et al., 2011A; Ammons et al., 2009). Such infections 
represent a serious challenge, since they can lead to devastating consequences and possibly 
to limb amputations (Powlson & Coll, 2010). Hence, this glycoprotein is endowed with 
natural antibacterial and wound healing properties that can be beneficial in the treatment of 
either infected or uninfected diabetic foot ulcers. However, given the complex convergence 
of pathologies which encompass diabetic foot syndrome, lactoferrin should not be 
considered as a panacea able by itself to cure this disorder.  
The aim of this chapter is to describe the applications of lactoferrin as an antibacterial and 
wound healing agent. We explore its use as an adjunctive agent to enhance the antibacterial 
activity of antibiotics and/or improve the efficacy of other adjunctive methods of antibiotic 
treatment, the latter of which include growth factors, dressings and other topical 
applications, debridement, and hyperbaric oxygen therapy (O´Meara et al., 2000). In parallel 
we give an overview of the biological and modulating properties of lactoferrin in relation to 
the inflammatory and immune responses, as these properties underlie the reestablishment 
of homeostasis at the dermal level and thus contribute to ulcer skin healing. Finally, we 
discuss the precautions that should be taken into account for the clinical applications of this 
glycoprotein. 
2. Lactoferrin: An overview 
2.1 Structural features 
Lactoferrin is a member of transferrins, a family of proteins with iron chelating properties. 
This monomeric glycoprotein has a molecular weight of 80 kDa, and is highly cationic with 
an isoelectric point of 9.6 (Baker & Baker, 2009). Its tertiary structure consists of two main N 
and C lobes, within which are found the N1/N2 and C1/C2 domains, respectively. The N 
and C lobes are linked at the N1 and C1 domains by a three turn alpha chain (Baker & 
Baker, 2009). Human milk lactoferrin contains two sites of glycosylation (Anderson et al., 
1987) with N-acetylneuraminic acid, N-acetylglucosamine, galactose and mannose (Spik et 
al., 1982).  In spite of the fact that bovine milk lactoferrin has five glycosylation sites, only 
four of them are actually glycosylated (Moore et al., 1997) with N-acetylneuraminic acid, 
galactose, manose, fucose, N-acetylglucosamine and N-acetylgalactosamine (Coddeville et 
al., 1992). Between the N1/N2 and C1/C2 regions, a cleft is formed by R amino acid groups 
of an aspartic, a histidine and two tyrosine residues. At this cleft, iron in ferric form (Fe3+) 
along with the bicarbonate (HCO31-) ion can be bound reversibly to lactoferrin (Anderson et 
al., 1987; Moore et al., 1997). The iron loaded state of lactoferrin is called hololactoferrin, 
while its iron free form is known as apolactoferrin. On the other hand, the N1 domain, 
devoid of any iron chelating activity, has a region known as lactoferricin, which is 
characterized by its strong cationic charge. Lactoferricin can be obtained as a free peptide by 
the enzymatic proteolysis of parental lactoferrin with pepsine. The iron independent 
properties of lactoferrin, such as some forms of antibacterial activity as well as various 
modulating properties of the immune and inflammatory responses, arise from this 
lactoferricin domain (Gifford et al., 2005).  
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2.2 Biological properties  
2.2.1 Distribution 
Lactoferrin is secreted in the milk of several mammals and is regarded as an essential 
component of innate mechanisms of host defense. Evidence of this role is the strategic 
location of lactoferrin at mucosal surfaces, which are frequently colonized and/or invaded 
by pathogenic micro-organisms (Russell et al., 2005). Lactoferrin is also stored in secondary 
(specific) granules of neutrophils, which upon degranulation normally release this 
glycoprotein in serum (Levay &Viljoen, 1995). The extent of neutrophil degranulation and 
the level of lactoferrin in serum increase during an inflammatory response from infectious 
origin (Legrand et al., 2004).  
2.2.2 Effects on cellular components of the adaptive immune response 
As aforementioned, lactoferrin is a modulator of humoral and cellular components involved 
in inflammatory and immune responses. Among its effects on the cellular components of the 
adaptive host defense, lactoferrin  positive or negatively modifies the activity of B 
lymphocytes, T cells, macrophages, dendritic cells, neutrophils, and Langerhans cells 
involved in specific immune responses (Actor et al., 2009). For instance, it is a factor in B 
lymphocyte maturation, a process that defines the phenotype and function of these cells 
(Zimecki et al., 1995). On the other hand, T cell proliferation (Bi et al., 1997) and maturation 
(Zimecki et al., 1991) are enhanced by lactoferrin, evidenced by an increased expression of 
CD4 antigen in the presence of this glycoprotein (Bi et al., 1997; Zimecki et al., 1991; 
Dhennin-Duthille et al., 2000). Other studies show that lactoferrin abrogates the inhibitory 
effect of the iron saturated transferrin on T cell proliferation (Djeha & Brock, 1992), and 
inhibits the proliferative response and cytokine production of Th1 but not Th2, which 
logically affects the activity of Th1/Th2 subpopulations (Zimecki et al., 1996).  
Lactoferrin is also able to modulate macrophages, as antigen presenting cells, to induce a 
Th1 response. That is, in the presence of this glycoprotein, there is an increase of IL 12, 
which in turn is required to combat intracellular pathogens (Wilk et al., 2007). It has been 
reported that lactoferrin expressed on the surface of neutrophils of healthy patients 
interacts with TCD4+ cells to up-regulate the production of IL 10 and down-regulate the 
production of interferon (IFN) gamma. In contrast, in patients with systemic lupus 
erythematosis, lactoferrin expressed on the surface of neutrophils negatively modulated 
the production of IL 10 and IFN gamma by TCD4+ cells.  These results suggest that 
endogenous lactoferrin is able to regulate the expression of interleukins by interacting 
with TCD4+ lymphocytes (Li et al., 2006). Moreover, Lactoferrin acts as a maturation 
factor of antigen presenting cells, such as dendritic  cells (De la Rosa et al., 2008; Spadaro 
et al., 2008) and macrophages (Sorimachi et al., 1997), evidenced by an up-regulated 
expression of CD80/86, the increased priming of T cells, and the enhanced secretion of 
pro-inflammatory mediators such TNF and IL 8.  
The modulatory effects of lactoferrin on cellular components (neutrophils, keratinocytes and 
Langerhans cells) as well as humoral components (cytokines) of the inflammatory response 
involved in the innate mechanisms of bacterial control or dermal homeostasis are addressed 
in section 4 of this chapter. 
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3. Anti-bacterial activity of lactoferrin  
3.1 Importance of iron in infections 
Human beings as well as microorganisms that infect them require iron for living, since this 
metal is necessary for all redox reactions. This transition element is part of the heme group 
in hemoglobin and is a cofactor of enzymes such as ribonucleotide-reductase, indispensable 
for DNA synthesis (Andrews et al., 2003). 
In the body, iron is usually bound to proteins. It is important for the body to maintain a low 
free-iron concentration, as otherwise free iron would lead to the overproduction of reactive 
oxygen species by the Fenton reaction, and these molecules are toxic for proteins, DNA and 
lipids. Moreover, an excessive free-iron concentration would easily be employed by 
invading pathogens for their survival and proliferation. The extracellular iron concentration 
in humans is approximately 10-18 M, a level too low to sustain the growth of microbes trying 
to colonize and invade a host (Bullen et al., 2005; Nairz et al., 2010; Weinberg, 2009). 
Mammals have evolved a general strategy of decreasing the free-iron concentration in order 
to protect themselves against invading microbes. Complex iron-withholding systems are 
based on iron-binding proteins that chelate this ion, such as transferrin that transports and 
delivers iron to all cells, ferritin that stores iron inside the cells in order to avoid its toxicity 
and to maintain cell iron homeostasis (Chiancone et al., 2004), and lactoferrin that, as a 
cationic glycoprotein of the innate immune system, sequesters iron in mucosae and infection 
sites, precisely to avoid the accessibility of iron to all intruders (Bullen et al., 1972, 2005; 
Arnold et al., 1977; Jenssen & Hancock, 2009). Indeed, this was one of the first properties of 
this glycoprotein to be discovered.  
3.2 Bacterial species that infect the diabetic foot 
One major problem caused by pathogenic bacteria to a human host is the constant infection 
suffered by diabetic patients in their inferior extremities. Infected foot ulcers are complex 
interactions of microorganisms that often progress to deeper spaces and tissues. These 
infections can become chronic and incurable, and may even degenerate into septic gangrene, 
which could require foot amputation. Although chronic infections are frequently 
polymicrobial, it has been reported that acute infections in patients not previously treated 
with antibiotics are mainly caused by a single pathogen, usually a Gram-positive coccus 
(Edmonds, 2006; Armstrong & Lipsky, 2004; Powlson & Coll, 2010). Accordingly, early 
surface infections of skin ulcers on the feet of untreated diabetic patients are associated with 
aerobic Gram positive cocci, including Staphylococcus aureus and beta haemolytic 
streptococci group A and B. On the other hand, for diabetic patients with chronic lesions, 
infections are characterized by a polymicrobial mixture of aerobic Gram positive and Gram 
negative bacteria (Escherichia coli, Proteus spp., Klebsiella spp.), anaerobic bacteria (Bacteroides 
spp, Clostridium spp, Peptococcus spp and Peptostreptococcus spp) and Pseudomonas aeruginosa 
(Citron et al., 2007; Dowd et al., 2008).  
Staphylococcus aureus methicillin-resistance strains (MRSA) and Pseudomonas aeruginosa are 
the most prominent components of biofilms, and bacterial biofilm is a major contributor to 
non-healing chronic lesions of diabetic patients. For instance, Pseudomonas aeruginosa is an 
opportunistic pathogen in chronic lesions that is refractory to the killing activity of 
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phagocytic cells (e.g., neutrophils), and it is an underlying factor promoting bacterial 
resistance to antibiotics (Guo & DiPietro, 2010). 
Some anaerobes are also responsible for infection in foot ulcers, and even skin commensal 
bacteria may cause damage to tissue (Edmonds, 2006). For mild and severe infections, some 
antibacterials have been shown to be effective in clinical trials, but have numerous side 
effects for patients. Both specific antibiotics as well as those of a wide spectrum have been 
reported to produce distinct side effects, such as nephro- and hepato-toxicity, blood 
dysplasias, diarrhea, and disorders in the commensal flora equilibrium that lead to other 
syndromes by opportunistic microbes (López-Novoa et al., 2011). A very serious problem 
with antibiotic treatments is the emergence of multiresistant strains, generally in long-
standing infections, a result of the fact that the rate of development of new antimicrobial 
drugs is slower than the evolution of resistance. In the case of anaerobes, metronidazole is 
the drug of choice, used together with antibiotics. However, metronidazole is toxic, causing 
nausea, vomiting, abdominal pain and other effects. In addition, it might be carcinogenic to 
patients when used at high doses and/or as a long-term treatment, evidenced by DNA 
breakages and chromosome aberrations caused by this drug in cultured cells, and by its 
carcinogenic effects in animal tests (Roe, 1983; Dobias et al, 1994; El-Nahas & El-Ashmawy, 
2004; Kapoor et al., 1999; Mudry et al., 1994). 
3.3 Lactoferrin as an option in therapy against microbial infections  
Due to the aforementioned problems with antibiotics and other drugs, alternative therapies 
against microbial pathogenic populations have been explored in the last few years. One such 
alternative is lactoferrin, mainly prescribed when infections are chronic and when bacteria 
are found to be resistant to all treatments. Lactoferrin is abundant in colostrum and milk as 
a defense mechanism in newborns. Its iron-free form (apolactoferrin) is secreted by the 
acinar glands to mucosae or by neutrophils in infection sites. This form can be 
microbiostatic, depriving pathogens of iron and thus leaving them in a latent state, or 
microbicidal, leading to the death of pathogens (Jenssen & Hancock, 2009; Ling & Schryvers, 
2006; Yamauchi et al., 2006).  
3.4 Lactoferrin is able to synergize with other proteins and antimicrobials 
3.4.1 Natural synergy of lactoferrin with innate immune-system proteins to combat 
pathogenic microorganisms 
It has been demonstrated that lactoferrin synergizes with other proteins of the innate 
immune system, such as lysozyme and IgA, in order to eliminate microbial infections. 
Indeed, these three proteins are secreted together to mucosae (Leitch & Willcox, 1998; 
Vaerman, 1984). Lactoferrin has large cationic patches on its surface, facilitating direct 
interaction with anionic lipid A from the lipopolysaccharide (LPS) in Gram-negative 
bacteria. This interaction leads to a greater permeability of the outer membrane of such 
bacteria (Jenssen & Hancock, 2009). In the case of Staphylococcus epidermidis, a Gram-positive 
bacterium, it has been proposed that lactoferrin interacts with lipoteicoic acid on the 
bacterial surface, leading to a decrease of the negative charge on the membrane, which in 
turn allows lysozyme to reach the cell wall-associated peptidoglycan where this enzyme acts 
(Leitch & Willcox, 1999A). 
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3.4.2 Lactoferrin also synergizes with drugs and antibiotics, enhancing their 
microbicidal action 
Lactoferrin has the great advantage of synergizing with antiviral and antiparasitic drugs as 
well as with antibiotics, intensifying the antimicrobial activity. In some cases an antibiotic 
dose can be decreased if administered with lactoferrin, which diminishes the side effects to 
patients (Jenssen & Hancock, 2009; Bullen et al., 1972; Arnold et al., 1977; Farnaud & Evans, 
2003; Leon-Sicairos et al., 2006; Sanchez & Watts, 1999; Diarra et al., 2002; Viani et al., 1999). 
Another adjunctive effect of lactoferrin is that biofilms of Staphylococcus epidermidis become 
more susceptible to lysozyme and vancomycin treatment when used in combination with 
this glycoprotein (Leitch & Willcox, 1999B). Interestingly, it was found that lactoferrin 
synergized with bacteriophages (bacterial viruses) in a patient suffering a prolonged 
antibiotic-resistant post-influenza otitis media infection due to Staphylococcus epidermidis, 
and the infection was resolved (Weber-Dabrowsca et al., 2006).  
3.5 Lactoferrin and lactoferricins are able to prevent the formation of biofilms 
Biofilms are a matrix-encased colonial organization of cells that more readily become 
resistant to drugs, antibiotics and antibodies than their free-living, planktonic counterparts. 
This matrix is composed of exopolysaccharide, and its formation is under the control of 
quorum sensing, a bacterial mechanism for assessing population density and altering gene 
expression in order to carry out processes that require the cooperation of a large number of 
cells (Miller & Bassler, 2001). Lactoferrin and its derivative peptides have been used against 
bacteria in biofilms. Furthermore, the synthetic peptides derived from the N-terminal of 
bovine lactoferrin, lactoferricin and lactoferrampin, and a fusion peptide of both, lactoferrin 
chimera, have been assayed against a wide range of pathogens, showing a very high 
probability of success against multiresistant bacteria as well as those accustomed to 
organizing and forming biofilms (Bolscher et al., 2009; Xu et al., 2010; Flores-Villaseñor et al., 
2010). Furthermore, synergistic activity of bovine lactoferricin (11 amino acids) with 
antibiotics was demonstrated against multiresistant clinical isolates of Staphylococcus aureus 
and Pseudomonas aeruginosa in vitro and in a model of corneal infection in mice. Lactoferricin 
also had an anti-inflammatory effect in cornea, suggesting that it leads to a decrease of 
cytokines and mediators involved in inflammation (Oo et al., 2010). Hence, lactoferrin as 
well as its derived peptides could be potential adjuncts to conventional antibiotics in 
combating these pathogens, which also infect diabetic foot ulcers.  
Singh et al. (2002) evaluated the effect of lactoferrin on biofilm development by Pseudomonas 
aeruginosa. In this study, the use of a green fluorescent protein, GFP, as a marker of the 
bacterial cells in continuous-culture allowed for the tracking of biofilm development over 
time. Interestingly, they demonstrated that lactoferrin disrupted biofilm pattern 
development, even at concentrations lower than those needed to kill bacteria or prevent 
their regular growth. By chelating iron, lactoferrin stimulated bacterial twitching, which is a 
specialized surface motility in which bacteria wander across the surface instead of forming 
cell clusters and biofilm. As was hypothesized, this lactoferrin effect was iron-dependent 
and only the iron-free form, apolactoferrin, showed this antimicrobial action. However, 
bacteria in an established biofilm were resistant to lactoferrin.  
Neutrophil derived lactoferrin also was able to prevent bacteria biofilm development of 
Pseudomonas aeruginosa (Leid et al., 2009). Other assays show that lactoferrin in combination 
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phagocytic cells (e.g., neutrophils), and it is an underlying factor promoting bacterial 
resistance to antibiotics (Guo & DiPietro, 2010). 
Some anaerobes are also responsible for infection in foot ulcers, and even skin commensal 
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antibacterials have been shown to be effective in clinical trials, but have numerous side 
effects for patients. Both specific antibiotics as well as those of a wide spectrum have been 
reported to produce distinct side effects, such as nephro- and hepato-toxicity, blood 
dysplasias, diarrhea, and disorders in the commensal flora equilibrium that lead to other 
syndromes by opportunistic microbes (López-Novoa et al., 2011). A very serious problem 
with antibiotic treatments is the emergence of multiresistant strains, generally in long-
standing infections, a result of the fact that the rate of development of new antimicrobial 
drugs is slower than the evolution of resistance. In the case of anaerobes, metronidazole is 
the drug of choice, used together with antibiotics. However, metronidazole is toxic, causing 
nausea, vomiting, abdominal pain and other effects. In addition, it might be carcinogenic to 
patients when used at high doses and/or as a long-term treatment, evidenced by DNA 
breakages and chromosome aberrations caused by this drug in cultured cells, and by its 
carcinogenic effects in animal tests (Roe, 1983; Dobias et al, 1994; El-Nahas & El-Ashmawy, 
2004; Kapoor et al., 1999; Mudry et al., 1994). 
3.3 Lactoferrin as an option in therapy against microbial infections  
Due to the aforementioned problems with antibiotics and other drugs, alternative therapies 
against microbial pathogenic populations have been explored in the last few years. One such 
alternative is lactoferrin, mainly prescribed when infections are chronic and when bacteria 
are found to be resistant to all treatments. Lactoferrin is abundant in colostrum and milk as 
a defense mechanism in newborns. Its iron-free form (apolactoferrin) is secreted by the 
acinar glands to mucosae or by neutrophils in infection sites. This form can be 
microbiostatic, depriving pathogens of iron and thus leaving them in a latent state, or 
microbicidal, leading to the death of pathogens (Jenssen & Hancock, 2009; Ling & Schryvers, 
2006; Yamauchi et al., 2006).  
3.4 Lactoferrin is able to synergize with other proteins and antimicrobials 
3.4.1 Natural synergy of lactoferrin with innate immune-system proteins to combat 
pathogenic microorganisms 
It has been demonstrated that lactoferrin synergizes with other proteins of the innate 
immune system, such as lysozyme and IgA, in order to eliminate microbial infections. 
Indeed, these three proteins are secreted together to mucosae (Leitch & Willcox, 1998; 
Vaerman, 1984). Lactoferrin has large cationic patches on its surface, facilitating direct 
interaction with anionic lipid A from the lipopolysaccharide (LPS) in Gram-negative 
bacteria. This interaction leads to a greater permeability of the outer membrane of such 
bacteria (Jenssen & Hancock, 2009). In the case of Staphylococcus epidermidis, a Gram-positive 
bacterium, it has been proposed that lactoferrin interacts with lipoteicoic acid on the 
bacterial surface, leading to a decrease of the negative charge on the membrane, which in 
turn allows lysozyme to reach the cell wall-associated peptidoglycan where this enzyme acts 
(Leitch & Willcox, 1999A). 
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3.4.2 Lactoferrin also synergizes with drugs and antibiotics, enhancing their 
microbicidal action 
Lactoferrin has the great advantage of synergizing with antiviral and antiparasitic drugs as 
well as with antibiotics, intensifying the antimicrobial activity. In some cases an antibiotic 
dose can be decreased if administered with lactoferrin, which diminishes the side effects to 
patients (Jenssen & Hancock, 2009; Bullen et al., 1972; Arnold et al., 1977; Farnaud & Evans, 
2003; Leon-Sicairos et al., 2006; Sanchez & Watts, 1999; Diarra et al., 2002; Viani et al., 1999). 
Another adjunctive effect of lactoferrin is that biofilms of Staphylococcus epidermidis become 
more susceptible to lysozyme and vancomycin treatment when used in combination with 
this glycoprotein (Leitch & Willcox, 1999B). Interestingly, it was found that lactoferrin 
synergized with bacteriophages (bacterial viruses) in a patient suffering a prolonged 
antibiotic-resistant post-influenza otitis media infection due to Staphylococcus epidermidis, 
and the infection was resolved (Weber-Dabrowsca et al., 2006).  
3.5 Lactoferrin and lactoferricins are able to prevent the formation of biofilms 
Biofilms are a matrix-encased colonial organization of cells that more readily become 
resistant to drugs, antibiotics and antibodies than their free-living, planktonic counterparts. 
This matrix is composed of exopolysaccharide, and its formation is under the control of 
quorum sensing, a bacterial mechanism for assessing population density and altering gene 
expression in order to carry out processes that require the cooperation of a large number of 
cells (Miller & Bassler, 2001). Lactoferrin and its derivative peptides have been used against 
bacteria in biofilms. Furthermore, the synthetic peptides derived from the N-terminal of 
bovine lactoferrin, lactoferricin and lactoferrampin, and a fusion peptide of both, lactoferrin 
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probability of success against multiresistant bacteria as well as those accustomed to 
organizing and forming biofilms (Bolscher et al., 2009; Xu et al., 2010; Flores-Villaseñor et al., 
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antibiotics was demonstrated against multiresistant clinical isolates of Staphylococcus aureus 
and Pseudomonas aeruginosa in vitro and in a model of corneal infection in mice. Lactoferricin 
also had an anti-inflammatory effect in cornea, suggesting that it leads to a decrease of 
cytokines and mediators involved in inflammation (Oo et al., 2010). Hence, lactoferrin as 
well as its derived peptides could be potential adjuncts to conventional antibiotics in 
combating these pathogens, which also infect diabetic foot ulcers.  
Singh et al. (2002) evaluated the effect of lactoferrin on biofilm development by Pseudomonas 
aeruginosa. In this study, the use of a green fluorescent protein, GFP, as a marker of the 
bacterial cells in continuous-culture allowed for the tracking of biofilm development over 
time. Interestingly, they demonstrated that lactoferrin disrupted biofilm pattern 
development, even at concentrations lower than those needed to kill bacteria or prevent 
their regular growth. By chelating iron, lactoferrin stimulated bacterial twitching, which is a 
specialized surface motility in which bacteria wander across the surface instead of forming 
cell clusters and biofilm. As was hypothesized, this lactoferrin effect was iron-dependent 
and only the iron-free form, apolactoferrin, showed this antimicrobial action. However, 
bacteria in an established biofilm were resistant to lactoferrin.  
Neutrophil derived lactoferrin also was able to prevent bacteria biofilm development of 
Pseudomonas aeruginosa (Leid et al., 2009). Other assays show that lactoferrin in combination 
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with xylitol (a sugar derived penta-hidroxy alcohol) decreases the viability of established 
Pseudomonas aeruginosa, a consequence of both the disruption of the biofilm structure and 
the permeabilization of the bacterial membrane (Ammons et al., 2009).  
3.5.1 Lactoferrin and lactoferricins in the battle against infections associated with 
diabetic foot 
Reproducing diabetic foot in animal models with the aim of studying ulcer infections has 
not proved easy. Nevertheless, an in vitro model of chronic lesion biofilms used to evaluate 
antimicrobial susceptibilities was recently reported. This model imitates the lesion 
environment and allows researchers to study various aspects of the physiology of biofilms, 
as well as the effect of drugs and antibiotics on the same. In this model, pretreatment with 
lactoferrin was employed to test for the inhibition of biofilm development by clinical isolates 
of diverse bacteria species. Results showed that this pretreatment did not affect biofilm 
formation or the number of bacteria, leading the authors to conclude that a continuous 
exposure of biofilm to lactoferrin is necessary in order to achieve this effect, as has been 
suggested in reports by other researchers (Hill et al., 2010). 
In relation to foot ulcers of diabetic patients, there are scant reports about the use of 
lactoferrin. The anti-biofilm efficacy of adjunctive methods, such as silver wound dressings, 
for the therapy of infections associated with chronic ulcers is significantly increased when 
combined with lactoferrin-xylitol. The mechanisms underlying this cooperative 
antimicrobial effect are the iron chelating property of lactoferrin, which destabilizes the 
bacterial membrane, and the inhibitory effect of xylitol on the ability of the bacteria to 
produce siderophores under conditions of iron restriction (Ammons et al., 2011A, 2011B). As 
is well-known, iron deprivation promotes siderophore secretion for acquisition of iron 
essential for bacterial growth (Skaar, 2010). These studies point to the great potential of 
lactoferrin and lactoferricins as an adjunct in the treatment of diabetic foot infections. 
Further studies are needed to explore this potential. 
4. Modulatory activities of lactoferrin on inflammation 
The pleitropic property of lactoferrin spans a wide array of regulatory activities on cellular 
and humoral components of the inflammatory response. The capacity of lactoferrin to 
modulate the inflammatory response has been explored in vitro and in vivo. The animal 
models include the use of exogenous lactoferrin from bovine and human origin (Legrand et 
al., 2004), as well as the observation of untreated animals in order to explore the role of 
endogenous lactoferrin (Legrand & Mazurier, 2010). Here we focus on the regulatory effects 
of lactoferrin on mielopoiesis, the production of cytokines and the generation of reactive 
oxygen species (ROS), and in particular on the inflammatory response in skin allergy and 
skin healing in non-infected lesions.  
4.1 Modulatory effects on ROS generation 
4.1.1 Up-regulation 
Lactoferrin is a key component of immune homeostasis, able to positively or negatively 
regulate the function of cellular components of innate mechanisms of defense involved in 
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inflammation, such as mononuclear cells (monocytes and macrophages) and neutrophils.  
According to in vitro assays with neutrophils treated with bovine lactoferrin, the ability of 
this glycoprotein to enhance phagocytosis may be a result of its direct contact along with an 
opsonin-like action on phagocytic cells (Miyauchi et al., 1998). However, the role of 
lactoferrin in phagocytosis has been linked with its ability to positively regulate the 
generation of ROS with bactericidal activity. Evidence of this up-regulating action is the fact 
that lactoferrin in secondary granules of neutrophils enhances the intracellular killing of 
Pseudomonas aeruginosa by promoting the generation of ROS during phagocytosis (Bullen & 
Armstrong, 1979). It has been reported that exogenous lactoferrin enhances the activity of 
ROS production in neutrophils (Ambruso & Johnston, 1981; Gahr et al., 1991) and 
macrophages (Lima & Kierszenbaum, 1987), and that the presence of iron is necessary for 
this effect to take place (Gahr et al., 1991; Lima & Kierszenbaum, 1987). Hololactoferrin (the 
iron- loaded form) seems to deliver the iron that can act as an enzymatic catalyst  of  Haber-
Weiss reactions, which in turn generate various types of ROS, including hydrogen peroxide 
(H2O2), superoxide anion (O2-) and the hydroxyl radical (OH·) (Actor et al., 2009). Reactive 
oxygen species are substrates for the enzymatic generation of antibacterial molecules. For 
instance, H2O2 is a precursor of hypochlorous (HClO). The latter is a strong bactericidal 
molecule generated enzymatically by mieloperoxidase (MPO) (Hampton et al., 1998), a 
prominent component of azurophil granules in neutrophils (Leffell & Spitznagel, 1974).  
4.1.2 Down-regulation 
Lactoferrin can also have a down-regulatory effect on ROS production, such as is the case 
with phagocytes. The mechanism of this effect is the reduction of oxidative stress and the 
control of an excessive inflammatory response (Actor et al., 2009). During the oxidative 
burst, intracellular generation of ROS is essential for the control of bacterial growth 
(Hampton et al, 1998). However, under conditions of oxidative stress the excessive release of 
ROS to the extracellular milieu has devastating effects on the structure of macromolecules 
and cell functions (Actor et al., 2009). Unlike azurophil granules that store MPO, usually 
associated with phagosomes during bacteria phagocytosis, secondary (specific) granules 
that contain lactoferrin usually become degranulated (Leffell & Spitznagel, 1974). Evidence 
from in vitro assays shows that lactoferrin released during neutrophil degranulation 
decreases the overproduction of ROS (Britigan el al., 1989). Moreover, the uptake of 
exogenous lactoferrin by mononuclear phagocytes that do not contain endogenous 
lactoferrin inhibits their ability to form the hydroxyl radical and protects them from 
membrane auto-peroxidation (Britigan et al., 1991). This effect may be linked to the property 
of lactoferrin to inhibit lipid peroxidation (Gutteridge et al., 1981). In the mouse model of 
pollen induced allergic airway, lactoferrin has been effective in inhibiting the generation of 
the superoxide anion. Pollen grains contain reduced nicotinamide adenine dinucleotide 
phosphate (NADH) oxidases. Their product, O2-, is a precursor of H2O2 and OH·, which 
increase pollen induced airway inflammation (Kruzel et al., 2006). 
Apart from its role in inhibiting the overproduction of ROS by phagocytes, lactoferrin can 
also down-regulate ROS production by neutrophils that are stimulated by LPS. 
Lipopolysaccharide interacts with the soluble receptor lipopolysaccharide binding protein 
(LPB), which in turn enables the binding of LPS to CD14, a membrane receptor of 
phagocytes (Van Amersfoort et al., 2003). After binding to the surface membrane via the 
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with xylitol (a sugar derived penta-hidroxy alcohol) decreases the viability of established 
Pseudomonas aeruginosa, a consequence of both the disruption of the biofilm structure and 
the permeabilization of the bacterial membrane (Ammons et al., 2009).  
3.5.1 Lactoferrin and lactoferricins in the battle against infections associated with 
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Reproducing diabetic foot in animal models with the aim of studying ulcer infections has 
not proved easy. Nevertheless, an in vitro model of chronic lesion biofilms used to evaluate 
antimicrobial susceptibilities was recently reported. This model imitates the lesion 
environment and allows researchers to study various aspects of the physiology of biofilms, 
as well as the effect of drugs and antibiotics on the same. In this model, pretreatment with 
lactoferrin was employed to test for the inhibition of biofilm development by clinical isolates 
of diverse bacteria species. Results showed that this pretreatment did not affect biofilm 
formation or the number of bacteria, leading the authors to conclude that a continuous 
exposure of biofilm to lactoferrin is necessary in order to achieve this effect, as has been 
suggested in reports by other researchers (Hill et al., 2010). 
In relation to foot ulcers of diabetic patients, there are scant reports about the use of 
lactoferrin. The anti-biofilm efficacy of adjunctive methods, such as silver wound dressings, 
for the therapy of infections associated with chronic ulcers is significantly increased when 
combined with lactoferrin-xylitol. The mechanisms underlying this cooperative 
antimicrobial effect are the iron chelating property of lactoferrin, which destabilizes the 
bacterial membrane, and the inhibitory effect of xylitol on the ability of the bacteria to 
produce siderophores under conditions of iron restriction (Ammons et al., 2011A, 2011B). As 
is well-known, iron deprivation promotes siderophore secretion for acquisition of iron 
essential for bacterial growth (Skaar, 2010). These studies point to the great potential of 
lactoferrin and lactoferricins as an adjunct in the treatment of diabetic foot infections. 
Further studies are needed to explore this potential. 
4. Modulatory activities of lactoferrin on inflammation 
The pleitropic property of lactoferrin spans a wide array of regulatory activities on cellular 
and humoral components of the inflammatory response. The capacity of lactoferrin to 
modulate the inflammatory response has been explored in vitro and in vivo. The animal 
models include the use of exogenous lactoferrin from bovine and human origin (Legrand et 
al., 2004), as well as the observation of untreated animals in order to explore the role of 
endogenous lactoferrin (Legrand & Mazurier, 2010). Here we focus on the regulatory effects 
of lactoferrin on mielopoiesis, the production of cytokines and the generation of reactive 
oxygen species (ROS), and in particular on the inflammatory response in skin allergy and 
skin healing in non-infected lesions.  
4.1 Modulatory effects on ROS generation 
4.1.1 Up-regulation 
Lactoferrin is a key component of immune homeostasis, able to positively or negatively 
regulate the function of cellular components of innate mechanisms of defense involved in 
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inflammation, such as mononuclear cells (monocytes and macrophages) and neutrophils.  
According to in vitro assays with neutrophils treated with bovine lactoferrin, the ability of 
this glycoprotein to enhance phagocytosis may be a result of its direct contact along with an 
opsonin-like action on phagocytic cells (Miyauchi et al., 1998). However, the role of 
lactoferrin in phagocytosis has been linked with its ability to positively regulate the 
generation of ROS with bactericidal activity. Evidence of this up-regulating action is the fact 
that lactoferrin in secondary granules of neutrophils enhances the intracellular killing of 
Pseudomonas aeruginosa by promoting the generation of ROS during phagocytosis (Bullen & 
Armstrong, 1979). It has been reported that exogenous lactoferrin enhances the activity of 
ROS production in neutrophils (Ambruso & Johnston, 1981; Gahr et al., 1991) and 
macrophages (Lima & Kierszenbaum, 1987), and that the presence of iron is necessary for 
this effect to take place (Gahr et al., 1991; Lima & Kierszenbaum, 1987). Hololactoferrin (the 
iron- loaded form) seems to deliver the iron that can act as an enzymatic catalyst  of  Haber-
Weiss reactions, which in turn generate various types of ROS, including hydrogen peroxide 
(H2O2), superoxide anion (O2-) and the hydroxyl radical (OH·) (Actor et al., 2009). Reactive 
oxygen species are substrates for the enzymatic generation of antibacterial molecules. For 
instance, H2O2 is a precursor of hypochlorous (HClO). The latter is a strong bactericidal 
molecule generated enzymatically by mieloperoxidase (MPO) (Hampton et al., 1998), a 
prominent component of azurophil granules in neutrophils (Leffell & Spitznagel, 1974).  
4.1.2 Down-regulation 
Lactoferrin can also have a down-regulatory effect on ROS production, such as is the case 
with phagocytes. The mechanism of this effect is the reduction of oxidative stress and the 
control of an excessive inflammatory response (Actor et al., 2009). During the oxidative 
burst, intracellular generation of ROS is essential for the control of bacterial growth 
(Hampton et al, 1998). However, under conditions of oxidative stress the excessive release of 
ROS to the extracellular milieu has devastating effects on the structure of macromolecules 
and cell functions (Actor et al., 2009). Unlike azurophil granules that store MPO, usually 
associated with phagosomes during bacteria phagocytosis, secondary (specific) granules 
that contain lactoferrin usually become degranulated (Leffell & Spitznagel, 1974). Evidence 
from in vitro assays shows that lactoferrin released during neutrophil degranulation 
decreases the overproduction of ROS (Britigan el al., 1989). Moreover, the uptake of 
exogenous lactoferrin by mononuclear phagocytes that do not contain endogenous 
lactoferrin inhibits their ability to form the hydroxyl radical and protects them from 
membrane auto-peroxidation (Britigan et al., 1991). This effect may be linked to the property 
of lactoferrin to inhibit lipid peroxidation (Gutteridge et al., 1981). In the mouse model of 
pollen induced allergic airway, lactoferrin has been effective in inhibiting the generation of 
the superoxide anion. Pollen grains contain reduced nicotinamide adenine dinucleotide 
phosphate (NADH) oxidases. Their product, O2-, is a precursor of H2O2 and OH·, which 
increase pollen induced airway inflammation (Kruzel et al., 2006). 
Apart from its role in inhibiting the overproduction of ROS by phagocytes, lactoferrin can 
also down-regulate ROS production by neutrophils that are stimulated by LPS. 
Lipopolysaccharide interacts with the soluble receptor lipopolysaccharide binding protein 
(LPB), which in turn enables the binding of LPS to CD14, a membrane receptor of 
phagocytes (Van Amersfoort et al., 2003). After binding to the surface membrane via the 
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LBP/CD14 receptor complex, LPS released by dead or growing bacteria causes neutrophil 
activation, as evidenced by the oxidative burst accompanied with ROS generation. 
Moreover, when LPS is massively released, such as in septic shock, it binds to L-selectin, an 
integral glycoprotein of membrane leukocytes, and this complex also results in the 
production of ROS (Malhotra et al., 1996). Both of these mechanisms of ROS production are 
impeded by the capacity of lactoferrin to bind to LPS (Wang et al., 1995). Additionally, 
lactoferrin blocks the interaction of LPS with the L-selectin of neutrophils, which also avoids 
the production of ROS (Baveye et al., 2000B). It has been shown that either endogenous 
lactoferrin secreted by neutrophils (Wang et al., 1995) or exogenous lactoferrin (Cohen et al., 
1992) can inhibit the ability of LPS to prime neutrophils for enhanced superoxide 
production.  
Interestingly, the IL 10 receptor (IL-10R), a component of secondary granules, also has an 
anti-inflammatory effect, like lactoferrin, in the presence of LPS. This receptor is exported 
from secondary granules to the membrane of neutrophils primed with LPS. When 
interacting with its respective ligand, these IL 10 receptors reduce the production of ROS 
stimulated by LPS (Elbim et al., 2001).  
4.2 Modulatory effects of lactoferrin on pro-inflammatory cytokines 
Lactoferrin is a modulatory agent whose positive or negative effects on cytokine production 
and phagocytes involved in the inflammatory response is highly dependent on the type of 
inductor recognized by the immune system and also on environmental conditions (Actor et 
al., 2009). The modulatory activity of lactoferrin in inflammation has been addressed in 
animal models, such as that of colitis induced by dextran sulfate (Håversen et al., 2003A; 
Togawa et al., 2002) and that of hind-foot inflammation by carrageenan (Zimecki et al., 
1998). This modulatory activity has also been assessed under in vitro and in vivo conditions 
by using LPS as an inducer (Puddu et al., 2010). The proven substantive regulatory effects of 
lactoferrin on inflammation induced by LPS are not fully understood. However, it is known 
that the intrinsic binding properties of lactoferrin to LPS and/or LPS receptors results in an 
interaction with toll like receptor (TLR)-4 and possibly with other unknown receptors, 
leading to the increase (Na et al., 2004) or decrease (Håversen et al., 2002) of cytokine 
production.  
4.2.1 Down-regulation 
The effects of lactoferrin on inflammation have been correlated with a decrease in three pro-
inflammatory mediators: TNF (Håversen et al., 2003A; Togawa et al., 2002; Zimecki et al., 
1998), IL 6 (Togawa et al., 2002; Zimecki et al., 1998) and IL 1 (Togawa et al., 2002). These 
effects have also been associated, in some cases, with an increase in two anti-inflammatory 
interleukins: IL 4 and IL 10 (Togawa et al., 2002). In animal models of infection with Shigella 
flexneri (Gómez et al., 2002), Salmonella typhimurium (Mosquito et al., 2010) and Lysteria 
monocytogenes (Lee et al., 2005), lactoferrin  from bovine or human origin has been  effective 
in reducing inflammatory necrosis in liver (Lee et al.,  2005) and intestine (Mosquito et al., 
2010), as well as in intestinal edema (Gomez et al., 2002). Owing to its anti-inflammatory 
effect, as evidenced by the reduced levels of TNF (Lee et al., 2005; Komine, et al., 2006; 
Zimecki et al., 2004) and IL 6 (Håversen et al., 2003B), lactoferrin contributes to a decrease in 
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tissue damage caused by the inflammation induced by bacterial pathogens. Other assays 
also have shown that lactoferrin released by phagocytes acts as a negative feedback factor 
by decreasing the TNF released from these cells, which in turn prevents their excessive 
recruitment and activation of phagocytes. In this way, lactoferrin modulates the recruitment 
to sites of inflammation (Crouch et al., 1992).  
There is also evidence that lactoferrin increases the expression of LFA-1, an adhesion 
molecule of blood mononuclear cells (Zimecki et al., 1999A). This is another molecule 
involved in the migration of phagocytes to inflammatory sites. On the other hand, 
lactoferrin inhibits LPS-induced expression of two adhesion molecules, E-selectin and 
ICAM-1, by endothelial cells (Baveye et al., 2000A). Furthermore, it decreases the IL 8 
production induced by LPS and competes with this chemokine for its binding to 
proteoglycans of endothelial cells (Elass et al., 2002).  
4.2.2 Up-regulation 
In addition to its role as a down-regulator of some pro-inflammatory cytokines, lactoferrin 
has also been found to stimulate the production of other pro-inflammatory cytokines 
associated with resistance to bacteria. For instance, the activation by lactoferrin of 
mononuclear cells and polymorphonuclear leukocytes has been correlated with its ability to 
stimulate the release of IL 8 (Spadaro et al., 2008; Sorimachi et al., 1997; Shinoda et al., 1996). 
Up-regulatory properties of lactoferrin on TNF levels increase the efficacy of the BCG 
vaccine by inducing the increase of pro-inflammatory cytokines like IL 6 and IFN gamma, 
involved in the resistance against Mycobacterium tuberculosis (Hwang et al., 2007). In 
transgenic mice carrying a functional human Lf gene and infected with Staphylococcus aureus, 
causing septic arthritis, the increase of a pro-inflammatory Th1 response due to greater TNF 
and IFN gamma levels (and a decreased Th2 response of anti-inflammatory mediators IL 5 
and IL 10) was associated with a reduced incidence of arthritis and mortality (Guillén et al., 
2002). Thus, the pro-inflammatory effects of lactoferrin contribute to resistance to infections 
caused by the aforementioned pathogens. 
4.3 Modulatory effects on mielopoiesis 
Another protective effect of bovine lactoferrin in the protection against Escherichia coli 
bacteremia in mice has been associated with an increased turnover of neutrophils (Zimecki 
et al., 2004). In this regard, the demand for neutrophils greatly increases in the inflammatory 
response caused by infections. Thus, the effect of lactoferrin on bacterial resistance may be 
linked to its regulatory properties on cytokines involved in mielopoiesis, including IL 1,IL 6, 
IL 8 and TNF, as well as on mielopoietic  growth factors, such as granulocyte macrophage 
colony stimulating factor (GM-CSF), G-CSF and M-CSF (Artym & Zimecki, 2007). These 
soluble factors favor mielopoiesis, i.e., the process of the generation of granulocyte and 
monocyte leukocytes from a bone marrow pluripotent cell.  
The modulatory activity on mielopoiesis has been described in relation to lactoferrin 
released by human neutrophils and exogenous lactoferrin tested with culture cells or 
administered to animals or human volunteers (Artym & Zimecki, 2007). The modulatory 
role of lactoferrin upon progenitor cells of the granulocyte/macrophage lineage has been 
controversial (Artym & Zimecki, 2007). In healthy humans orally treated with bovine 
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LBP/CD14 receptor complex, LPS released by dead or growing bacteria causes neutrophil 
activation, as evidenced by the oxidative burst accompanied with ROS generation. 
Moreover, when LPS is massively released, such as in septic shock, it binds to L-selectin, an 
integral glycoprotein of membrane leukocytes, and this complex also results in the 
production of ROS (Malhotra et al., 1996). Both of these mechanisms of ROS production are 
impeded by the capacity of lactoferrin to bind to LPS (Wang et al., 1995). Additionally, 
lactoferrin blocks the interaction of LPS with the L-selectin of neutrophils, which also avoids 
the production of ROS (Baveye et al., 2000B). It has been shown that either endogenous 
lactoferrin secreted by neutrophils (Wang et al., 1995) or exogenous lactoferrin (Cohen et al., 
1992) can inhibit the ability of LPS to prime neutrophils for enhanced superoxide 
production.  
Interestingly, the IL 10 receptor (IL-10R), a component of secondary granules, also has an 
anti-inflammatory effect, like lactoferrin, in the presence of LPS. This receptor is exported 
from secondary granules to the membrane of neutrophils primed with LPS. When 
interacting with its respective ligand, these IL 10 receptors reduce the production of ROS 
stimulated by LPS (Elbim et al., 2001).  
4.2 Modulatory effects of lactoferrin on pro-inflammatory cytokines 
Lactoferrin is a modulatory agent whose positive or negative effects on cytokine production 
and phagocytes involved in the inflammatory response is highly dependent on the type of 
inductor recognized by the immune system and also on environmental conditions (Actor et 
al., 2009). The modulatory activity of lactoferrin in inflammation has been addressed in 
animal models, such as that of colitis induced by dextran sulfate (Håversen et al., 2003A; 
Togawa et al., 2002) and that of hind-foot inflammation by carrageenan (Zimecki et al., 
1998). This modulatory activity has also been assessed under in vitro and in vivo conditions 
by using LPS as an inducer (Puddu et al., 2010). The proven substantive regulatory effects of 
lactoferrin on inflammation induced by LPS are not fully understood. However, it is known 
that the intrinsic binding properties of lactoferrin to LPS and/or LPS receptors results in an 
interaction with toll like receptor (TLR)-4 and possibly with other unknown receptors, 
leading to the increase (Na et al., 2004) or decrease (Håversen et al., 2002) of cytokine 
production.  
4.2.1 Down-regulation 
The effects of lactoferrin on inflammation have been correlated with a decrease in three pro-
inflammatory mediators: TNF (Håversen et al., 2003A; Togawa et al., 2002; Zimecki et al., 
1998), IL 6 (Togawa et al., 2002; Zimecki et al., 1998) and IL 1 (Togawa et al., 2002). These 
effects have also been associated, in some cases, with an increase in two anti-inflammatory 
interleukins: IL 4 and IL 10 (Togawa et al., 2002). In animal models of infection with Shigella 
flexneri (Gómez et al., 2002), Salmonella typhimurium (Mosquito et al., 2010) and Lysteria 
monocytogenes (Lee et al., 2005), lactoferrin  from bovine or human origin has been  effective 
in reducing inflammatory necrosis in liver (Lee et al.,  2005) and intestine (Mosquito et al., 
2010), as well as in intestinal edema (Gomez et al., 2002). Owing to its anti-inflammatory 
effect, as evidenced by the reduced levels of TNF (Lee et al., 2005; Komine, et al., 2006; 
Zimecki et al., 2004) and IL 6 (Håversen et al., 2003B), lactoferrin contributes to a decrease in 
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tissue damage caused by the inflammation induced by bacterial pathogens. Other assays 
also have shown that lactoferrin released by phagocytes acts as a negative feedback factor 
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recruitment and activation of phagocytes. In this way, lactoferrin modulates the recruitment 
to sites of inflammation (Crouch et al., 1992).  
There is also evidence that lactoferrin increases the expression of LFA-1, an adhesion 
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proteoglycans of endothelial cells (Elass et al., 2002).  
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stimulate the release of IL 8 (Spadaro et al., 2008; Sorimachi et al., 1997; Shinoda et al., 1996). 
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vaccine by inducing the increase of pro-inflammatory cytokines like IL 6 and IFN gamma, 
involved in the resistance against Mycobacterium tuberculosis (Hwang et al., 2007). In 
transgenic mice carrying a functional human Lf gene and infected with Staphylococcus aureus, 
causing septic arthritis, the increase of a pro-inflammatory Th1 response due to greater TNF 
and IFN gamma levels (and a decreased Th2 response of anti-inflammatory mediators IL 5 
and IL 10) was associated with a reduced incidence of arthritis and mortality (Guillén et al., 
2002). Thus, the pro-inflammatory effects of lactoferrin contribute to resistance to infections 
caused by the aforementioned pathogens. 
4.3 Modulatory effects on mielopoiesis 
Another protective effect of bovine lactoferrin in the protection against Escherichia coli 
bacteremia in mice has been associated with an increased turnover of neutrophils (Zimecki 
et al., 2004). In this regard, the demand for neutrophils greatly increases in the inflammatory 
response caused by infections. Thus, the effect of lactoferrin on bacterial resistance may be 
linked to its regulatory properties on cytokines involved in mielopoiesis, including IL 1,IL 6, 
IL 8 and TNF, as well as on mielopoietic  growth factors, such as granulocyte macrophage 
colony stimulating factor (GM-CSF), G-CSF and M-CSF (Artym & Zimecki, 2007). These 
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lactoferrin, the up-regulatory action of lactoferrin on granulopoiesis was linked to the 
increased output of neutrophil precursors along with an attenuated release of TNF and IL-6 
(Zimecki et al., 1999B). The effect of lactoferrin in promoting granulopoiesis apparently 
results from its ability to stimulate the increase in CSF production, as was shown under in 
vitro and in vivo conditions (Sawatzki & Rich, 1989). With assays of mouse bone marrow and 
peritoneal cells, both cultured with or without indomethacin (a non-steroidal anti-
inflammatory drug used as an inhibitor of prostaglandin synthesis), mouse or human 
lactoferrin promoted an increase in CSF. On the other hand, injection of mice with endotoxin 
free mouse lactoferrin stimulated an early increase in CSF production, and a more delayed 
increase in bone marrow granulocyte macrophage progenitor cells (GM-CFC) (Sawatzki & 
Rich, 1989).  
Lactoferrin also can have a negative effect on mielopoiesis, as evidenced by the iron 
dependent capacity of human lactoferrin to suppress the number of granulocyte 
macrophage progenitor cells from femur and spleen of mice (Gentile & Broxmeyer, 1983). 
This iron dependent suppressor effect of human lactoferrin, when tested in human bone 
marrow derived cells and blood monocytes, was linked to the decrease of GM-CSF 
(Broxmeyer et al., 1980). However, the role of lactoferrin as a modulating agent on 
granulopoiesis was not at all confirmed by some other studies (DelForge et al., 1985; Winton 
et al., 1981).  
These divergent results in regard to the modulatory effects of lactoferrin on leukocyte 
generation have probably arisen from variations in experimental design. After all, the 
inflammatory response is a very complex spatio-temporal process of multiple steps. The 
effect of lactoferrin on mielopoiesis must therefore be dependent on the stage of the 
inflammatory response. Lactoferrin as an immunoregulatory protein should presumable act 
first by enhancing the inflammatory response, and later by suppressing the same (Artym & 
Zimecki, 2007). 
4.4 Modulatory effects of lactoferrin on inflammation in models of skin allergy and 
skin wound healing 
The skin is the largest organ of the human body, made up of three main layers: epidermis, 
dermis and the hypodermis (Kanitakis, 2002). The epidermis layer contains no blood 
vessels and is made up of 90-95 % keratinocytes and 5% Langerhans cells, melanocytes 
and Merkel cells. Keratinocytes, upon dying due to a lack of blood supply, are responsible 
for skin keratinization by releasing keratin to extracellular surroundings. Langerhans cells 
are mobile dendritic presenting cells derived from CD34+ bone marrow precursor cells. 
Melanocytes produce melanin, a natural dye to protect skin from ultraviolet radiation. 
Merkel cells display neuroendocrine and epithelial features and function  
as mechanoreceptors by their contact through synaptic junctions with dermal sensory 
axons.  
The dermis, the second layer of the skin, is tightly connected to epidermis by a basement 
membrane which protects the latter layer from stress. The dermis is a vascularized layer 
formed by an elastic and compressible connective tissue that contains fibroblasts, dermal 
dendrocytes (mesenchymal dendritic cells), mast cells and a dense network of collagen 
fibers.  
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The hypodermis represents the inner layer of skin and is made up of loose connective tissue 
and elastin. The main types of cells present in this layer are fibroblasts, macrophages and 
adipocytes. This layer contains 50% body fat and plays a relevant role in thermoregulation, 
insulation and supply of energy. It also acts as a shield against mechanical injuries 
(Kanitakis, 2002). 
Lactoferrin displays a role in skin homeostasis by its ability to positively or negatively 
modulate the generation cytokines derived from keratinocytes and Langerhans cells, with 
an essential role in immune and inflammatory responses (Wang et al., 1999).  
4.4.1 Modulation of the inflammatory response associated with skin allergy 
Trials with human volunteers and assays on mice have addressed down-regulatory 
properties of bovine or human lactoferrin on pro-inflammatory cytokines generated during 
dermal allergic responses induced by diphenylcyclopropenone (DPC) (Griffiths et al., 2001; 
Kimber et al., 2002) and oxazolone (Cumberbatch et al., 2000).  
In models of skin allergy induced by DPC or oxazolone, epidermal Langerhans cells migrate 
to skin-draining lymph nodes. As a consequence, there is an accumulation and maturation 
of Langerhans cells as dendritic cells able to perform their antigen presentation role to naïve 
T cells (Wang et al., 1999). In the aforementioned models of skin allergy, the migration of 
Langerhans cells depends on the local production by skin keratinocytes of IL 1beta, which in 
turn is dependent on de novo production of TNFalpha. In humans, TNF alpha stimulates the 
activation and migration of Langerhans cells from the dermis, and their subsequent 
accumulation in human skin-draining lymph nodes (Cumbertbach et al., 1999). This 
cytokine also promotes the migration of immature Langerhans cells to human lymph nodes 
involved in chronic skin inflammation (Geissmann et al., 2002). In this regard, the anti-
inflammatory property of lactoferrin applied topically to humans and mice has been linked 
to a decrease in the migration of skin Langerhans cells induced by DPC or oxazolone 
(Griffiths et al., 2001; Kimber et al., 2002; Cumberbatch et al., 2000). As in the case of DPC or 
oxazonolone, homolog lactoferrin inhibits the mobilization of Langerhans cells induced by 
intradermic IL 1beta in humans (Cumberbatch et al., 2003) and mice (Cumberbatch et al., 
2000). However, in mice, homolog lactoferrin fails to reduce the migration of Langerhans 
cells induced by the application of exogenous TNF alpha (Cumberbatch et al., 2000). It 
seems that the down-regulatory effect of lactoferrin on Langerhans cell migration induced 
by DPC or oxazolone allergens, occurs after inhibiting de novo synthesis of TNF alpha by 
epidermal keratinocytes.  
Another down-regulatory effect of bovine lactoferrin has also been described in the mouse 
model of zymosan-ear skin inflammation (Hartog et al., 2007). In this model, bovine 
lactoferrin had an anti-inflammatory effect by suppressing local production of TNF alpha. 
Furthermore, a combination of lactoferrin and glycine generated a synergistic anti-
inflammatory effect (Hartog et al., 2007). 
In patients with eczematous dermatitis caused by contacting nickel, recombinant human 
lactoferrin decreased the inflammatory response by inhibiting type 1 and type 2 T cell 
responses. In that study lactoferrin suppressed T cell proliferation and inhibited the 
expression of chemokine receptors CCR10, CXCR3 (expressed on Th1) and CCR4 (expressed 
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This iron dependent suppressor effect of human lactoferrin, when tested in human bone 
marrow derived cells and blood monocytes, was linked to the decrease of GM-CSF 
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dermis and the hypodermis (Kanitakis, 2002). The epidermis layer contains no blood 
vessels and is made up of 90-95 % keratinocytes and 5% Langerhans cells, melanocytes 
and Merkel cells. Keratinocytes, upon dying due to a lack of blood supply, are responsible 
for skin keratinization by releasing keratin to extracellular surroundings. Langerhans cells 
are mobile dendritic presenting cells derived from CD34+ bone marrow precursor cells. 
Melanocytes produce melanin, a natural dye to protect skin from ultraviolet radiation. 
Merkel cells display neuroendocrine and epithelial features and function  
as mechanoreceptors by their contact through synaptic junctions with dermal sensory 
axons.  
The dermis, the second layer of the skin, is tightly connected to epidermis by a basement 
membrane which protects the latter layer from stress. The dermis is a vascularized layer 
formed by an elastic and compressible connective tissue that contains fibroblasts, dermal 
dendrocytes (mesenchymal dendritic cells), mast cells and a dense network of collagen 
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The hypodermis represents the inner layer of skin and is made up of loose connective tissue 
and elastin. The main types of cells present in this layer are fibroblasts, macrophages and 
adipocytes. This layer contains 50% body fat and plays a relevant role in thermoregulation, 
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inflammatory property of lactoferrin applied topically to humans and mice has been linked 
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intradermic IL 1beta in humans (Cumberbatch et al., 2003) and mice (Cumberbatch et al., 
2000). However, in mice, homolog lactoferrin fails to reduce the migration of Langerhans 
cells induced by the application of exogenous TNF alpha (Cumberbatch et al., 2000). It 
seems that the down-regulatory effect of lactoferrin on Langerhans cell migration induced 
by DPC or oxazolone allergens, occurs after inhibiting de novo synthesis of TNF alpha by 
epidermal keratinocytes.  
Another down-regulatory effect of bovine lactoferrin has also been described in the mouse 
model of zymosan-ear skin inflammation (Hartog et al., 2007). In this model, bovine 
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on Th2 cells). However, the production of IFN gamma by Th1 and IL 5 by Th2 was partially 
suppressed by lactoferrin (Moed et al., 2004).  
4.4.2 Effect of lactoferrin on cutaneous homeostasis and skin wound healing 
4.4.2.1 Stages of skin wound healing 
Some of the humoral and cellular components of the inflammatory and immune responses 
that are modulated by lactoferrin in turn regulate mechanisms with an essential role in 
cutaneous homeostasis and wound healing. As is known, dermal wound healing is a normal 
process of repair that involves four continuous, overlapping and precisely programmed 
stages: i) hemostasis ii) inflammation, iii) fibroplasia, and iv) remodeling (Hardy, 1989; Guo 
& DiPietro, 2010).  
Hemostasis results from vasoconstriction and clotting by fibrin deposition to control 
bleeding caused by the vascular injury. The clot along with injured surrounding tissue 
release pro-inflammatory mediators and growth cell factors, such as transforming growth 
factor (TGF) beta1, fibroblast growth factor (FGF) and epidermal growth factor (EGF) (Guo 
& DiPietro, 2010).  
In the inflammatory phase, sequential infiltration of neutrophils, macrophages and 
lymphocytes occurs in damaged tissue. The presence of phagocytes is mandatory for 
bacterial and cellular debris clearance (Hardy, 1989). The pro-inflammatory contribution of 
lactoferrin in this stage may be linked to its ability to up-regulate the bactericidal activity of 
neutrophils (Ambruso & Johnston, 1981; Gahr et al., 1991) and macrophages (Lima & 
Kierszenbaum, 1987) aimed at the control of bacterial growth. During this stage, lactoferrin 
also modulates the overproduction of ROS released during neutrophil degranulation in 
order to protect the organism from toxic effects of the same (Britigan el al., 1989).  
In the early inflammatory phase, TNF alpha has an essential role in wound healing. 
However, since its overproduction can cause tissue damage, the fact that lactoferrin 
decreases TNF released from phagocytes may contribute to preventing the excessive 
recruitment and activation of phagocytes to sites of inflammation (Crouch et al., 1992). 
Evidence from in vitro cultures of peripheral and bone marrow monocytes of human origin 
suggest that the down-regulating effects of lactoferrin on inflammation may also be linked 
to its suppression of the release of IL 1 from monocytes. This in turn decreases GM-CSF 
production by fibroblasts (Zucali et al., 1989), which may contribute to controlling the 
mobilization of peripheral blood cells to inflammatory sites.   
The fibroplastic phase is characterized by three processes: i) re-epithelialization, ii) wound 
contraction and iii) production of extracellular matrix components such as collagen (Hardy, 
1989). Numerous subtypes of keratinocytes (Patel et al., 2006) and fibroblasts (El Ghalbzouri et 
al., 2004) play an essential role in scar tissue formation by contributing to wound re-
epithelialization. In the early response to injury, re-epithelialization occurs when fibroblasts in 
the neighborhood of the wound proliferate and then migrate to the wound bed, where they 
are induced by chemotactic mediators to produce extracellular matrix components (Hardy, 
1989). Among these components are proteoglycans (heparan-, chondroitin- and keratan-
sulfate), non-proteoglycan polysaccharide (hyalouronic acid) and fibers (collagen, elastin) 
(Labat-Robert et al., 1990). Dermal healing is accompanied by a process of granulation, which 
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results from the accumulation of fibroblasts and extracellular matrix components along with 
the formation of new blood vessels to constitute granular tissue (Hardy, 1989).   
Generation of granular tissue is a complex process regulated by cytokines such as TGF beta1 
produced by keratinocytes, macrophages and fibroblasts (Werner et al., 2007). Transforming 
growth factor beta1 stimulates the expression of integrins in keratinocytes, which facilitates 
their migration to perform the re-epithelialization during wound healing (Gailit et al., 1994). 
Granulation is also dependent on growth factors such as EGF, platelet derived growth factor 
(PDGF) and basic fibroblast growth factor (bFGF) (Werner et al., 2007).  In vitro assays show 
that TGF beta1 and PDGF regulate fibroblast attachment, which represents the step between 
cell migration and proliferation in vivo during wound healing (Ihn et al., 1995). Additionally, 
TGF beta1, bFGF and other blood derived factors promote cell migration and proliferation 
leading to the increase of cells in the denuded area, or wound space (Schreier et al., 1993). 
Other agents that exercise healing effects, by enhancing migration and proliferation of 
keratinocytes for re-epithelializing of the wound bed, include keratinocyte growth factor 2 
(Soler et al., 1999), heparin binding EGF like growth factor (Shirakata et al., 2005), skin beta-
defensins (Niyonsaba et al., 2007) and insulin (Liu et al., 2009). 
4.4.2.2 Effects of lactoferrin on wound healing  
The role of lactoferrin in the fibroplastic phase has been addressed in some in vitro cultures 
of human skin fibroblasts (Tang et al., 2010A) and keratinocytes (Tang et al., 2010B). These 
assays show that recombinant human lactoferrin sustains the survival of fibroblasts and 
keratinocytes by protecting them from apoptosis, and in this way enhances re-
epithelialization by stimulating the proliferation and migration of these cells.  
It has been reported that bovine lactoferrin is also able to enhance collagen gel-contractile 
activity in human fibroblasts, which is the in vitro model for the reorganization of the 
collagen matrix during the wound healing process. Gel contractile activity induced by 
bovine lactoferrin is accompanied by the activation of extracellular regulated kinase (ERK) 
1/2 and myosin light chain kinase (MLCK), and the subsequent elevation of myosin light 
chain phosphorylation. The effects of lactoferrin on gel contractile activity and its signaling 
pathway were mediated by the low density lipoprotein receptor related protein (LRP) 
(Takayama et al., 2003).  
Lactoferrin may contribute to wound healing in the fibroplastic stage by its promotion of the 
synthesis and secretion of the nerve growth factor, which was observed in one study during 
the contact of bovine lactoferrin with mouse fibroblasts (Shinoda et al., 1994). The nerve 
growth factor (NGF) is an angiogenic agent with healing activity on diabetic skin ulcers in 
humans (Aloe, 2004) and mice (Graiani et al., 2004). Also in the fibroplastic stage, lactoferrin 
promotes the synthesis of components of extracellular matrix, such as type 1 collagen and 
hyaluronan, the latter through the activation of the TFG beta1 signaling pathway. This has 
been shown in vitro with assays on human fibroblasts (Saito et al., 2011). 
5. Applications of lactoferrin as an adjunctive agent in the treatment of 
infections associated with diabetic foot ulcers   
Whereas the previous discussion demonstrates that lactoferrin possesses pleitotropic 
properties on cell components involved in the inflammation associated with skin allergy or 
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skin reparation of non-infected surface wounds, what follows is intended to describe 
potential applications of lactoferrin as an adjunctive agent to control bacterial growth in 
infected foot ulcers, which can threaten a limb or even the life of diabetic patients. Diabetic 
foot syndrome encompasses a complex convergence of pathologies, including diabetic 
neuropathy, peripheral vascular disease, Charcot´s neuroarthropathy, and osteomyelitis and 
foot ulceration. Diabetic foot ulcers are usually detected at the plantar surface and result 
from neuropathy, inadequate blood supply (ischemia) (Khanolkar et al., 2008), hypoxia 
(Tamir, 2007) and disturbances in neutrophil phagocytic function (Bader, 2008). Neuropathy 
plays a major role in foot ulceration since it underlies the loss of limb sensibility to skin pain 
caused by dermal abrasions and blisters, owing to disturbances of sensory, motor and 
autonomic functions (Khanolkar et al., 2008). 
At present, the evaluation of lactoferrin as an agent with wound healing properties has been 
limited to only two studies: an experimental study on diabetic mice (Engelmeyer et al., 2008) 
and a clinical study on patients (Lyons et al., 2007). In the former, topically applied 
Talactoferrin, versus the vehicle or becaplermin (a recombinant human platelet-derived 
growth factor), increased the closure rate. In vitro culture assays suggest that the underlying 
mechanism of the healing effect of Talactoferrin on mouse diabetic ulcers could be linked 
with its ability to enhance the migration of dermal fibroblasts, THP-1 macrophages, Jurkat T 
cells and mouse granulocytes. Other activities of Talactoferrin associated with its healing 
properties include its ability to enhance the production of IL-8, IL-6, MIP-1 alpha and TNF 
, all of which have an essential role in the early inflammatory phase of wound healing 
(Engelmayer et al., 2008).   
In the clinical study, Talactoferrin was delivered topically in gel to the non-healing chronic 
ulcers from fifty five diabetic patients (patients with any sign of osteomyelitis, gangrene o 
deep tissue infection were excluded). The first phase, an open label, sequential, dose-
escalation study, evaluated the safety of Talactoferrin. Groups of patients were treated with 
1% (n=3), 2.5% (n=3) or 8.5% (n=3) of Talactoferrin gel applied topically at the ulcer twice 
daily for 30 days in combination with standard wound care. No adverse effects were 
detected. The second phase assessed the efficacy of two distinct doses of Talactoferrin. This 
was a single blind randomized, stratified placebo controlled pilot study of three groups of 
patients treated with gel containing 2.5% (n=15) and 8.5% (n=15) of Talactoferrin gel or 
placebo gel (n=16). In combination with standard wound care, Talactoferrin gel was 
administered topically twice daily to the ulcers for 12 weeks. The results from the second 
phase showed that Talactoferrin was effective as a healing agent, evidenced by a significant 
difference (P<0.01) between the results in the Tlactoferrin-treated and control groups. The 
incidence in the reduction of the size of ulcers in the groups treated with 2.5% and 8.5 % 
Talactoferrin gel was ≥ 75% compared with 45%-25% in the groups treated with placebo gel. 
Accordingly, Talactoferrin has been shown to be an effective agent with healing properties 
and seems to be pharmacologically safe and well tolerated. Thus, it may be useful in the 
treatment of foot ulcers in diabetic patients (Lyons et al., 2007).  
Due to the multifactorial characteristic of the diabetic foot syndrome, lactoferrin does not 
fulfill the therapeutic requirements for use as a single healing agent. However, some 
standard techniques of un-infected and un-ischemic diabetic ulcers like debridement (i.e., 
removal of unhealthy tissue from the wound bed) (Tamir, 2007) may be improved by 
including lactoferrin as an adjunctive therapeutic agent.  
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Some pharmaceutical formulations of lactoferrin, including liposomes administered intra-
articularly in joints (Trif et al., 2001) or by oral route (Ishikado et al., 2005) to control the 
chronic inflammation of arthritis or other pathologies, as well as bioadhesive tablets 
administered to treat inflammation associated with oral ulcers (Takahashi et al., 2007; 
Takeda et al., 2007), may represent systemic or oral delivery formulations for adjunctive 
treatment of chronic wounds. As is known, a prolonged inflammatory response is a 
contributing factor of chronic wounds, since it abrogates the normal process of ulcer healing 
(Pierce, 2001).    
Diabetic patients usually suffer skin dryness, which prompts injuries that are highly 
susceptible to bacterial infections. When foot skin of the plantar surface is injured, 
microorganisms that are normally retained gain access to underlying layers where bacterial 
replication leads to local and/or systemic infections (Guo & DiPietro, 2010). Bacterial 
infections associated with chronic non-healing foot ulcerations, apart from being a common 
cause of limb amputation, put the life of the diabetic patient at risk (Bader, 2008).  
The effectiveness of standard methods of care, including off-loading, debridement, systemic 
and local antibiotics and topical antiseptics, can be substantially improved when combined 
with adjunctive techniques. In some cases, adjuncts like wound dressings (Hilton et al., 
2004), hyperbaric oxygen and growth factors are needed to provide better conditions for 
closure. Such conditions include a moist environment to enhance an optimal inflammatory 
milieu, as well as an adequate supply of oxygen and nutritional factors (Hopf et al., 2001).  
Silver wound dressings have been applied to control the formation of biofilms associated with 
acute and chronic ulcers in diabetic patients (Hilton et al., 2004). However, as the treatment 
progresses, the single antibacterial effect of the silver is surpassed by the generation of 
antibacterial resistance caused by the establishment of bacterial biofilms which in turn impede 
healing of chronic ulcers in diabetic patients. Lactoferrin may be included in the list of adjuncts 
with a role in the establishment of the proper conditions for the healing of the wound bed, 
owing to its aforementioned natural antibacterial and wound healing properties. In this 
regard, a pharmaceutical presentation of lactoferrin and xylitol in hydrogel proved effective in 
enhancing the antibiofilm efficacy of a commercial silver wound dressing (Ammons et al., 
2011B). That study showed that the combination of lactoferrin, xylitol and silver provides 
significant antimicrobial efficacy against established biofilms formed by methicillin-resistant 
Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. Consequently, lactoferrin in 
combination with xylitol would be recommended to increase the antibacterial effect of silver 
wound dressings applied to infected wounds of diabetic patients.  
Thus, wound healing and anti-biofilm properties enable lactoferrin, acting as an adjunctive 
agent, to enhance the efficacy of anti-biofilm targeted techniques for the treatment of 
infected chronic ulcers like silver wound dressings.   
6. Safety measures in the use of Lactoferrin  
Toxicological assays on rats chronically treated by the oral route with human recombinant 
(Cerven et al., 2008; Appel et al, 2006) or native bovine (Yamauchi et al., 2000) lactoferrin 
show that regardless of their origin, these proteins are pharmacological safe products. In 
spite of their free toxicity status, some concerns have been raised, including bacterial 
resistance to human lactoferrin, as in the case of Streptococcus pneumoniae (Hammerschmidt 
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et al., 1999), and the autoimmune potential of cross reactive anti-lactoferrin antibodies which 
recognize bacterial antigens like the 65 kDa protein of Mycobacterium tuberculosis (Esaguy et 
al., 1991). Although neither Streptococcus pneumoniae or Mycobacterium tuberculosis are 
associated with infections in diabetic foot ulcers, bacterial resistance and the autoimmune 
potential of cross reactive anti-lactoferrin antibodies warn of the need to be alert to possible 
problems in the application of lactoferrin as an antibacterial agent. While this requires 
attention to side effects that could present themselves, it does not in any way undermine all 
of the positive results of lactoferrin found to date.  
The pathological relevance of anti-lactoferrin autoantibodies remains uncertain (Audrain et 
al., 1996). However, it is possible that in some chronic degenerative diseases such as 
rheumatoid arthritis (Esaguy et al., 1993), ulcerative colitis, primary sclerosing cholangitis 
and Crohn´s disease, autoantibodies to lactoferrin may aggravate and sustain the 
inflammatory condition (Peen et al., 1993).  
Host-produced lactoferrin has been associated with some degenerative diseases and 
therefore the administration of exogenous lactoferrin may aggravate and contribute to the 
multifunctional pathology of diabetic foot syndrome. In this regard, endogenous lactoferrin 
has been reported as a major component of amyloid depots in patients with gelatinous 
drop-like corneal dystrophy (Klinworth et al., 1997), and it has been detected in pathological 
lesions in a variety of neurodegenerative disorders as Alzheimer´s disease, amyotrophic 
lateral sclerosis/parkinsonism dementia complex of Guam and sporadic amyotrophic lateral 
sclerosis, or Pick´s disease (Leveugle et al., 1994).  
On the other hand, in some sensitized individuals, lactoferrin from bovine milk can be a strong 
milk allergen (Gaudin et al., 2008). Therefore in such individuals with diabetic foot, the 
allergenic potential of bovine lactoferrin should be taken into account before prescribing its 
oral administration. Additionally, the undesirable pro-inflammatory effects of iron loaded 
lactoferrin on vascular permeability, as evidenced in the dermis of rats by the increase of 
albumin extravasation (Erga et al., 2001), could negatively affect the process of skin healing.  
7. Conclusion  
The antibacterial and wound healing properties of lactoferrin may contribute to enhancing 
the effectiveness of standard techniques for treatment of infections of diabetic foot ulcers. 
Futures studies are needed to address the substantive therapeutic contribution of lactoferrin 
as an adjunctive agent in the treatment of infections associated with diabetic ulcer, including 
the concerns and limitations of its application.  
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Charcot Neuro-Osteoarthropathy 
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Internal Medicine, Academic Medical Center Amsterdam, Amsterdam 
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1. Introduction 
Charcot neuro-osteoarthropathy (CN) is most often seen in patients with diabetes although 
it has been associated with syringomyelia, tabes dorsalis, leprosy and hereditary sensory 
neuropathy. It is defined by painful or relatively painless bone and joint destruction and 
deformity in limbs that have lost sensory innervation, it commonly develops in the mid-foot 
but also in the forefoot and hind foot [1]. The estimated prevalence in diabetic population is 
between 0,1% and 7,5% [2]. Due to the rapid severe and irreversible foot deformity, 
recognition of acute CN is extremely important. The clinical presentation between type 1 
and type 2 diabetes is not different, but on epidemiological level the age of presentation of 
an acute CN is at an earlier age and longer disease duration [3]. 
2. Risk factors and pathophysiology 
Trauma, previous ulcer, infection or surgery of the foot are predisposing factors for CN as 
well as neuropathy, osteopenia and renal impairment, although the exact pathogenesis is 
still unknown [3].  
In peripheral blood monocytes isolated from Charcot patients, the osteoclast formation was 
significant increased compared to diabetic patients and healthy controls. The osteoclastic 
resorption increased after addition of receptor activator of NFB ligand (RANKL). So in the 
acute stage of CN, the osteoclast activity is increased probably by increased expression of 
receptor activator of NFB ligand (RANKL) via release of proinflammatory cytokines as 
TNF-alfa [4,5]. Central role in this process of local inflammation is trauma. Patients with 
diabetes do not notice most traumas due to the peripheral neuropathy. Trauma will induce 
pro-inflammatory cytokines like TNF-alfa and RANKL will be expressed. Due to loss in 
pain perception by the distal neuropathy, the TNF-alfa release will persist and the RANKL 
pathway is persistently stimulated [6].  
3. Clinical presentation 
The acute stage is characterized by unilateral erythema and oedema of the affected foot. The 
temperature is at least 2° Celsius higher than the non-affected foot, which can be measured 
with an infrared skin thermometer. Mostly the mid foot is affected, followed by the fore foot 
and hind foot. 
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The differential diagnosis of a red, hot swollen foot is: severe infection (osteomyelitis) in 
case of a concurrent foot ulcer, cellulitis, bone fracture, gout or septic arthritis. Most difficult 
is to differentiate between an acute CN and osteomyelitis if a foot ulcer is present. Clinical 
directions in favour for osteomyelitis are a positive probe to the bone test and radiological 
abnormalities in relation to the ulcer, that is mostly located on pressure points like 
metatarsal heads or rocker-bottom. Radiological abnormalities in favour of CN are 
radiological abnormalities in the mid foot. The chronic not active Charcot foot is 
characterized with joint deformity, and or (sub) luxation of the metatarsals leading to 
rocker-bottom. These deformities cause elevated plantar pressure leading to abundant callus 
formation and an increased risk for foot ulcers. 
 
Fig. 1. Red hot swollen foot. 
4. Diagnosis 
Although in a very early stage of an acute CN the plain X-ray can be false negative, the 
initial screening tool for an acute CN is still a plain X-ray in three directions: dorsoplantar, 
lateral and pronated oblique). The radiological description is according to the five D’s: bone 
density, joint distention, bony debris, joint disorganization and dislocation of the joint [2].  
The density of the bone is usually normal, except in elderly or type 1 diabetic patients. Large 
joint effusions cause distention. The most frequent dislocation is the tarsometatarsal 
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tomography (CT) is not well investigated. The five D’s as mentioned above can be adapted 
to CT images. Bone scintigraphy (technetium) is the most often used nuclear method. Focal 
hyperperfusion and or focal bony uptake are seen on the scintigraphy but are not specific 
for CN. Also in osteomyelitis these characteristics are seen.  
 







The current standard treatment is off-loading the affected foot with a total contact cast or a 
prefabricated walking cast. Off-loading will prevent extensive bone damage, which can lead 
to sub-luxation and dislocation leading to severe foot deformity. Off-loading is continued 
until clinical signs of activity (temperature differential) are resolved and there is no longer 
evidence on X-ray of continuing bone destruction. Median time of off-loading treatment is 9 
(7-12) months [8].  
Chronic CN 
If the CN is inactive, the patients have to be rehabilitated. This process has to be gradually to 
prevent recurrence for CN leading to further bone destruction. Patients need orthopaedic 
shoes during this process and the walking distance is extended slowly, first with two 
crutches followed with one and finally without.    
Operative orthopaedic treatment is indicated for chronic recurrent ulcers on pressure points 
like rocker-bottom or joint instability. Operative procedures in acute CN are strongly not 
recommended: the bone structure is too instable for internal of external fixation and every 
orthopaedic intervention is a risk factor for increase in activity of CN. Osteotomy is possible 
in inactive CN in combination with bony prominence that cause recurrent ulcers. Obvious, 
arterial insufficiency is ruled out or has been treated before elective surgery.  
6. Additional treatment with bisphosphonates? 
To shorten the time of CN activity, intervention at the level of osteoclasts and or osteoblasts 
might be useful. Because bisphosphonates induce osteoclast apoptosis [9], several trials with 
bisphosphonates were performed. In the acute setting of CN the use of oral alendronate 70 
mg once weekly on top of standard care (total contact cast immobilisation) was studied in a 
small double blind placebo controlled trial [10]. After 6 months, a reduction in bone 
turnover markers was demonstrated, but not in skin temperature. In another double blind 
placebo controlled trial studied the additional effect of one single infusion of intravenous 
pamidronate in patients with acute CN [11]. The intervention group had a faster fall in 
temperature of the affected foot at four weeks, a greater reduction in bone turnover markers 
and significant reduction in Charcot related symptoms during the study. In one not-
randomized study confirmed the effect of pamidronate on temperature reduction and fall in 
bone turnover markers in acute CN [12]. However, all three studies did not report reduction 
in immobilisation time, as a clinical marker for the activity of CN. 
Risk of bisphosphonates 
Minor side effects of oral bisphosphonates are gastrointestinal symptoms, hypocalcaemia, 
skin reactions, acute phase reactions like malaise or fever or skin. These side effects have 
biological plausibility and causality has been proven. 
No causality is proven for some severe adverse effects of bisphosphonates: osteonecrosis of 
jaw, atypical hip fractures, possible oesophagus cancer, atrial fibrillation and 
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musculoskeletal pain. But clinical correlations were seen and reported in literature, for 
example osteonecrosis of the jaw [13]. Risk factors for developing osteonecrosis of the jaw 
are intravenous administration of bisphosphonates, history of inflammatory dental disease, 
glucocorticoids use and long duration of bisphosphonates use [14]. Of note, all severe events 
were seen if the bisphosphonates were used for several years. Furthermore, the reported 
data are conflicting and sometimes incomplete.  
In conclusion, there is no indication for bisphosphonates in the treatment of an acute CN if 
no data are known about reduction is immobilisation time.   
7. Possible candidates for additional treatment in acute CN 
Strontium ranelate 
Another potential intervention is strontium ranelate that is successfully used in the 
treatment of osteoporosis [15-17]. This drug has a direct inhibitive action on both osteoclast 
activity and differentiation. In addition, strontium ranelate stimulates the osteoprogenitor 
cells and collagen in osteoblasts [18,19]. Recent evidence has shown that strontium ranelate 
induced osteoprotegerin-  (OPG) mRNA expression and suppressed RANKL mRNA in 
human osteoblasts [20]. Furthermore strontium ranelate induced osteoblast replication and 
differentiation [20]. Strontium ranelate is to date it has not yet been used as treatment in the 
acute stage of CN. 
Denosumab 
Denosumab is a fully human monoclonal antibody to the receptor activator of nuclear 
factor-κB ligand (RANKL) that blocks its binding to RANK, inhibiting the development and 
activity of osteoclasts, decreasing bone resorption, and increasing bone density. Given its 
unique actions, denosumab may be useful in the treatment of osteoporosis and bone 
metastatic disease. Some clinical trials have been performed and show favourable results 
[21,22]. In acute CN, no studies have been performed so far.  
8. Summary 
Charcot neuro-osteoarthropathy is most often seen in patients with diabetes and is 
characterized as red, hot swollen foot. In the presence of a foot ulcer, the differential 
diagnosis with osteomyelitis is very difficult. In the early stage of acute CN, X ray can be 
false negative in contrast to MRI or CT. The latter investigations can be useful to 
differentiate between osteomyelitis and acute CN. The treatment of acute CN is offloading 
in plaster cast until the active CN is clinical and radiological inactive.  
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